SVEUČILIŠTE U ZAGREBU
FARMACEUTSKO-BIOKEMIJSKI FAKULTET

IVANA PERKOVIĆ

SINTEZA, KARAKTERIZACIJA I BIOLOŠKO DJELOVANJE KARBAMIDNIH, SEMIKARBAZIDNIH, KARBAZIDNIH I ESTERSKIH DERIVATA AMINOKISELINA I NESTEROIDNIH PROTUUPALNIH LIJEKOVA

DOKTORSKI RAD

Zagreb, 2012.

UNIVERSITY OF ZAGREB
FACULTY OF PHARMACY AND BIOCHEMISTRY

IVANA PERKOVIĆ

SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL ACTIVITY OF CARBAMIDE, SEMICARBAZIDE, CARBAZIDE AND ESTER DERIVATIVES OF AMINO ACIDS AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS

DOCTORAL THESIS

Zagreb, 2012

SVEUČILIŠTE U ZAGREBU
FARMACEUTSKO-BIOKEMIJSKI FAKULTET

IVANA PERKOVIĆ

SINTEZA, KARAKTERIZACIJA I BIOLOŠKO DJELOVANJE KARBAMIDNIH, SEMIKARBAZIDNIH, KARBAZIDNIH I ESTERSKIH DERIVATA AMINOKISELINA I NESTEROIDNIH PROTUUPALNIH LIJEKOVA

DOKTORSKI RAD

Mentor: Prof. dr. sc. Branka Zorc

Zagreb, 2012.

SAŽETAK

U okviru ovog doktorskog rada, koji je nastavak istraživanja o mogućnostima korištenja benzotriazola u sintetskoj kemiji na Zavodu za Farmaceutsku kemiju Farmaceutsko-biokemijskog fakulteta u Zagrebu, sintetizirano je nekoliko serija spojeva. Polazni spoj u sintezi svih prekursora bio je klorid 1-benzotriazolkarboksilne kiseline (BtcCl) koji daje vrlo reaktivne derivate. BtcCl vrlo lako reagira s nukleofilima dajući cijeli niz reaktivnih spojeva iz kojih je do sada pripravljen velik broj organskih spojeva. Derivati aminokiselina ureidoamidi **4a-o** pripravljeni su reakcijom klorida *N*-(1-benzotriazol-karbonil)aminokiselina **3** i odgovarajućih aminoalkohola, a *N*- i *O*- supstituirane hidroksiuree **6a-l** iz amida *N*-(1-benzotriazolkarbonil)aminokiselina i odgovarajućih hidroksilamina. Derivati nesteroidnih protuupalnih lijekova (NSAID, ibuprofena, fenoprofena i ketoprofena) sintetizirani su iz NSAID hidrazida **11** koji su dobiveni aminolizom NSAID benzotriazolida **10** i hidrazina. Hidrazidi **11** su u reakciji s 1-karbamoilbenzotriazolima (aktivne uree, **7**) dali 1-acilsemikarbazidne derivate NSAID **13a-v**, a u reakciji s 1-(1-benzotriazolkarbonil)-4-benziloksisemikarbazidom (**9**) 1-acil-5-benziloksikarbamoilkarbazide **14a-c**. Reakcije u talini uz TEA bitno su skratile vrijeme reakcije. 4-Hidroksisemikarbazidni derivati NSAID **13w-y** i **14d-f** pripravljeni su katalitičkim hidrogeniranjem *O*-benzilnih derivata **13t-v** i **14a-c** uz Pd/C. Iz benzotriazolida ketoprofena (**10d**) i odgovarajućih ureidoamida (**4b,i,j,m**) pripravljeni su esteri s dvije molekule ketoprofena kovalentno povezane ureidoamidima u jednu molekulu („dvojni lijekovi").

Svi sintetizirani spojevi karakterizirani su uobičajenim analitičkim postupcima i spektroskopskim metodama te biološki ispitani *in vitro* na citostatsko, antivirusno, antimikrobno i antioksidativno djelovanje. Nadalje, ispitana je inhibicija lipooksigenaze i lipidne perkosidacije. Najbolje antitumorsko djelovanje pokazao je spoj **6l**, antivirusno **13a,g,m**, a antiooksidativno spoj **9**. Najjači inhibitor lipooksigenaze bio je spoj **13s**, a lipidne peroksidacije **13c,l,t**. Uočeno je ponavljanje benzhidrilnog supstituenta u spojevima s istaknutom aktivnosti, što je dobar pokazatelj za daljnje usmjeravanje istraživanja.

Ključne riječi: aminokiselina/hidroksiurea/nesteroidni protuupalni lijek/
semikarbazid/ester/sinteza/biološko djelovanje

SUMMARY

The research described in the thesis is a continuation of the previous work on the use of benzotriazole in the synthetic chemistry which has been carring out at Department of Medicinal Chemistry, Faculty of Pharmacy and Biochemistry in Zagreb for many years. The thesis includes synthesis of several types of compounds. The initial compound for the synthesis of all the intermediates was benzotriazole carboxylic acid chloride (BtcCl), which upon the reaction with nucleophiles gives reactive products, useful in the preparation of various organic compounds. Amino acid derivatives ureidoamides **4a-o** were syntehsized by aminolysis of *N*-(1-benzotriazolecarbonyl)amino acid chlorides **3** with corresponding aminoalcohols and *N*- i *O*- substituted hydroxyureas **6a-l** were synthesizes from *N*-(1-benzotriazolecarbonyl)amino acid amides **5** and hydroxylamines. Nonsteroidal antiinflammatory drugs (NSAID, ibuprofen, fenoprofen and ketoprofen) derivatives were prepared from NSAID hydrazides **11** which were obtained by aminolysis of NSAID benzotriazolides **10** and hydrazine hydrate. The reaction of hydrazides **11** and 1-benzotriazole carboxylic acid amides **7** gave 1-acylsemicarbazides **13a-v**, while with 1-(1-benzotriazolecarbonyl)-4-benzyloxysemicarbazide (**9**) gave 1-acyl-5-benzyloxycarbamoyl-carbazides **14a-c**. Reactions in melted state in the presence of TEA significantly reduced the reaction time. 4-Hydroxysemicarbazide compounds **13w-y** and **14d-f** were prepared by catalytic hydrogenation of *O*-benzylated compounds **13t-v** i **14a-c** with Pd/C. Ketoprofen benzotriazolide (**10d**) reacted with several ureidoamides (**4b,i,j,m**) and gave esters with two molecules of ketoprofen combined covalently in one („twin drugs").

The compounds were evaluated for their biological activity *in vitro*: antitumor, antimicrobial, antiviral and antioxidant activity, inhibition of lipoxygenase and linoleic acid lipid peroxidation. The best antitumor activity was exerted by **6l**, antiviral by **13a,g,m**, antioxidant by compound **9**. The strongest inhibitor of lipoxygenase was **13s**. Compounds **13c,l,t** showed the highest inhibition of linoleic acid lipid peroxidation. It is worth to note that compounds with the highest biological activity contained benzhydryl substituent.

<h1 style="text-align:center">SADRŽAJ</h1>

TEMELJNA DOKUMENTACIJSKA KARTICA

BASIC DOCUMENTATION CARD

KRATICE

AAPH	2,2'-azobis(2-amidinopropan) dihidroklorid
AKR	Aldo-keto reduktaza
3-AP	triapin
ATCC	American Type Culture Collection
Bn	benzil
BtcCl	klorid 1-benzotriazolkarboksilne kiseline
BtH	benzotriazol
CDI	1,1'-karbonildiimidazol
CEM	stanična linija zloćudno preobraženih T-limfocita
CLSI	Clinical and Laboratory Standards Institute
COX	ciklooksigenaza
CRFK	Crandell Rees stanice mačjeg bubrega
DCC	*N,N'*-dicikloheksilkarbodiimid
DMF	*N,N*-dimetilformamid
DSC	*N,N'*-disukcinimidil karbonat
DPPH	1,1-difenil-2-pikrilhidrazil radikal
EC_{50}	efektivna koncentracija pri kojoj je stvaranje plakova virusa smanjeno za 50 %
Fen	fenoprofen
GIT	gastrointestinalni trakt
H 460	stanična linija karcinoma pluća
HCT 116	stanična linija karcinoma debelog crijeva
HEL	ljudske embrionalne stanice pluća
HeLa	stanična linija karcinoma grlića maternice
Hep G2	stanična linija karcinoma jetre
HSV-1 (KOS)	herpes simpleks virus tip 1
HSV-2 (G)	herpes simpleks virus tip 2
HU	hidroksiurea
Ibu	ibuprofen
IC_{50}	koncentracija spoja koja inhibira rast stanica za 50 %
IR	infracrveno elektromagnetsko zračenje

L1210	stanična linija leukemije porijeklom iz miša
LO	lipooksigenaza iz soje
5-LOX	5-lipooksigenaza
LP	lipidna peroksidacija
MCC	minimalna citotoksična koncentracija
MCF-7	stanična linija karcinoma dojke
MDCK	Madin-Darby stanice psećeg bubrega
MeKet	2-(3-benzilfenil)propanska kiselina
MiaPaCa-2	stanična linija karcinoma gušterače
MIC	minimalna inhibitorna koncentracija
MMcC	minimalna mikrobicidna koncentracija
MOLT-4	stanična linija akutne limfoblastične leukemije
Molt4/C8	stanična linija zloćudno preobraženih T-limfocita
NCCLS	National Committee for Clinical Laboratory Standards
NDGA	nordihidrogvajaretična kiselina
NMR	nuklearna magnetska rezonancija
NSAID	nesteroidni protuupalni lijek
PC-3	stanična linija karcinoma prostate
Pd/C	paladij na ugljenu
RR	ribonukleotid reduktaza
s.t.	sobna temperatura
SW620	stanična linija karcinoma debelog crijeva
TEA	trietilamin
TMS	tetrametilsilan
t_t	temperatura taljenja
WI 38	stanična linija normalnih fibroblasta porijeklom iz čovjeka

1. UVOD

1.1. OBRAZLOŽENJE TEME

1.1.1. Hidroksiuree i srodni spojevi

N-Hidroksiurea (HU, Slika 1) je citostatik koji se već dugi niz godina koristi u liječenju melanoma, kronične mijelocitne leukemije, neoperabilnog karcinoma jajnika te u lokalnoj kontroli primarnih karcinoma skvamoznih (epidermalnih) stanica glave i vrata (Lemke *et al*, 2008).

Slika 1. Hidroksiurea.

N-Hidroksiurea je također učinkovita u terapiji srpaste anemije i HIV infekcije, a koristi se samostalno ili u kombinaciji s poznatim antiretrovirusnim lijekovima. Nadalje, istražuje se njezina djelotvornost u terapiji trombocitopenije, policitemije vere, psorijaze, beta-talasemije i reumatoidnog artritisa (Mai *et al*, 2010; Navarra *et al*, 1999; Leavell *et al*, 1970).

Najvažniji nedostatak hidroksiuree je kratko poluvrijeme eliminacije (1,9-3,9 h) koje je posljedica relativno male molekulske mase (M_r = 76,06) i velike polarnosti. Zbog toga se HU upotrebljava u visokim dozama (80 mg/kg svaki treći dan ili 20-30 mg/kg dnevno). Drugi važni nedostatak je brzi razvoj otpornosti na terapiju (Mai *et al*, 2010; Ren *et al*, 2002).

HU inhibira ribonukleotid reduktazu (RR, EC 1.17.4.1.), enzim koji katalizira redukciju ribonukleotida u deoksiribonukleotide te tako osigurava građevni materijal za *de novo* sintezu DNA u svim stanicama koje imaju sposobnost dijeljenja. Osim toga RR igra važnu ulogu u karcinogenezi (Szekeres *et al*, 1997; Nocentini, 1996). Zbog svojstva kompleksiranja metala HU ima inhibitorni učinak na hidrolitičke enzime koji u sebi sadrže metale: ureaze (Uesato *et al*, 2002; Fishbein *et al*, 1965), karboksipeptidazu A (Chung *et al*, 2001), ribonukleaze (Higgin *et al*, 2003) i 5-lipooksigenazu (Connolly *et al*, 1999; Kolasa *et al*, 1997; Adams *et al*, 1996; Kolasa *et al*, 1996).

HU se može smatrati derivatom hidroksamske kiseline. U hidroksamske kiseline ubrajamo neke analgetike i antiinflamatorike (ibuproksam, oksametacin, bufeksamat),

citostatike (vorinostat, didoks), antiastmatike (zileuton, atreleuton), kelatore željeza (desferioksamin), α-adrenergike i antidepresive (adrafinil).

Tijekom prijašnjih istraživanja na Zavodu za farmaceutsku kemiju sintetizirana je serija nesupstituiranih derivata hidroksiurea kojima je ispitano antitumorsko i antivirusno djelovanje (Opačić *et al*, 2005). Neki od derivata pokazali su relativno dobro antitumorsko djelovanje te su zato u okviru ovog rada pripravljeni njihovi strukturni analozi, *N-* i *O-*supstituirane hidroksiuree te im je ispitano biološko djelovanje (Slika 2) (Perković *et al*, 2008).

Slika 2. a) Nesupstituirane; b) *O*-benzilne; c) *N*-metilne hidroksiuree.

Kao nastavak ovih istraživanja, sintetizirana je serija ureidoamida (Slika 3), strukturnih analoga hidroksiurea, kod kojih je hidroksilna skupina udaljena od dušika za dva, tri ili pet ugljikovih atoma. Ti derivati su također biološki ispitani te im je djelovanje uspoređeno s hidroksiureama (Perković *et al*, 2010).

Slika 3. Ureidoamidi.

1.1.2. Derivati NSAID

Nesteroidni protuupalni lijekovi (*nonsteroidal antiinflammatory drug*, NSAID), jedni od najčešće upotrebljavanih lijekova danas, svoje djelovanje temelje na inhibiciji ciklooksigenaze (COX), enzima uključenog u sintezu endogenih eikozanoida. Aktivacijom fosfolipaze-A_2 dolazi do otpuštanja arahidonske kiseline koja se metabolizira pomoću dva enzima, ciklooksigenaze (put stvaranja prostaglandina, prostaciklina i tromboksana) i 5-lipooksigenaze (put stvaranja leukotriena) (Lemke *et al*, 2008). Inhibicija ciklooksigenaze

nesteroidnim protuupalnim lijekovima dovodi do preusmjeravanja metabolizma arahidonske kiseline preko 5-lipooksigenaze, što ima za rezultat povećanje sinteze leukotriena (pojava upale i neželjenih učinaka NSAID) i smanjene sinteze gastroprotektivnih prostaglandina (gastrointestinalne nuspojave) (Charlier *et al*, 2003; Muri *et al*, 2002).

Kemijskim modificiranjem NSAID željelo se postići nekoliko ciljeva. Smatra se da gastrointestinalnim nuspojavama doprinosi akumulacija kiselih lijekova u želucu nakon oralne primjene te inhibicija COX-1 (konstitutivna izoforma ciklooksigenaze odgovorna za sintezu gastroprotektivnih prostaglandina, protok krvi kroz bubrege i agregaciju trombocita). S druge strane, inhibicija COX-2 je poželjna jer se ona povezuje s protuupalnim djelovanjem NSAID (inducibilna izoforma ciklooksigenaze, javlja se u upaljenom tkivu, a konstitutivna je samo u bubrezima i reproduktivnim organima, povezuje se i s nekoliko tipova karcinoma, Alzheimerovom i Parkinsonovom bolesti) (Charlier *et al*, 2003). Zaštitom karboksilne skupine dobiveni su derivati s očuvanim protuupalnim učinkom, ali i novim učincima (smanjeni ulcerogeni učinak, selektivnost za COX-2, inhibicija 5-lipooksigenaze, dualno COX/5-LOX djelovanje, antitumorsko, anivirusno i antimikrobno djelovanje, smanjena lipidna peroksidacija). Općenito se smatra da bi tvari koje inhibiraju COX i 5-LOX mogle imati manje nuspojava uz očuvanu aktivnost (Liu *et al*, 2011; Fogli *et al*, 2010; Fun *et al*, 2009; Amir *et al*, 2007; Metwally *et al*, 2007; Gobec *et al*, 2005; Amir *et al*, 2004; Omar *et al*, 1996).

Najjednostavniji primjer kemijske modifikacije karboksilne skupine u svrhu smanjenja ulcerogenog učinka je esterifikacija pa je u okviru ovog rada pripravljena i serija estera NSAID (ketoprofena) s ureidoamidima gdje su na jednu molekulu ureidoamida vezane dvije molekule NSAID (Slika 4) i to pojednostavljenom metodom koja je prethodno razvijena na Zavodu za farmaceutsku kemiju (Zorc *et al*, 1994; Zorc *et al*, 1993). Može se reći da su dobiveni esteri „dvojni lijekovi" jer sadrže dvije identične farmakoforne skupine povezane kovalentnom vezom u jednu molekulu (Huzjak *et al*, 2008). Pojam dvojnih lijekova u skupini NSAID je već poznat. Autori Fadl i Omar načinili su seriju esterskih derivata paracetamola i nekoliko NSAID sa slobodnom karboksilnom skupinom koji su bili stabilni na pH 7,4. Također, imali su analgetski učinak, bolju biodostupnost i slabiji ulcerogeni učinak od ekvivalentne smjese samih lijekova (Fadl *et al*, 1998). Biološka ispitivanja sintetiziranih esterskih derivata nadilaze okvire ovoga rada.

Slika 4. Esteri ketoprofena i ureidoamida.

Mnogo je dokaza koji govore u prilog tvrdnji da su NSAID potencijalni antitumorski lijekovi. Brojne epidemiološke i eksperimentalne studije potvrdile su da NSAID sprečavaju pojavu i rast tumora i da je njihova dugotrajna primjena povezana sa smanjenim rizikom od pojave karcinoma debelog crijeva, mokraćnog mjehura, jednjaka, pluća, jajnika, prostate, želuca, jetre, gušterače i jezika (Sivak-Sears *et al*, 2004; Thun *et al*, 2002). Točan mehanizam odgovoran za antitumorsko djelovanje NSAID još nije u potpunosti razjašnjen. Smatra se da su ključni inhibicija proizvodnje prostaglandina (upalni PGE_2 ima glavnu ulogu u promoviranju rasta tumora) i aktivnosti COX-2 (Wang *et al*, 2010; Wang *et al*, 2006). Poznato je da upala igra važnu ulogu u inicijaciji, progresiji i prognozi karcinoma. Nekoliko je razloga tome. Kronična upala je karakterizirana infiltracijom stanica imunološkog sustava (makrofaga, limfocita i plazma stanica), oštećenjem tkiva, fibrozom te povećanom angiogenezom, učestalim oštećenjem genoma, povećanom sintezom DNA i staničnom proliferacijom, prekidom popravaka DNA i inhibicijom apoptoze, a ti procesi su povezani i s inicijacijom i progresijom karcinoma (Rayburn *et al*, 2009). Osim toga, u kanceroznom i prekanceroznom tkivu nađena je pretjerana ekspresija COX-2. Aktivnost COX-2 utječe i na angiogenezu u tumorima te potiče njihovu progresiju aktivirajući brojne signalne puteve (Sivak-Sears *et al*, 2004).

Nadalje, NSAID inhibiraju aldo-keto reduktazu (AKR1C3) koja slabo aktivne hormone estron i androstendion reducira u aktivne 17β-estradiol, odnosno testosteron. Takvi inhibitori bi mogli naći primjenu u liječenju hormon-ovisnih oblika karcinoma prostate, dojki i endometrija (Gobec *et al*, 2005).

Semikarbazidi i semikarbazoni su tvari raznolike primjene. Derivati su uree koja ima važnu ulogu u metabolizmu tvari koje sadrže dušik, koriste se kao reagensi za UV detekciju α-keto kiselina u tankoslojnoj kromatografiji, a u novije vrijeme su prepoznati kao farmakofori u otkrivanju novih lijekova raznolike biološke aktivnosti. Manje su istraženi od njihovih srodnika tiosemikarbazida i tiosemikarbazona koji su pokazali antivirusno, antitumorsko i antimikrobno djelovanje (Sayin *et al*, 2010; Beraldo *et al*, 2004). Jedan

predstavnik tiosemikarbazona, triapin (3-aminopiridin-2-karboksaldehid tiosemikarb-azon, 3-AP, Slika 5) snažniji je inhibitor RR od HU. Pokazao se djelotvoran *in vitro* na stanice otporne na HU i može proći krvno-moždanu barijeru te inhibirati rast L1210 stanica (leukemija) u mozgu. U kombinaciji s drugim citostaticima ima sinergistički učinak. Nalazi se u fazama I i II kliničkih ispitivanja za liječenje nekoliko vrsta tumora, sam ili u kombinaciji s drugim citostaticima (Kolesar *et al*, 2011a; Kolesar *et al*, 2011b; Finch *et al*, 2000; Beraldo *et al*, 2004).

Slika 5. Triapin.

Pripravljen je semikarbazidni analog zileutona (Slika 6) te je ispitano njegovo djelovanje na inhibiciju 5-LOX. Nije se pokazao boljim inhibitorom od samog zileutona *in vitro* (Stewart *et al*, 1997).

Slika 6. a) Zileuton; b) semikarbazidni analog zileutona.

Hidroksisemikarbazidi u strukturi imaju hidroksikarbamidnu, semikarbazidnu i hidroksamsku skupinu. Zbog sličnosti s hidroksamskim kiselinama i hidroksiureama može se očekivati i slično farmakološko djelovanje (Ren *et al*, 2002).

U okviru ovog doktorskog rada pripravljena je serija semikarbazidnih/hidroksi-semikarbazidnih derivata NSAID (ibuprofena, fenoprofena i reduciranog ketoprofena) te je ispitano njihovo antitumorsko, antivirusno i antioksidativno djelovanje te njihov učinak na lipooksigenazu i lipidnu peroksidaciju linolne kiseline (Slika 7) (Perković *et al*, u tisku).

Slika 7. Semikarbazidni derivati NSAID.

1.2. LITERATURNI PREGLED

1.2.1. Hidroksiuree i srodni spojevi

1.2.1.1. *Biološko djelovanje hidroksiurea i srodnih spojeva*

Kao što je već navedeno u prethodnom poglavlju, mehanizam djelovanja HU je inhibicija ribonukleotid reduktaze čime je zaustavljeno dijeljenje stanica u ranoj S fazi staničnog ciklusa (Tomita *et al*, 1979). Osim toga, otkriveno je da HU inducira ekspresiju gena za proupalne citokine (npr. TNFα *tumor necrosis factor* i IL *interleukine*) (Navarra *et al*, 1999; Navarra *et al*, 1997).

RR se sastoji od dvije podjedinice: R1/B1 i R2/B2. R1/B1 sadrži vezna mjesta za supstrate enzima i ditiolnu skupinu koji sudjeluje u oksidoreduktivnim procesima, a R2/B2 tirozinski slobodni radikal nužan za aktivnost enzima te dva nehemska željeza koji sudjeluju u obnovi i stabilizaciji radikala (Szekeres *et al*, 1997; Nocentini, 1996). Lijekovi mogu inhibirati jednu ili obje podjedinice. HU inhibira R2/B2 podjedinicu tako da reducira tirozinski radikal (Navarra *et al*, 1999). Drugu podjedinicu inhibiraju deoksiribonukleotidi (npr. dATP, dTTP ili dGTP). Najbolji inhibitorni učinak na rast staničnih linija karcinoma (L1210-leukemija) dala je kombinacija inhibitora obje podjedinice (sinergistička inhibicija) (Szekeres *et al*, 1997).

Osim HU, još jedan derivat hidroksamskih kiselina je snažan inhibitor RR, didoks (derivat polihidroksibenzohidroksamske kiseline). On je u brojnim *in vitro* i *in vivo* istraživanjima pokazao bolju učinkovitost i manju toksičnost u usporedbi s HU (Slika 8) (Inayat *et al*, 2010; Inayat *et al*, 2002; Nocentini, 1996).

Slika 8. Didoks.

Osim inhibicije RR derivati HU pokazali su niz različitih djelovanja:

- *Inhibicija ureaze.* Ureaza katalizira hidrolizu uree do amonijaka i karbaminske kiseline koja se razlaže na još jednu molekulu amonijaka i ugljičnu kiselinu. Bakterija *Helicobacter pylori* (uzročnik gastritisa, ulkusa i karcinoma želuca) preživljava u vrlo kiselom mediju želuca upravo zbog ureaze koja razgradnjom uree iz želučanog soka povisuje pH želuca (Muri *et al*, 2004; Amtul *et al*, 2002; Odake *et al*, 1994). Tvari koje inhibiraju ureazu mogle bi biti učinkovite u liječenju infekcija s *H. pylori* (Uesato *et al*, 2002).

- *Inhibicija 5-lipooksigenaze (5-LOX).* 5-LOX je enzim koji katalizira pretvorbu arahidonske kiseline u prekursor leukotriena 5-hidroperoksieikozatetraensku kiselinu. Leukotrieni su signalne molekule uključene u procese upale i alergije (Charlier *et al*, 2003). Već je u prethodnom poglavlju naglašeno da bi tvari koje mogu inhibirati oba enzima uključena u metabolizam arahidonske kiseline (COX i 5-LOX) mogle imati bolje protuupalno djelovanje i uzrokovati manje nuspojava od konvencionalnih NSAID (Charlier *et al*, 2003; Connolly *et al*, 1999). Tako je uspoređeno djelovanje derivata atreleutona (hidroksiurea) i tepoksalina (hidroksamska kiselina). Utvrđeno je da su derivati hidroksiuree bili primarno 5-LOX inhibitori, dok su hidroksamske kiseline inhibirale oba enzima. Glavni nedostatak tepoksalina (brzi metabolizam *in vivo* do karboksilata) pokazali su i njegovi derivati (Connolly *et al*, 1999). Kod hidroksiurea derivata NSAID također se željela postići dualna inhibicija. Autori su spojili strukturu NSAID (naproksen, ibuprofen i indometacin) za koju se zna da inhibira COX s hidroksiureom koja inhibira 5-LOX te je uočen gubitak aktivnosti za COX-1 i COX-2 dok je inhibicija 5-LOX ostala očuvana (Kolasa *et al*, 1997).

- *Hipoglikemijski učinak.* Neki derivati HU snizuju razinu glukoze u krvi tako što povećavaju koncentraciju transportera za glukozu u krvi GLUT1 (Goldstein *et al*, 1993).

- Neki derivati HU pokazali su *antagonistički učinak na B_1 bradikininske receptore* za koje se zna da igraju ulogu u boli uzrokovanoj kroničnom upalom (Schnatbaum *et al*, 2010).

1.2.1.2. *Sinteza hidroksiurea*

HU je prvi put sintetizirana 1869. i od tada je razvijeno mnogo metoda za sintezu njezinih derivata. Dresler i Stein su opisali sintezu tretiranjem vodene otopine hidroksilamin hidroklorida natrijevim ili drugim odgovarajućim izocijanatima (Shema 1a) (Šaban *et al*;

2009; Dresler *et al*, 1869). Tu metodu spominje i Uesato koji je u svom radu opisao sintezu niza *N*-supstituiranih HU i metodu sinteze pomoću *O*-benziloksiamina kojom se u zadnjem koraku *O*-benzilna zaštita uklanja hidrogenolizom uz 10 % Pd/C kao katalizator (Shema 1b). Za nezaštićene HU koristi metodu od Harmona i suradnika (Uesato *et al*, 2002; Harmon *et al*, 1970). Osim izocijanata, hidroksiureu daje i reakcija etil-karbamata s hidroksilamin hidrokloridom uz natrijevu lužinu (Shema 1c) (Degenghi, 1960).

Shema 1. Načini sinteze hidroksiurea

Kolasa i suradnici opisali su metodu sinteze kiralnih derivata HU iz odgovarajućeg kiralnog alkohola i *N,O*-bis(fenoksikarbonil)hidroksilamina, preko uretanskog međuprodukta koji je demaskiran hidroksilaminom u metanolu (Shema 2) (Kolasa *et al*, 1996; Mitsunobu, 1981).

Shema 2. Sinteza kiralnih derivata HU

Zanimljiva je i sinteza NSAID derivata „terminalnih" (hidroksilna skupina vezana je na dušik na koji nije vezan ostatak NSAID-a) i „unutarnjih" (hidroksilna skupina vezana je na

dušik na koji je vezan ostatak NSAID-a) HU. Karboksilna skupina NSAID (naproksen, ibuprofen i indometacin) prevedena je pomoću difenilfosforazidata (DPPA) Curtiusovom pregradnjom u odgovarajući izocijanat koji je u reakciji s hidroksilaminom dao „terminalne" NSAID hidroksiuree (Shema 3a). „Unutarnje" HU dobivene su pretvorbom odgovarajućih oksaziridina u NSAID hidroksilamine i tretiranjem potonjih s trimetilsilil izocijanatom (Shema 3b) (Kürti *et al*, 2005; Kolasa *et al*, 1997).

Shema 3. Sinteza NSAID hidroksiurea

Parrish i suradnici opisuju metodu sinteze derivata HU kondenzacijom različitih amina s 1-(4-nitrofenol)-*N*-(*O*-benziloksi)karbamatom uz TEA do *O*-benziliranih HU te njihovom hidrogenolizom uz Pd/BaSO$_4$ kao katalizator kako je već spomenuto (Shema 4) (Parrish *et al*, 2005).

Shema 4. Sinteza derivata hidroksiurea uz hidrogenolizu

Zaitsev i suradnici započinju sintezu hidroksiurea pripravom oksima iz ketona i hidroksilamina, koji redukcijom uz cijanoborhidrid daju odgovarajuće hidroksilamine. Dalje slijedi uobičajena reakcija hidroksilamina s kalijevim izocijanatom (Shema 5) (Onuchina *et al*, 2006; Zaitsev *et al*, 2005). Na analogan način su Goldstein i suradnici dobili derivate HU i iz aldehida (Goldstein *et al*, 1993).

Shema 5. Sinteza hidroksiurea iz ketona

N,N'-disukcinimidil karbonat (DSC) je kemijski reagens koji je našao primjenu u mnogobrojnim sintezama pa tako i u sintezi hidroksiurea (Shema 6) (Schnatbaum *et al*, 2010; Ghosh *et al*, 1992).

Shema 6. Primjena DSC-a u sintezi hidroksiurea

Na Zavodu za farmaceutsku kemiju razvijena je metoda sinteze aminokiselinskih derivata hidroksiurea iz klorida 1-benzotriazolkarboksilne kiseline (BtcCl) u četiri reakcijska koraka. Zadnji korak je aminoliza amida *N*-(1-benzotriazolkarbonil)aminokiselina s hidroksilaminom (Shema 7) (Opačić *et al*, 2005).

Shema 7. Sinteza aminokiselinskih hidroksiurea

1.2.2. Biološko djelovanje i sinteza NSAID i njihovih derivata

NSAID čine skupinu lijekova različite kemijske strukture, a većina ima tri glavna tipa djelovanja: protuupalni, analgetski i antipiretski. Farmakološka aktivnost NSAID je povezana

sa supresijom biosinteze prostaglandina, prostaciklina i tromboksana iz arahidonske kiseline zbog inhibicije enzima ciklooksigenaze (Lemke *et al*, 2008). Već je spomenuto da se kao glavni uzroci gastrointestinalnih nuspojava smatraju karboksilna skupina koja je prisutna u većini NSAID-a i neselektivna inhibicija oba izoenzima koja uzrokuje manjak gastroprotektivnih prostaglandina (Charlier *et al*, 2003). Zato se većina kemijskih modifikacija na molekulama NSAID provodi upravo na karboksilnoj skupini. Osim toga, uočeno je da su derivati dobiveni zamjenom karboksilne skupine pretežno sačuvali protuupalni učinak, ali su dobili i novi (smanjeni ulcerogeni učinak, selektivnost za COX-2, inhibicija 5-LOX, dualno COX/5-LOX djelovanje, antitumorsko, anivirusno i antimikrobno djelovanje, smanjena lipidna peroksidacija) (Liu *et al*, 2011; Fogli *et al*, 2010; Fun *et al*, 2009; Amir *et al*, 2007; Metwally *et al*, 2007; Gobec *et al*, 2005; Amir *et al*, 2004; Omar *et al*, 1996). U nastavku je dan pregled sinteza i biološkog djelovanja derivata NSAID.

1.2.2.1. *Hidrazidi NSAID i derivati nastali iz hidrazida*

Hidrazidi (RCONHNH$_2$) se često koriste kao početni spojevi u različitim sintezama, najčešće heterocikličkih spojeva. Najčešće se dobivaju reakcijom amida, estera ili tioestera s hidrazin hidratom (Li *et al*, 2005; Edwards, 1985). Također, poznata je sinteza iz kiselinskih klorida i hidrazin hidrata, iako u toj reakciji postoji opasnost od nastajanja nusprodukta, 1,2-diacil hidrazina (Shema 8) (Li *et al*, 2005).

Shema 8. a) Nastajanje hidrazida iz estera ili amida; b) nastajanje hidrazida i diacil hidrazina iz kiselinskog klorida

Hidrazidi NSAID (ibuprofen, diklofenak, indometacin, flurbiprofen, naproksen) pronađeni u literaturi pretežno su dobiveni iz metilnih ili etilnih estera i hidrazin hidrata

refluksiranjem u etanolu 4-20 sati ili na s.t. 3 sata uz relativno dobra iskorištenja (50-80 %). Najčešće su korišteni kao početni spojevi za sintezu diacil hidrazina (Hacking *et al*, 2000) ili heterocikličkih derivata kao npr. supstituiranih pirazola (Amir *et al*, 2005), 3-supstituiranih-5-merkapto-1,2,4-triazola i 3,5-disupstituiranih-triazolo-tiadiazola (Shema 9) (Metwally *et al*, 2007; Udupi *et al*, 2000), pirazolona i 1,3,4-oksadiazola (Sharma *et al*, 2003), oksadiazola, triazina, triazola i tiadiazola (Amir *et al*, 2007; Amir *et al*, 2004; Omar *et al*, 1996).

Shema 9. Sinteza derivata NSAID iz NSAID hidrazida

Dobivenim derivatima ispitan je analgetski, protuupalni i ulcerogeni učinak te postotak lipidne peroksidacije u mukozi (Amir *et al*, 2007; Amir *et al*, 2005; Amir *et al*, 2004; Omar *et al*, 1996) (pojačana lipidna peroksidacija u želučanoj mukozi povećava udio malondialdehida koji pogoduje ulcerogenom učinku NSAID) ili akutna toksičnost (Omar *et al*, 1996). Većina ispitanih derivata imala je sačuvano protuupalno i analgetsko djelovanje, ali puno slabiji ulcerogeni učinak i lipidnu peroksidaciju u odnosu na ishodni NSAID. Neki derivati NSAID pokazali su bolji analgetski i protuupalni učinak i smanjeni ulcerogeni učinak u usporedbi s indometacinom (Metwally *et al*, 2007; Sharma *et al*, 2003).

1.2.2.2. *NSAID hidroksamske kiseline i srodni spojevi*

Sinteze NSAID hidroksamskih kiselina većinom su opisane u patentima. Poznate su hidroksamske kiseline sljedećih NSAID-a: ibuprofena (ibuproksam), fenoprofena, diklofenaka, indometacina (oksametacin), meklofenaminske kiseline i sulindaka. Prvi korak u njihovoj sintezi najčešće je aktivacija karboksilne kiseline (prevođenje u ester, kiselinski klorid, anhidrid ili aktivacija pomoću CDI-a) (Kleeman *et al*, 2001; Sallmann, 1991; Cetenko, 1990; Summers *et al*, 1987; Božnar, 1987; Orzalesi, 1974; Sallmann, 1972; Marshall, 1971; Aries, 1970).

Ibuproksam i oksametacin (protuupalni lijekovi), ali i sve druge NSAID hidroksamske kiseline, imale su dualno djelovanje (inhibicija ciklooksigenaze i 5-lipooksigenaze) te su zbog toga pokazale manju akutnu toksičnost i manje nuspojava vezanih za dugotrajnu primjenu NSAID (smanjeni ulcerogeni učinak) (Muri *et al*, 2002; Flynn *et al*, 1990).

Sulindak hidroksamska kiselina i njezini sulfonski i sulfidni metaboliti pokazali su bolje *in vitro* antitumorsko (stanične linije karcinoma gušterače i debelog crijeva), proapoptotsko i antiangiogeno djelovanje u odnosu na karboksilne derivate što se objašnjava COX-ovisnim i COX-neovisnim mehanizmima. Pripravljene su iz karboksilne kiseline u reakciji s *O*-(*tert*-butil-dimetilsilil)hidroksilaminom (TBDMSiONH$_2$) u prisutnosti *N*-3-dime-tilaminopropil-*N*-etilkarbodiimid hidroklorida (EDCI). Dobivenim *O*-siliranim hidroksa-matima skinuta je zaštita trifluoroctenom kiselinom (Fogli *et al*, 2010).

Na Zavodu za farmaceutsku kemiju sintetizirane su NSAID hidroksamske kiseline i njihovi *O*-benzil/etil/metil derivati te im je ispitano biološko djelovanje (antitumorsko, antivirusno, antimikrobno, antioksidativno, inhibicija ureaze, lipooksigenaze i lipidne peroksidacije linolne kiseline). Sintetizirani su benzotriazolskom metodom koja je korištena i u okviru ovog doktorskog rada, gdje je karboksilna skupina NSAID-a aktivirana uvođenjem benzotriazola te je nastali benzotriazolid reagirao s odgovarajućim supstituiranim ili nesupstituiranim hidroksilaminom. Nesupstituirane hidroksamske kiseline dobivene su na dva načina; u reakciji NSAID benzotriazolida s hidroksilaminom sa ili bez TEA ili katalitičkim hidrogeniranjem *O*-benziliranih hidroksamskih kiselina. Ti derivati su pokazali slabo antimikrobno i antivirusno djelovanje dok su u ostalim biološkim ispitivanjima pokazali relativno dobre rezultate (Shema 10) (Kraljević Pavelić *et al*, 2010; Rajić *et al*, 2009a; Rajić *et al*, 2009b; Zovko Končić *et al*, 2009).

Shema 10. Sinteza NSAID hidroksamskih kiselina

1.2.2.3. *NO-otpuštajući NSAID*

NSAID koji otpuštaju dušikov oksid (NO) prepoznati su kao nova klasa spojeva koja ima sačuvano protuupalno, analgetsko i antipiretsko djelovanje kao i originalni NSAID ali zbog zaštitnog djelovanja NO uzrokuju manje nuspojava u gastrointestinalnom traktu i bubrezima. Također se pokazalo da bi mogli imati i antitumorsko djelovanje što su pokazala brojna *in vitro* i *in vivo* ispitivanja (poznato je da NO inducira apoptozu u stanicama putem nekoliko različitih mehanizama). Huguenin i suradnici su tako ispitali *in vitro* antitumorski potencijal nekoliko NO-otpuštajućih NSAID-a (acetilsalicilna kiselina, indometacin, piroksikam, ibuprofen, flurbiprofen i sulindak) od kojih je najbolje djelovanje pokazao NO-sulindak (NCX 1102) te je uzet u detaljnije razmatranje (Huguenin *et al*, 2005). Andrews i suradnici usporedili su *in vitro* antitumorsko djelovanje nekoliko NSAID (*R*-flurbiprofen, sulindak-sulfon i celekoksib) i NO-acetilsalicilne kiseline na stanične linije različitih tipova karcinoma. NO-acetilsalicilna kiselina i celekoksib pokazali su značajno bolje djelovanje u odnosu na ostale ispitane spojeve. Općenito, NO-NSAID sastoje se od 3 segmenta: NSAID ostatka, razmaknice (*spacer*) i skupine koja otpušta NO (Slika 9) (Andrews *et al*, 2008).

Slika 9. NO-otpuštajući NSAID.

1.2.2.4. *Amidi i esteri NSAID-a*

Već je puno puta spomenut štetni učinak dugotrajne primjene NSAID-a na gastrointestinalni trakt. Najjednostavniji način zaštite od učinka karboksilne skupine na mukozu je njezino privremeno maskiranje u odgovarajuće amide i estere. Takvi prolijekovi su se pokazali korisnima u smanjivanju nuspojava u odnosu na ishodne spojeve (Khan *et al*, 2006; Zhao *et al*, 2006; Shanbhag *et al*, 1992). Osim toga, modifikacijom molekule moguće je postići i neke nove učinke. Tako su npr. fenolni esteri i amidi naproksena pokazali bolje antioksidativno i antiproliferativno djelovanje od samog naproksena (Hellberg, 1999). Isto tako, koristeći nosač koji prolazi krvno-moždanu barijeru dobiveni su prolijekovi NSAID koji bi mogli biti učinkoviti u liječenju Alzheimerove bolesti (Perioli *et al*, 2004).

Neki amidi fenoprofena i ketoprofena i amidokarbamatni derivati ketoprofena (Slika 10) sintetizirani na Zavodu za farmaceutsku kemiju pokazali su jače antiproliferativno i/ili antioksidativno djelovanje ili su snažnije inhibirali LO od samih NSAID (Rajić *et al*, 2011; Rajić *et al*, 2010; Marjanović *et al*, 2007; Zovko *et al*, 2003; Zovko *et al*, 2001).

Slika 10. Amidi NSAID sintetizirani na Zavodu za farmaceutsku kemiju.

Esterifikacijom karboksilne skupine također je moguće dobiti prolijekove s poboljšanim svojstvima u odnosu na ishodni NSAID (Shanbhag, 1992). Jedan od glavnih problema u dizajniranju esterskih prolijekova je njihova slaba topljivost i brza hidroliza u GIT-u. Pripravljeni su esterski derivati ibuprofena i 1,3-dipalmitoil/distearil glicerola koji su pokazali dobru apsorpciju i hidrolizu tek pri pH 7,4 tako da je sluznica želuca ostala sačuvana (Khan *et al*, 2005). Topljivost esterskih prolijekova ibuprofena povećana je tvorbom glukopiranozidnih derivata (Zhao *et al*, 2006). Također, već su spomenuti esterski „dvojni lijekovi" paracetamola i NSAID sa slobodnom karboksilnom skupinom i njihova poboljšana svojstva (Shema 11) (Fadl *et al*, 1998).

Shema 11. Dvojni lijekovi paracetamola i NSAID s karboksilnom skupinom

Na Zavodu za farmaceutsku kemiju pripravljeni su metilni i etilni esteri nekih NSAID (Zorc *et al*, 1993; Zorc *et al*, 1994).

Postupci dobivanja estera i amida arilalkanskih kiselina iz skupine NSAID-a brojni su u literaturi i najčešće patentno zaštićeni. Najjednostavniji način njihovog dobivanja je prevođenje karboksilne skupine u kiselinski klorid i reakcija s alkoholom/aminom. Karboksilna skupina može se aktivirati i pomoću karbodiimida (Staab *et al*, 1998). Na Zavodu za farmaceutsku kemiju razvijen je postupak dobivanja amida i estera iz odgovarajućih benzotriazolida. Spojevi sa slobodnom karboksilnom skupinom reagiraju s kloridom 1-benzotriazolkarboksilne kiseline (BtcCl) dajući mješovite anhidride koji nakon dekarboksilacije stvaraju benzotriazolide u kojima je karboksilna skupina dovoljno aktivirana da s aminima i alkoholima daje amide i estere u vrlo blagim reakcijskim uvjetima, uz odcjepljenje benzotriazola. Amidi pretežno nastaju na sobnoj temperaturi, dok je za estere potrebna povišena temperatura (refluks) (Butula *et al*, 2007).

1.2.3. Sinteza i biološko djelovanje semikarbazida i srodnih spojeva

Već je ranije spomenuta raznolikost primjene semikarbazida i semikarbazona. Derivati su uree koja ima važnu ulogu u metabolizmu tvari koje sadrže dušik, koriste se kao reagensi za UV detekciju α-ketokiselina u tankoslojnoj kromatografiji, djeluju kao herbicidi (Hirai, 2010; Brantley, 1970), intermedijeri su u sintezi brojnih heterocikličkih spojeva (Shema 9) (Farshori *et al*, 2010) a u novije vrijeme su prepoznati kao farmakofori potencijalnih lijekova različite biološke aktivnosti (npr. antiprotozoici i antikonvulzivi) (Beraldo *et al*, 2004). Manje su istraženi od njihovih srodnika tiosemikarbazida i tiosemikarbazona koji su pokazali antivirusno, antitumorsko i antibakterijsko i antifungalno djelovanje (Sayin *et al*, 2010; Beraldo *et al*, 2004).

U literaturi se najčešće spominje postupak dobivanja semikarbazida iz odgovarajućih hidrazina i izocijanata (Shema 12a) (Brantley, 1970; Baker, 1966). U patentu US 4,725,608 opisano je još nekoliko načina dobivanja semikarbazida:

- hidrazin + karbamat (Shema 12b)
- hidrazin karboksilna kiselina (ili reaktivni derivat) + amin (Shema 12c)
- redukcija piridinium-1-il uree (Shema 12d) (Nakaguchi, 1988)

Shema 12. Sinteza semikarbazida

Neki od spomenutih semikarbazida pokazali su antiinflamatorno i analgetsko djelovanje (Nakaguchi, 1988).

Benzotiadiazinski semikarbazidi sintetizirani su iz tioetera i hidroklorida semikarbazida uz TEA (Pomarnacka *et al*, 2003). Zanimljiva je sinteza cikličkih semikarbazida 1,2,4-triazin-

-3-ona koji su pokazali selektivno djelovanje na 5-LOX. U pronađenoj literaturi opisano je nekoliko načina njihovog dobivanja:

- iz brometilamina preko etoksikarbamata i intramolekularne ciklizacije (Shema 13a).

- iz 2-kloretil izocijanata i odgovarajućeg hidrazina; nastali produkt ciklizira na povišenoj temperaturi u DMF-u uz NaI (Shema 13b).

- *N*-hidroksi triazinoni (ciklički semikarbazidi) mogu se dobiti iz karbamata, preko odgovarajućeg oksima, koji je reduciran do hidroksilamina i cikliziran obradom s kalijevim *tert*-butoksidom (Shema 13c) (Bhatia *et al*, 1996).

Shema 13. Sinteza cikličkih semikarbazida

Ako umjesto hidrazina, izocijanat ili izotiocijanat reagira s hidrazidima nastaju semikarbazidi ili tiosemikarbazidi s dodatnim karbonilom u strukturi, koji zatim u zadanim uvjetima cikliziraju u peteročlani prsten oksadiazol ili tiadiazol (Shema 16) (Asghar *et al*, 2010; Farshori *et al*, 2010; El-Sabbagh *et al*, 2009). Aciklički derivati (semikarbazidi i tiosemikarbazidi) pokazali su jače citotoksično djelovanje na ispitane stanične linije nekih tumora od njihovih cikličkih analoga (El-Sabbagh *et al*, 2009). Široki spektar mogućnosti ciklizacija iz semikarbazidnih i tiosemikarbazidnih derivata NSAID-a dan je u prethodnom poglavlju (poglavlje 1.2.2.1., Shema 9).

Shema 16. Sinteza karbonilsemikarbazida

4-Hidroksisemikarbazidi (Slika 11) također se koriste kao intermedijeri u sintezi cikličkih spojeva (*O*-supstituiranih triazolinona) (Müller, 1996), ali i kao spojevi s potencijalnim biološkim djelovanjem. Najčešće se spominju kao potencijalni antitumorski lijekovi zbog hidroksamske skupine koja je prisutna u cijelom nizu spojeva s antitumorskom aktivnošću (Ren *et al*, 2002).

Slika 11. 4-Hidroksisemikarbazid.

Neki od prvih radova u kojima se spominju 4-hidroksisemikarbazidi su iz šezdesetih godina prošlog stoljeća. Opisana je sinteza 4-hidroksisemikarbazida iz etoksikarbonil hidrazina i hidroksilamina (Zinner, 1968), *O*-metilhidroksisemikarbazid dobiven je iz estera *N*-metoksikarbaminske kiseline i hidrazina (Petersen, 1972; Ohme *et al*, 1971), dok esteri karbazinske kiseline s hidroksilaminima daju 4-hidroksisemikarbazide (Shema 13c) (Bhatia *et al*, 1996). Zilz opisuje postupak sinteze 4-hidroksisemikarbazida iz supstituiranih hidrazina i hidroksilamina uz CDI (Shema 17) (Zilz, 2000).

Shema 17. Sinteza 4-hidroksisemikarbazida uz CDI

Godine 2002. skupina autora objavila je sintezu serije Schiffovih baza hidroksisemikarbazida (SB-HSC) prema modificiranom ranije opisanom postupku (Grobner *et al*, 1974; Steinberg *et al*, 1956) koji su sintetizirani iz samog 4-hidroksisemikarbazida (dobiven iz *N*-hidroksifenil karbamata i hidrazin hidrata u etanolu) i odgovarajućeg aldehida u ekvimolarnim omjerima (Shema 18) (Ren *et al*, 2002). Provedena QSAR analiza tih derivata potvrdila je da su hidroksiurea i lipofilnost važni čimbenici za antitumorsko djelovanje (Raichurkar *et al*, 2003).

Shema 18. Schiffove baze 4-hidroksisemikarbazida

1.2.4. Benzotriazol u sintetskoj kemiji

Benzotriazol (BtH) pripada u skupinu azola (aromatski peteročlani heterociklički ili benzenom kondenzirani heterociklički spojevi s dva ili više dušikova atoma, npr. imidazol, pirazol, triazol, tetrazol, benzimidazol i drugi) (Staab *et al*, 1998). Benzotriazol se u kemijskim sintezama počeo koristiti osamdesetih godina prošlog stoljeća i od tada je upotrebljen u sintezi cijelog niza spojeva. Benzotriazol se pokazao kao vrlo korisno pomoćno sredstvo u sintezama: lako se izdvaja iz reakcijske smjese te se može ponovo upotrijebiti, lako se ugrađuje u početni spoj te ga aktivira za njegovu daljnju kemijsku pretvorbu, stabilan je pri različitim kemijskim operacijama. Osim toga nije skup, dobro je topljiv u velikom broju organskih otapala i zaluženoj vodi te djelomično topljiv u vodi (Katritzky *et al*, 2010; Katritzky *et al*, 1998). Također, benzotriazol reagira s fozgenom u molarnom omjeru 1:1 dajući klorid 1-benzotriazolkarboksilne kiseline (BtcCl) koji poput običnih kiselinskih klorida daje derivate koji pokazuju osobito reaktivna svojstva. Zbog otežanog rukovanja fozgenom i sigurnosti u radu u laboratoriju, danas se u sintezi BtcCl-a pretežno upotrebljava čvrsti trifozgen (trimer fozgena) koji se zagrijavanjem razlaže u fozgen (Shema 20) (Kalčić *et al*, 2003; Butula *et al*, 1977). BtcCl vrlo lako reagira s nukleofilima dajući cijeli niz reaktivnih spojeva iz kojih je do sada pripravljen velik broj organskih spojeva. Neki od njih su karbamati, simetrične i asimetrične uree, semikarbazidi, karbazidi, sulfoniluree, sulfonilkarbazidi, esteri nitroalkanskih kiselina, brojni heterociklički spojevi (derivati benzoksazina, kinazolina, triazintriona, hidantoina i oksadiazina), derivati aminokiselina (esteri i amidi aminokiselina, di- i tripeptidi, hidantoinske kiseline, hidroksiuree) i derivati ljekovitih tvari. Funkcionalne skupine NSAID-a ketoprofena, fenoprofena, ibuprofena, diklofenaka i indometacina, urikozurika probenecida, antihiperlipemika gemfibrozila i estrogena estradiol-benzoata aktivirane su uvođenjem benzotriazola pomoću BtcCl-a te su dobiveni benzotriazolidi koji su s odgovarajućim reagensima dali amide, hidroksamske kiseline, estere i polimer-lijek konjugate (polimerni prolijekovi u kojima je ljekovita tvar povezana kovalentnom vezom na polimerni nosač poliaspartamidnog tipa). Pregled „benzotriazolskih" sinteza do sada napravljenih na Zavodu za farmaceutsku kemiju dan je u Shemi 19 (Butula *et al*, 2007). Također, ovaj doktorski rad dat će uvid u daljnje mogućnosti primjene benzotriazolske kemije u sintezi organskih spojeva.

Shema 19. Raznolikost primjene benzotriazola u sintetskoj kemiji

2. MATERIJALI I METODE

2.1. SINTEZE

2.1.1. Materijali i instrumenti

Tališta (t_t) su određena na Stuart SMP3 instrumentu za određivanje tališta (Barloworld Scientific, UK) i nisu korigirana. Iskorištenja nisu optimirana. CHN analiza je provedena na CHN-LECO-932 instrumentu za elementarnu analizu (LECO Corporation, USA) te su sve elementarne analize bile unutar 0,4 %.

Za tankoslojnu kromatografiju upotrebljene su silikagel ploče 60 F_{254} (Kemika, Hrvatska), te diklormetan/metanol (9:1, 4:1, 9,5:0,5), cikloheksan/etil-acetat (1:1), petroleter/etil-acetat/metanol (3:1:0,5) i etil-acetat/petroleter/metanol (2:1:0,1) kao pokretna faza. Za kromatografiju na koloni kao nepokretna faza korišten je silikagel veličine čestica 0,063–0,200 nm (Merck, Njemačka i Kemika, Hrvatska), a cikloheksan/etil-acetat/metanol (3:1:0,6), diklormetan/metanol (9:1 i 8,5:1,5, 4:1, 9,4:0,6), kloroform/metanol (9,5:0,5) kao pokretne faze. Analizirani spojevi detektirani su UV zračenjem (λ = 254 nm), parama joda, etanolnom otopinom fosfomolibdenske kiseline i otopinom željezovog(III) klorida (w = 1 %).

IR spektri snimljeni su na Paragon FT-IR spektrofotometru (Perkin Elmer, UK). NMR spektri snimljeni su Bruker AV-600 spektrometrom (Bruker, USA) kod 600,13 ili 300,13 MHz za ^{1}H, odnosno kod 150,917 ili 75,47 MHz za ^{13}C jezgru. Uzorci su mjereni u DMSO-d_6 u NMR cjevčicama od 5 mm. Kemijski pomaci dani su u ppm u odnosu na tetrametilsilan (TMS) kao unutarnji standard. FID rezolucija u ^{1}H NMR i ^{13}C NMR spektrima bila je 0,29 Hz i 0,54 Hz po točki.

Benzotriazol, trifozgen, N-metilhidroksilamin hidroklorid, O-benzilhidroksil-amin hidroklorid, ciklopentilamin, cikloheksilamin, cikloheksanmetilamin, benzilamin, feniletilamin, benzhidrilamin, 2-aminoetanol, 3-aminopropanol, 5-aminopentanol L-alanin i 10 %-tni Pd/C nabavljeni su od tvrtke Aldrich (Njemačka), TEA od Sigme (USA), L-valin, L-leucin i L-fenilalanin od Kemike (Hrvatska). D-fenilglicin i NSAID-i (ketoprofen, fenoprofen i ibuprofen) dobiveni su susretljivošću tvornica lijekova Pliva i Belupo (Hrvatska) i Sveučilišta u Potchefstroomu (Južnoafrička Republika).

U eksperimentalnom dijelu korištena su bezvodna otapala. Bezvodni toluen dobiven je sljedećim postupkom: toluen je ekstrahiran vodom, zatim je osušen nad bezvodnim kalcijevim kloridom, destiliran i čuvan nad elementarnim natrijem. Bezvodni eter priređen je na sljedeći način: eter je ekstrahiran 3 puta otopinom kalcijevog klorida (w = 10 %), 1 put otopinom sumporne kiseline (w = 5 %), 1 put vodom, 1 put otopinom natrijevog karbonata

(w = 5 %) i 1 put otopinom željezovog(II) sulfata (w = 5 %). Nakon toga eter je opran do neutralnog pH, sušen nad bezvodnim kalcijevim kloridom 24 h, predestiliran i čuvan nad elementarnim natrijem. Bezvodni dioksan: dioksan je refluksiran 24 h nad elementarnim natrijem, predestiliran i čuvan nad elementarnim natrijem.

Sve ostale kemikalije bile su *p. a.* čistoće.

2.1.2. Sinteza klorida 1-benzotriazolkarboksilne kiseline (1)

Otopina BtH (1,191 g, 10 mmol) i trifozgena (2,523 g, 8,5 mmol) u bezvodnom toluenu (20 mL) refluksirana je 3 h. Reakcijska smjesa uparena je pod sniženim tlakom i nekoliko puta naparena toluenom. Dobiveni klorid 1-benzotriazolkarboksilne kiseline (BtcCl, **1**) upotrebljen je u daljnjim reakcijama bez čišćenja.

2.1.3. Sinteza *N*-(1-benzotriazolkarbonil)aminokiselina 2a-e. Opća metoda

Suspenziji odgovarajuće aminokiseline (20 mmol) u bezvodnom dioksanu (40 mL) uz miješanje je dokapana otopina BtcCl (**1**) (1,810 g, 10 mmol) u bezvodnom dioksanu (10 mL) tijekom 0,25 h. Nakon dokapavanja reakcijska smjesa miješana je 24 h na sobnoj temperaturi. Talog hidroklorida aminokiseline je odsisan, a otapalo upareno pod sniženim tlakom. Dobivena sirova *N*-(1-benzotriazolkarbonil)aminokiselina je zatim isprana vrućim toluenom (**2a**, **2b**, **2e**) ili prekristalizirana iz toluena (**2c** i **2d**). IR spektri i tališta spojeva **2a-e** u potpunosti odgovaraju ranije sintetiziranim spojevima (Butula *et al*, 1981a).

2.1.4. Sinteza klorida *N*-(1-benzotriazolkarbonil)aminokiselina 3a-e. Opća metoda

Otopina odgovarajuće *N*-(1-benzotriazolkarbonil)aminokiseline **2a-e** (4 mmol) u tionil-kloridu (20 mL) miješana je na sobnoj temperaturi 24 h. Tionil-klorid uparen je pod sniženim tlakom, a dobiveni ostatak nekoliko puta naparen bezvodnim toluenom. Dobiveni kloridi **3a-e** upotrebljeni su u daljnjim reakcijama bez čišćenja.

2.1.5. Sinteza ureidoamida 4a-o. Opća metoda

U otopinu klorida *N*-(1-benzotriazolilkarbonil)-aminokiseline (**3a-e**) (1 mmol) u dioksanu dodana je otopina 0,183 g (3mmol) 2-aminoetanola ili 0,225 g (3 mmol) 3-

aminopropanola ili 0,309 g (3 mmol) 5-aminopentanola u dioksanu. Reakcijska smjesa je miješana na sobnoj temperaturi 24 sata te je uparena pod sniženim tlakom. Čisti produkt dobiven je kromatografijom na koloni te prekristalizacijom.

1-(1-(2-Hidroksietilkarbamoil)etil-3-(2-hidroksietil)urea (4a)

Količina reaktanta: 0,253 g spoja **3a**. Sirovi produkt **4a** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklormetan/metanol 8,5:1,5 → 4:1 i rastrljavanjem u eteru.

Iskorištenje: 0,132 g (61 %).

t_t 150–154 ºC.

IR (KBr): ν_{max} 3422, 3274, 2969, 2937, 2879, 1644, 1570, 1056 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,87 (t, 1H, 1'(amid), J = 5,4 Hz), 6,21 (d, 1H, 3, J = 7,9 Hz), 6,14 (t, 1H, 1'(urea), J = 5,5 Hz), 4,69, 4,67 (2t, 2H, 4', J = 5,6 Hz, J = 5,2 Hz), 4,16–4,06 (m, 1H, 2), 3,38–3,32 (m, 4H, 3'), 3,13–3,00 (m, 4H, 2'), 1,12 (d, 3H, 5, J = 7,4 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,78 (1), 157,98 (4), 61,19, 60,21 (3'), 49,07 (2), 42,46, 41,86 (2'), 20,11 (5).

1-(1-(3-Hidroksipropilkarbamoil)etil-3-(3-hidroksipropil)urea (4b)

Količina reaktanta: 0,253 g spoja **3a**. Sirovi produkt **4b** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklormetan/metanol 4:1 i rastrljavanjem u eteru.

Iskorištenje: 0,139 g (56 %).

t_t 152–156 ºC.

IR (KBr): ν_{max} 3275, 2941, 2875, 1638, 1560, 1060 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,85 (t, 1H, 1'(amid), J = 5,5 Hz), 6,05–6,02 (d, t, 2H, 1'(urea), 3), 4,43, 4,42 (2t, 2H, 5', J = 4,8 Hz, J = 5,1 Hz), 4,14–4,05 (m, 1H, 2), 3,39 (q, 4H, 4', J = 6,1 Hz), 3,12–3,00 (m, 4H, 2'), 1,58–1,44 (m, 4H, 3'), 1,12 (d, 3H, 5, J = 6,8 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,63 (1), 157,97 (4), 58,83, 58,82 (4'), 49,02 (2), 36,70, 36,12 (2'), 33,66, 32,79 (3'), 20,23 (5).

1-(1-(5-Hidroksipentilkarbamoil)etil-3-(5-hidroksipentil)urea (4c)

Količina reaktanta: 0,253 g spoja **3a**. Sirovi produkt **4c** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklormetan/metanol 4:1 i rastrljavanjem u eteru.

Iskorištenje: 0,180 g (59 %).

t_t 142–146 ºC.

IR (KBr): ν_{max} 3360, 3282, 3111, 2936, 2862, 1627, 1561, 1056 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,84 (t, 1H, 1'(amid), J = 5,3 Hz), 6,03 (t, 1H, 1'(urea), J = 5,5 Hz), 5,96 (d, 1H, 3, J = 7,8 Hz), 4,34 (t, 2H, 7', J = 5,1 Hz), 4,15–4,05 (m, 1H, 2), 3,37 (q, 4H, 6', J = 5,8 Hz), 3,05–2,92 (m, 4H, 2'), 1,45–1,29 (m, 12H, 3'–5'), 1,12 (d, 3H, 5).

^{13}C NMR (DMSO-d_6, δ ppm): 173,44 (1), 157,77 (4), 61,13, 61,08 (6'), 48,95 (2), 39,63, 38,89 (2'), 32,72, 32,63 (5'), 30,35, 29,39 (3'), 23,39, 23,30 (4'), 20,36 (5).

1-(1-(2-Hidroksietilkarbamoil)-2-metilpropil-3-(2-hidroksietil)urea (4d)

Količina reaktanta: 0,281 g spoja **3b**. Sirovi produkt **4d** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklorometan/metanol 8,5:1,5 → 4:1 i prekristalizacijom iz metanola i etera.

Iskorištenje: 0,140 g (57 %).

t_t 194–198 ºC.

IR (KBr): ν_{max} 3280, 3102, 2969, 2874, 1626, 1571, 1063 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,87 (t, 1H, 1'(amid), J = 5,4 Hz), 6,16 (t, 1H, 1'(urea), J = 5,5 Hz), 6,11 (d, 1H, 3, J = 9,1 Hz), 4,65, 4,64 (2t, 2H, 4', J = 4,8 Hz, J = 5,1 Hz), 3,97 (dd, 1H, 2, J = 6,0 Hz, J = 2,9 Hz), 3,45–3,33 (m, 4H, 3'), 3,18–3,03 (m, 4H, 2'), 1,91–1,80 (m, 1H, 5), 0,82 (d, 3H, 6, J = 6,8 Hz), 0,78 (d, 3H, 7, J = 6,8 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 172,60 (1), 158,44 (4), 61,25, 60,28 (3'), 58,34 (2), 42,49, 41,76 (2'), 31,59 (5), 19,73, 18,25 (6, 7).

1-(1-(3-Hidroksipropilkarbamoil)-2-metilpropil-3-(3-hidroksipropil)urea (4e)

Količina reaktanta: 0,281 g spoja **3b**. Sirovi produkt **4e** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklorometan/metanol 9:1 → 4:1 i prekristalizacijom iz metanola i etera.

Iskorištenje: 0,154 g (56 %).

t_t 178–181 ºC.

IR (KBr): ν_{max} 3350, 3279, 3102, 2963, 2874, 1630, 1566, 1234, 1078, 1044 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,90 (t, 1H, 1'(amid), J = 5,6 Hz), 6,06 (t, 1H, 1'(urea), J = 5,7 Hz), 5,96 (d, 1H, 3, J = 9,1 Hz), 4,42, 4,41 (2t, 2H, 5', J = 5,4 Hz), 3,95 (dd, 1H, 2, J = 6,1 Hz, J = 3,0 Hz), 3,39 (q, 4H, 4', J = 6,0 Hz), 3,19–3,00 (m, 4H, 2'), 1,89–1,78 (m, 1H, 5), 1,58–1,45 (m, 4H, 3'), 0,82 (d, 3H, 6, J = 6,8 Hz), 0,79 (d, 3H, 7, J = 7,0 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 172,40 (1), 158,45 (4), 58,89, 58,79 (4'), 58,28 (2), 36,68, 36,07 (2'), 33,71, 32,86 (3'), 31,72 (5), 19,71, 18,35 (6, 7).

1-(1-(5-Hidroksipentilkarbamoil)-2-metilpropil-3-(5-hidroksipentil)urea (4f)

Količina reaktanta: 0,281 g spoja **3b**. Sirovi produkt **4f** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklorometan/metanol 9:1 → 4:1 i rastrljavanjem u eteru.

Iskorištenje: 0,171 g (52 %).

t_t 159–162 ºC.

IR (KBr): ν_{max} 3349, 3278, 3107, 2935, 2861, 1628, 1572, 1236, 1059 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,89 (t, 1H, 1'(amid), J = 5,5 Hz), 6,05 (t, 1H, 1'(urea), J = 5,4 Hz), 5,90 (d, 1H, 3, J = 9,0 Hz), 4,35–4,32 (m, 2H, 7'), 3,95 (dd, 1H, 2, J = 6,2 Hz, J = 2,7 Hz), 3,38–3,35 (m, 4H, 6'), 3,12–2,93 (m, 4H, 2'), 1,88–1,77 (m, 1H, 5), 1,44–1,25 (m, 12H, 3'–5'), 0,81 (d, 3H, 6, J = 6,8 Hz), 0,78 (d, 3H, 7, J = 6,9 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 172,23 (1), 158,25 (4), 61,13, 61,08 (6'), 58,21 (2), 39,67, 38,83 (2'), 32,72, 32,62 (5'), 31,78 (5), 30,35, 29,41 (3'), 23,39, 23,35 (4'), 19,70, 18,33 (6, 7).

1-(1-(2-Hidroksietilkarbamoil)-3-metilbutil-3-(2-hidroksietil)urea (4g)

Količina reaktanta: 0,295 g spoja **3c**. Sirovi produkt **4g** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklormetan/metanol 8,5:1,5 i prekristalizacijom iz metanola i etera.

Iskorištenje: 0,138 g (53 %).

t_t 157–161 ºC.

IR (KBr): ν_{max} 3290, 3098, 2954, 2928, 2872, 1625, 1569, 1059 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,87 (t, 1H, 1'(amid), J = 5,3 Hz), 6,11 (d, 1H, 3, J = 8,9 Hz), 6,04 (t, 1H, 1'(urea), J = 5,4 Hz), 4,65–4,64 (m, 2H, 4'), 4,15–4,07 (m, 1H, 2), 3,40–3,34 (m, 4H, 3'), 3,13–3,01 (m, 4H, 2'), 1,60–1,52 (m, 1H, 6), 1,42–1,27 (m, 2H, 5), 0,86 (2d, 6H, 7, 8, J = 6,2 Hz, J = 5,4 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,69 (1), 158,18 (4), 61,21, 60,24 (3'), 51,95 (2), 42,84, 42,49 (2'), 41,83 (5), 24,69 (6), 23,51, 22,39 (7, 8).

1-(1-(3-Hidroksipropilkarbamoil)-3-metilbutil-3-(3-hidroksipropil)urea (4h)

Količina reaktanta: 0,295 g spoja **3c**. Sirovi produkt **4h** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklormetan/metanol 8,5:1,5 i rastrljavanjem u eteru.

Iskorištenje: 0,150 g (52 %).

t_t 109–111 ºC.

IR (KBr): ν_{max} 3308, 3098, 2957, 2872, 1630, 1572, 1252, 1073 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,89 (t, 1H, 1'(amid), J = 5,5 Hz), 5,97–5,94 (m, 2H, 3, 1'(urea)), 4,42, 4,40 (2t, 2H, 5', J = 5,3 Hz), 4,13–4,05 (m, 1H, 2), 3,42–3,35 (m, 4H, 4'), 3,15–2,99 (m, 4H, 2'), 1,59–1,44 (m, 5H, 6, 3'), 1,39–1,30 (m, 2H, 5), 0,87 (d, 3H, 7, J = 6,2 Hz), 0,85 (d, 3H, 8, J = 6,2 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,50 (1), 158,19 (4), 58,90, 58,85 (4'), 51,95 (2), 42,92 (5), 36,73, 36,11 (2'), 33,68, 32,81 (3'), 24,74 (6), 23,43, 22,49 (7, 8).

1-(1-(5-Hidroksipentilkarbamoil)-3-metilbutil-3-(5-hidroksipentil)urea (4i)

Količina reaktanta: 0,295 g spoja **3c**. Sirovi produkt **4i** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklorometan/metanol 9:1 → 8,5:1,5 i rastrljavanjem u eteru.

Iskorištenje: 0,270 g (78 %).

t_t 83–86 ºC.

IR (KBr): ν_{max} 3349, 3280, 3100, 2937, 2862, 1626, 1562, 1262, 1059 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,88 (t, 1H, 1'(amid), J = 5,4 Hz), 5,94 (t, 1H, 1' (urea), J = 5,7 Hz), 5,88 (d, 1H, 3, J = 9,0 Hz), 4,33 (t, 2H, 7', J = 5,1 Hz), 4,13–4,06 (m, 1H, 2), 3,39–3,33 (m, 4H, 6'), 3,08–2,92 (m, 4H, 2'), 1,58–1,22 (m, 15H, 6, 5, 3'–5'), 1,39–1,30 (m, 2H, 5), 0,87 (d, 3H, 7, J = 6,1 Hz), 0,85 (d, 3H, 8, J = 6,1 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,29 (1), 157,98 (4), 61,13, 61,09 (6'), 51,90 (2), 43,03 (5), 39,70, 38,87 (2'), 32,73, 32,64 (5'), 30,35, 29,37 (3'), 24,74 (6), 23,41, 22,57 (7, 8), 23,38, 23,31 (4').

1-((2-Hidroksietilkarbamoil)(fenil)metil)-3-(2-hidroksietil)urea (4j)

Količina reaktanta: 0,315 g spoja **3d**. Sirovi produkt **4j** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklorometan/metanol 8,5:1,5 → 4:1 i rastrljavanjem u eteru.

Iskorištenje: 0,171 g (61 %).

t_t 206–208 ºC.

IR (KBr): ν_{max} 3291, 3092, 2934, 2878, 1626, 1571, 1226, 1057 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 8,31 (t, 1H, 1'(amid), J = 5,5 Hz), 7,37–7,21 (m, 5H, arom.), 6,78 (d, 1H, 3, J = 8,4 Hz), 6,29 (t, 1H, 1'(urea), J = 5,5 Hz), 5,31 (d, 1H, 2, J = 8,4 Hz), 4,66, 4,64 (2t, 2H, 4', J = 5,3 Hz, J = 5,1 Hz), 3,40–3,34 (m, 4H, 3'), 3,23–2,97 (m, 4H, 2').

^{13}C NMR (DMSO-d_6, δ ppm): 171,25 (1), 157,63 (4), 141,05 (5), 128,61, 127,10 (6, 7, 9 10), 127,57 (8), 61,18, 60,11 (3'), 56,93 (2), 42,46, 42,01 (2').

1-((3-Hidroksipropilkarbamoil)(fenil)metil)-3-(3-hidroksipropil)urea (4k)

Količina reaktanta: 0,315 g spoja **3d**. Sirovi produkt **4j** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklorometan/metanol 8,5:1,5 i prekristalizacijom iz metanola i etera.

Iskorištenje: 0,170 g (55 %).

t_t 182–185 ºC.

IR (KBr): ν_{max} 3289, 3092, 2942, 2883, 1626, 1561, 1059 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 8,27 (t, 1H, 1'(amid), J = 5,5 Hz), 7,36–7,22 (m, 5H, arom.), 6,65 (d, 1H, 3, J = 8,3 Hz), 6,21 (t, 1H, 1'(urea), J = 5,5 Hz), 5,26 (d, 1H, 2, J = 8,5 Hz), 4,41, 4,39 (2t, 2H, 5', J = 5,2 Hz), 3,42–3,32 (m, 4H, 4'), 3,12–2,99 (m, 4H, 2'), 1,56–1,44 (m, 4H, 3').

^{13}C NMR (DMSO-d_6, δ ppm): 171,06 (1), 157,67 (4), 141,10 (5), 128,63, 126,96 (6, 7, 9, 10), 127,59 (8), 58,79, 58,72 (4'), 56,98 (2), 39,15, 36,69 (2'), 36,33, 36,28 (3').

1-((3-Hidroksipentilkarbamoil)(fenil)metil)-3-(5-hidroksipentil)urea (4l)

Količina reaktanta: 0,315 g spoja **3d**. Sirovi produkt **4l** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklorometan/metanol 8,5:1,5 i prekristalizacijom iz metanola i etera.

Iskorištenje: 0,222 g (61 %).

t_t 178–180 ºC.

IR (KBr): ν_{max} 3362, 3286, 3093, 2937, 2861, 1628, 1564, 1352, 1061 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 8,26 (t, 1H, 1'(amid), J = 5,5 Hz), 7,36–7,21 (m, 5H, arom.), 6,60 (d, 1H, 3, J = 8,4 Hz), 6,21 (t, 1H, 1'(urea), J = 5,5 Hz), 5,26 (d, 1H, 2, J = 8,4 Hz), 4,35, 4,31 (2t, 2H, 7', J = 5,3 Hz), 3,40–3,30 (m, 4H, 6'), 3,05–2,92 (m, 4H, 2'), 1,44–1,16 (m, 12H, 3'–5').

^{13}C NMR (DMSO-d_6, δ ppm): 170,90 (1), 157,49 (4), 141,21 (5), 128,59, 126,93 (6, 7, 9, 10), 127,54 (8), 61,13, 61,06 (6'), 56,94 (2), 39,63, 39,04 (2'), 32,71, 32,58 (5'), 30,31, 29,24 (3'), 23,38, 23,25 (4').

1-(1-(2-Hidroksietilkarbamoil)-2-feniletil)-3-(2-hidroksietil)urea (4m)

Količina reaktanta: 0,329 g spoja **3e**. Sirovi produkt **4m** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklorometan/metanol 8,5:1,5 i rastrljavanjem u eteru.

Iskorištenje: 0,230 g (78 %).

t_t 140–143 ºC.

IR (KBr): v_{max} 3310, 3105, 2937, 2876, 1626, 1569, 1496, 1231, 1056 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,90 (t, 1H, 1'(amid), J = 5,1 Hz), 7,28–7,17 (m, 5H, arom.), 6,16 (d, 1H, 3, J = 8,6 Hz), 6,10 (t, 1H, 1'(urea), J = 5,1 Hz), 4,64–4,59 (m, 2H, 4), 4,37–4,30 (m, 1H, 2), 3,33–3,29 (m, 4H, 3'), 3,12–2,67 (m, 6H, 2', 5).

^{13}C NMR (DMSO-d_6, δ ppm): 172,51 (1), 158,00 (4), 138,41 (6), 129,71, 128,43 (7, 8, 10, 11), 126,58 (9), 61,16, 60,18 (3'), 54,80 (2), 42,42, 41,81 (2'), 39,42 (5).

1-(1-(3-Hidroksipropilkarbamoil)-2-feniletil)-3-(3-hidroksipropil)urea (4n)

Količina reaktanta: 0,329 g spoja **3e**. Sirovi produkt **4n** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklorometan/metanol 8,5:1,5 i rastrljavanjem u eteru.

Iskorištenje: 0,243 g (75 %).

t_t 110–113 ºC.

IR (KBr): v_{max} 3280, 3106, 2942, 2878, 1628, 1564, 1235, 1050 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,88 (t, 1H, 1'(amid), J = 4,6 Hz), 7,27–7,14 (m, 5H, arom.), 6,04–6,02 (d, t, 2H, 3, 1'(urea)), 4,42–4,28 (m, 3H, 2, 5'), 3,39–3,34 (m, 4H, 4'), 3,12–2,69 (m, 6H, 2', 5), 1,50–1,43 (m, 4H, 3').

^{13}C NMR (DMSO-d_6, δ ppm): 172,28 (1), 158,00 (4), 138,35 (5), 129,68, 128,43 (7, 8, 10, 11), 126,58 (9), 58,93 (4'), 54,79 (2), 39,46 (5), 36,68, 36,14 (2'), 33,61, 32,72 (3').

1-(1-(5-Hidroksipentilkarbamoil)-2-feniletil)-3-(5-hidroksipentil)urea (4o)

Količina reaktanta: 0,329 g spoja **3e**. Sirovi produkt **4o** pročišćen je kromatografijom na koloni, uz pokretnu fazu diklorometan/metanol 9:1 i rastrljavanjem u eteru.

Iskorištenje: 0,197 g (52 %).

t_t 89–93 ºC.

IR (KBr): v_{max} 3282, 3106, 2931, 2859, 1626, 1559, 1236, 1060 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,86 (t, 1H, 1'(amid), J = 5,5 Hz), 7,27–7,14 (m, 5H, arom.), 6,01 (t, 1H, 1'(urea), J = 5,5 Hz), 5,96 (d, 1H, 3, J = 8,7 Hz), 4,35–4,28 (m, 3H, 2, 7'), 3,37–3,33 (m, 4H, 6'), 3,07–2,69 (m, 6H, 2', 5), 1,43–1,16 (m, 12H, 3'–5').

^{13}C NMR (DMSO-d_6, δ ppm): 172,06 (1), 157,79 (4), 138,34 (5), 129,70, 128,40 (7, 8, 10, 11), 126,55 (9), 61,13, 61,07 (6'), 54,72 (2), 39,62, 39,55 (2'), 38,91 (5), 32,72, 32,67 (5'), 30,30, 29,33 (3'), 23,36, 23,29 (4').

2.1.6. Sinteza amida *N*-(1-benzotriazolkarbonil)aminokiselina 5a-f. Opća metoda

U otopinu odgovarajućeg klorida *N*-(1-benzotriazolkarbonil)aminokiseline **3c-e** (4 mmol) u bezvodnom toluenu (40 mL) dokapana je otopina odgovarajućeg amina (4 mmol) i TEA (0,558 mL, 4 mmol) u toluenu (30 mL). Reakcijska smjesa miješana je 1 h na sobnoj temperaturi. Istaloženi TEA hidroklorid je odsisan, a matičnica ekstrahirana vodom (3×70 mL), kloridnom kiselinom (*w* = 1 %, 3×70 mL) i vodom do neutralnog pH, a zatim osušena nad bezvodnim natrijevim sulfatom. Nakon uparavanja otapala pod sniženim tlakom dobiven je sirovi produkt koji kristalizira. Produkti **5a-f** prekristalizirani su iz odgovarajućeg otapala. IR spektri i tališta spojeva **5a**-**f** u potpunosti odgovaraju ranije sintetiziranim spojevima (Opačić *et al*, 2005).

2.1.7. Sinteza *N*- i *O*-supstituiranih hidroksiurea 6a-l. Opća metoda

U suspenziju odgovarajućeg amida *N*-(1-benzotriazolkarbonil)aminokiseline (**5a-f**) (1 mmol) i odgovarajućeg hidroksilamin hidroklorida (1,2 mmol) u 8 ml suhog toluena dodana je otopina TEA (0,167 mL, 1,2 mmol) u 8 ml suhog toluena. Reakcijska smjesa je mješana na temperaturama od sobne do 125ºC 10 minuta do 72 h. Toluen je uparen a dobivena smola je otopljena u smjesi acetona i vode te zakiseljena 10 % HCl do pH 1. Uparavanjem acetona pod sniženim tlakom taloži se sirovi produkt.

N-Benzhidrilamid-2-(*N*'-benziloksiureido)-L-4-metilpentanske kiseline (6a)

Količine reaktanata: 0,442 g spoja **5a**, 0,191 g *O*-benzilhidroksilamin hidroklorida.

Trajanje reakcije: 20 h.

Temperatura reakcije: 15,5 h na 70 ºC i 4,5 h na 114 ºC.

Sirovi produkt je pročišćen koromatografijom na koloni uz pokretnu fazu diklormetan/metanol 9,4:0,6.

Iskorištenje: 0,122 g (27 %).

t_t 100–103 ºC.

IR (KBr): ν_{max} 3308, 3061, 3030, 2957, 2930, 2872, 1645, 1525, 1496, 1453, 1336, 1240, 1212, 1078, 1028, 902, 752, 698, 607 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, *J*/Hz): 9,18 (s, 1H, 1'), 8,82 (d, 1H, 1", *J* = 8,51 Hz), 7,33–7,16 (m, 15H, arom.), 6,45 (d, 1H, 3, *J* = 8,92 Hz), 6,03 (d, 1H, 2", *J* = 8,51 Hz), 4,64 (dd, 2H, 3',

$J_{\text{vic H,H}}$=11,6 Hz), 4,32–4,28 (m, 1H, 2), 1,43–1,32 (m, 3H, 5, 6), 0,79 (2d, 6H, 7, 8, J = 6,43 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 171,66 (1), 158,95 (4), 142,25, 142,21 (3", 9"), 136,26 (4'), 128,73, 128,35, 128,30, 128,26, 127,39, 127,09 (5', 6', 8', 9', 4", 5", 7", 8", 10", 11", 13", 14"), 128,09, 126,94, 126,90 (7', 6", 12"), 77,40 (3'), 55,84 (2"), 51,16 (2), 41,67 (5), 24,17, 23,04, 21,72 (6–8).

N-Benzhidrilamid-2-(N'-metil-N'-hidroksiureido)-L-4-metilpentanske kiseline (6b)

Količine reaktanta: 0,442 g spoja **5a**, 0,100 g *N*-metilhidroksilamin hidroklorida.

Trajanje reakcije: 0,15 h.

Temperatura: 125 ℃.

Reakcija rađena u talini bez otapala. Sirovi produkt je rastrljan u eteru.

Iskorištenje: 0,283 g (77 %).

t_t 219–222 ℃ (raspad).

IR (KBr): ν_{max} 3407, 3309, 3162, 3031, 2964, 2930, 2900, 2872, 1648, 1548, 1515, 1496, 1471, 1450, 1437, 1368, 1296, 1185, 1173, 1120, 761, 749, 701 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,52 (s, 1H, 2'), 8,90 (d, 1H, 1", J = 8,47 Hz), 7,38–7,18 (m, 10H, arom.), 6,68 (d, 1H, 3, J = 8,97 Hz), 6,10 (d, 1H, 2", J = 8,47 Hz), 4,38–4,32 (m, 1H, 2), 2,95 (s, 3H, 3'), 1,58–1,39 (m, 3H, 5, 6), 0,85 (2d, 6H, 7, 8, J = 3,24 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 171,81 (1), 160,34 (4), 142,30 (3", 9"), 128,39, 128,35, 127,41, 127,10 (4", 5", 7", 8", 10", 11", 13", 14"), 127,01, 126,97 (6", 12"), 55,84 (2"), 51,85 (2), 42,03 (5), 38,59 (3'), 24,24, 23,05, 21,84 (6–8).

N-Cikloheksanmetilamid-2-(N'-benziloksiureido)-D-2-feniletanske kiseline (6c)

Količine reaktanata: 0,391 g spoja **5b**, 0,191 g *O*-benzilhidroksilamin hidroklorida.

Trajanje reakcije: 5 h.

Temperatura reakcije: 114 ℃.

Sirovi produkt je pročišćen koromatografijom na koloni uz pokretnu fazu cikloheksan/etil-
-acetat/metanol 3:1:0,6.

Iskorištenje: 0,117 g (30 %).

t_t 148–150 ℃.

IR (KBr): ν_{max} 3310, 3091, 3063, 3032, 2926, 2854, 1639, 1533, 1450, 1355, 1221, 1154, 985, 931, 907, 747, 697 cm^{-1}.

¹H NMR (DMSO-d_6, δ ppm, J/Hz): 9,40 (s, 1H, 1'), 8,29 (t, 1H, 1", J = 5,57 Hz), 7,43–7,22 (m, 10H, arom.), 6,91 (d, 1H, 3, J = 7,98 Hz), 5,28 (d, 1H, 2, J = 7,98 Hz), 4,76 (dd, 2H, 3', $J_{vic\ H,H}$=11,26 Hz), 2,93–2,82 (m, 2H, 2"), 1,61–0,83 (m, 11H, 3"–8").

¹³C NMR (DMSO-d_6, δ ppm): 169,68 (1), 158,24 (4), 139,79 (5), 136,09 (4'), 129,00, 128,42, 128,20, 126,37 (6, 7, 9, 10, 5', 6', 8', 9'), 128,29, 127,36 (8, 7'), 77,54 (3'), 55,76 (2), 44,88 (2"), 37,35 (3"), 30,19, 30,14, 25,32 (4", 5", 7", 8"), 25,93 (6").

N-Cikloheksanmetilamid-2-(N'-metil-N'-hidroksiureido)-D-2-feniletanske kiseline (6d)

Količine reaktanata: 0,391 g spoja **5b**, 0,100 g *N*-metilhidroksilamin hidroklorida.

Trajanje reakcije: 24 h.

Temperatura reakcije: s.t.

Sirovi produkt je pročišćen koromatografijom na koloni uz pokretnu fazu cikloheksan/etil--acetat 1:1.

Iskorištenje: 0,127 g (40 %).

t_t 123–126 ºC.

IR (KBr): ν_{max} 3425, 3310, 2925, 2853, 1650, 1532, 1450, 1367, 1184, 1120, 698, 668 cm^{-1}.

¹H NMR (DMSO-d_6, δ ppm, J/Hz): 9,85 (bs, 1H, 2'), 8,33 (t, 1H, 1", J = 5,76 Hz), 7,39–7,23 (m, 5H, arom.), 7,07 (d, 1H, 3, J = 8,16 Hz), 5,28 (d, 1H, 2, J = 8,16 Hz), 2,95 (s, 3H, 3'), 2,92–2,87 (m, 2H, 2"), 1,60–0,77 (m, 11H, 3"–8").

¹³C NMR (DMSO-d_6, δ ppm): 170,32 (1), 160,05 (4), 140,51 (5), 128,69, 126,89 (6, 7, 9, 10), 127,84 (8), 56,86 (2), 45,34 (2"), 38,76 (3'), 37,81 (3"), 30,66, 30,62, 25,78 (4", 5", 7", 8"), 26,39 (6").

N-Benzhidrilamid-2-(N'-benziloksiureido)-D-2-feniletanske kiseline (6e)

Količine reaktanata: 0,462 g spoja **5c**, 0,191 g *O*-benzilhidroksilamin hidroklorida.

Trajanje reakcije: 4,5 h.

Temperatura reakcije: 114 ºC.

Sirovi produkt je prekristaliziran iz acetona i vode.

Iskorištenje: 0,093 g (20 %).

t_t 161–165 ºC.

IR (KBr): ν_{max} 3308, 3062, 3031, 2934, 1667, 1642, 1536, 1496, 1453, 1366, 1231, 1213, 1031, 934, 743, 700, 640, 614 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,33 (s, 1H, 1'), 9,19 (d, 1H, 1'', J = 8,28 Hz), 7,35–6,98 (m, 20H, arom.), 6,85 (d, 1H, 3, J = 7,96 Hz), 6,01 (d, 1H, 2'', J = 7,96 Hz), 5,43 (d, 1H, 2, J = 7,96 Hz), 4,68 (dd, 2H, 3', $J_{\text{vic H,H}}$=10,94 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 169,08 (1), 158,25 (4), 141,90, 141,77 (3'', 9''), 139,34 (5), 136,05 (4'), 128,94, 128,42, 128,38, 128,23, 127,51, 126,79, 126,46 (6, 7, 9, 10, 4', 5', 7', 8', 4'', 5'', 7'', 8'', 10'', 11'', 13'', 14''), 77,52 (3'), 56,02, 55,63 (2, 2'').

N-Benzhidrilamid-2-(N'-metil-N'-hidroksiureido)-D-2-feniletanske kiseline (6f)

Količine reaktanata: 0,462 g spoja **5c**, 0,100 g *N*-metilhidroksilamin hidroklorida.

Trajanje reakcije: 1,75 h.

Temperatura reakcije: 70 ºC.

Iskorištenje: 0,331 g (85 %).

t_t 165–168 ºC (raspad).

IR (KBr): $\nu_{\max}$ 3439, 3376, 3210, 3064, 3031, 2924, 2892, 1637, 1584, 1520, 1496, 1450, 1367, 1177, 1120, 1030, 748, 697, 636 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,71 (s, 1H, 2'), 9,31 (d, 1H, 1'', J = 8,40 Hz), 7,45–7,04 (m, 16H, arom., 3), 6,09 (d, 1H, 2'', J = 8,19 Hz), 5,53 (d, 1H, 2, J = 8,19 Hz), 2,96 (s, 3H, 3').

^{13}C NMR (DMSO-d_6, δ ppm): 169,72 (1), 160,03 (4), 142,47, 142,25 (3'', 9''), 140,11 (5), 128,93, 128,77, 128,74, 127,97, 127,31, 127,01 (6, 7, 9, 10, 4'', 5'', 7'', 8'', 10'', 11'', 13'', 14''), 27,97, 127,66, 127,43 (8, 6'', 12''), 56,68, 56,51 (2, 2''), 38,78 (3').

N-Cikloheksilamid-2-(N'-benziloksiureido)-L-3-fenilpropanske kiseline (6g)

Količine reaktanata: 0,391 g spoja **5d**, 0,191 g *O*-benzilhidroksilamin hidroklorida.

Trajanje reakcije: 1 h.

Temperatura reakcije: 114 ºC.

Sirovi produkt je pročišćen rastrljavanjem u eteru.

Iskorištenje: 0,267 g (65 %).

t_t 129–131 ºC.

IR (KBr): $\nu_{\max}$ 3296, 3206, 3064, 3031, 2931, 2854, 1639, 1533, 1498, 1453, 1364, 1250, 1075, 952, 814, 750, 698 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,24 (s, 1H, 1'), 7,88 (d, 1H, 1'', J = 7,66 Hz), 7,35–7,13 (m, 10H, arom.), 6,53 (d, 1H, 3, J = 8,61 Hz), 4,64 (s, 1H, 3'), 4,41 (q, 1H, 2, J = 7,48 Hz), 3,52–3,49 (m, 1H, 2''), 2,96–2,88 (d, 2H, 5), 1,73–1,03 (m, 10H, 3''–7'').

¹³C NMR (DMSO-*d*₆, δ ppm): 170,36 (1), 159,14 (4), 137,93 (6), 136,59 (4'), 129,82, 129,17, 128,36 (7, 8, 10, 11, 5', 6', 8', 9'), 128,60, 126,63 (9, 7'), 77,84 (3'), 54,00 (2), 47,96 (2''), 39,01 (5), 32,74, 32,73, 24,90, 24,85 (3'', 4'', 6'', 7''), 25,65 (5'').

N-Cikloheksilamid-2-(N'-metil-N'-hidroksiureido)-L-3-fenilpropanske kiseline (6h)

Količine reaktanata: 0,391 g spoja **5d**, 0,100 g *N*-metilhidroksilamin hidroklorida.

Trajanje reakcije: 48 h.

Temperatura reakcije: s.t.

Iskorištenje: 0,183 g (57 %).

*t*ₜ 153–155 ºC.

IR (KBr): ν_max 3390, 3289, 3089, 2935, 2854, 1648, 1627, 1550, 1452, 1390, 1182, 751, 702 cm⁻¹.

¹H NMR (DMSO-*d*₆, δ ppm, *J*/Hz): 9,50 (s, 1H, 2'), 7,83 (d, 1H, 1'', *J* = 7,84 Hz), 7,27–7,15 (m, 5H, arom.), 6,59 (d, 1H, 3, *J* = 8,56 Hz), 4,36 (q, 1H, 2, *J* = 6,82 Hz, 8,27 Hz), 3,52–3,43 (m, 1H, 2''), 2,91 (s, 3H, 3'), 2,88 (d, 2H, 5, *J* = 6,97 Hz), 1,71–1,02 (m, 10H, 3''–7'').

¹³C NMR (DMSO-*d*₆, δ ppm): 170,38 (1), 160,61 (4), 137,91 (6), 129,77, 128,43 (8, 7, 10, 11), 126,68 (9), 54,62 (2), 47,86 (2''), 39,32 (5), 38,99 (3'), 32,70, 24,92, 24,87 (3'', 4'', 6'', 7''), 25,64 (5'').

N-Cikolheksanmetilamid-2-(N'-benziloksiureido)-L-3-fenilpropanske kiseline (6i)

Količine reaktanata: 0,405 g spoja **5e**, 0,191 g *O*-benzilhidroksilamin hidroklorida.

Trajanje reakcije: 4,5 h.

Temperatura reakcije: 70 ºC.

Sirovi produkt je pročišćen rastrljavanjem u eteru.

Iskorištenje: 0,243 g (59 %).

*t*ₜ 130–131 ºC.

IR (KBr): ν_max 3313, 3214, 3064, 3031, 2921, 2852, 1661, 1640, 1542, 1496, 1449, 1363, 1276, 1242, 1072, 948, 813, 748, 698, 632, 616 cm⁻¹.

¹H NMR (DMSO-*d*₆, δ ppm, *J*/Hz): 9,24 (s, 1H, 1'), 7,96 (t, 1H, 1'', *J* = 5,57 Hz), 7,39–7,19 (m, 10H, arom.), 6,56 (d, 1H, 3, *J* = 8,44 Hz), 4,65 (s, 1H, 3'), 4,43 (q, 1H, 2, *J* = 8,12, 5,89 Hz), 2,99–2,82 (m, 4H, 2'', 5), 1,66–0,81 (m, 11H, 3''–8'').

^{13}C NMR (DMSO-d_6, δ ppm): 170,38 (1), 158,12 (4), 136,98 (4'), 135,56 (6), 128,68, 128,08, 127,69, 127,43 (7, 8, 10, 11, 5', 6'. 8', 9'), 127,52, 125,67 (9, 7'), 76,78 (3'), 53,22 (2), 44,24 (2''), 37,81 (5), 36,74 (3''), 29,72, 24,82 (4'', 5'', 7'', 8''), 25,42 (6'').

N-Cikolheksanmetilamid-2-(*N'*-metil-*N'*-hidroksiureido)-L-3-fenilpropanske kiseline(6j)

Količine reaktanata: 0,405 g spoja **5e**, 0,100 g *N*-metilhidroksilamin hidroklorida.

Trajanje reakcije: 2 h.

Temperatura reakcije: 40 ºC.

Sirovi produkt je pročišćen rastrljavanjem u eteru.

Iskorištenje: 0,268 g (80 %).

t_t 157–159 ºC.

IR (KBr): ν_{max} 3371, 3329, 3194, 2924, 2853, 1658, 1642, 1580, 1528, 1495, 1445, 1190, 1123, 746, 700, 669 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,48 (s, 1H, 2'), 7,93 (t, 1H, 1'', J = 5,21 Hz), 7,29–7,16 (m, 5H, arom.), 6,63 (d, 1H, 3, J = 8,54 Hz), 4,38 (q, 1H, 2, J = 7,32 Hz), 2,97–2,75 (m, 7H, 5, 2''), 2,91 (s, 3H, 3'), 1,69–0,76 (m, 11H, 3''–8'').

^{13}C NMR (DMSO-d_6, δ ppm): 171,48 (1), 160,64 (4), 138,03 (6), 129,68, 128,47 (7, 8, 10, 11), 126,67 (9), 54,88 (2), 45,26 (2''), 39,14 (5), 38,98 (3'), 37,77 (3''), 30,76, 25,87 (4'', 5'', 7'', 8''), 26,46 (6'').

N-Benzhidrilamid-2-(*N'*-benziloksiureido)-L-3-fenilpropanske kiseline (6k)

Količine reaktanata: 0,476 g spoja **5f**, 0,191 g *O*-benzilhidroksilamin hidroklorida.

Trajanje reakcije: 52,5 h.

Temperatura: 70 ºC.

Sirovi produkt je pročišćen rastrljavanjem u eteru.

Iskorištenje: 0,185 g (39 %).

t_t 161–164 ºC.

IR (KBr): ν_{max} 3288, 3062, 3030, 1649, 1535, 1495, 1454, 1229, 1030, 910, 750, 698 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,17 (s, 1H, 1'), 8,89 (d, 1H, 1'', J = 8,47 Hz), 7,32–7,11 (m, 20H, arom.), 6,54 (d, 1H, 3, J = 8,74 Hz), 6,03 (d, 1H, 2'', J = 8,34 Hz), 4,54 (q+s, 3H, 2, 3''), 2,93–2,84 (m, 2H, 5).

^{13}C NMR (DMSO-d_6, δ ppm): 170,55 (1), 158,75 (4), 142,15, 142,14 (3'', 9''), 137,41 (6), 136,10 (4'), 129,31, 128,62, 128,34, 128,25, 128,00, 127,39, 127,14 (7, 8, 10, 11, 4'', 5'', 7'',

8″, 10″, 11″, 13″, 14″), 128,07, 127,00, 126,91, 126,28 (9, 6″, 12″), 77,34 (5), 55,96, 53,75 (2, 2″), 38,16 (3′).

_N_-Benzhidrilamid-2-(_N'_-metil-_N'_-hidroksiureido)-L-3-fenilpropanske kiseline (6l)

Količine reaktanata: 0,476 g spoja **5f**, 0,100 g _N_-metilhidroksilamin hidroklorida.

Temperatura: s.t.

Trajanje reakcije: 72 h.

Sirovi produkt je pročišćen rastrljavanjem u eteru.

Iskorištenje: 0,179 g (44 %).

t_t 152–154 ºC (raspad).

IR (KBr): ν_{max} 3432, 3347, 3062, 3030, 2867, 1664, 1629, 1536, 1496, 1450, 1384, 1230, 1179, 1117, 1030, 744, 700 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,52 (s, 1H, 2′), 8,96 (d, 1H, 1″, J = 8,32 Hz), 7,37–7,15 (m, 15H, arom.), 6,69 (d, 1H, 3, J = 8,32 Hz), 6,09 (d, 1H, 2″, J = 8,32 Hz), 4,60 (q, 1H, 2, J = 6,93 Hz), 2,95–2,91 (m, 2H, 5), 2,91 (s, 3H, 3′).

^{13}C NMR (DMSO-d_6, δ ppm): 171,10 (1), 160,71 (4), 142,70, 142,63 (3″, 9″), 137,91 (6), 129,78, 128,84, 128,78, 128,51, 127,89, 127,61 (7, 8, 10, 11, 4″, 5″, 7″, 8″, 10″, 11″, 13″, 14″), 127,51, 127,39, 126,73 (9, 6″, 12″), 56,37, 54,87 (2, 2″), 38,98 (3′).

2.1.8. Sinteza 1-karbamoilbenzotriazola (amida 1-benzotriazolkarboksilne kiseline) 7a-g

Metoda A. U otopinu BtcCl (**1**) (1,810 g, 10 mmol) u bezvodnom toluenu dokapana je otopina TEA (1,394mL, 10 mmol) i odgovarajućeg amina (10 mmol) u toluenu tijekom 0,25 h. Nakon dokapavanja reakcijska smjesa miješana je 1 h na sobnoj temperaturi. Reakcijska smjesa uparena je pod sniženim tlakom, zatim je otopljena u smjesi etil-acetata i vode (1:1, 30 mL). Organski sloj ekstrahiran je vodom (3×30 mL), osušen nad bezvodnim natrijevim sulfatom, profiltriran i uparen pod sniženim tlakom. Dobiveni sirovi 1-karbamoilbenzotriazoli **7a-f** pročišćeni su prekristalizacijom iz etera/petroletera (**7a**), metanola i vode (**7b-d**, **7f**) ili acetona i vode (**7e**). IR spektri i tališta spojeva **7b** i **7e** u potpunosti odgovaraju ranije sintetiziranim spojevima (Butula *et al*, 1977, Butula *et al*, 1978).

1-(*N*-Ciklopentilkarbamoil)benzotriazol (7a)

Metoda A. Količina reaktanta: 0,852 g ciklopentilamina.

Iskorištenje: 1,428 g (62 %).

t_t 67–68 ºC.

IR (KBr): ν_{max} 3255, 2949, 2866, 1736, 1523, 1487, 1448, 1371, 1287, 1233, 1185, 1130, 1073, 1000, 944, 925, 815, 747, 652 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, *J*/Hz): 9,09 (d, 1H, 1', *J* = 6,62 Hz), 8,19 (d, 2H, arom., *J* = 8,27 Hz), 7,71, 7,54 (2t, 2H, arom., *J* = 7,72 Hz, *J* = 6,62 Hz), 4,29–4,22 (m, 1H, 2'), 1,97–1,56 (m, 8H, 3'–6').

^{13}C NMR (DMSO-d_6, δ ppm): 148,98 (1), 145,87, 131,85 (2, 7), 130,24, 125,90, 120,16, 114,11 (3–6), 52,55 (2'), 32,18, 24,01 (3'–6').

1-(*N*-Cikloheksilkarbamoil)benzotriazol (7b)

Metoda A. Količina reaktanta: 0,992 g cikloheksilamina.

Iskorištenje: 1,710 g (70 %).

t_t 73–74 °C (Butula *et al*, 1977).

IR (KBr): ν_{max} 3327, 2938, 2856, 1733, 1517, 1488, 1447, 1360, 1285, 1226, 1151, 1090, 1059, 1002, 968, 928, 835, 791, 755, 612 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, *J*/Hz): 8,98 (d, 1H, 1', *J* = 8,18 Hz), 8,19 (d, 2H, arom., *J* = 9,20 Hz), 7,71, 7,54 (2t, 2H, arom., *J* = 7,67 Hz), 3,81–3,73 (m, 1H, 2'), 1,93–1,11 (m, 10H, 3'–7').

^{13}C NMR (DMSO-d_6, δ ppm): 148,61 (1), 145,91, 131,89 (2, 7), 130,24, 125,94, 120,17, 114,05 (3–6), 50,34 (2'), 32,41, 25,35 (3', 4', 6', 7'), 25,46 (5').

1-(*N*-Cikloheksanmetilkarbamoil)benzotriazol (7c)

Metoda A. Količina reaktanta: 1,132 g cikloheksanmetilamina.

Iskorištenje: 2,531 g (98 %).

t_t 66–68 °C.

IR (KBr): ν_{max} 3360, 2925, 2852, 1739, 1527, 1488, 1448, 1364, 1286, 1232, 1152, 1072, 1011, 954, 786, 771, 753, 593 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, *J*/Hz): 9,18 (t, 1H, 1', *J* = 5,62 Hz), 8,20 (d, 2H, arom., *J* = 9,20 Hz), 7,71, 7,54 (2t, 2H, arom., *J* = 7,67 Hz), 3,23 (t, 2H, 2', *J* = 6,14 Hz), 1,77–1,58, 1,27–0,93 (2m, 11H, 3'–8').

^{13}C NMR (DMSO-d_6, δ ppm): 149,54 (1), 145,94, 131,83 (2, 7), 130,28, 125,90, 120,18, 114,05 (3–6), 40,60 (2'), 37,77 (3'), 30,76, 25,78 (4', 5', 7', 8'), 25,86 (6').

1-(*N*-Benzilkarbamoil)benzotriazol (7d)

Metoda A. Količina reaktanta: 1,072 g benzilamina.

Iskorištenje: 1,867 g (74 %).

t_t 110 °C.

IR (KBr): ν_{max} 3362, 1733, 1526, 1486, 1447, 1358, 1288, 1256, 1231, 1130, 1076, 1002, 793, 752, 696, 609, 580, 562 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,78 (t, 1H, 1', J = 5,81 Hz), 8,20 (d, 2H, arom., J = 8,72 Hz), 7,72, 7,55 (2t, 2H, arom., J = 7,89 Hz), 7,45–7,25 (m, arom., 5H), 4,59 (d, 2H, 2', J = 6,23 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 149,67 (1), 145,96, 131,84 (2, 7), 139,10 (3'), 130,39, 125,98, 120,24, 114,02 (3–6), 128,84, 127,88 (4', 5', 7', 8'), 127,54 (6'), 43,94 (2').

1-(*N*-Feniletilkarbamoil)benzotriazol (7e)

Metoda A. Količina reaktanta: 1,212 g feniletilamina.

Iskorištenje: 2,157 g (74 %).

t_t 114–115 °C (lit. 115–117 °C, Butula *et al*, 1978).

IR (KBr): ν_{max} 3369, 3024, 2949, 1736, 1530, 1497, 1447, 1363, 1288, 1231, 1128, 1097, 1034, 1002, 920, 840, 749, 699, 588, 563 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,27 (t, 1H, 1', J = 6,06 Hz), 8,21 (d, 2H, arom., J = 8,48 Hz), 7,71, 7,54 (2t, 2H, arom., J = 7,27 Hz), 7,34–7,19 (m, arom., 5H), 3,63 (q, 2H, 2', J = 6,67 Hz), 2,98 (t, 2H, 3', J = 7,88 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 149,37 (1), 145,92, 131,78 (2, 7), 139,42 (4'), 130,34, 125,94, 120,20, 114,01 (3–6), 129,15, 128,85 (5', 6', 8', 9'), 126,69 (7'), 41,96, 35,36 (2', 3').

1-(*N*-Benzhidrilkarbamoil)benzotriazol (7f)

Metoda A. Količina reaktanta: 1,833 g benzhidrilamina.

Iskorištenje: 2,135 g (65 %).

t_t 119–122 °C.

IR (KBr): ν_{max} 3288, 3028, 2931, 1707, 1520, 1449, 1375, 1293, 1231, 1069, 1031, 931, 864, 752, 695, 644, 607, 535 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 10,00 (d, 1H, 1', J = 8,57 Hz), 8,21, 8,17 (2d, 2H, arom., J = 8,04 Hz), 7,74–7,28 (m, 12H, arom.), 6,40 (d, 1H, 2', J = 9,11 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 149,16 (1), 145,93, 131,95 (2, 7), 141,62 (3', 9'), 130,42, 126,08, 120,27, 113,96 (3–6), 128,87, 128,23 (4', 5', 7', 8', 10', 11', 13', 14'), 127,82 (6', 12'), 58,37 (2').

1-(*N*-Benziloksikarbamoil)benzotriazol (7g)

Metoda B. Otopina BtcCl (**1**) (1,810 g, 10 mmol) u bezvodnom dioksanu dokapana je u suspenziju *O*-benzilhidroksilamin hidroklorida (1,596 g, 10 mmol) i TEA (2,788 mL, 20 mmol) u dioksanu tijekom 0,25 h. Nakon dokapavanja reakcijska smjesa miješana je 2 h na sobnoj temperaturi. Talog TEA hidroklorida je odsisan a matičnica je uparena pod sniženim tlakom. Dobiven sirovi produkt **7g** je prekristailziran iz smjese etil-acetat/eter. IR spektar i talište spoja **7g** u potpunosti odgovara ranije sintetiziranom spoju (Butula *et al*, 2000).

Iskorištenje: 2,254 g (84 %).

t_t 113–114 °C (Butula *et al*, 2000).

IR (KBr): ν_{max} 3246, 3133, 3030, 2947, 2884, 1728, 1603, 1484, 1367, 1289, 1231, 1132, 1093, 1003, 924, 869, 751, 699, 563 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,95 (s, 1H, 1'), 8,27, 8,09 (2d, 2H, J = 8,20 Hz, 8,50 Hz), 7,67, (t, 2H, arom., J = 7,7 Hz), 7,48–7,34 (m, arom., 5H), 5,14 (s, 2H, 2').

^{13}C NMR (DMSO-d_6, δ ppm): 148,68 (1), 145,72, 131,54 (2, 7), 134,46 (3'), 130,23, 125,66, 120,07, 113,49 (3–6), 129,28, 128,63 (4', 5', 7', 8'), 126,97 (6'), 79,24 (2').

2.1.9. Sinteza 4-benziloksisemikarbazida (8)

U otopinu hidrazin hidrata (0,534 mL, 11 mmol) u dioksanu dokapana je otopina 1-(*N*-benziloksikarbamoil)benzotriazola (**7g**) (2,683 g, 10 mmol) u dioksanu tijekom 0,25 h. Reakcijska smjesa je miješana 1 h na s.t. i zatim uparena. Sirovi produkt **8** kromatografiran je na koloni, uz pokretnu fazu diklorometan/metanol 9,5:0,5 te je rastrljan u eteru.

Iskorištenje: 1,486 g (82 %).

t_t 90–92 °C.

IR (KBr): ν_{max} 3332, 3287, 3217, 3061, 3030, 2962, 2925, 2875, 1655, 1637, 1517, 1456, 1366, 1325, 1228, 1210, 1192, 1096, 1070, 980, 915, 797, 751, 702, 680, 607 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,18 (s, 1H, 4), 7,84 (s, 1H, 2), 7,42–7,29 (m, 5H, arom.), 4,71 (s, 2H, 5), 4,01 (s, 2H, 1).

^{13}C NMR (DMSO-d_6, δ ppm): 161,67 (3), 137,18 (6), 129,08, 128,63 (7, 8, 10, 11), 128,37 (9), 77,70 (5).

2.1.10. Sinteza 1-(1-benzotriazolkarbonil)-4-benziloksisemikarbazida (9)

U otopinu BtcCl (**1**) (1,357 g, 8 mmol) u bezvodnom dioksanu dokapana je otopina 4-benziloksisemikarbazida **8** (1,450 g, 8 mmol) i TEA (1,115 mL, 8 mmol) u bezvodnom dioksanu tijekom 0,25 h. Reakcijska smjesa miješana je na sobnoj temperaturi 1 h, zatim uparena je pod sniženim tlakom te otopljena u smjesi etil-acetata i vode (1:1, 40 mL). Organski sloj ekstrahiran je vodom (3×40 mL), osušen nad bezvodnim natrijevim sulfatom, profiltriran i uparen pod sniženim tlakom. Sirovi produkt **9** pročišćen je prekristalizacijom iz etera.

Iskorištenje: 1,906 g (73 %).

t_t 90–93 °C (raspad).

IR (KBr): ν_{max} 3482, 3376, 3340, 3164, 3005, 2924, 2854, 1738, 1674, 1556, 1487, 1449, 1387, 1287, 1235, 1066, 1033, 905, 754, 744, 704, 680, 652, 609, 580, 539 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 10,97, 9,87, 9,31 (3s, 3H, 1, 2, 4), 8,26–8,18 (2d, 2H, arom.), 7,77, 7,59 (2t, 2H, arom.), 7,49–7,35 (m, 5H, arom., 7–11), 4,85 (s, 2H, 5).

^{13}C NMR (DMSO-d_6, δ ppm): 159,37 (3), 149,86 (1'), 145,66, 131,92 (2', 7'), 136,74 (6), 130,78, 126,31, 120,42, 113,79 (3'–6'), 129,20, 128,68 (7, 8, 10, 11), 128,54 (9), 78,11 (5).

2.1.11. Sinteza NSAID benzotriazolida 10a-d. Opća metoda

U otopinu odgovarajućeg NSAID (ibuprofena, fenoprofena, ketoprofena i reduciranog derivata ketoprofena) (10 mmol) i TEA (1,393 mL, 10 mmol) u bezvodnom toluenu (30 mL) dokapana je otopina BtcCl (**1**) (1,696 g, 10 mmol) u bezvodnom toluenu (30 mL) tijekom 0,25 h. Reakcijska smjesa miješana je na sobnoj temperaturi 2 h, a zatim ekstrahirana vodom (3×60 mL). Organski sloj sušen je nad bezvodnim natrijevim sulfatom, profiltriran i uparen pod sniženim tlakom. Dobiveni sirovi benzotriazolid je zatim prekristaliziran iz smjese acetona i vode (**10a,b**) ili rastrljan eterom (**10c,d**). Tališta spojeva **10a-d** i njihovi

spektroskopski podaci u potpunosti odgovaraju ranije sintetiziranim spojevima (Rajić *et al*, 2010; Zorc *et al*, 1994; Zorc *et al*,1993).

2.1.12. Sinteza hidrazida NSAID 11a-c. Opća metoda

Otopina odgovarajućeg NSAID benzotriazolida **10a-c** (10 mmol) u dioksanu dokapana je otopini hidrazin hidrata (50 mmol) u dioksanu tijekom 0,25 h. Reakcijska smjesa miješana je na sobnoj temperaturi 1 h, uparena pod sniženim tlakom i otopljena u etil-acetatu (30 mL). Organski sloj ekstrahiran je zaluženom vodom (3×30 mL, 10 kapi 5 % NaOH) i vodom (1×30 mL), osušen nad bezvodnim natrijevim sulfatom, profiltriran i uparen pod sniženim tlakom. Produkti **11a-c** prekristalizirani su iz etera/petroletera (**11a,c**) ili pročišćeni kromatografijom na koloni (**11b**).

2-(4-Izobutilfenil)propanhidrazid (11a)

Količina reaktanta: 3,074 g spoja **10a**. Sirovi produkt **11a** pročišćen je prekristalizacijom iz etera/petroletera.

Iskorištenje: 1,96 g (89 %).

t_t 80 ºC (lit. 73–75 ºC, Sharma *et al*, 2003).

IR (KBr): ν_{max} 3276, 3180, 3052, 2954, 2919, 1688, 1641, 1535, 1510, 1452, 1416, 1358, 1257, 1237, 1124, 1074, 1007, 965, 848, 800, 786, 731, 690, 521 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,12 (s, 1H, 2), 7,12 (dd, 4H, arom., J = 8,32 Hz, 38,27 Hz), 4,15 (s, 2H, 1), 3,46 (q, 1H, 4, J = 6,96 Hz), 2,38 (d, 2H, 12, J = 6,96 Hz), 1,82–1,73 (m, 1H, 13), 1,30 (d, 3H, 5, J = 6,96 Hz), 0,83 (d, 6H, 14,15, J = 6,65 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,37 (3), 139,78, 139,70 (6, 9), 129,15, 127,44 (7, 8, 10, 11), 44,70 (12), 43,37 (4), 30,09 (13), 22,63 (14, 15), 18,82 (5).

2-(3-Fenoksifenil)propanhidrazid (11b)

Količina reaktanta: 3,434 g spoja **10b**. Sirovi produkt **11b** pročišćen je kromatografijom na koloni uz pokretnu fazu diklormetan/metanol 9,5:0,5.

Iskorištenje: 2,307 g (90 %).

Ulje.

IR (KBr): ν_{max} 3285, 3040, 2978, 1659, 1631, 1582, 1487, 1445, 1244, 1210, 1164, 963, 928, 757, 692 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,19 (s, 1H, 2), 7,43–6,82 (m, 9H, arom.), 4,25 (s, 2H, 1), 3,53 (q, 1H, 4, J = 6,99 Hz), 1,32 (d, 3H, 5, J = 7,14 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 172,87 (3), 157,01, 156,92, 144,73 (6, 10, 12), 130,50, 119,04 (13, 14, 16, 17), 130,15, 123,88, 122,86, 118,06, 117,02 (7–9, 11, 15), 43,58 (4), 18,76 (5).

2-(3-Benzilfenil)propanhidrazid (11c)

Količina reaktanta: 3,554 g spoja **10c**. Sirovi produkt **11c** pročišćen je prekristalizacijom iz etera/petroletera.

Iskorištenje: 2,0 g (78 %).

t_t 80–82 ºC.

IR (KBr): ν_{max} 3289, 3191, 3168, 3063, 3023, 2975, 2919, 1637, 1601, 1534, 1486, 1453, 1382, 1261, 1008, 976, 786, 759, 722, 696, 685, 599 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,14 (s, 1H, 2), 7,31–7,03 (m, 9H, arom.), 4,17 (s, 2H, 1), 3,90 (s, 2H, 12), 3,48 (q, 1H, 4, J = 6,91 Hz), 1,33 (d, 3H, 5, J = 7,27 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,19 (3), 142,66, 141,65, 141,47 (6, 10, 13), 129,14, 128,88 (13, 14, 16, 17), 128,69, 128,15, 127,38, 126,42, 125,44 (7–9, 11, 15), 43,72 (4), 41,64 (12), 18,88 (5).

2.1.13. Sinteza estera ketoprofena i ureidoamida 12a-d. Opća metoda

Benzotriazolid ketoprofena (**10d**) (0,341 g, 1 mmol), odgovarajući ureidoamid **4b,i,j,m** (0,5 mmol) i TEA (0,279 mL, 2 mmol) pomiješani su i zagrijani na temperaturu taljenja reakcijske smjese. Reakcijska smjesa je miješana na toj temperaturi 0,25 h, ohlađena i otopljena u etil-acetatu (30 mL). Organski sloj ekstrahiran je zalužеnom vodom (3×30 mL, 10 kapi 5 % NaOH) i vodom (1×30 mL), osušen nad bezvodnim natrijevim sulfatom, profiltriran i uparen pod sniženim tlakom. Produkti **12a-d** su pročišćeni kromatografijom na koloni uz pokretnu fazu diklormetan/metanol 9,5:0,5 (**12a,b**) ili etil-acetat/petroleter/metanol 3:1:0,1 (**12c,d**).

15-(3-Benzoilfenil)-6-metil-5,8,14-triokso-13-oksa-4,7,9-triazaheksadecil-2-(3-benzoil-fenil)propanoat (12a)

Količina reaktanta: 0,124 g spoja **4b**.

Temperatura reakcije: 125 °C.

Iskorištenje: 0,295 g (82 %).

Ulje.

IR (KBr): ν_{max} 3302, 3065, 2927, 2869, 1731, 1659, 1635, 1569, 1556, 1449, 1380, 1318, 1284, 1250, 1206, 1173, 1079, 960, 719, 644 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,91 (t, 1H, 1'(amid), J = 5,62 Hz), 7,74–7,50 (m, 18H, arom.), 6,08 (t, 1H, 1'(urea), J = 5,62 Hz), 6,01 (d, 1H, 3, J = 7,79 Hz), 4,10–3,90 (m, 7H, 2, 4', 2"), 3,08–2,93 (m, 4H, 2'), 1,70–1,59 (m, 4H, 3'), 1,43 (d, 6H, 3", J = 7,07 Hz), 1,11 (d, 3H, 5, J = 6,89 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 196,07 (10"), 174,00, 173,95 (1"), 173,60 (1), 157,72 (4), 141,58, 137,65, 137,41 (4", 8", 11"), 133,20, 132,22, 129,30, 128,95, 128,90, (5"–7", 9", 14"), 130,05, 129,04 (12", 13", 15", 16"), 62,82, 62,73 (4'), 49,01 (2), 44,71 (2"), 36,23, 35,57 (2'), 29,61, 28,70 (3'), 20,19 (5), 18,91 (3").

2-(3-Benzoilfenil)-12-izobutil-3,11,14-triokso-4-oksa-10,13,15-triazaikozan-20-il-2-(3--benzoilfenil)propanoat (12b)

Količina reaktanta: 0,173 g spoja **4i**.

Temperatura reakcije: 100 °C.

Iskorištenje: 0,299 g (73 %).

Ulje.

IR (KBr): ν_{max} 3291, 3064, 2932, 2869, 1732, 1659, 1633, 1566, 1556, 1448, 1378, 1318, 1283, 1206, 1176, 1077, 954, 721, 706, 643 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 7,87 (t, 1H, 1'(amid), J = 5,50 Hz), 7,73–7,50 (m, 18H, arom.), 5,92 (t, 1H, 1'(urea), J = 5,50 Hz), 5,87 (d, 1H, 3, J = 8,84 Hz), 4,13–3,89 (m, 7H, 2, 6', 2"), 3,02–2,86 (m, 4H, 2'), 1,54–1,13 (m, 21H, 5, 6, 3'–5', 3"), 0,84 (2d, 6H, 7, 8, J = 5,85 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 196,04 (10"), 173,95 (1"), 173,30 (1), 157,95 (4), 141,62, 137,63, 137,41 (4", 8", 11"), 133,21, 132,20, 129,36, 128,92, (5"–7", 9", 14"), 130,03, 129,04 (12", 13", 15", 16"), 64,75 (6'), 51,89 (2), 44,75 (2"), 43,00 (5), 39,43, 38,56 (2'), 29,95, 28,95, 28,18, 28,09, 23,05, 23,00 (3'–5'), 24,73, 23,38, 22,54 (6–8), 18,82 (3").

13-(3-Benzoilfenil)-4,7,12-triokso-5-fenil-11-oksa-3,6,8-triazatetradecil 2-(3-benzoil-fenil)propanoat (12c)

Količina reaktanta: 0,141 g spoja **4j**.

Temperatura reakcije: 115 °C.

Iskorištenje: 0,245 g (65 %).

Ulje.

IR (KBr): ν_{max} 3296, 3064, 2980, 1735, 1633, 1564, 1449, 1374, 1284, 1172, 1077, 698, 643 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 8,47 (t, 1H, 1'(amid), J = 4,34 Hz), 7,75–7,49 (m, 18H, arom.), 7,37–7,22 (m, 5H, arom.), 6,84 (d, 1H, 3, J = 8,31 Hz), 6,36 (t, 1H, 1'(urea), J = 5,54 Hz), 5,32 (d, 1H, 2, J = 8,01 Hz), 4,10–3,78 (m, 6H, 3', 2"), 3,32–3,21 (m, 4H, 2'), 1,43, 1,37 (2d, 6H, 3", J = 7,32 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 196,04 (10"), 173,93, 173,85 (1"), 171,40 (1), 157,44 (4), 141,47, 141,39, 140,72, 140,70, 140,66, 137,62, 137,39 (5, 4", 8", 11",), 133,20, 132,31, 132,27, 129,28, 128,94, (5"–7", 9", 14"), 130,08, 129,04 (12", 13", 15", 16"), 127,64, 127,01 (6, 7, 9, 10), 127,68 (8), 64,59, 63,32 (3'), 56,97 (2), 44,75, 44,68 (2"), 38,59, 38,03 (2'), 18,99, 18,89 (3").

13-(3-Benzoilfenil)-5-benzil-4,7,12-triokso-11-oksa-3,6,8-triazatetradecil 2-(3-benzoil-fenil)propanoat (12d)

Količina reaktanta: 0,148 g spoja **4m**.

Temperatura reakcije: 115 °C.

Iskorištenje: 0,303 g (79 %).

Ulje.

IR (KBr): ν_{max} 3302, 3063, 2979, 2938, 1732, 1663, 1646, 1569, 1554, 1451, 1380, 1284, 1205, 1177, 1078, 956, 823, 722, 644 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 8,14 (t, 1H, 1'(amid), J = 5,25 Hz), 7,74–7,48 (m, 18H, arom.), 7,22–7,09 (m, 5H, arom.), 6,22–6,18 (d+t, 2H, 3, 1' (urea)), 4,36 (q, 1H, 2, J = 6,44 Hz), 4,07–3,88 (m, 6H, 3', 2"), 3,31–3,14 (m, 4H, 5, 2'), 2,88–2,66 (m, 2H, 2'), 1,44–1,41 (m, 6H, 3").

^{13}C NMR (DMSO-d_6, δ ppm): 196,04, 196,01 (10"), 173,93 (1"), 172,59 (1), 157,73 (4), 141,48, 141,46, 138,17, 138,14, 137,62, 137,61, 137,39 (6, 4", 8", 11"), 133,20, 132,30, 129,29, 128,96 (5"–7", 9", 14"), 130,07, 129,03 (12", 13", 15", 16"), 129,67, 128,39 (7, 8, 10, 11), 126,59 (9), 64,54 63,54, 63,40 (3'), 54,69 (2), 44,74 (2"), 39,34 (5), 38,55, 37,90 (2'), 19,00 (3").

2.1.14. Sinteza 1-acil-4-cikloalkil, 1-acil-4-aril i 1-acil-4-hidroksisemikarbazida NSAID 13a-y

Metoda A. Odgovarajući 1-karbamoilbenzotriazol (**7a-f**, 1 mmol), hidrazid NSAID-a **11a-c** (1 mmol) i TEA (0,418 mL, 3 mmol) rastaljeni su na temperaturi 75-120 °C. Reakcijska smjesa miješana je na toj temperaturi 0,25 h, ohlađena i otopljena u etil-acetatu (20 mL). Organski sloj ekstrahiran je zaluženom vodom (3×20 mL, 10 kapi 5 % NaOH) i vodom (1×20 mL), osušen nad bezvodnim natrijevim sulfatom, profiltriran i uparen pod sniženim tlakom.

Metoda B. Odgovarajući 1-karbamoilbenzotriazol **7a-f** (1 mmol), hidrazid NSAID-a **11a-c** (1 mmol) i TEA (0,418 mL, 3 mmol) rastaljeni su na temperaturi 75–120 °C. Reakcijska smjesa miješana je na toj temperaturi 0,25 h te ohlađena. Nastali talog rastrljan je u smjesi acetona i zakiseljene vode (pH = 1) i odsisan.

Sirovi produkti **13a-s** pročišćeni su prekristalizacijom iz etera/petroletera.

Metoda C. 1-(*N*-Benziloksikarbamoil)benzotriazol **7g** (0,268 g, 1 mmol) i odgovarajući hidrazid NSAID-a **11a-c** (1 mmol) otopljeni su u dioksanu i miješani 6-8 h na 55 °C. Reakcijska smjesa je uparena pod sniženim tlakom i otopljena u etil-acetatu. Organski sloj ekstrahiran je zaluženom vodom (3×20 mL, 6 kapi 5 % NaOH) i vodom (1×20 mL), osušen nad bezvodnim natrijevim sulfatom, profiltriran i uparen pod sniženim tlakom. Sirovi produkti **13t-v** su prekristalizirani iz acetona/ petroletera (**13t**), etera/petroletera (**13v**) ili pročišćeni kromatografijom na koloni (**13u**).

Metoda D. Suspenzija *O*-benzilnog derivata (**13t-v**, 0,5 mmol) i 50 mg 10 %-tnog Pd/C u metanolu (10 mL) hidrogenirana je pod atmosferskim tlakom vodika na sobnoj temperaturi tijekom 1,5 h. Katalizator je odfiltriran, a otapalo upareno pod sniženim tlakom. Sirovi produkti su pročišćeni prekristalizacijom iz etera/petroletera (**13w**) ili rastrljavanjem u eteru (**13x**, **13y**).

4-Ciklopentil-1-[2-(4-izobutilfenil)propanoil]semikarbazid (13a)
Metoda A. Količine reaktanata: 0,230 g spoja **7a**, 0,220 g spoja **11a**.
Temperatura reakcije: 75 °C.

Iskorištenje: 0,212 g (64 %).

t_t 123–128 °C.

IR (KBr): ν_{max} 3355, 3254, 2956, 2871, 1684, 1650, 1557, 1513, 1465, 1315, 1243, 1151, 1079, 1008, 937, 850, 786, 655 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,63, 7,59, (2s, 2H, 1, 2), 7,15 (dd, 4H, arom, J = 7,55 Hz, 87,09 Hz), 6,50 (bs, 1H, 2'), 3,84–3,80 (m, 1H, 3'), 3,59 (q, 1H, 4, J = 7,02 Hz), 2,40 (d, 2H, 12, J = 7,17 Hz), 1,84–1,20 (m, 9H, 13, 4'–7'), 1,32 (d, 3H, 5, J = 7,02 Hz), 0,85 (d, 6H, 14,15, J = 6,58 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 175,27 (3), 159,64 (1'), 141,54, 141,08 (6, 9), 130,96, 129,18 (7, 8, 10, 11), 53,09 (3'), 46,42 (12), 44,76 (4), 34,86, 25,33 (4'–7'), 31,76 (13), 24,34 (14, 15), 20,37 (5).

4-Cikloheksil-1-[2-(4-izobutilfenil)propanoil]semikarbazid (13b)

Metoda A. Količine reaktanata: 0,244 g spoja **7b**, 0,220 g spoja **11a**.

Temperatura reakcije: 90 °C.

Iskorištenje: 0,276 g (80 %).

t_t 165–166 °C.

IR (KBr): ν_{max} 3307, 3253, 3019, 2986, 2951, 2930, 2852, 1708, 1683, 1641, 1562, 1531, 1506, 1453, 1322, 1253, 1226, 1153, 1079, 1056, 1023, 999, 936, 892, 850, 709, 634, 614 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,67, 7,64, (2d, 2H, 1, 2, J = 1,77 Hz), 7,15 (dd, 4H, arom., J = 7,76 Hz, 39,23 Hz), 5,71 (d, 1H, 2', J = 6,43 Hz), 3,59 (q, 1H, 4, J = 6,87 Hz), 3,39–3,28 (m, 2H, 3'), 2,40 (d, 2H, 12, J = 7,10 Hz), 1,84–1,75 (m, 1H, 13), 1,69–0,95 (m, 10H, 4'–8'), 1,32 (d, 3H, 5, J = 6,87 Hz), 0,85 (d, 6H, 14, 15, J = 6,65 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,56 (3), 157,60 (1'), 139,84, 139,36 (6, 9), 129,27, 127,47 (7, 8, 10, 11), 48,28 (3'), 44,70 (12), 43,03 (4), 33,42, 33,38, 24,90 (4', 5', 7', 8'), 30,09 (13), 25,65 (6'), 22,64 (14, 15), 18,64 (5).

4-Cikloheksilmetil-1-[2-(4-izobutilfenil)propanoil]semikarbazid (13c)

Metoda B. Količine reaktanata: 0,258 g spoja **7c**, spoja **11a**.

Temperatura reakcije: 75 °C.

Iskorištenje: 0,338 g (94 %).

t_t 172–174 °C.

IR (KBr): ν_{max} 3339, 3236, 3122, 2952, 2926, 2849, 1699, 1615, 1565, 1476, 1448, 1368, 1263, 1247, 1175, 1084, 1019, 854, 780, 651, 618 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,65 7,66 (2s, 2H, 1, 2), 7,15 (dd, 4H, arom., J = 7,74 Hz, 40,61 Hz), 5,99 (t, 1H, 2', J = 4,78 Hz), 3,59 (q, 1H, 4, J = 6,86 Hz), 2,82 (t, 2H, 3', J = 6,22 Hz), 2,40 (d, 2H, 12, J = 7,02 Hz), 1,84–1,75 (m, 1H, 13), 1,66–0,78 (m, 11H, 4'–9'), 1,33 (d, 3H, 5, J = 6,53 Hz), 0,85 (d, 6H, 14, 15, J = 5,87 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,66 (3), 158,47 (1'), 139,79, 139,35 (6, 9), 129,22, 127,50 (7, 8, 10, 11), 45,80 (3'), 44,71 (12), 43,06 (4), 38,37 (4'), 30,67, 30,65, 25,88 (5', 6', 8', 9'), 30,09 (13), 26,56 (7'), 22,64 (14, 15), 18,69 (5).

4-Benzil-1-[2-(4-izobutilfenil)propanoil]semikarbazid (13d)

Metoda B. Količine reaktanata: 0,252 g spoja **7d**, 0,220 g spoja **11a**.

Temperatura reakcije: 110 °C.

Iskorištenje: 0,293 g (83 %).

t_t 173–175 °C.

IR (KBr): ν_{max} 3316, 3222, 3123, 3028, 2954, 1654, 1611, 1566, 1469, 1454, 1364, 1236, 1171, 1077, 851, 749, 699, 668 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,70, 7,85 (2s, 2H, 1, 2), 7,32–7,05 (m, 9H, arom.), 6,70 (t, 1H, 2', J = 6,01 Hz), 4,22 (d, 2H, 3', J = 6,01 Hz), 3,59 (q, 1H, 4, J = 6,94 Hz), 2,39 (d, 2H, 12, J = 6,94 Hz), 1,83–1,74 (m, 1H, 13), 1,34 (d, 3H, 5, J = 6,94 Hz), 0,84 (d, 6H, 14, 15, J = 6,48 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,83 (3), 158,59 (1'), 140,90 (4'), 139,78, 139,34 (6, 9), 129,21, 128,58, 127,55, 127,35, (7, 8, 10, 11, 5', 6', 8', 9'), 127,00 (7'), 44,70 (12), 43,11 (4), 43,07 (3'), 30,08 (13), 22,64 (14, 15), 18,81 (5).

4-Feniletil-1-[2-(4-izobutilfenil)propanoil]semikarbazid (13e)

Metoda A. Količine reaktanata: 0,252 g spoja **7e**, 0,220 g spoja **11a**.

Temperatura reakcije: 115 °C.

Iskorištenje: 0,268 g (73 %).

t_t 173–175 °C.

IR (KBr): ν_{max} 3566, 3434, 3312, 3026, 2953, 2926, 2869, 1648, 1587, 1557, 1514, 1497, 1455, 1374, 1253, 1168, 1074, 1054, 999, 934, 853, 796, 746, 700, 547 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,66, 7,79 (2s, 2H, 1, 2), 7,38–7,00 (m, 9H, arom.), 6,15 (t, 1H, 2', J = 5,52 Hz), 3,59 (q, 1H, 4, J = 6,81 Hz), 3,22 (q, 2H, 3', J = 6,49 Hz), 2,67 (t, 2H, 4', J = 7,14 Hz), 2,40 (d, 2H, 12, J = 6,81 Hz), 1,85–1,76 (m, 1H, 13), 1,34 (d, 3H, 5, J = 7,14 Hz), 0,86 (d, 6H, 14, 15, J = 6,49 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,72 (3), 158,36 (1'), 139,99, 139,79, 139,33 (6, 9, 5'), 129,21, 129,10, 128,78, 127,54, (7, 8, 10, 11, 6', 7', 9', 10'), 126,48 (8'), 44,70 (12), 43,06 (4), 41,32 (3'), 36,38 (4'), 30,08 (13), 22,64 (14, 15), 18,78 (5).

4-Benzhidril-1-[2-(4-izobutilfenil)propanoil]semikarbazid (13f)

Metoda A. Količine reaktanata: 0,328 g spoja **7f**, 0,220 g spoja **11a**.

Temperatura reakcije: 120 °C.

Iskorištenje: 0,314 g (73 %).

t_t 151–154 °C.

IR (KBr): ν_{max} 3343, 3202, 3028, 2953, 2869, 1647, 1616, 1538, 1495, 1456, 1366, 1268, 1230, 1168, 1077, 1052, 1028, 1004, 942, 848, 746, 700, 669, 631 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,76, 7,84 (2s, 2H, 1, 2), 7,34–7,05 (m, 14H, arom.), 6,95 (bs, 1H, 2'), 5,91 (d, 1H, 3', J = 8,38 Hz), 3,58 (q, 1H, 4, J = 6,85 Hz), 2,39 (d, 2H, 12, J = 7,11 Hz), 1,83–1,74 (m, 1H, 13), 1,33 (d, 3H, 5, J = 6,85 Hz), 0,84 (d, 6H, 14, 15, J = 6,60 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,70 (3), 157,58 (1'), 143,51, 143,46 (4', 10'), 139,83, 139,26 (6, 9), 129,25, 128,81, 128,79, 127,49, 127,47, 127,44 (7, 8, 10, 11, 5', 6', 8', 9', 11', 12', 14', 15'), 127,35, 127,31 (7', 13'), 57,14 (3'), 44,71 (12), 43,05 (4), 30,06 (13), 22,65 (14, 15), 18,78 (5).

4-Ciklopentil-1-[2-(3-fenoksifenil)propanoil]semikarbazid (13g)

Metoda A. Količine reaktanata: 0,230 g spoja **7a**, 0,256 g spoja **11b**.

Temperatura reakcije: 90 °C.

Iskorištenje: 0,293 g (80 %).

t_t 133–135 °C.

IR (KBr): ν_{max} 3414, 3281, 3237, 3101, 3025, 2961, 2910, 2869, 1696, 1627, 1638, 1582, 1556, 1532, 1489, 1455, 1443, 1311, 1244, 1213, 1162, 1146,1131, 1073, 942, 913, 880, 774, 760, 691, 618 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,69, 7,63 (2s, 2H, 1, 2), 7,42–6,82 (m, 9H, arom.), 5,94 (d, 1H, 2', J = 6,73 Hz), 3,89–3,78 (m, 2H, 3'), 3,63 (q, 1H, 4, J = 6,73 Hz), 1,79–1,22 (m, 8H, 4'–7'), 1,32 (d, 3H, 5, J = 6,73 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,08 (3), 157,89 (1'), 156,99, 156,94, 144,29 (6, 10, 12), 130,49, 119,01 (13, 14, 16, 17), 130,23, 123,87 , 122,93, 118,17, 117,12 (7–9, 11, 15), 51,40 (3'), 43,25 (4), 33,13, 24,91 (4'–7'), 18,66 (5).

4-Cikloheksil-1-[2-(3-fenoksifenil)propanoil]semikarbazid (13h)

Metoda A. Količine reaktanata: 0,244 g spoja **7b**, 0,256 g spoja **11b**.

Temperatura reakcije: 90 °C.

Iskorištenje: 0,229 g (60 %).

t_t 144–146 °C.

IR (KBr): ν_{max} 3343, 3215, 2933, 2853, 1695, 1618, 1580, 1555, 1490, 1472, 1448, 1314, 1273, 1235, 1213, 1166, 1074, 1062, 1025, 944, 887, 748, 689, 640 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,70, 7,66 (2s, 2H, 1, 2), 7,42–6,83 (m, 9H, arom.), 5,84 (d, 1H, 2', J = 7,00 Hz), 3,63 (q, 1H, 4, J = 6,73 Hz), 3,39–3,33 (m, 2H, 3'), 1,71–1,00 (m, 10H, 4'–8'), 1,33 (d, 3H, 5, J = 7,00 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,08 (3), 157,55 (1'), 156,99, 156,94, 144,29 (6, 10, 12), 130,49, 119,01 (13, 14, 15, 16), 130,24, 123,87 , 122,95, 118,16, 117,12 (7–9, 11, 15), 48,33 (3'), 43,24 (4), 33,41, 24,91 (4', 5', 7', 8'), 25,65 (6'), 18,66 (5).

4-Cikloheksanmetil-1-[2-(3-fenoksifenil)propanoil]semikarbazid (13i)

Metoda A. Količine reaktanata: 0,258 g spoja **7c**, 0,256 g spoja **11b**.

Temperatura reakcije: 75 °C.

Iskorištenje: 0,198 g (50 %).

t_t 104–105 °C.

IR (KBr): ν_{max} 3339, 3230, 3115, 3026, 2924, 2850, 1701, 1619, 1582, 1568, 1490, 1447, 1373, 1246, 1212, 1166, 1146, 1074, 1024, 1012, 962, 933, 888, 749, 691, 668 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,70, 7,70 (2s, 2H, 1, 2), 7,43–6,84 (m, 9H, arom.), 6,09 (t, 1H, 2', J = 5,20 Hz), 3,63 (q, 1H, 4, J = 6,82 Hz), 2,84 (t, 2H, 3', J = 6,17 Hz), 1,62–0,79 (m, 11H, 4'–9'), 1,34 (d, 3H, 5, J = 6,82 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,18 (3), 158,43 (1'), 157,03, 156,91, 144,29 (6, 10, 12), 130,19, 118,98 (13, 14, 16, 17), 130,21, 123,85 , 122,98, 118,23, 117,14 (7–9, 11, 15), 45,82 (3'), 43,29 (4), 38,38 (4'), 30,68, 25,88 (4', 5', 8', 9'), 26,56 (7'), 18,70 (5).

4-Benzil-1-[2-(3-fenoksifenil)propanoil]semikarbazid (13j)

Metoda A. Količine reaktanata: 0,252 g spoja **7d**, 0,256 g spoja **11b**.

Temperatura reakcije: 110 °C.

Iskorištenje: 0,233 g (60 %).

t_t 154–156 °C.

IR (KBr): ν_{max} 3323, 3266, 3209, 3109, 3028, 1654,1621, 1584, 1565, 1490, 1453, 1369, 1315, 1278, 1249, 1235, 1162, 1143, 1071, 935,876, 751, 694, 644 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,74, 7,89 (2s, 2H, 1, 2), 7,41–6,82 (m, 14H, arom.), 6,76 (t, 1H, 2', J = 5,58 Hz), 4,22 (d, 2H, 3', J = 5,58 Hz), 3,63 (q, 1H, 4, J = 6,50 Hz), 1,34 (d, 3H, 5, J = 6,81 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,35 (3), 158,54 (1'), 157,03, 156,90, 144,28 (6, 10, 12), 140,91 (4'), 130,49, 128,59, 127,34, 119,00 (13, 14, 16, 17, 5', 6', 8', 9'), 130,20, 127,00, 123,84, 123,02, 118,29, 117,14 (7–9, 11, 15, 7'), 43,36 (4), 43,08 (3'), 18,77 (5).

4-Feniletil-1-[2-(3-fenoksifenil)propanoil]semikarbazid (13k)

Metoda B. Količine reaktanata: 0,252 g spoja **7e**, 0,256 g spoja **11b**.

Temperatura reakcije: 115 °C.

Iskorištenje: 0,254 g (63 %).

t_t 116–118 °C.

IR (KBr): ν_{max} 3367, 3236, 3026, 2942, 1682, 1642, 1583, 1560, 1542, 1488, 1454, 1379, 1310, 1247, 1211, 1162, 1075, 1012, 944, 916, 866, 796, 747, 698, 637 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,70, 7,82 (2s, 2H, 1, 2), 7,42–6,84 (m, 14H, arom.), 6,21 (t, 1H, 2', J = 5,36 Hz), 3,63 (q, 1H, 4, J = 6,80 Hz), 3,23 (q, 2H, 3', J = 6,59 Hz), 2,68 (t, 2H, 4', J = 7,21 Hz), 1,34 (d, 3H, 5, J = 7,00 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,23 (3), 158,31 (1'), 157,03, 156,90, 144,29 (6, 10, 12), 139,99 (5'), 130,49, 129,11, 128,79, 119,00, (13, 14, 16, 17, 6', 7', 9', 10'), 130,21, 126,48, 123,85, 123,02, 118,26, 117,14 (7–9, 11, 15, 8'), 43,29 (4), 41,32 (3'), 36,38 (4'), 18,78 (5).

4-Benzhidril-1-[2-(3-fenoksifenil)propanoil]semikarbazid (13l)

Metoda A. Količine reaktanata: 0,328 g spoja **7f**, 0,256 g spoja **11b**.

Temperatura reakcije: 120 °C.

Iskorištenje: 0,219 g (47 %).

t_t 126–131 °C.

IR (KBr): ν_{max} 3350, 3236, 3031, 2973, 1655, 1613, 1587, 1560, 1488, 1448, 1247, 1210, 1164, 1070, 1052, 1030, 949, 912, 753, 698, 668, 634, 614 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,78, 7,85 (2s, 2H, 1, 2), 7,38–6,98 (m, 19H, arom.), 6,83 (d, 1H, 2', J = 7,36 Hz), 5,91 (d, 1H, 3', J = 8,83 Hz), 3,64 (q, 1H, 4, J = 6,31 Hz), 1,33 (d, 3H, 5, J = 6,75 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 172,70 (3), 157,02 (1'), 156,50 156,47, 143,70 (6, 10, 12), 142,96, 143,03 (4', 10'), 129,97, 118,53 (13, 14, 16, 17), 129,73, 123,35, 122,43, 117,71, 116,65 (7–9, 11, 15), 128,37, 128,33, 126,97, 126,93 (5', 6', 8', 9', 11', 12', 14', 15'), 126,85, 126,81 (7',13'), 56,71 (3'), 42,80 (4), 18,24 (5).

4-Ciklopentil-1-[2-(3-benzilfenil)propanoil]semikarbazid (13m)

Metoda A. Količine reaktanata: 0,230 g spoja **7a**, 0,254 g spoja **11c**.

Temperatura reakcije: 75 °C.

Iskorištenje: 0,259 g (71 %).

t_t 133–134 °C.

IR (KBr): ν_{max} 3279, 3027, 2962, 2872, 1710, 1646, 1555, 1494, 1452, 1372, 1242, 1191, 1152, 1077, 1010, 941, 728, 698, 638cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,67, 7,60 (2s, 2H, 1, 2), 7,31–7,05 (m, 9H, arom.), 5,90 (d, 1H, 2', J = 6,27 Hz), 3,91 (s, 2H, 12), 3,82 (m, 1H, 3'), 3,59 (q, 1H, 4, J = 6,86 Hz), 1,76–1,22 (m, 8H, 4'–7'), 1,32 (d, 3H, 5, J = 7,05 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,40 (3), 157,93 (1'), 142,22, 141,61, 141,55 (6, 10, 13), 129,14, 128,86 (14, 15, 17, 18), 128,76, 128,25, 127,48, 126,42, 125,45 (7–9, 11, 16), 51,38 (3'), 43,36 (4), 41,65 (12), 33,13, 23,62 (4'–7'), 18,73 (5).

4-Cikloheksil-2-[2-(3-benzilfenil)propanoil]semikarbazid (13n)

Metoda A. Količine reaktanata: 0,244 g spoja **7b**, 0,254 g spoja **11c**.

Temperatura reakcije: 90 °C.

Iskorištenje: 0,334 g (85 %).

t_t 143–144 °C.

IR (KBr): ν_{max} 3327, 3216, 3027, 2932, 2853, 1658, 1617, 1589, 1477, 1452, 1255, 1232, 1182, 1074, 1065, 943, 891, 769, 751, 701, 639,618 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,68, 7,64 (2s, 2H, 1, 2), 7,30–7,05 (m, 9H, arom.), 5,80 (d, 1H, 2', J = 7,29 Hz), 3,91 (s, 2H, 12), 3,59 (q, 1H, 4, J = 6,97 Hz), 3,38–3,29 (m, 1H, 3'), 1,70–0,97 (m, 10H, 4'–8'), 1,32 (d, 3H, 5, J = 6,97 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,40 (3), 157,60 (1'), 142,22, 141,61, 141,55 (6, 10, 13), 129,14, 128,86 (14, 15, 17, 18), 128,77, 128,24, 127,48, 126,42, 125,45 (7–9, 11, 16), 48,31 (3'), 43,36 (4), 41,65 (12), 33,38, 24,89 (4', 5', 7', 8'), 25,66 (6'), 18,73 (5).

4-Cikloheksilmetil-1-[2-(3-benzilfenil)propanoil]semikarbazid (13o)

Metoda B. Količine reaktanata: 0,258 g spoja **7c**, 0,254 g spoja **11c**.

Temperatura reakcije: 75 °C.

Iskorištenje: 0,268 g (68 %).

t_t 134–137 °C.

IR (KBr): ν_{max} 3344, 3216, 3027, 2919, 2850, 1663, 1622, 1589, 1474, 1450, 1370, 1273, 1257, 1239, 1184, 1075, 1030, 963, 746, 723, 702, 652, 618 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,67, 7,66 (2s, 2H, 1, 2), 7,31–7,05 (m, 9H, arom.), 6,04 (t, 1H, 2', J = 5,23 Hz), 3,91 (s, 2H, 12), 3,59 (q, 1H, 4, J = 6,82 Hz), 2,82 (t, 2H, 3', J = 6,14 Hz), 1,66–0,78 (m, 11H, 4'–9'), 1,32 (d, 3H, 5, J = 6,82 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,48 (3), 158,47 (1'), 142,21, 141,62, 141,52 (6, 10, 13), 129,13, 128,86 (14, 15, 17, 18), 128,74, 128,24, 127,46, 126,41, 125,47 (7–9, 11, 16), 45,81 (3'), 43,38 (4), 41,65 (12), 38,36 (4'), 30,66, 25,88 (5', 6', 8', 9'), 26,55 (7'), 18,76 (5).

4-Benzil-1-[2-(3-benzilfenil)propanoil]semikarbazid (13p)

Metoda B. Količine reaktanata: 0,252 g spoja **7d**, 0,256 g spoja **11c**.

Temperatura reakcije: 110 °C.

Iskorištenje: 0,325 g (84 %).

t_t 150–154 °C.

IR (KBr): ν_{max} 3331, 3261, 3211, 3028, 2986, 1707, 1660, 1620, 1563, 1494, 1453, 1431, 1371, 1246, 1174, 1075, 750, 723, 698, 642, 618 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,72, 7,86 (2s, 2H, 1, 2), 7,32–7,04 (m, 14H, arom.), 6,73 (t, 1H, 2', J = 6,19 Hz), 4,22 (d, 2H, 3', J = 5,77 Hz), 3,89 (s, 2H, 12), 3,60 (q, 1H, 4, J = 7,01 Hz), 1,34 (d, 3H, 5, J = 7,01 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,67 (3), 158,59 (1'), 142,23, 141,63, 141,52 (6, 10, 13), 140,92 (4'), 129,15, 128,87, 128,59, 127,35 (14, 15, 17, 18, 5', 6', 8', 9'), 128,74, 128,28, 127,46, 127,01, 126,41, 125,55 (7–9, 11, 16, 7'), 43,46 (4), 43,08 (3'), 41,64 (12), 18,88 (5).

4-Feniletil-1-[2-(3-benzilfenil)propanoil]semikarbazid (13r)

Metoda A. Količine reaktanata: 0,252 g spoja **7e**, 0,254 g spoja **11c**.

Temperatura reakcije: 115 °C.

Iskorištenje: 0,303 g (73 %).

t_t 118–120 °C.

IR (KBr): ν_{max} 3365, 3301, 3239, 3027, 2939, 1686, 1649, 1601, 1555, 1495, 1455, 1379, 1269, 1242, 1154, 1073, 945, 751, 726, 699, 661 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,66, 7,78 (2s, 2H, 1, 2), 7,29–7,04 (m, 14H, arom.), 6,17 (t, 1H, 2', J = 5,61 Hz), 3,90 (s, 2H, 12), 3,58 (q, 1H, 4, J = 6,83 Hz), 3,21 (q, 2H, 3', J = 6,58 Hz), 2,65 (t, 2H, 4', J = 7,31 Hz), 1,32 (d, 3H, 5, J = 7,07 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,55 (3), 158,37 (1'), 142,23, 141,63, 141,52 (6, 10, 13), 140,00 (5'), 129,15, 129,11, 128,87, 128,79 (14, 15, 17, 18, 6', 7', 9', 10'), 128,75, 128,28, 127,46, 126,48, 126,41, 125,54 (7–9, 11, 16, 8'), 43,41 (4), 41,65 (12), 41,33 (3'), 36,39 (4'), 18,87 (5).

4-Benzhidril-1-[2-(3-benzilfenil)propanoil]semikarbazid (13s)

Metoda A. Količine reaktanata: 0,328 g spoja **7f**, 0,254 g spoja **11c**.

Temperatura reakcije: 120 °C.

Iskorištenje: 0,339 g (71 %).

t_t 166–170 °C.

IR (KBr): ν_{max} 3346, 3231, 3028, 1981, 1662, 1611, 1590, 1560, 1494, 1472, 1453, 1372, 1258, 1236, 1078, 1030, 948, 751, 700, 668, 634, 613 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,78, 7,84 (2s, 2H, 1, 2), 7,33–7,00 (m, 19H, arom.), 6,99 (d, 1H, 2', J = 8,85 Hz), 5,91 (d, 1H, 3', J =8,38 Hz), 3,89 (s, 2H, 12), 3,60 (q, 1H, 4, J = 6,99 Hz), 1,33 (d, 3H, 5, J = 6,99 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,67 (3), 157,56 (1'), 143,52, 143,47 (4', 10'), 142,13, 141,59, 141,56, (6, 10, 13), 129,14, 128,86, 128,82, 128,80, 127,45 (14, 15, 17, 18, 5', 6', 8', 9', 11', 12', 14', 15'), 128,22, 127,34, 127,32, 126,40, 125,47 (7–9, 11, 16, 7', 13'), 57,16 (3'), 43,48 (4), 41,63 (12), 18,84 (5).

4-Benziloksi-1-[2-(4-izobutilfenil)propanoil]semikarbazid (13t)

Metoda C. Količina reaktanta: 0,220 g spoja **11a**.

Trajanje reakcije: 6 h.

Iskorištenje: 0,336 g (91 %).

t_t 87 °C (raspad).

IR (KBr): ν_{max} 3472, 3319, 3240, 3114, 3064, 3031, 2953, 2867, 1714, 1698, 1681, 1638, 1594, 1548, 1514, 1455, 1366, 1349, 1226, 1147, 1082, 994, 933, 910, 850, 802, 751, 698, 620, 592, 545 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,73, 9,47, 8,71 (3s, 3H, 1, 2, 2'), 7,43–7,32 (m, 5H, arom.), 7,17 (dd, 4H, arom., J = 8,03 Hz, 45,43 Hz), 4,74 (s, 2H, 3'), 3,62 (q, 1H, 4, J = 6,81 Hz), 2,40 (d, 2H, 12, J = 6,99 Hz), 1,87–1,76 (m, 1H, 13), 1,34 (d, 3H, 5, J = 7,16 Hz), 0,85 (d, 6H, 14, 15, J = 6,46 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,55 (3), 159,52 (1'), 139,77, 139,25 (6, 9), 136,90 (4'), 129,17, 129,12, 128,61, 127,62 (7, 8, 10, 11, 5', 6', 8', 9'), 128,42 (7'), 77,90 (3'), 44,71 (12), 43,05 (4), 30,10 (13), 22,65 (14,15), 18,93 (5).

4-Benziloksi-1-[2-(3-fenoksifenil)propanoil]semikarbazid (13u)

Metoda C. Količina reaktanta: 0,256 g spoja **11b**.

Trajanje reakcije: 7 h.

Iskorištenje: 0,369 g (91 %).

Ulje.

IR (KBr): ν_{max} 3237, 3063, 3034, 2979, 2934, 2877, 1668, 1583, 1488, 1455, 1371, 1312, 1244, 1211, 1163, 1073, 942, 914, 753, 695, 614 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,74, 9,47, 8,70 (3s, 3H, 1, 2, 2'), 7,41–6,83 (m, arom., 14H), 4,75 (s, 2H, 3'), 3,66 (q, 1H, 4, J = 6,94 Hz), 1,35 (d, 3H, 5, J = 6,94 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 172,59 (3), 158,95 (1'), 156,57, 156,38, 143,70 (6, 10, 12), 136,37 (4'), 129,98, 128,62, 128,11, 118,48 (13, 14, 16, 17, 5', 6', 8', 9'), 129,65, 127,93, 123,32, 122,59, 117,87, 116,65 (7–9, 11, 15, 7'), 77,42 (3'), 42,80 (4), 18,37 (5).

4-Benziloksi-1-[2-(3-benzilfenil)propanoil]semikarbazid (13v)

Metoda C. Količina reaktanta: 0,254 g spoja **11c**.

Trajanje reakcije: 8 h.

Iskorištenje: 0,201 g (50 %).

t_t 104–105 °C.

IR (KBr): ν_{max} 3306, 3235, 3029, 2925, 2880, 1691, 1654, 1599, 1520, 1493, 1454, 1382, 1366, 1356, 1273, 1238, 1152, 1074, 1032, 1007, 947, 788, 751, 727, 699, 668, 555, 532, 497 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,72, 9,46, 8,69 (3s, 3H, 1, 2, 2'), 7,37–7,02 (m, arom., 14H), 4,72 (s, 2H, 3'), 3,88 (s, 2H, 12), 3,59 (q, 1H, 4, J = 6,46 Hz), 1,31 (d, 3H, 5, J = 6,85 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,40 (3), 159,52 (1'), 142,13, 141,65, 141,47 (6, 10, 13), 136,90 (4'), 129,16, 129,13, 128,87, 128,61 (14, 15, 17, 18, 5', 6', 8', 9'), 128,70, 128,43, 128,34, 127,44, 126,41, 125,61 (7–9, 11, 16, 7'), 77,90 (3'), 43,39 (4), 41,65 (12), 19,00 (5).

4-Hidroksi-1-[2-(4-izobutilfenil)propanoil]semikarbazid (13w)

Metoda D. Količina reaktanta: 0,185 g spoja **13t**.

Iskorištenje: 0,134 g (96 %).

t_t 123–125 °C.

IR (KBr): ν_{max} 3330, 3235, 3027, 2954, 2924, 2869, 1704, 1652, 1556, 1514, 1465, 1383, 1320, 1262, 1141, 1078, 1002, 935, 850, 766, 727, 653, 531 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,65, 8,70, 8,64, 8,41 (4s, 4H, 1, 2, 2', 3'), 7,15 (dd, 4H, arom, J = 7,92 Hz, 46,47 Hz), 3,61 (q, 1H, 4, J = 6,89 Hz), 2,40 (d, 2H, 12, J = 7,11 Hz), 1,85–1,76 (m, 1H, 13), 1,33 (d, 3H, 5, J = 6,89 Hz), 0,85 (d, 6H, 14, 15, J = 6,45 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,45 (3), 160,82 (1'), 139,71, 139,33 (6, 9), 129,14, 127,62 (7, 8, 10,11), 44,71 (12), 43,00 (4), 30,09 (13), 22,65 (14,15), 19,01 (5).

4-Hidroksi-1-[2-(3-fenoksifenil)propanoil]semikarbazid (13x)

Metoda D. Količina reaktanta: 0,203 g spoja **13u**.

Iskorištenje: 0,118 g (75 %).

t_t 150 °C (raspad).

IR (KBr): ν_{max} 3298, 3214, 3026, 2983, 2941, 1685, 1643, 1582, 1567, 1489, 1446, 1362, 1313, 1268, 1232, 1212, 1161, 1140, 1080, 1023, 969, 939, 876, 788, 756, 693, 649, 596, 558, 523 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,68, 8,72, 8,65, 8,45 (4s, 4H, 1, 2, 2', 3'), 7,42–6,82 (m, arom., 9H), 3,65 (q, 1H, 4, J = 6,95 Hz), 1,33 (d, 3H, 5, J = 6,95 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 172,98 (3), 160,78 (1'), 157,06, 156,84, 144,29 (6, 10, 12), 130,49, 118,98 (13, 14,16, 17), 130,13, 123,81, 123,10, 118,36, 117,11 (7–9, 11, 15), 43,24 (4), 18,95 (5).

4-Hidroksi-1-(2-(3-benzilfenil)propanoil]semikarbazid (13y)

Metoda D. Količina reaktanta: 0,202 g spoja **13v**.

Iskorištenje: 0,150 g (96 %).

t_t 123–125 °C.

IR (KBr): ν_{max} 3288, 3060, 3028, 2979, 2938, 1687, 1644, 1562, 1516, 1494, 1483, 1451, 1380, 1263, 1159, 1144, 1100, 1077, 1061, 1027, 938, 782, 721, 700, 596, 533 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,66, 8,73, 8,66, 8,43 (4s, 4H, 1, 2, 2', 3'), 7,32–7,05 (m, arom., 9H), 3,92 (s, 2H, 12), 3,62 (q, 1H, 4, J = 6,81 Hz), 1,34 (d, 3H, 5, J = 7,01 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,29 (3), 160,82 (1'), 142,22, 141,66, 141,45 (6, 10, 13), 129,16, 128,87 (14, 15, 17, 18), 128,68, 128,34, 127,38, 126,40, 125,60 (7–9, 11, 16), 43,34 (4), 41,65 (12), 19,08 (5).

2.1.15. Sinteza 1-acil-5-benziloksi i 1-acil-5-hidroksikarbamoil karbazida NSAID 14a-f

Metoda A. Odgovarajući hidrazid NSAID-a **11a**-**c** (1 mmol) i 1-(1-benzotriazolkarbonil)-4-benziloksisemikarbazid (**9**) (0,326 g, 1 mmol) rastaljeni su na 93 °C. Reakcijska smjesa je na toj temperaturi miješana 0,3 h, ohlađena i otopljena u etil-acetatu. Organski sloj ekstrahiran je zalužеnom vodom (3×20 mL, 6 kapi 5 % NaOH) i vodom (1×20 mL), osušen nad bezvodnim natrijevim sulfatom, profiltriran i uparen pod sniženim tlakom. Sirovi produkti **14a**-**c** pročišćeni su kromatografijom na koloni uz pokretnu fazu diklormetan/metanol 9,5:0,5 i prekristalizacijom iz etera/petroletera.

Metoda B. Suspenzija *O*-benzilnog derivata (**14a**-**c**, 0,5 mmol) i 50 mg 10 %-tnog Pd/C u metanolu (10 mL) hidrogenirana je pod atmosferskim tlakom vodika na sobnoj temperaturi

tijekom 2 h. Katalizator je odfiltriran, a otapalo upareno pod sniženim tlakom. Sirovi produkti su pročišćeni rastrljavanjem u eteru.

5-(Benziloksikarbamoil)-1-[2-(4-izobutilfenil)propanoil]karbazid (14a)

Metoda A. Količina reaktanta: 0,220 g spoja **11a**.

Iskorištenje: 0,304 g (71 %).

t_t 85–90 °C.

IR (KBr): ν_{max} 3266, 3032, 2955, 2930, 2869, 1677, 1513, 1466, 1455, 1366, 1309, 1271, 1212, 1188, 1075, 1030, 1002, 934, 909, 849, 751, 699, 620, 547 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,75, 9,43, 8,54, 8,15, 8,03 (5s, 5H, 1, 2, 2', 3', 5'), 7,44–7,30 (m, 5H, arom., 8'–12'), 7,16 (dd, 4H, arom., J = 7,99 Hz, 46,08), 4,77 (s, 2H, 6'), 3,62 (q, 1H, 4, J = 6,94 Hz), 2,41 (d, 2H, 12, J = 7,15 Hz), 1,85–1,76 (m, 1H, 13), 1,35 (d, 3H, 5, J = 6,94 Hz), 0,86 (d, 6H, 14, 15, J = 6,52 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,52 (3), 160,03, 158,37 (1', 4'), 139,75, 139,34, (6, 9), 136,97 (7'), 129,17, 129,14, 128,61, 127,59 (7, 8, 10, 11, 8', 9', 11', 12'), 128,41 (10'), 77,87 (6'), 44,71 (12), 43,00 (4), 30,09 (13), 22,65 (14, 15), 18,85 (5).

5-Benziloksikarbamoil-1-[2-(3-fenoksifenil)propanoil]karbazid (14b)

Metoda A. Količina reaktanta: 0,256 g spoja **11b**.

Iskorištenje: 0,338 g (73 %).

t_t 72–76 °C.

IR (KBr): ν_{max} 3251, 3062, 3034, 2971, 2933, 2873, 1677, 1583, 1523, 1488, 1455, 1369, 1312, 1243, 1211, 1163, 1073, 1023, 1002, 942, 914, 816, 752, 694, 614 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,78, 9,43, 8,55, 8,18, 8,05 (5s, 5H, 1, 2, 2', 3', 5'), 7,44–6,82 (m, 14H, arom.), 4,77 (s, 2H, 6'), 3,65 (q, 1H, 4, J = 6,97 Hz), 1,34 (d, 3H, 5, J = 7,12 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,03 (3), 160,03, 158,32 (1', 4'), 157,05, 156,87, 144,28 (6, 10, 12), 136,97 (7'), 130,50, 129,14, 128,61, 118,99 (13, 14, 16, 17, 8', 9', 11', 12'), 130,16, 128,41, 123,83, 123,06, 118,33, 117,13 (7–9, 11, 15, 10'), 77,88 (6'), 43,25 (4), 18,79 (5).

5-Benziloksikarbamoil-1-[2-(3-benzilfenil)propanoil]karbazid (14c)

Metoda A. Količina reaktanta: 0,254 g spoja **11c**.

Iskorištenje: 0,337 g (73 %).

t_t 73–77 °C.

IR (KBr): ν_{max} 3248, 3060, 3028, 2880, 2836, 1675, 1602, 1519, 1494, 1453, 1369, 1310, 1270, 1210, 1075, 1030, 974, 941, 908, 751, 699, 620, 556 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,76, 9,43, 8,55, 8,16, 8,03 (5s, 5H, 1, 2, 2', 3', 5'), 7,44–7,05 (m, 14H, arom.), 4,78 (s, 2H, 6'), 3,92 (s, 2H, 12), 3,62 (q, 1H, 4, J = 6,77 Hz), 1,34 (d, 3H, 5, J = 7,02 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 173,35 (3), 160,02, 158,36 (1', 4'), 142,21, 141,64, 141,48 (6, 10, 13), 136,96 (7'), 129,15, 128,87, 128,61 (14, 15, 17, 18, 8', 9', 11', 12'), 128,70, 128,41, 128,31, 127,42, 126,40, 125,58 (7–9, 11, 16, 10'), 77,88 (6'), 43,34 (4), 41,65 (12), 18,91 (5).

5-Hidroksikarbamoil-1-[2-(4-izobutilfenil)propanoil]karbazid (14d)

Metoda B. Količina reaktanta: 0,214 g spoja **14a**.

Iskorištenje: 0,120 g (71 %).

t_t 145–148 °C (raspad).

IR (KBr): ν_{max} 3261, 2955, 2928, 2870, 1670, 1514, 1466, 1383, 1367, 1281, 1206, 1077, 1002, 934, 850, 783 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,73, 8,66, 8,57, 8,23, 8,08, 7,92 (5s, bs, 6H, 1, 2, 2', 3', 5', 6'), 7,15 (dd, 4H, arom., J = 7,93 Hz, 95,99 Hz), 3,61 (q, 1H, 4, J = 7,01 Hz), 2,40 (d, 2H, 12, J = 7,28 Hz), 1,82–1,78 (m, 1H, 13), 1,33 (d, 3H, 5, J = 7,01 Hz), 0,85 (d, 6H, 14, 15, J = 6,47 Hz).

^{13}C NMR (DMSO-d_6, δ ppm): 172,90 (3), 160,70, 157,83 (1', 4'), 139,24, 138,85 (6, 9), 128,6, 127,07 (7, 8, 10, 11), 44,22 (12), 42,49 (4), , 29,55 (13), 22,14 (14, 15), 18,35 (5).

5-Hidroksikarbamoil-1-[2-(3-fenoksifenil)propanoil]karbazid (14e)

Metoda B. Količina reaktanta: 0,232 g spoja **14b**.

Iskorištenje: 0,159 g (85 %).

t_t 100–103 °C (raspad).

IR (KBr): ν_{max} 3263, 2978, 2925, 2855, 1670, 1583, 1540, 1488, 1456, 1445, 1376, 1313, 1244, 1210, 1163, 1074, 943, 917, 755, 692 cm^{-1}.

^{1}H NMR (DMSO-d_6, δ ppm, J/Hz): 9,80, 8,67, 8,29, 8,14, 7,96 (5s, bs, 6H, 1, 2, 2', 3', 5', 6'), 7,42–6,81 (m, 9H, arom.), 3,64 (q, 1H, 4, J = 7,03 Hz), 1,34 (d, 3H, 5, J = 6,95 Hz).

13C NMR (DMSO-d_6, δ ppm): 172,92 (3), 161,24, 158,30 (1', 4'), 157,03, 156,88, 144,28, (6, 10, 12), 130,50, 119,01 (13, 14, 16, 17), 130,16, 123,84, 123,03, 118,30, 117,11 (7–9, 11, 15), 43,22 (4), 18,78 (5).

5-Hidroksikarbamoil-1-[2-(3-benzilfenil)propanoil]karbazid (14f)

Metoda B. Količina reaktanta: 0,231 g spoja **14c**.

Iskorištenje: 0,147 g (79 %).

t_t 101–105 °C.

IR (KBr): ν_{max} 3258, 3060, 3027, 2981, 2934, 1670, 1601, 1538, 1494,1453, 1375, 1321, 1195, 1075, 1030, 943, 784, 728, 699, 622, 557 cm^{-1}.

1H NMR (DMSO-d_6, δ ppm, J/Hz): 9,78, 8,67, 8,28, 8,11, 7,95 (5s, bs, 6H, 1, 2, 2', 3', 5', 6'), 7,31–7,04 (m, 9H, arom.), 3,91 (s, 2H, 12), 3,61 (q, 1H, 4, J = 6,88 Hz), 1,33 (d, 3H, 5, J = 7,14 Hz).

13C NMR (DMSO-d_6, δ ppm): 173,23 (3), 161,24, 158,34 (1', 4'), 142,22, 141,64, 141,48 (6, 10, 13), 129,16, 128,88 (14, 15, 17, 18), 128,71, 128,29, 127,42, 126,41, 125,56 (7–9, 11, 16), 43,32 (4), 41,65 (12), 18,90 (5).

3. REZULTATI I RASPRAVA

3.1. SINTEZE

Početni spoj za pripravu derivata aminokiselina *N*-(1-benzotriazolkarbonil)-aminokiselina (*N*-Btc-aminokiselina) (**2**), 1-karbamoilbenzotriazola (**7**), 1-(1-benzotriazol-karbonil)-4-benziloksisemikarbazida (**9**) i NSAID benzotriazolida (**10**) bio je klorid 1-benzotriazolkarboksilne kiseline (BtcCl, **1**). Taj spoj dobiven je refluksiranjem benzotriazola i trifozgena u toluenskoj otopini (Shema 20) (Kalčić *et al*, 2003). Klorid **1** može se prirediti i iz benzotriazola i 20 %-tne otopine fozgena u toluenu ili uvođenjem plinovitog fozgena iz metalnog spremnika u toluensku otopinu benzotriazola (Butula *et al*, 1977). Zbog otežanog rukovanja i sigurnosti na radu u laboratoriju, danas se sve više upotrebljava čvrsti trifozgen (trimer fozgena) koji se zagrijavanjem razlaže u fozgen prema jednadžbi prikazanoj na Shemi 20.

Shema 20. Sinteza klorida 1-benzotriazolkarboksilne kiseline (BtcCl, **1**)

3.1.1. Sinteza aminokiselinskih derivata: ureidoamida 4a-o i *N*- i *O*-supstituiranih hidroksiurea 6a-l

Prvi korak u sintezi ureidoamida i hidroksiurea je sinteza *N*-(1-benzotriazolkarbonil)aminokiselina (*N*-Btc-aminokiselina) **2a**-**e**. Klorid 1-benzotriazol-karboksilne kiseline reagira s amino skupinom aminokiselina (L-alanin, L-valin, L-leucin, D-fenilglicin i L-fenilalanin) pri čemu nastaju *N*-Btc-aminokiseline (Butula *et al*, 1981a). Reakcija se provodi u bezvodnom dioksanu, na sobnoj temperaturi, uz množinski omjer reaktanata 1:2 (jedan mol aminokiseline služi kao akceptor klorovodika oslobođenog u reakciji, a drugi reagira s BtcCl). Nastali hidroklorid aminokiseline netopljiv je u dioksanu te se uklanja odsisavanjem, a uparavanjem matičnice dobije se sirovi produkt **2**.

N-(1-Benzotriazolkarbonil)aminokiseline **2a-e** prevedene su pomoću tionil-klorida (SOCl$_2$) u odgovarajuće kiselinske kloride **3a-e**, koji su upotrebljeni u daljnjim reakcijama aminolize bez čišćenja. Reakcijom s amino skupinom odgovarajućih aminoalkohola (2-aminoetanol, 3-aminopropanol i 5-aminopentanol) priređeni su ureidoamidi **4** (Shema 21) prema ranije opisanom postupku (Butula *et al*, 1981b). Množinski omjer aminoalkohola i klorida **3** iznosi 3:1 (dva mola aminoalkohola reagira s kloridom **3**, a treći služi kao akceptor klorovodika oslobođenog u reakciji). Reakcija se provodi na sobnoj temperaturi, gdje klorid reagira trenutno, dok je za supstituciju na benzotriazolskoj strani molekule potrebno više vremena. U zadanim uvjetima ne nastaje produkt klorida **3** s hidroksilnom skupinom aminoalkohola.

	4a	4b	4c	4d	4e	4f	4g	4h
R^1	CH$_3$	CH$_3$	CH$_3$	H$_3$C−CH−CH$_3$	H$_3$C−CH−CH$_3$	H$_3$C−CH−CH$_3$	H$_3$C−CH−CH$_2$	H$_3$C−CH−CH$_2$
R^2	(CH$_2$)$_2$OH	(CH$_2$)$_3$OH	(CH$_2$)$_5$OH	(CH$_2$)$_2$OH	(CH$_2$)$_3$OH	(CH$_2$)$_5$OH	(CH$_2$)$_2$OH	(CH$_2$)$_3$OH

	4i	4j	4k	4l	4m	4n	4o
R^1	H$_3$C−CH−CH$_2$	phenyl	phenyl	phenyl	benzyl	benzyl	benzyl
R^2	(CH$_2$)$_5$OH	(CH$_2$)$_2$OH	(CH$_2$)$_3$OH	(CH$_2$)$_5$OH	(CH$_2$)$_2$OH	(CH$_2$)$_3$OH	(CH$_2$)$_5$OH

Shema 21. Sinteza ureidoamida **4a-o**

Pripravljeni su sljedeći ureidoamidi:

1-(1-(2-hidroksietilkarbamoil)etil-3-(2-hidroksietil)urea (**4a**),

1-(1-(3-hidroksipropilkarbamoil)etil-3-(3-hidroksipropil)urea (**4b**),

1-(1-(5-hidroksipentilkarbamoil)etil-3-(5-hidroksipentil)urea (**4c**),

1-(1-(2-hidroksietilkarbamoil)-2-metilpropil-3-(2-hidroksietil)urea (**4d**),

1-(1-(3-hidroksipropilkarbamoil)-2-metilpropil-3-(3-hidroksipropil)urea (**4e**),

1-(1-(5-hidroksipentilkarbamoil)-2-metilpropil-3-(5-hidroksipentil)urea (**4f**),

1-(1-(2-hidroksietilkarbamoil)-3-metilbutil-3-(2-hidroksietil)urea (**4g**),

1-(1-(3-hidroksipropilkarbamoil)-3-metilbutil-3-(3-hidroksipropil)urea (**4h**),

1-(1-(5-hidroksipentilkarbamoil)-3-metilbutil-3-(5-hidroksipentil)urea (**4i**),

1-((2-hidroksietilkarbamoil)(fenil)metil)-3-(2-hidroksietil)urea (**4j**),

1-((3-hidroksipropilkarbamoil)(fenil)metil)-3-(3-hidroksipropil)urea (**4k**),

1-((3-hidroksipentilkarbamoil)(fenil)metil)-3-(5-hidroksipentil)urea (**4l**),

1-(1-(2-hidroksietilkarbamoil)-2-feniletil)-3-(2-hidroksietil)urea (**4m**),

1-(1-(3-hidroksipropilkarbamoil)-2-feniletil)-3-(3-hidroksipropil)urea (**4n**),

1-(1-(5-hidroksipentilkarbamoil)-2-feniletil)-3-(5-hidroksipentil)urea (**4o**).

Sinteze novih spojeva i njihova čistoća praćeni su tankoslojnom kromatografijom, a strukture su potvrđene IR, ^{1}H i ^{13}C NMR spektroskopijom i elementarnom analizom.

IR spektri ureidoamida **4a-o** pokazuju karakteristične vrpce kod 3422–3092 (NH, OH), 1644–1625 (C=O, amid I) i 1559–1572 (C=O, amid II) cm^{-1} (Tablica 1). ^{1}H NMR spektri ispitivanih spojeva otkrivaju da se amidni NH nalazi u području 7,84–8,31 ppm, dok su karbamidni NH u području 5,88–6,78 ppm. Alkoholne skupine nalaze se u području 4,28–4,69 ppm (Tablica 2). Analizom ^{13}C NMR spektara utvrđeno je da se karbonil u položaju 1 (amid) nalazi u području 170,90–173,78 ppm, a karbonil u položaju 4 (urea) u području 157,49–158,45 ppm (Tablica 3).

Tablica 1. Analitički i IR podaci za ureidoamide **4a-o**

Spoj	R^1	R^2	t_t (°C)	Mol. formula (M_r)	IR (KBr/film) ν_{max} (cm^{-1})
4a	CH$_3$	HO~~S	150–154	C$_8$H$_{17}$N$_3$O$_4$ (219,24)	3422, 3274, 2969, 2937, 2879, 1644, 1570, 1056
4b		HO~~S	152–156	C$_{10}$H$_{21}$N$_3$O$_4$ (247,29)	3275, 2941, 2875, 1638, 1560, 1060

Spoj	R¹	R²	m.p. (°C)	Formula (M)	IR (cm⁻¹)
4c	CH₃	HO–(CH₂)₄–S	142–146	$C_{14}H_{29}N_3O_4$ (303,4)	3360, 3282, 3111, 2936, 2862, 1627, 1561, 1056
4d	(isopropyl)	HO–CH₂CH₂–S	194–198	$C_{10}H_{21}N_3O_4$ (247,29)	3280, 3102, 2969, 2874, 1626, 1571, 1063
4e		HO–(CH₂)₃–S	178–181	$C_{12}H_{25}N_3O_4$ (275,34)	3350, 3279, 3102, 2963, 2874, 1630, 1566, 1234, 1078, 1044
4f		HO–(CH₂)₄–S	159–162	$C_{16}H_{33}N_3O_4$ (331,45)	3349, 3278, 3107, 2935, 2861, 1628, 1572, 1236, 1059
4g	(isobutyl)	HO–CH₂CH₂–S	153–161	$C_{11}H_{23}N_3O_4$ (261,32)	3290, 3098, 2954, 2928, 2872, 1625, 1569, 1059
4h		HO–(CH₂)₃–S	109–111	$C_{13}H_{27}N_3O_4$ (289,37)	3308, 3098, 2957, 2872, 1630, 1572, 1252, 1073
4i		HO–(CH₂)₄–S	83–86	$C_{17}H_{35}N_3O_4$ (345,48)	3349, 3280, 3100, 2937, 2862, 1626, 1562, 1262, 1059
4j	(phenyl)	HO–CH₂CH₂–S	206–208	$C_{13}H_{19}N_3O_4$ (281,31)	3291, 3092, 2934, 2878, 1626, 1571, 1226, 1057
4k		HO–(CH₂)₃–S	182–185	$C_{15}H_{23}N_3O_4$ (309,36)	3289, 3092, 2942, 2883, 1626, 1561, 1059
4l		HO–(CH₂)₄–S	178–180	$C_{19}H_{31}N_3O_4$ (365,47)	3362, 3286, 3093, 2937, 2861, 1628, 1564, 1352, 1061
4m	(benzyl)	HO–CH₂CH₂–S	140–143	$C_{14}H_{21}N_3O_4$ (295,33)	3310, 3105, 2937, 2876, 1626, 1569, 1496, 1231, 1056
4n		HO–(CH₂)₃–S	110–113	$C_{16}H_{25}N_3O_4$ (323,39)	3280, 3106, 2942, 2878, 1628, 1564, 1235, 1050
4o		HO–(CH₂)₄–S	89–93	$C_{20}H_{33}N_3O_4$ (379,49)	3282, 3106, 2931, 2859, 1626, 1559, 1236, 1060

Tablica 2. ¹H NMR spektroskopski podaci za ureidoamide **4a-o**

Spoj	R¹	R²	¹H NMR (DMSO-d_6, δ ppm)
4a	⁵CH₃	HO–4′CH₂–3′CH₂–2′–S	7,87 (t, 1H, 1'(amid), J = 5,4 Hz), 6,21 (d, 1H, 3, J = 7,9 Hz), 6,14 (t, 1H, 1'(urea), J = 5,5 Hz), 4,69, 4,67 (2t, 2H, 4', J = 5,6 Hz, J = 5,2 Hz), 4,16–4,06 (m, 1H, 2), 3,38–3,32 (m, 4H, 3'), 3,13–3,00 (m, 4H, 2'), 1,12 (d, 3H, 5, J = 7,4 Hz)

4b	⁵CH₃		7,85 (t, 1H, 1'(amid), *J* = 5,5 Hz), 6,05–6,02 (d, t, 2H, 1'(urea), 3), 4,43, 4,42 (2t, 2H, 5', *J* = 4,8 Hz, *J* = 5,1 Hz), 4,14–4,05 (m, 1H, 2), 3,39 (q, 4H, 4', *J* = 6,1 Hz), 3,12–3,00 (m, 4H, 2'), 1,58–1,44 (m, 4H, 3'), 1,12 (d, 3H, 5, *J* = 6,8 Hz)
4c			7,84 (t, 1H, 1'(amid), *J* = 5,3 Hz), 6,03 (t, 1H, 1'(urea), *J* = 5,5 Hz), 5,96 (d, 1H, 3, *J* = 7,8 Hz), 4,34 (t, 2H, 7', *J* = 5,1 Hz), 4,15–4,05 (m, 1H, 2), 3,37 (q, 4H, 6', *J* = 5,8 Hz), 3,05–2,92 (m, 4H, 2'), 1,45–1,29 (m, 12H, 3'–5'), 1,12 (d, 3H, 5)
4d			7,87 (t, 1H, 1'(amid), *J* = 5,4 Hz), 6,16 (t, 1H, 1'(urea), *J* = 5,5 Hz), 6,11 (d, 1H, 3, *J* = 9,1 Hz), 4,65, 4,64 (2t, 2H, 4', *J* = 4,8 Hz, *J* = 5,1 Hz), 3,97 (dd, 1H, 2, *J* = 6,0 Hz, *J* = 2,9 Hz), 3,45–3,33 (m, 4H, 3'), 3,18–3,03 (m, 4H, 2'), 1,91–1,80 (m, 1H, 5), 0,82 (d, 3H, 6, *J* = 6,8 Hz), 0,78 (d, 3H, 7, *J* = 6,8 Hz)
4e			7,90 (t, 1H, 1'(amid), *J* = 5,6 Hz), 6,06 (t, 1H, 1'(urea), *J* = 5,7 Hz), 5,96 (d, 1H, 3, *J* = 9,1 Hz), 4,42, 4,41 (2t, 2H, 5', *J* = 5,4 Hz), 3,95 (dd, 1H, 2, *J* = 6,1 Hz, *J* = 3,0 Hz), 3,39 (q, 4H, 4', *J*=6,0 Hz), 3,19–3,00 (m, 4H, 2'), 1,89–1,78 (m, 1H, 5), 1,58–1,45 (m, 4H, 3'), 0,82 (d, 3H, 6, *J* = 6,8 Hz), 0,79 (d, 3H, 7, *J* = 7,0 Hz)
4f			7,89 (t, 1H, 1'(amid), *J* = 5,5 Hz), 6,05 (t, 1H, 1'(urea), *J* = 5,4 Hz), 5,90 (d, 1H, 3, *J* = 9,0 Hz), 4,35–4,32 (m, 2H, 7'), 3,95 (dd, 1H, 2, *J* = 6,2 Hz, *J* = 2,7 Hz), 3,38–3,35 (m, 4H, 6'), 3,12–2,93 (m, 4H, 2'), 1,88–1,77 (m, 1H, 5), 1,44–1,25 (m, 12H, 3'–5'), 0,81 (d, 3H, 6, *J* = 6,8 Hz), 0,78 (d, 3H, 7, *J* = 6,9 Hz)
4g			7,87 (t, 1H, 1'(amid), *J* = 5,3 Hz), 6,11 (d, 1H, 3, *J* = 8,9 Hz), 6,04 (t, 1H, 1'(urea), *J* = 5,4 Hz), 4,65–4,64 (m, 2H, 4'), 4,15–4,07 (m, 1H, 2), 3,40–3,34 (m, 4H, 3'), 3,13–3,01 (m, 4H, 2'), 1,60–1,52 (m, 1H, 6), 1,42–1,27 (m, 2H, 5), 0,86 (2d, 6H, 7, 8, *J* = 6,2 Hz, *J* = 5,4 Hz)
4h			7,89 (t, 1H, 1'(amid), *J* = 5,5 Hz), 5,97–5,94 (m, 2H, 3, 1'(urea)), 4,42, 4,40 (2t, 2H, 5', *J* = 5,3 Hz), 4,13–4,05 (m, 1H, 2), 3,42–3,35 (m, 4H, 4'), 3,15–2,99 (m, 4H, 2'), 1,59–1,44 (m, 5H, 6, 3'), 1,39–1,30 (m, 2H, 5), 0,87 (d, 3H, 7, *J* = 6,2 Hz), 0,85 (d, 3H, 8, *J* = 6,2 Hz)
4i			7,88 (t, 1H, 1'(amid), *J* = 5,4 Hz), 5,94 (t, 1H, 1'(urea), *J* = 5,7 Hz), 5,88 (d, 1H, 3, *J* = 9,0 Hz), 4,33 (t, 2H, 7', *J* = 5,1 Hz), 4,13–4,06 (m, 1H, 2), 3,39–3,33 (m, 4H, 6'), 3,08–2,92 (m, 4H, 2'), 1,58–1,22 (m, 15H, 6, 5, 3'–5'), 1,39–1,30 (m, 2H, 5), 0,87 (d, 3H, 7, *J* = 6,1 Hz), 0,85 (d, 3H, 8, *J* = 6,1 Hz)
4j			8,31 (t, 1H, 1'(amid), *J* = 5,5 Hz), 7,37–7,21 (m, 5H, arom., 6–10), 6,78 (d, 1H, 3, *J* = 8,4 Hz), 6,29 (t, 1H, 1'(urea), *J* = 5,5 Hz), 5,31 (d, 1H, 2, *J* = 8,4 Hz), 4,66, 4,64 (2t, 2H, 4', *J* = 5,3 Hz, *J* = 5,1 Hz), 3,40–3,34 (m, 4H, 3'), 3,23–2,97 (m, 4H, 2')
4k			8,27 (t, 1H, 1'(amid), *J* = 5,5 Hz), 7,36–7,22 (m, 5H, arom., 6–10), 6,65 (d, 1H, 3, *J* = 8,3 Hz), 6,21 (t, 1H, 1'(urea), *J* = 5,5 Hz), 5,26 (d, 1H, 2, *J* = 8,5 Hz), 4,41, 4,39 (2t, 2H, 5', *J* = 5,2 Hz), 3,42–3,32 (m, 4H, 4'), 3,12–2,99 (m, 4H, 2'), 1,56–1,44 (m, 4H, 3')
4l			8,26 (t, 1H, 1'(amid), *J* = 5,5 Hz), 7,36–7,21 (m, 5H, arom., 6–10), 6,60 (d, 1H, 3, *J* = 8,4 Hz), 6,21 (t, 1H, 1'(urea), *J* = 5,5 Hz), 5,26 (d, 1H, 2, *J* = 8,4 Hz), 4,35, 4,31 (2t, 2H, 7', *J* = 5,3 Hz), 3,40–3,30 (m, 4H, 6'), 3,05–2,92 (m, 4H, 2'), 1,44–1,16 (m, 12H, 3'–5')

Spoj	R¹	R²	
4m		HO–3'–2'–(S) (4')	7,90 (t, 1H, 1'(amid), *J* = 5,1 Hz), 7,28–7,17 (m, 5H, arom., 6–10), 6,16 (d, 1H, 3, *J* = 8,6 Hz), 6,10 (t, 1H, 1'(urea), *J* = 5,1 Hz), 4,64–4,59 (m, 2H, 4'), 4,37–4,30 (m, 1H, 2), 3,33–3,29 (m, 4H, 3'), 3,12–2,67 (m, 6H, 2', 5)
4n	(benzyl: 5,6,7,8,9,10,11)	HO–5'–4'–3'–2'–(S)	7,88 (t, 1H, 1'(amid)', *J* = 4,6 Hz), 7,27–7,14 (m, 5H, arom., 6–10), 6,04–6,02 (d, t, 2H, 3, 1'(urea)), 4,42–4,28 (m, 3H, 2, 5'), 3,39–3,34 (m, 4H, 4'), 3,12–2,69 (m, 6H, 2', 5), 1,50–1,43 (m, 4H, 3')
4o		HO–7'–6'–5'–4'–3'–2'–(S)	7,86 (t, 1H, 1'(amid), *J* = 5,5 Hz), 7,27–7,14 (m, 5H, arom., 6–10), 6,01 (t, 1H, 1'(urea), *J* = 5,5 Hz), 5,96 (d, 1H, 3, *J* = 8,7 Hz), 4,35–4,28 (m, 3H, 2, 7'), 3,37–3,33 (m, 4H, 6'), 3,07–2,69 (m, 6H, 2', 5), 1,43–1,16 (m, 12H, 3'–5')

Tablica 3. ^{13}C NMR spektroskopski podaci za ureidoamide **4a-o**

Spoj	R¹	R²	^{13}C NMR (DMSO-d_6, δ ppm)
4a		HO–3'–2'–(S) (4')	173,78 (1), 157,98 (4), 61,19, 60,21 (3'), 49,07 (2), 42,46, 41,86 (2'), 20,11 (5)
4b	^{5}CH$_3$	HO–4'–3'–2'–(S) (5')	173,63 (1), 157,97 (4), 58,83, 58,82 (4'), 49,02 (2), 36,70, 36,12 (2'), 33,66, 32,79 (3'), 20,23 (5)
4c		HO–6'–5'–4'–3'–2'–(S) (7')	173,44 (1), 157,77 (4), 61,13, 61,08 (6'), 48,95 (2), 39,63, 38,89 (2'), 32,72, 32,63 (5'), 30,35, 29,39 (3'), 23,39, 23,30 (4'), 20,36 (5)
4d		HO–3'–2'–(S) (4')	172,60 (1), 158,44 (4), 61,25, 60,28 (3'), 58,34 (2), 42,49, 41,76 (2'), 31,59 (5), 19,73, 18,25 (6, 7)
4e	(isopropyl: 5,6,7)	HO–4'–3'–2'–(S) (5')	172,40 (1), 158,45 (4), 58,89, 58,79 (4'), 58,28 (2), 36,68, 36,07 (2'), 33,71, 32,86 (3'), 31,72 (5), 19,71, 18,35 (6, 7)
4f		HO–6'–5'–4'–3'–2'–(S) (7')	172,23 (1), 158,25 (4), 61,13, 61,08 (6'), 58,21 (2), 39,67, 38,83 (2'), 32,72, 32,62 (5'), 31,78 (5), 30,35, 29,41 (3'), 23,39, 23,35 (4'), 19,70, 18,33 (6,7)
4g		HO–3'–2'–(S) (4')	173,69 (1), 158,18 (4), 61,21, 60,24 (3'), 51,95 (2), 42,84, 42,49 (2'), 41,83 (5), 24,69 (6), 23,51, 22,39 (7, 8)
4h	(isobutyl: 5,6,7,8)	HO–4'–3'–2'–(S) (5')	173,50 (1), 158,19 (4), 58,90, 58,85 (4'), 51,95 (2), 42,92 (5), 36,73, 36,11 (2'), 33,68, 32,81 (3'), 24,74 (6), 23,43, 22,49 (7, 8)
4i		HO–6'–5'–4'–3'–2'–(S) (7')	173,29 (1), 157,98 (4), 61,13, 61,09 (6'), 51,90 (2), 43,03 (5), 39,70, 38,87 (2'), 32,73, 32,64 (5'), 30,35, 29,37 (3'), 24,74 (6),

			23,41, 22,57 (7, 8), 23,38, 23,31 (4')
4j		HO–3'–2'–S (4')	171,25 (1), 157,63 (4), 141,05 (5), 128,61, 127,10 (6, 7, 9 10), 127,57 (8), 61,18, 60,11 (3'), 56,93 (2), 42,46, 42,01 (2')
4k		HO–4'–3'–2'–S (5')	171,06 (1), 157,67 (4), 141,10 (5), 128,63, 126,96 (6, 7, 9, 10), 127,59 (8), 58,79, 58,72 (4'), 56,98 (2), 39,15, 36,69 (2'), 36,33, 36,28 (3')
4l		HO–6'–5'–4'–3'–2'–S (7')	170,90 (1), 157,49 (4), 141,21 (5), 128,59, 126,93 (6, 7, 9, 10), 127,54 (8), 61,13, 61,06 (6'), 56,94 (2), 39,63, 39,04 (2'), 32,71, 32,58 (5'), 30,31, 29,24 (3'), 23,38, 23,25 (4')
4m		HO–3'–2'–S (4')	172,51 (1), 158,00 (4), 138,41 (6), 129,71, 128,43 (7, 8, 10, 11), 126,58 (9), 61,16, 60,18 (3'), 54,80 (2), 42,42, 41,81 (2'), 39,42 (5)
4n		HO–4'–3'–2'–S (5')	172,28 (1), 158,00 (4), 138,35 (5), 129,68, 128,43 (7, 8, 10, 11), 126,58 (9), 58,93 (4'), 54,79 (2), 39,46 (5), 36,68, 36,14 (2'), 33,61, 32,72 (3')
4o		HO–6'–5'–4'–3'–2'–S (7')	172,06 (1), 157,79 (4), 138,34 (5), 129,70, 128,40 (7, 8, 10, 11), 126,55 (9), 61,13, 61,07 (6'), 54,72 (2), 39,62, 39,55 (2'), 38,91 (5), 32,72, 32,67 (5'), 30,30, 29,33 (3'), 23,36, 23,29 (4')

Ureidoamidi **4b**,**i**,**j**,**m** poslužili su kao alkoholi u sintezi estera ketoprofena **12a**-**d**.

Reakcijom klorida *N*-(1-benzotriazolkarbonil)aminokiseline **3c**-**e** s različitim aminima (cikloheksilamin, cikloheksanmetilamin i benzhidrilamin) sintetizirani su amidi *N*-(1-benzotriazolkarbonil)aminokiselina **5a-f** prema ranije opisanom postupku (Butula *et al*, 1981b), a opisana je i sinteza i potpuna karakterizacija (tališta, elementarne analize, IR, ^{1}H i ^{13}C NMR) tih i srodnih spojeva (Opačić *et al*, 2005).

Pripravljeni su sljedeći amidi:

N-(1-benzotriazolkarbonil)-L-leucin benzhidrilamid (**5a**),

N-(1-benzotriazolkarbonil)-D-fenilglicin cikloheksanmetilamid (**5b**),

N-(1-benzotriazolkarbonil)-D-fenilglicin benzhidrilamid (**5c**),

N-(1-benzotriazolkarbonil)-L-fenilalanin cikloheksilamid (**5d**),

N-(1-benzotriazolkarbonil)-L-fenilalanin cikloheksanmetilamid (**5e**),

N-(1-benzotriazolkarbonil)-L-fenilalanin benzhidrilamid (**5f**).

Novi derivati hidroksiuree **6a-l** (Shema 22) sintetizirani su aminolizom amida *N*-(1-benzotriazolkarbonil)aminokiselina **5a-f** s *O*-benzilhidroksilaminom ili *N*-metilhidroksil-

aminom uz TEA koji služi kao akceptor klorovodika oslobođenog iz hidroklorida hidroksilamina prema ranije opisanom postupku (Opačić *et al*, 2005).

	6a	6b	6c	6d	6e	6f	6g	6h
R^1								
R^2								
R^3	H	-CH$_3$	H	-CH$_3$	H	-CH$_3$	H	-CH$_3$
R^4		H		H		H		H

	6i	6j	6k	6l
R^1				
R^2				
R^3	H	-CH$_3$	H	-CH$_3$
R^4		H		H

Shema 22. Sinteza *N*- i *O*-supstituiranih hidroksiurea **6a-l**

Pripravljene su sljedeće *N*- i *O*-supstituirane hidroksiuree:

N-benzhidrilamid-2-(*N'*-benziloksiureido)-l-4-metilpentanske kiseline (**6a**),

N-benzhidrilamid-2-(*N'*-metil-*N'*-hidroksiureido)-l-4-metilpentanske kiseline (**6b**),

N-cikloheksanmetilamid-2-(*N'*-benziloksiureido)-d-2-feniletanske kiseline (**6c**),

N-cikloheksanmetilamid-2-(*N'*-metil-*N'*-hidroksiureido)-d-2-feniletanske kiseline (**6d**),

N-benzhidrilamid-2-(*N'*-benziloksiureido)-d-2-feniletanske kiseline (**6e**),

N-benzhidrilamid-2-(*N'*-metil-*N'*-hidroksiureido)-d-2-feniletanske kiseline (**6f**),

N-cikloheksilamid-2-(*N'*-benziloksiureido)-l-3-fenilpropanske kiseline (**6g**),

N-cikloheksilamid-2-(*N'*-metil-*N'*-hidroksiureido)-l-3-fenilpropanske kiseline (**6h**),

N-cikolheksanmetilamid-2-(*N'*-benziloksiureido)-l-3-fenilpropanske kiseline (**6i**),

N-cikloheksanmetilamid-2-(*N'*-metil-*N'*-hidroksiureido)-l-3-fenilpropanske kiseline (**6j**),

N-benzhidrilamid-2-(*N'*-benziloksiureido)-l-3-fenilpropanske kiseline (**6k**),

N-benzhidrilamid-2-(*N'*-metil-*N'*-hidroksiureido)-l-3-fenilpropanske kiseline (**6l**).

IR spektri hidroksiurea **6a-l** pokazuju karakteristične vrpce kod 3439–3030 (NH, OH), 1627–1667 (C=O, amid I) i 1520–1584 (C=O, amid II) cm^{-1} (Tablica 4). ^{1}H NMR spektri ispitivanih spojeva otkrivaju da se jedan karbamidni NH (3) nalazi u području 6,45–7,07 ppm, dok je drugi karbamidni NH (1', prisutan samo u *O*-benzilnim derivatima) u području 9,17–9,40 ppm. OH (prisutan samo u *N*-metilnim derivatima) se nalaze u području 9,48–9,85 ppm. Zanimljiva je pojava cijepanja signala metilenskog mosta na dublet dubleta s velikom konstantom povratne sprege (*J* = 10,94–11,6 Hz) u *O*-benzilu koja je uočena u nekoliko derivata; **6a,c,e** dok je u **6g,i,k** taj signal prisutan u obliku očekivanog singleta (Tablica 5). Analizom ^{13}C NMR spektara utvrđeno je da se karbonil u položaju 1 (amid) nalazi u području 169,08–171,81 ppm, a karbonil u položaju 4 (urea) u području 158,12–160,71 ppm. Kemijski pomaci protona u ^{1}H, te atoma ugljika u ^{13}C NMR spektrima u skladu su s predloženim strukturama novih spojeva (Tablica 6).

**Tablica 4.** Analitički i IR podaci za hidroksiuree **6a-l**

| Spoj	R¹	R²	t_t (°C)	Mol. formula (M_r)	IR (KBr) ν_{max} (cm⁻¹)
6a			100–103	$C_{27}H_{31}N_3O_3$ (445,55)	3308, 3061, 3030, 2957, 2930, 2872, 1645, 1525, 1496, 1453, 1336, 1240, 1212, 1078, 1028, 902, 752, 698, 607
6b			219–222 (raspad)	$C_{21}H_{27}N_3O_3$ (369,46)	3407, 3309, 3162, 3031, 2964, 2930, 2900, 2872, 1648, 1548, 1515, 1496, 1471, 1450, 1437, 1368, 1296, 1185, 1173, 1120, 761, 749, 701
6c			148–150	$C_{23}H_{29}N_3O_3$ (395,49)	3310, 3091, 3063, 3032, 2926, 2854, 1639, 1533, 1450, 1355, 1221, 1154, 985, 931, 907, 747, 697
6d			123–126	$C_{17}H_{25}N_3O_3$ (319,40)	3425, 3310, 2925, 2853, 1650, 1532, 1450, 1367, 1184, 1120, 698, 668
6e			161–165	$C_{29}H_{27}N_3O_3$ (465,54)	3308, 3062, 3031, 2934, 1667, 1642, 1536, 1496, 1453, 1366, 1231, 1213, 1031, 934, 743, 700, 640, 614
6f			165–168 (raspad)	$C_{23}H_{23}N_3O_3$ (389,45)	3439, 3376, 3210, 3064, 3031, 2924, 2892, 1637, 1584, 1520, 1496, 1450, 1367, 1177, 1120, 1030, 748, 697, 636
6g			129–131	$C_{23}H_{29}N_3O_3$ (395,49)	3296, 3206, 3064, 3031, 2931, 2854, 1639, 1533, 1498, 1453, 1364, 1250, 1075, 952, 814, 750, 698
6h			153–155	$C_{17}H_{25}N_3O_3$ (319,40)	3390, 3289, 3089, 2935, 2854, 1648, 1627, 1550, 1452, 1390, 1182, 751, 702
6i			130–131	$C_{24}H_{31}N_3O_3$ (409,52)	3313, 3214, 3064, 3031, 2921, 2852, 1661, 1640, 1542, 1496, 1449, 1363, 1276, 1242, 1072, 948, 813, 748, 698, 632, 616
6j			157–159	$C_{18}H_{27}N_3O_3$ (333,43)	3371, 3329, 3194, 2924, 2853, 1658, 1642, 1580, 1528, 1495, 1445, 1190, 1123, 746, 700, 669
6k			161–164	$C_{30}H_{29}N_3O_3$ (479,57)	3288, 3062, 3030, 1649, 1535, 1495, 1454, 1229, 1030, 910, 750, 698
6l			152–154 (raspad)	$C_{24}H_{25}N_3O_3$ (403,47)	3432, 3347, 3062, 3030, 2867, 1664, 1629, 1536, 1496, 1450, 1384, 1230, 1179, 1117, 1030, 744, 700

Tablica 5. ¹H NMR za hidroksiuree **6a-l**

6a,c,e,g,i,k

6b,d,f,h,j,l

Spoj	R^1	R^2	^{1}H NMR (DMSO-d_6, δ ppm)
6a			9,18 (s, 1H, 1'), 8,82 (d, 1H, 1", J = 8,51 Hz), 7,33–7,16 (m, 15H, arom.), 6,45 (d, 1H, 3, J = 8,92 Hz), 6,03 (d, 1H, 2", J = 8,51 Hz), 4,64 (dd, 2H, 2', $J_{vic\ H,H}$ = 11,6 Hz), 4,32–4,28 (m, 1H, 2), 1,43–1,32 (m, 3H, 5, 6), 0,79 (2d, 6H, 7, 8, J = 6,43 Hz)
6b			9,52 (s, 1H, 2'), 8,90 (d, 1H, 1", J = 8,47 Hz), 7,38–7,18 (m, 10H, arom.), 6,68 (d, 1H, 3, J = 8,97 Hz), 6,10 (d, 1H, 2", J = 8,47 Hz), 4,38–4,32 (m, 1H, 2), 2,95 (s, 3H, 3'), 1,58–1,39 (m, 3H, 5, 6), 0,85 (2d, 6H, 7, 8, J = 3,24 Hz)
6c			9,40 (s, 1H, 1'), 8,29 (t, 1H, 1", J = 5,57 Hz), 7,43–7,22 (m, 10H, arom.), 6,91 (d, 1H, 3, J = 7,98 Hz), 5,28 (d, 1H, 2, J = 7,98 Hz), 4,76 (dd, 2H, 2', $J_{vic\ H,H}$ = 11,26 Hz), 2,93–2,82 (m, 2H, 2"), 1,61–0,83 (m, 11H, 3"–8")
6d			9,85 (bs, 1H, 2'), 8,33 (t, 1H, 1", J = 5,76 Hz), 7,39–7,23 (m, 5H, arom.), 7,07 (d, 1H, 3, J = 8,16 Hz), 5,28 (d, 1H, 2, J = 8,16 Hz), 2,95 (s, 3H, 3'), 2,92–2,87 (m, 2H, 2"), 1,60–0,77 (m, 11H, 3"–8")
6e			9,33 (s, 1H, 1'), 9,19 (d, 1H, 1", J = 8,28 Hz), 7,35–6,98 (m, 20H, arom.), 6,85 (d, 1H, 3, J = 7,96 Hz), 6,01 (d, 1H, 2", J = 7,96 Hz), 5,43 (d, 1H, 2, J = 7,96 Hz), 4,68 (dd, 2H, 2', $J_{vic\ H,H}$ = 10,94 Hz)
6f			9,71 (s, 1H, 2'), 9,31 (d, 1H, 1", J = 8,40 Hz), 7,45–7,04 (m, 16H, arom., 3), 6,09 (d, 1H, 2", J = 8,19 Hz), 5,53 (d, 1H, 2, J = 8,19 Hz), 2,96 (s, 3H, 3')
6g			9,24 (s, 1H, 1'), 7,88 (d, 1H, 1", J = 7,66 Hz), 7,35–7,13 (m, 10H, arom.), 6,53 (d, 1H, 3, J = 8,61 Hz), 4,64 (s, 1H, 2'), 4,41 (q, 1H, 2, J = 7,48 Hz), 3,52–3,49 (m, 1H, 2"), 2,96–2,88 (d, 2H, 5), 1,73–1,03 (m, 10H, 3"–7")
6h			9,50 (s, 1H, 2'), 7,83 (d, 1H, 1", J = 7,84 Hz), 7,27–7,15 (m, 5H, arom.), 6,59 (d, 1H, 3, J = 8,56 Hz), 4,36 (q, 1H, 2, J = 6,82 Hz, 8,27 Hz), 3,52–3,43 (m, 1H, 2"), 2,91 (s, 3H, 3'), 2,88 (d, 2H, 5, J = 6,97 Hz), 1,71–1,02 (m, 10H, 3"–7")
6i			9,24 (s, 1H, 1'), 7,96 (t, 1H, 1", J = 5,57 Hz), 7,39–7,19 (m, 10H, arom.), 6,56 (d, 1H, 3, J = 8,44 Hz), 4,65 (s, 1H, 2'), 4,43 (q, 1H, 2, J = 8,12, 5,89 Hz), 2,99–2,82 (m, 4H, 2", 5), 1,66–0,81 (m, 11H, 3"–8")
6j			9,48 (s, 1H, 2'), 7,93 (t, 1H, 1", J = 5,21 Hz), 7,29–7,16 (m, 5H, arom.), 6,63 (d, 1H, 3, J = 8,54 Hz), 4,38 (q, 1H, 2, J = 7,32 Hz), 2,97–2,75 (m, 7H, 5, 2"), 2,91 (s, 3H, 3'), 1,69–0,76 (m, 11H, 3"–8")
6k			9,17 (s, 1H, 1'), 8,89 (d, 1H, 1", J = 8,47 Hz), 7,32–7,11 (m, 20H, arom.), 6,54 (d, 1H, 3, J = 8,74 Hz), 6,03 (d, 1H, 2", J = 8,34 Hz), 4,54 (q+s, 3H, 2, 2'), 2,93–2,84 (m, 2H, 5)
6l			9,52 (s, 1H, 2'), 8,96 (d, 1H, 1", J = 8,32 Hz), 7,37–7,15 (m, 15H, arom.), 6,69 (d, 1H, 3, J = 8,32 Hz), 6,09 (d, 1H, 2", J = 8,32 Hz), 4,60 (q, 1H, 2, J = 6,93 Hz), 2,95–2,91 (m, 2H, 5), 2,91 (s, 3H, 3')

**Tablica 6.** ^{13}C NMR za hidroksiuree **6a-l**

6a,c,e,g,i,k

6b,d,f,h,j,l

Spoj	R^1	R^2	^{13}C NMR (DMSO-d_6, δ ppm)
6a			171,66 (1), 158,95 (4), 142,25, 142,21 (3", 9"), 136,26 (3'), 128,73, 128,35, 128,30, 128,26, 127,39, 127,09 (4', 5', 7', 8', 4", 5", 7", 8", 10", 11", 13", 14"), 128,09, 126,94, 126,90 (7', 6', 12"), 77,40 (2'), 55,84 (2"), 51,16 (2), 41,67 (5), 24,17, 23,04, 21,72 (6–8)
6b			171,81 (1), 160,34 (4), 142,30 (3", 9"), 128,39, 128,35, 127,41, 127,10 (4", 5", 7", 8", 10", 11", 13", 14"), 127,01, 126,97 (6", 12"), 55,84 (2"), 51,85 (2), 42,03 (5), 38,59 (3'), 24,24, 23,05, 21,84 (6–8)
6c			169,68 (1), 158,24 (4), 139,79 (5), 136,09 (3'), 129,00, 128,42, 128,20, 126,37 (6, 7, 9, 10, 4', 5', 7', 8'), 128,29, 127,36 (8, 7'), 77,54 (2'), 55,76 (2), 44,88 (2"), 37,35 (3"), 30,19, 30,14, 25,32 (4", 5", 7", 8"), 25,93 (6")
6d			170,32 (1), 160,05 (4), 140,51 (5), 128,69, 126,89 (6, 7, 9, 10), 127,84 (8), 56,86 (2), 45,34 (2"), 38,76 (3'), 37,81 (3"), 30,66, 30,62, 25,78 (4", 5", 7", 8"), 26,39 (6")
6e			169,08 (1), 158,25 (4), 141,90, 141,77 (3", 9"), 139,34 (5), 136,05 (3'), 128,94, 128,42, 128,38, 128,23, 127,51, 126,79, 126,46 (6, 7, 9, 10, 4', 5', 7', 8', 4", 5", 7", 8", 10", 11", 13", 14"), 77,52 (2'), 56,02, 55,63 (2, 2")
6f			169,72 (1), 160,03 (4), 142,47, 142,25 (3", 9"), 140,11 (5), 128,93, 128,77, 128,74, 127,97, 127,31, 127,01 (6, 7, 9, 10, 4", 5", 7", 8", 10", 11", 13", 14"), 27,97, 127,66, 127,43 (8, 6", 12"), 56,68, 56,51 (2, 2"), 38,78 (3')
6g			170,36 (1), 159,14 (4), 137,93 (6), 136,59 (3'), 129,82, 129,17, 128,36 (7, 8, 10, 11, 4', 5', 7', 8'), 128,60, 126,63 (9, 7'), 77,84 (2'), 54,00 (2), 47,96 (2"), 39,01 (5), 32,74, 32,73, 24,90, 24,85 (3", 4", 6", 7"), 25,65 (5")
6h			170,38 (1), 160,61 (4), 137,91 (6), 129,77, 128,43 (8, 7, 10, 11), 126,68 (9), 54,62 (2), 47,86 (2"), 39,32 (5), 38,99 (3'), 32,70, 24,92, 24,87 (3", 4", 6", 7"), 25,64 (5")
6i			170,38 (1), 158,12 (4), 136,98 (3'), 135,56 (6), 128,68, 128,08, 127,69, 127,43 (7, 8, 10, 11, 4', 5', 7', 8'), 127,52, 125,67 (9, 7'), 76,78 (2'), 53,22 (2), 44,24 (2"), 37,81 (5), 36,74 (3"), 29,72, 24,82 (4", 5", 7", 8"), 25,42 (6")
6j			171,48 (1), 160,64 (4), 138,03 (6), 129,68, 128,47 (7, 8, 10, 11), 126,67 (9), 54,88 (2), 45,26 (2"), 39,14 (5), 38,98 (3'), 37,77 (3"), 30,76, 25,87 (4", 5", 7", 8"), 26,46 (6")
6k			170,55 (1), 158,75 (4), 142,15, 142,14 (3", 9"), 137,41 (6), 136,10 (3'), 129,31, 128,62, 128,34, 128,25, 128,00, 127,39, 127,14 (7, 8, 10, 11, 4', 5', 7', 8', 10", 11", 13", 14"), 128,07, 127,00, 126,91, 126,28 (9, 6", 12"), 77,34 (5), 55,96, 53,75 (2, 2"), 38,16 (3')

| 6l | | | 171,10 (1), 160,71 (4), 142,70, 142,63 (3", 9"), 137,91 (6), 129,78, 128,84, 128,78, 128,51, 127,89, 127,61 (7, 8, 10, 11, 4", 5", 7", 8", 10", 11", 13", 14"), 127,51, 127,39, 126,73 (9, 6", 12"), 56,37, 54,87 (2, 2"), 38,98 (3') |

3.1.2. Sinteza 1-karbamoilbenzotriazola (amida 1-benzotriazolkarboksilne kiseline) 7a-g

Klorid **1** u reakciji s aminima (ciklopentilamin, cikloheksilamin, cikloheksanmetilamin, benzilamin, feniletilamin, benzhidrilamin i *O*-benzilhidroksilamin hidroklorid) daje reaktivne spojeve 1-karbamoilbenzotriazole **7** (aktivne uree). Reakcija se provodi uz ekvimolarni omjer TEA koji veže klorovodik oslobođen u reakciji. Dvostruko više TEA potrebno je u reakciji dobivanja 1-(*N*-benziloksikarbamoil)benzotriazola (**7g**) gdje se drugi mol TEA troši za oslobađanje *O*-benzilhidroksilamina iz oblika soli. Svi produkti su dobiveni prema već opisanom postupku (Butula *et al*, 2000; Butula *et al*, 1977). Nastali 1--karbamoilbenzotriazoli **7** (aktivne uree) su reaktivni spojevi koji već u blagim uvjetima s aminima i srodnim spojevima reagiraju dajući uree, semikarbazide i karbazide, a s alkoholima karbamate (Butula *et al*, 2007).

	7a	7b	7c	7d	7e	7f	7g
R							

Shema 23. Sinteza 1-karbamoilbenzotriazola **7a**-**g**

Pripravljeni su sljedeći 1-karbamoilbenzotriazoli:

1-(*N*-ciklopentilkarbamoil)benzotriazol (**7a**),

1-(*N*-cikloheksilkarbamoil)benzotriazol (**7b**),

1-(*N*-cikloheksanmetilkarbamoil)benzotriazol (**7c**),

1-(*N*-benzilkarbamoil)benzotriazol (**7d**),

1-(*N*-feniletilkarbamoil)benzotriazol (**7e**),

1-(*N*-benzhidrilkarbamoil)benzotriazol (**7f**),

1-(*N*-benziloksikarbamoil)benzotriazol (**7g**).

Od sintetiziranih spojeva novi spojevi su derivati **7a**,**c**,**d**,**f**. Sinteze svih derivata i njihova čistoća praćeni su tankoslojnom kromatografijom, a strukture su potvrđene IR, ^{1}H i ^{13}C NMR spektroskopijom te elementarnom analizom.

IR spektri 1-karbamoilbenzotriazola pokazuju karakteristične vrpce kod 3246–3369 (NH), 1707–1739 (C=O, amid I) i 1517–1603 (C=O, amid II) cm^{-1}. ^{1}H NMR spektri ispitivanih spojeva otkrivaju da se NH nalazi u području 8,98–10,00 ppm. Analizom ^{13}C NMR spektara utvrđeno je da se karbonil nalazi u području 148,61–149,67 ppm. Kemijski pomaci protona u ^{1}H, te atoma ugljika u ^{13}C NMR spektrima u skladu su s predloženim strukturama novih spojeva.

Kako u prijašnjim publikacijama nedostaju NMR spektroskopski podaci, u Tablicama 7–9 dan je pregled analitičkih i spektroskopskih podataka za sve spojeve **7**.

Tablica 7. Analitički podaci za 1-karbamoilbenzotriazole **7a-g**

Spoj	R	t_t (°C)	Mol. formula (M_r)	IR (KBr) ν_{max} (cm^{-1})
7a		67–68	$C_{12}H_{14}N_4O$ (230,27)	3255, 2949, 2866, 1736, 1523, 1487, 1448, 1371, 1287, 1233, 1185, 1130, 1073, 1000, 944, 925, 815, 747, 652
7b		140^a	$C_{13}H_{16}N_4O$ (244,29)	3327, 2938, 2856, 1733, 1517, 1488, 1447, 1360, 1285, 1226, 1151, 1090, 1059, 1002, 968, 928, 835, 791, 755, 612
7c		66–68	$C_{14}H_{18}N_4O$ (258,32)	3360, 2925, 2852, 1739, 1527, 1488, 1448, 1364, 1286, 1232, 1152, 1072, 1011, 954, 786, 771, 753, 593
7d		110	$C_{14}H_{12}N_4O$ (252,27)	3362, 1733, 1526, 1486, 1447, 1358, 1288, 1256, 1231, 1130, 1076, 1002, 793, 752, 696, 609, 580, 562
7e		114–115 115–117^b	$C_{15}H_{14}N_4O$ (266,30)	3369, 3024, 2949, 1736, 1530, 1497, 1447, 1363, 1288, 1231, 1128, 1097, 1034, 1002, 920, 840, 749, 699, 588, 563
7f		120–122	$C_{20}H_{16}N_4O$ (328,37)	3288, 3028, 2931, 1707, 1520, 1449, 1375, 1293, 1231, 1069, 1031, 931, 864, 752, 695, 644, 607, 535

| **7g** | (structure: benzyloxy) | 113–114[c] | $C_{14}H_{12}N_4O_2$ (268,27) | 3246, 3133, 3030, 2947, 2884, 1728, 1603, 1484, 1367, 1289, 1231, 1132, 1093, 1003, 924, 869, 751, 699, 563 (Butula *et al*, 2000) |

[a]Butula *et al*, 1977; [b]Butula *et al*, 1978; [c]Butula *et al*, 2000

Tablica 8. ^{1}H NMR za 1-karbamoilbenzotriazole **7a-g**

Spoj	R	^{1}H NMR (DMSO-d_6, δ ppm)
7a	(cyclopentyl, positions 2'–6')	9,09 (d, 1H, 1', J = 6,62 Hz), 8,19 (d, 2H, arom., J = 8,27 Hz), 7,71, 7,54 (2t, 2H, J = 7,72 Hz, J = 6,62 Hz), 4,29–4,22 (m, 1H, 2'), 1,97–1,56 (m, 8H, 3'–6')
7b	(cyclohexyl, positions 2'–7')	8,98 (d, 1H, 1', J = 8,18 Hz), 8,19 (d, 2H, arom., J = 9,20 Hz), 7,71, 7,54 (2t, 2H, arom., J = 7,67 Hz), 3,81–3,73 (m, 1H, 2'), 1,93–1,11 (m, 10H, 3'–7')
7c	(cyclohexylmethyl, positions 2'–8')	9,18 (t, 1H, 1', J = 5,62 Hz), 8,20 (d, 2H, arom., J = 9,20 Hz), 7,71, 7,54 (2t, 2H, arom., J = 7,67 Hz), 3,23 (t, 2H, 2', J = 6,14 Hz), 1,77–1,58, 1,27–0,93 (2m, 11H, 3'–8')
7d	(benzyl, positions 2'–8')	9,78 (t, 1H, 1', J = 5,81 Hz), 8,20 (d, 2H, arom., J = 8,72 Hz), 7,72, 7,55 (2t, 2H, arom., J = 7,89 Hz), 7,45–7,25 (m, arom., 5H), 4,59 (d, 2H, 2', J = 6,23 Hz)
7e	(phenethyl, positions 2'–9')	9,27 (t, 1H, 1', J = 6,06 Hz), 8,21 (d, 2H, arom., J = 8,48 Hz), 7,71, 7,54 (2t, 2H, arom., J = 7,27 Hz), 7,34–7,19 (m, arom., 5H), 3,63 (q, 2H, 2', J = 6,67 Hz), 2,98 (t, 2H, 3', J = 7,88 Hz)
7f	(diphenylmethyl, positions 2'–14')	10,00 (d, 1H, 1', J = 8,57 Hz), 8,21, 8,17 (2d, 2H, arom., J = 8,04 Hz), 7,74–7,28 (m, 12H, arom.), 6,40 (d, 1H, 2', J = 9,11 Hz)
7g	(benzyloxy, positions 2'–8')	9,95 (s, 1H, 1'), 8,27, 8,09 (2d, 2H, J = 8,20 Hz, 8,50 Hz), 7,67, (t, 2H, J = 7,7 Hz), 7,48–7,34 (m, arom., 5H), 5,14 (s, 2H, 2') (Butula *et al*, 2000)

Tablica 9. ^{13}C NMR za 1-karbamoilbenzotriazole **7a-g**

Spoj	R	^{13}C NMR (DMSO-d_6, δ ppm)
7a		148,98 (1), 145,87, 131,85 (2, 7), 130,24, 125,90, 120,16, 114,11 (3–6), 52,55 (2'), 32,18, 24,01 (3'–6')
7b		148,61 (1), 145,91, 131,89 (2, 7), 130,24, 125,94, 120,17, 114,05 (3–6), 50,34 (2'), 32,41, 25,35 (3', 4', 6', 7'), 25,46 (5')
7c		149,54 (1), 145,94, 131,83 (2, 7), 130,28, 125,90, 120,18, 114,05 (3–6), 40,60 (2'), 37,77 (3'), 30,76, 25,78 (4', 5', 7', 8'), 25,86 (6')
7d		149,67 (1), 145,96, 131,84 (2, 7), 139,10 (3'), 130,39, 125,98, 120,24, 114,02 (3–6), 128,84, 127,88 (4', 5', 7', 8'), 127,54 (6'), 43,94 (2')
7e		149,37 (1), 145,92, 131,78 (2, 7), 139,42 (4'), 130,34, 125,94, 120,20, 114,01 (3–6), 129,15, 128,85 (5', 6', 8', 9'), 126,69 (7'), 41,96, 35,36 (2', 3')
7f		149,16 (1), 145,93, 131,95 (2, 7), 141,62 (3', 9'), 130,42, 126,08, 120,27, 113,96 (3–6), 128,87, 128,23 (4', 5', 7', 8', 10', 11', 13', 14'), 127,82 (6', 12'), 58,37 (2')
7g		148,68 (1), 145,72, 131,54 (2, 7), 134,46 (3'), 130,23, 125,66, 120,07, 113,49 (3–6), 129,28, 128,63 (4', 5', 7', 8'), 126,97 (6'), 79,24 (2') (Butula *et al*, 2000)

3.1.3 Sinteza 4-benziloksisemikarbazida (8) i 1-(1-benzotriazolkarbonil)-4-benziloksi-semikarbazida (9)

1-(*N*-Benziloksikarbamoil)benzotriazol **7g** korišten je za pripravu 4-benziloksisemi-karbazida (**8**). BtH je u reakciji nukleofilne supstitucije zamijenjen hidrazinom. Reakcija je izvođena uz mali suvišak hidrazin hidrata da bi spriječili kondenzaciju nastalog semikarbazida sa spojem **7g**. Iz istog razloga je otopina spoja **7g** polako dokapavana u hidrazin hidrat, a ne obrnuto. U reakciji nije uočen nastanak mogućeg kondenziranog derivata.

Dobiveni semikarbazid je zatim u reakciji s kloridom **1** dao 1-(1-benzotriazolkarbonil)-4-benziloksisemikarbazid (**9**). Spoj **9** se u kasnijim reakcijama pokazao kao vrlo prikladan reagens za uvođenje acilhidroksisemikarbazidne skupine u molekule. Nije pokazao sklonost intramolekulskoj ciklizaciji.

**Shema 24.** Sinteza 4-benziloksisemikarbazida **8** i 1-(1-benzotriazolkarbonil)-4-benziloksisemikarbazida **9**

Sinteze novih spojeva i njihova čistoća praćeni su tankoslojnom kromatografijom, a strukture su potvrđene IR, ^{1}H i ^{13}C NMR spektroskopijom i elementarnom analizom.

IR spektri spojeva **8** i **9** pokazuju karakteristične vrpce kod 3164–3482 (NH). Vrpce karakteristične za karbonilne skupine se razlikuju, kod spoja **8** je 1655 (amid I) i 1517 (amid II) dok se kod spoja **9** osim tih vrpca 1674 (amid I) i 1556 (amid II) javlja još jedna vrpca karbonila na 1738 cm^{-1}. ^{1}H NMR spektri ispitivanih spojeva otkrivaju da se NH vezan na karbonile nalazi u području 7,84–10,97 ppm, a u spoju **8** se još jedan NH javlja na 4,01 ppm. Analizom ^{13}C NMR spektara utvrđeno je da se karbonil u položaju 3 nalazi u području 159,37–161,67 ppm, a karbonil u položaju 1' (spoj **9**) na 149,86 ppm. Kemijski pomaci protona u ^{1}H, te atoma ugljika u ^{13}C NMR spektrima u skladu su s predloženim strukturama novih spojeva. Analitički i spektroskopski podaci za nove spojeve dani su u Tablicama 10 i 11.

Tablica 10. Analitički i IR podaci za spojeve **8** i **9**

Spoj	R	t_t (°C)	Mol. formula (M_r)	IR (KBr) ν_{max} (cm^{-1})
8	H	90–92	C$_8$H$_{11}$N$_3$O$_2$ (181,19)	3332, 3287, 3217, 3061, 3030, 2962, 2925, 2875, 1655, 1637, 1517, 1456, 1366, 1325, 1228, 1210, 1192, 1096, 1070, 980, 915, 797,

				751, 702, 680, 607
9		90–93 (raspad)	$C_{15}H_{14}N_6O_3$ (326,31)	3482, 3376, 3340, 3164, 3005, 2924, 2854, 1738, 1674, 1556, 1487, 1449, 1387, 1287, 1235, 1066, 1033, 905, 754, 744, 704, 680, 652, 609, 580, 539

**Tablica 11**. ^1H i ^{13}C NMR podaci za spojeve **8** i **9**

Spoj	R	^1H i ^{13}C NMR (DMSO-d_6, δ ppm)
8	H	9,18 (s, 1H, 4), 7,84 (s, 1H, 2), 7,42–7,29 (m, 5H, arom.), 4,71 (s, 2H, 5), 4,01 (s, 2H, 1) 161,67 (3), 137,18 (6), 129,08, 128,63 (7, 8, 10, 11), 128,37 (9), 77,70 (5)
9		10,97, 9,87, 9,31 (3s, 3H, 1, 2, 4), 8,26–8,18 (2d, 2H, arom.), 7,77, 7,59 (2t, 2H, arom.), 7,49–7,35 (m, 5H, arom., 7–11), 4,85 (s, 2H, 5) 159,37 (3), 149,86 (1'), 145,66, 131,92 (2', 7'), 136,74 (6), 130,78, 126,31, 120,42, 113,79 (3'–6'), 129,20, 128,68 (7, 8, 10, 11), 128,54 (9), 78,11 (5)

3.1.4. Sinteza derivata NSAID 10-14

3.1.4.1. *Sinteza NSAID benzotriazolida **10a-d***

NSAID benzotriazolidi **10a-d** pravljeni su reakcijom klorida **1** s odgovarajućim NSAID (ibuprofen, fenoprofen, ketoprofen i njegov reducirani derivat) u omjeru 1:1, u prisutnosti TEA (Rajić *et al*, 2010; Zorc *et al*, 1994; Zorc *et al*, 1993). Reakcijom prvo nastaje mješoviti anhidrid koji dekarboksilacijom daje benzotriazolid **10** (Shema 25). U benzotriazolidima je karboksilna skupina dovoljno aktivirana da s aminima i alkoholima daje amide, odnosno estere u blagim uvjetima, uz odcjepljenje BtH što je korišteno u sintezi svih derivata NSAID pripravljenih u okviru ove disertacije (Butula *et al*, 2007).

Shema 25. Sinteza NSAID benzotriazolida **10a**-**d**.

Sinteza i čistoća spojeva **10a-d** praćeni su tankoslojnom kromatografijom, a njihove strukture potvrđene su IR, ^{1}H i ^{13}C NMR spektroskopijom. Tališta ranije pripravljenih spojeva **10a**-**d** i njihovi spektroskopski podaci u skladu su s literaturnim podacima (Rajić *et al*, 2010; Zorc *et al*, 1994; Zorc *et al*, 1993).

3.1.4.2. *Sinteza NSAID hidrazida 11a-c*

BtH je u spojevima **10a-c** u reakciji nukleofilne supstitucije zamijenjen hidrazinom (Shema 26). Reakcije su izvođene uz suvišak hidrazin hidrata da bi spriječili kondenzaciju nastalog produkta hidrazida s neizreagiranim benzotriazolidom **10** pri čemu može nastati diacil hidrazin (Shema 27).

Shema 26. Sinteza NSAID hidrazida **11a**-**c**

Shema 27. Kondenzacija NSAID benzotriazolida i hidrazida u diacil hidrazine

Pokušaj sinteze ketoprofenskog hidrazida nije uspio zbog reakcije keto skupine s hidrazin hidratom (Kürti *et al*, 2005) tako da je on isključen iz daljnih sinteza. U zamjenu je uzet njegov reducirani derivat (keto skupina reducirana do metilenske).

Priređeni su sljedeći NSAID hidrazidi:

2-(4-izobutilfenil)propanhidrazid (**11a**),

2-(3-fenoksifenil)propanhidrazid (**11b**),

2-(3-benzilfenil)propanhidrazid (**11c**).

Od sintetiziranih spojeva novi spojevi su **11b,c**, a svi su pripravljeni novom, do sada neobjavljenom metodom. Sinteza spojeva **11a-c** i njihova čistoća praćeni su tankoslojnom kromatografijom, a strukture potvrđene IR, ^{1}H i ^{13}C NMR spektroskopijom i elementarnom analizom. Tališta i spektroskopski podaci ranije pripravljenog derivata podudaraju se s literaturnim podacima (Sharma *et al*, 2003).

IR spektri ispitivanih spojeva pokazuju karakteristične vrpce kod 3023–3289 (NH) i 1637–1688 (C=O, amid I) i 1534–1582 (C=O, amid II) cm^{-1}. ^{1}H NMR spektri ispitivanih spojeva otkrivaju da se NH vezan na karbonil nalazi u području 9,12–9,14 ppm, a NH$_2$ se javlja na 4,15–4,25 ppm. Analizom ^{13}C NMR spektara utvrđeno je da se karbonil nalazi u području 172,87–173,37 ppm. Kemijski pomaci protona u ^{1}H, te atoma ugljika u ^{13}C NMR spektrima u skladu su s predloženim strukturama novih spojeva. Analitički i spektroskopski podaci prikazani su u Tablicama 12 i 13.

Tablica 12. Analitički i IR podaci za NSAID hidrazide **11a-c**

Spoj	R¹	t_t (°C)	Molekulska formula (M_r)	IR (KBr/film) ν_{max} (cm⁻¹)
11a		80	$C_{13}H_{20}N_2O$ (220,31)	3276, 3180, 3052, 2954, 2919, 1688, 1641, 1535, 1510, 1452, 1416, 1358, 1257, 1237, 1124, 1074, 1007, 965, 848, 800, 786, 731, 690, 521
11b		ulje	$C_{15}H_{16}N_2O_2$ (256,30)	3285, 3040, 2978, 1659, 1631, 1582, 1487, 1445, 1244, 1210, 1164, 963, 928, 757, 692
11c		80–82	$C_{16}H_{18}N_2O$ (254,33)	3289, 3191, 3168, 3063, 3023, 2975, 2919, 1637, 1601, 1534, 1486, 1453, 1382, 1261, 1008, 976, 786, 759, 722, 696, 685, 599

Tablica 13. ¹H i ¹³C NMR podaci za NSAID hidrazide **11a-c**

Spoj	R	¹H i ¹³C NMR (DMSO-d_6, δ ppm)
11a		9,12 (s, 1H, 2), 7,12 (dd, 4H, arom., J = 8,32 Hz, 38,27 Hz), 4,15 (s, 2H, 1), 3,46 (q, 1H, 4, J = 6,96 Hz), 2,38 (d, 2H, 12, J = 6,96 Hz), 1,82–1,73 (m, 1H, 13), 1,30 (d, 3H, 5, J = 6,96 Hz), 0,83 (d, 6H, 14,15, J = 6,65 Hz) 173,37 (3), 139,78, 139,70 (6, 9), 129,15, 127,44 (7, 8, 10, 11), 44,70 (12), 43,37 (4), 30,09 (13), 22,63 (14, 15), 18,82 (5)
11b		9,19 (s, 1H, 2), 7,43–6,82 (m, 9H, arom.), 4,25 (s, 2H, 1), 3,53 (q, 1H, 4, J = 6,99 Hz), 1,32 (d, 3H, 5, J = 7,14 Hz) 172,87 (3), 157,01, 156,92, 144,73 (6, 10, 12), 130,50, 119,04 (13, 14, 16, 17), 130,15, 123,88, 122,86, 118,06, 117,02 (7–9, 11, 15), 43,58 (4), 18,76 (5)
11c		9,14 (s, 1H, 2), 7,31–7,03 (m, 9H, arom.), 4,17 (s, 2H, 1), 3,90 (s, 2H, 12), 3,48 (q, 1H, 4, J = 6,91 Hz), 1,33 (d, 3H, 5, J = 7,27 Hz) 173,19 (3), 142,66, 141,65, 141,47 (6, 10, 13), 129,14, 128,88 (13, 14, 16, 17), 128,69, 128,15, 127,38, 126,42, 125,44 (7–9, 11, 15), 43,72 (4), 41,64 (12), 18,88 (5)

3.1.4.3. *Sinteza estera ketoprofena i ureidoamida* **12a-d**

U sklopu ranijih istraživanja na Zavodu za farmaceutsku kemiju razvijena je metoda dobivanja estera iz NSAID benzotriazolida. Sintetizirani su metilni i etilni esteri te esterski polimer-lijek konjugati (Zorc *et al*, 1994; Zorc *et al*, 1993). Ta metoda korištena je i u sintezi estera **12a-d** (Shema 28) uz male modifikacije reakcijskih uvjeta čime je znatno skraćeno trajanje reakcije. Reakcije su provođene bez otapala na temperaturi taljenja smjese reaktanata uz suvišak TEA. Usporedba reakcijskih uvjeta dana je u tablici (Tablica 14).

Tablica 14. Usporedba različitih reakcijskih uvjeta u sintezi estera NSAID

	Otapalo	NSAID-Bt/ TEA	Temp./°C	Trajanje reakcije/h	Iskorištenje/ %
Metoda I (Zorc *et al*, 1993)	Metanol/etanol (ujedno i reagens)	1:4	Refluks	3	82–100
Metoda II (nova)	–	1:2	100–125[a]	0,25	65–82

[a] temperatura taljenja reakcijske smjese

HO—(—)$_n$—NH—CO—NH—CH(R)—CO—NH—(—)$_n$—OH + 2 (10d) $\xrightarrow[\text{-BtH}]{\text{TEA}}$

4b,i,j,m $n = 2,3,5$ 10d

12a-d

	12a	**12b**	**12c**	**12d**
R	CH$_3$			
n	3	5	2	2

Shema 28. Sinteza estera ketoprofena **12a**-**d**

Priređeni su sljedeći esteri:

2-(3-benzilfenil)-*N*-ciklopentilpropanamid (1**2a**),

2-(3-benzilfenil)-*N*-cikloheksilpropanamid (**12b**),

2-(3-benzilfenil)-*N*-(cikloheksanmetil)propanamid (**12c**),

N-benzil-2-(3-benzilfenil)propanamid (**12d**).

Svi sintetizirani esteri su novi spojevi. Tijek sinteze i čistoća spojeva praćeni su tankoslojnom kromatografijom, a njihove strukture potvrđene su IR, ^{1}H i ^{13}C NMR spektroskopijom i elementarnom analizom.

U IR spektrima prisutne su karakteristične vrpce za NH u području 3063–3302 i za karbonilne skupine u području 1731–1735 cm^{-1} (ester), 1633–1663 cm^{-1} (amid I) i 1556–1569 cm^{-1} (amid II). U ^{1}H NMR spektrima spojeva karbamidni NH se javljaju u području 5,92–6,36 ppm (1') i 5,87–6,84 ppm (3), a amidni NH u području 7,87–8,47 ppm (1'). U spojevima 12 nalazi se 4 vrste karbonilnih skupina: keto skupina na položaju 10" je u području 196,01–196,01 ppm, esterska na položaju 1" 173,85–174,00 ppm, amidna na položaju 1 171,40–173,60 ppm i karbamidna na položaju 4 157,44–157,95 ppm. Analitički i spektroskopski podaci dani su u Tablicama 15–17.

Tablica 15. Analitički i IR podaci za estere **12a-d**

| Spoj	R	⟨CH₂⟩$_n$	Mol. formula (M_r)	IR (NaCl/film) ν_{max} (cm^{-1})
12a	CH$_3$		C$_{42}$H$_{45}$N$_3$O$_8$ (719,82)	3302, 3065, 2927, 2869, 1731, 1659, 1635, 1569, 1556, 1449, 1380, 1318, 1284, 1250, 1206, 1173, 1079, 960, 719, 644
12b			C$_{49}$H$_{59}$N$_3$O$_8$ (818,01)	3291, 3064, 2932, 2869, 1732, 1659, 1633, 1566, 1556, 1448, 1378, 1318, 1283, 1206, 1176, 1077, 954, 721, 706, 643
12c			C$_{45}$H$_{43}$N$_3$O$_8$ (753,84)	3296, 3064, 2980, 1735, 1633, 1564, 1449, 1374, 1284, 1172, 1077, 698, 643
12d			C$_{46}$H$_{45}$N$_3$O$_8$ (767,86)	3302, 3063, 2979, 2938, 1732, 1663, 1646, 1569, 1554, 1451, 1380, 1284, 1205, 1177, 1078, 956, 823, 722, 644

Tablica 16. ^{1}H NMR podaci za estere **12a-d**

Spoj	R	$\left(\right)_n$	^{1}H NMR (DMSO-d_6, δ ppm, J/Hz)
12a	$^5CH_3$	(4' 3' 2')	7,91 (t, 1H, 1'(amid), J = 5,62 Hz), 7,74–7,50 (m, 18H, arom.), 6,08 (t, 1H, 1'(urea), J = 5,62 Hz), 6,01 (d, 1H, 3, J = 7,79 Hz), 4,10–3,90 (m, 7H, 2, 4', 2''), 3,08–2,93 (m, 4H, 2'), 1,70–1,59 (m, 4H, 3'), 1,43 (d, 6H, 3'', J = 7,07 Hz), 1,11 (d, 3H, 5, J = 6,89 Hz)
12b	(5 6 7 8)	(6' 5' 4' 3' 2')	7,87 (t, 1H, 1'(amid), J = 5,50 Hz), 7,73–7,50 (m, 18H, arom.), 5,92 (t, 1H, 1'(urea), J = 5,50 Hz), 5,87 (d, 1H, 3, J = 8,84 Hz), 4,13–3,89 (m, 7H, 2, 6', 2''), 3,02–2,86 (m, 4H, 2'), 1,54–1,13 (m, 21H, 5, 6, 3'–5', 3''), 0,84 (2d, 6H, 7, 8, J = 5,85 Hz)
12c	(5 6 7 8 9 10)	(3' 2')	8,47 (t, 1H, 1'(amid), J = 4,34 Hz), 7,75–7,49 (m, 18H, arom.), 7,37–7,22 (m, 5H, arom.), 6,84 (d, 1H, 3, J = 8,31 Hz), 6,36 (t, 1H, 1'(urea), J = 5,54 Hz), 5,32 (d, 1H, 2, J = 8,01 Hz), 4,10–3,78 (m, 6H, 3', 2''), 3,32–3,21 (m, 4H, 2'), 1,43, 1,37 (2d, 6H, 3'', J = 7,32 Hz)
12d	(5 6 7 8 9 10 11)		8,14 (t, 1H, 1'(amid), J = 5,25 Hz), 7,74–7,48 (m, 18H, arom.), 7,22–7,09 (m, 5H, arom.), 6,22–6,18 (d+t, 2H, 3, 1' (urea)), 4,36 (q, 1H, 2, J = 6,44 Hz), 4,07–3,88 (m, 6H, 3', 2''), 3,31–3,14 (m, 4H, 5, 2'), 2,88–2,66 (m, 2H, 2'), 1,44–1,41 (m, 6H, 3'')

Tablica 17. ^{13}C NMR podaci za estere **12a-d**

Spoj	R	$\left(\right)_n$	^{13}C NMR (DMSO-d_6, δ ppm, J/Hz)
12a	$^5CH_3$	(4' 3' 2')	196,07 (10''), 174,00, 173,95 (1''), 173,60 (1), 157,72 (4), 141,58, 137,65, 137,41 (4'', 8'', 11''), 133,20, 132,22, 129,30, 128,95, 128,90, (5''–7'', 9'', 14''), 130,05, 129,04 (12'', 13'', 15'', 16''), 62,82, 62,73 (4'), 49,01 (2), 44,71 (2''), 36,23, 35,57 (2'), 29,61, 28,70 (3'), 20,19 (5), 18,91 (3'')
12b	(5 6 7 8)	(6' 5' 4' 3' 2')	196,04 (10''), 173,95 (1''), 173,30 (1), 157,95 (4), 141,62, 137,63, 137,41 (4'', 8'', 11''), 133,21, 132,20, 129,36, 128,92, (5''–7'', 9'', 14''), 130,03, 129,04 (12'', 13'', 15'', 16''), 64,75 (6'), 51,89 (2), 44,75 (2''), 43,00 (5), 39,43, 38,56 (2'), 29,95, 28,95, 28,18, 28,09, 23,05, 23,00 (3'–5'), 24,73, 23,38, 22,54 (6–8), 18,82 (3'')
12c	(5 6 7 8 9 10)	(3' 2')	196,04 (10''), 173,93, 173,85 (1''), 171,40 (1), 157,44 (4), 141,47, 141,39, 140,72, 140,70, 140,66, 137,62, 137,39 (5, 4'', 8'', 11'',), 133,20, 132,31, 132,27, 129,28, 128,94, (5''–7'', 9'', 14''), 130,08, 129,04 (12'', 13'', 15'', 16''), 127,64, 127,01 (6, 7, 9, 10), 127,68 (8), 64,59, 63,32 (3'), 56,97 (2), 44,75, 44,68 (2''), 38,59, 38,03 (2'), 18,99, 18,89 (3'')
12d	(5 6 7 8 9 10 11)		196,04, 196,01 (10''), 173,93 (1''), 172,59 (1), 157,73 (4), 141,48, 141,46, 138,17, 138,14, 137,62, 137,61, 137,39 (6, 4'', 8'', 11''), 133,20, 132,30, 129,29, 128,96 (5''–7'', 9'', 14''), 130,07, 129,03 (12'', 13'', 15'', 16''), 129,67, 128,39 (7, 8, 10, 11), 126,59 (9), 64,54 63,54, 63,40 (3'), 54,69 (2), 44,74 (2''), 39,34 (5), 38,55, 37,90 (2'), 19,00 (3'')

**3.1.4.4.** *Sinteza 4-supstituiranih 1-acilsemikarbazida NSAID **13a-y***

Semikarbazidni derivati NSAID **13** (Shema 29) pripravljeni su iz NSAID hidrazida **11** i odgovarajućeg 1-karbamoilbenzotriazola **7**. Ovisno o supstituentu na položaju 4 semikarbazidne okosnice upotrebljeni su različiti reakcijski uvjeti. Tako su dobiveni cikloaklil/aril (**13a-s**), benziloksi (**13t-v**) i hidroksi (**13w-y**) derivati. 1-Acil-4-hidroksisemikarbazidi **13w-y** dobiveni su hidrogenolizom benzilne skupine benziloksisemikarbazida **13t-v**.

Sinteza 4-cikloalkil/aril derivata **13a-s** izvođene su uz suvišak TEA, na minimalnoj temperaturi taljenja smjese reaktanata (75–120 °C) i bez otapala. Takvi uvjeti omogućili su brz završetak reakcije (15 minuta) i pojednostavljenu obradu reakcijske smjese (ekstrakcija u lužnatom radi uklanjanja oslobođenog benzotriazola). U reakcijama nije uočena ciklizacija niti raspad bilo reaktanata bilo produkata.

Suprotno tome, derivati **13t-v** s benziloksi skupinom u položaju 4 pripravljeni su na nižoj temperature (55 °C), u otapalu (dioksan) i bez TEA. Razlog tome je mogućnost ciklizacije koja se često javlja kod spojeva s *O*-benzilnom skupinom, a koja je u blažim reakcijskim uvjetima uspješno izbjegnuta. Zato su te reakcije trajale puno dulje (6–8 sati). Iskorištenja su podjednaka za oba načina sinteze. Uvjeti obrade reakcija nakon njihovog završetka se također razlikuju, ovisno o topljivosti nastalog produkta u etil-acetatu koji je korišten kao organski sloj u ekstrakciji. Ukoliko produkt nije bio topljiv, ekstrakcija je zamijenjena obradom u smjesi acetona i zakiseljene vode čime je uspješno uklonjen BtH oslobođen u reakciji. U Tablici 18 dan je pregled reakcijskih uvjeta i pripadajućih iskorištenja za sve semikarbazidne derivate.

Tablica 18. Reakcijski uvjeti za spojeve **13**

Spoj 13	Množinski omjer reaktanata (7:11:TEA)	Otapalo	Temp. (°C)	Trajanje reakcije (h)	Obrada	Iskorištenje (%)
a,b,e-j,l-n,r,s	1:1:3	–	75–120	0,25	ekstrakcija u lužnatom	47–85
c,d,k,o,p	1:1:3	–	75–120	0,25	smjesa acetona i zakiseljene vode	63–94
t-v	1:1:0	dioksan	55	6–8	ekstrakcija u lužnatom	50–91
w-y		metanol	s.t.	1,5	–	75–96

Shema 29. Sinteza 1-acilsemikarbazida NSAID **13a-y**

Pripravljeni su sljedeći 1-acilsemikarbazidi:

4-ciklopentil-1-[2-(4-izobutilfenil)propanoil]semikarbazid (**13a**),

4-cikloheksil-1-[2-(4-izobutilfenil)propanoil]semikarbazid (**13b**),

4-cikloheksanmetil-1-[2-(4-izobutilfenil)propanoil]semikarbazid (**13c**),

4-benzil-1-[2-(4-izobutilfenil)propanoil]semikarbazid (**13d**),

4-feniletil-1-[2-(4-izobutilfenil)propanoil]semikarbazid (**13e**),

4-benzhidril-1-[2-(4-izobutilfenil)propanoil]semikarbazid (**13f**),

4-ciklopentil-1-[2-(3-fenoksifenil)propanoil]semikarbazid (**13g**),

4-cikloheksil-1-[2-(3-fenoksifenil)propanoil]semikarbazid (**13h**),

4-cikloheksanmetil-1-[2-(3-fenoksifenil)propanoil]semikarbazid (**13i**),

4-cenzil-1-[2-(3-fenoksifenil)propanoil]semikarbazid (**13j**),

4-feniletil-1-[2-(3-fenoksifenil)propanoil]semikarbazid (**13k**),

4-benzhidril-1-[2-(3-fenoksifenil)propanoil]semikarbazid (**13l**),

4-ciklopentil-1-[2-(3-benzilfenil)propanoil]semikarbazid (**13m**),

4-cikloheksil-2-[2-(3-benzilfenil)propanoil]semikarbazid (**13n**),

4-cikloheksanmetil-1-[2-(3-benzilfenil)propanoil]semikarbazid (**13o**),

4-benzil-1-[2-(3-benzilfenil)propanoil]semikarbazid (**13p**),

4-feniletil-1-[2-(3-benzilfenil)propanoil]semikarbazid (**13r**),

4-benzhidril-1-[2-(3-benzilfenil)propanoil]semikarbazid (**13s**),

4-benziloksi-1-[2-(4-izobutilfenil)propanoil]semikarbazid (**13t**),

4-benziloksi-1-[2-(3-fenoksifenil)propanoil]semikarbazid (**13u**),

4-benziloksi-1-[2-(3-benzilfenil)propanoil]semikarbazid (**13v**),

4-hidroksi-1-[2-(4-izobutilfenil)propanoil]semikarbazid (**13w**),

4-hidroksi-1-[2-(3-fenoksifenil)propanoil]semikarbazid (**13x**),

4-hidroksi-1-(2-(3-benzilfenil)propanoil]semikarbazid (**13y**).

Tijek sinteze i čistoća spojeva praćeni su tankoslojnom kromatografijom, a njihove strukture potvrđene su IR, ^{1}H i ^{13}C NMR spektroskopijom i elementarnom analizom.

IR spektri semikarbazida **13** pokazuju karakteristične vrpce kod 3025–3472 (NH i OH), 1601–1699 (amid I) i 1506–1590 (amid II) cm^{-1}. U ^{1}H NMR spektrima derivata **13a-s** signali NH na položajima 1 i 2 javljaju se u području 9,63–9,78 i 7,59–7,89 ppm, a na položaju 2' ima širi raspon od 5,71–6,99 ppm (pomaci u niže polje posljedica su blizine aromatskih prstenova koji ju otkrivaju) u derivatima **d-f**, **j-l** i **p-s**. U derivatima **13t-z** zbog elektron odvlačećeg utjecaja atoma kisika, signali NH su pomaknuti u niže polje osim najdaljeg NH na položaju 2 koji se kao i kod derivata **a-s** nalazi u području 9,72–9,74 ppm, dok su preostala dva NH u derivatima **t-v** nalaze u području 9,46–9,47 i 8,69–8,71 ppm. Derivatima **w-z** NH na položajima 1 i 2' te OH nalaze se u području 8,41–8,73 ppm. Karbonilna skupina na položaju 3 u ^{13}C NMR spektrima nalazi se u području 172,59–175,27 ppm, a na položaju 1' u području 157,02–160,82 ppm.

Svi spojevi serije **13** su novi. Njihovi analitički i spektroskopski podaci dani su u Tablicama 19–21.

Tablica 19. Analitički i IR podaci za 1-acilsemikarbazide NSAID **13a-y**

Spoj	R^1	R^2	t_t (°C)	Mol. formula (M_r)	IR (KBr) ν_{max} (cm^{-1})

13a			123–128	C$_{19}$H$_{29}$N$_3$O$_2$ (331,45)	3355, 3254, 2956, 2871, 1684, 1650, 1557, 1513, 1465, 1315, 1243, 1151, 1079, 1008, 937, 850, 786, 655
13b			165–166	C$_{20}$H$_{31}$N$_3$O$_2$ (345,48)	3307, 3253, 3019, 2986, 2951, 2930, 2852, 1708, 1683, 1641, 1562, 1531, 1506, 1453, 1322, 1253, 1226, 1153, 1079, 1056, 1023, 999, 936, 892, 850, 709, 634, 614
13c			172–174	C$_{21}$H$_{33}$N$_3$O$_2$ (359,51)	3339, 3236, 3122, 2952, 2926, 2849, 1699, 1615, 1565, 1476, 1448, 1368, 1263, 1247, 1175, 1084, 1019, 854, 780, 651, 618
13d			173–175	C$_{21}$H$_{27}$N$_3$O$_2$ (353,46)	3316, 3222, 3123, 3028, 2954, 1654, 1611, 1566, 1469, 1454, 1364, 1236, 1171, 1077, 851, 749, 699, 668
13e			93–97	C$_{22}$H$_{29}$N$_3$O$_2$ (367,48)	3566, 3434, 3312, 3026, 2953, 2926, 2869, 1648, 1587, 1557, 1514, 1497, 1455, 1374, 1253, 1168, 1074, 1054, 999, 934, 853, 796, 746, 700, 547
13f			151–154	C$_{27}$H$_{31}$N$_3$O$_2$ (429,55)	3343, 3202, 3028, 2953, 2869, 1647, 1616, 1538, 1495, 1456, 1366, 1268, 1230, 1168, 1077, 1052, 1028, 1004, 942, 848, 746, 700, 669, 631
13g			133–135	C$_{21}$H$_{25}$N$_3$O$_3$ (367,44)	3414, 3281, 3237, 3101, 3025, 2961, 2910, 2869, 1696, 1627, 1638, 1582, 1556, 1532, 1489, 1455, 1443, 1311, 1244, 1213, 1162, 1146,1131, 1073, 942, 913, 880, 774, 760, 691, 618
13h			144–146	C$_{22}$H$_{27}$N$_3$O$_3$ (381,47)	3343, 3215, 2933, 2853, 1695, 1618, 1580, 1555, 1490, 1472, 1448, 1314, 1273, 1235, 1213, 1166, 1074, 1062, 1025, 944, 887, 748, 689, 640
13i			104–105	C$_{23}$H$_{29}$N$_3$O$_3$ (395,49)	3339, 3230, 3115, 3026, 2924, 2850, 1701, 1619, 1582, 1568, 1490, 1447, 1373, 1246, 1212, 1166, 1146, 1074, 1024, 1012, 962, 933, 888, 749, 691, 668
13j			154–156	C$_{23}$H$_{23}$N$_3$O$_3$ (389,45)	3323, 3266, 3209, 3109, 3028, 1654,1621, 1584, 1565, 1490, 1453, 1369, 1315, 1278, 1249, 1235, 1162, 1143, 1071, 935,876, 751, 694, 644
13k			116–118	C$_{24}$H$_{25}$N$_3$O$_3$ (403,47)	3367, 3236, 3026, 2942, 1682, 1642, 1583, 1560, 1542, 1488, 1454, 1379, 1310, 1247, 1211, 1162, 1075, 1012, 944, 916, 866, 796, 747, 698, 637

	Structure 1	Structure 2	M.p. (°C)	Formula (M)	IR (cm⁻¹)
13l	(3-phenoxyphenyl)-CH(CH₃)–	(C₆H₅)₂CH–	126–131	$C_{29}H_{27}N_3O_3$ (465,54)	3350, 3236, 3031, 2973, 1655, 1613, 1587, 1560, 1488, 1448, 1247, 1210, 1164, 1070, 1052, 1030, 949, 912, 753, 698, 668, 634, 614
13m		cyclopentyl–	133–134	$C_{22}H_{27}N_3O_2$ (365,47)	3279, 3027, 2962, 2872, 1710, 1646, 1555, 1494, 1452, 1372, 1242, 1191, 1152, 1077, 1010, 941, 728, 698, 638
13n		cyclohexyl–	143–144	$C_{23}H_{29}N_3O_2$ (379,50)	3327, 3216, 3027, 2932, 2853, 1658, 1617, 1589, 1477, 1452, 1255, 1232, 1182, 1074, 1065, 943, 891, 769, 751, 701, 639, 618
13o		cyclohexyl-CH₂–	133–137	$C_{24}H_{31}N_3O_2$ (393,52)	3344, 3216, 3027, 2919, 2850, 1663, 1622, 1589, 1474, 1450, 1370, 1273, 1257, 1239, 1184, 1075, 1030, 963, 746, 723, 702, 652, 618
13p		benzyl–	150–154	$C_{24}H_{25}N_3O_2$ (387,47)	3331, 3261, 3211, 3028, 2986, 1707, 1660, 1620, 1563, 1494, 1453, 1431, 1371, 1246, 1174, 1075, 750, 723, 698, 642, 618
13r		phenethyl–	118–120	$C_{25}H_{27}N_3O_2$ (401,50)	3365, 3301, 3239, 3027, 2939, 1686, 1649, 1601, 1555, 1495, 1455, 1379, 1269, 1242, 1154, 1073, 945, 751, 726, 699, 661
13s		(C₆H₅)₂CH–	166–170	$C_{30}H_{29}N_3O_2$ (463,57)	3346, 3231, 3028, 1981, 1662, 1611, 1590, 1560, 1494, 1472, 1453, 1372, 1258, 1236, 1078, 1030, 948, 751, 700, 668, 634, 613
13t	(4-isobutylphenyl)-CH(CH₃)–		87 (raspad)	$C_{21}H_{27}N_3O_3$ (369,46)	3472, 3319, 3240, 3114, 3064, 3031, 2953, 2867, 1714, 1698, 1681, 1638, 1594, 1548, 1514, 1455, 1366, 1349, 1226, 1147, 1082, 994, 933, 910, 850, 802, 751, 698, 620, 592, 545
13u	(3-phenoxyphenyl)-CH(CH₃)–	benzyloxy–O–CH₂–	ulje	$C_{23}H_{23}N_3O_4$ (405,45)	3237, 3063, 3034, 2979, 2934, 2877, 1668, 1583, 1488, 1455, 1371, 1312, 1244, 1211, 1163, 1073, 942, 914, 753, 695, 614
13v	(3-benzylphenyl)-CH(CH₃)–		104–105	$C_{24}H_{25}N_3O_3$ (403,47)	3306, 3235, 3029, 2925, 2880, 1691, 1654, 1599, 1520, 1493, 1454, 1382, 1366, 1356, 1273, 1238, 1152, 1074, 1032, 1007, 947, 788, 751, 727, 699, 668, 555, 532, 497
13w	(4-isobutylphenyl)-CH(CH₃)–	–OH	123–125	$C_{14}H_{21}N_3O_3$ (279,33)	3330, 3235, 3027, 2954, 2924, 2869, 1704, 1652, 1556, 1514, 1465, 1383, 1320, 1262, 1141, 1078, 1002, 935, 850, 766, 727, 653, 531

| 13x | | | 150 (raspad) | C$_{16}$H$_{17}$N$_3$O$_4$ (315,32) | 3298, 3214, 3026, 2983, 2941, 1685, 1643, 1582, 1567, 1489, 1446, 1362, 1313, 1268, 1232, 1212, 1161, 1140, 1080, 1023, 969, 939, 876, 788, 756, 693, 649, 596, 558, 523 |
| 13y | | -OH | 123–125 | C$_{17}$H$_{19}$N$_3$O$_3$ (313,35) | 3288, 3060, 3028, 2979, 2938, 1687, 1644, 1562, 1516, 1494, 1483, 1451, 1380, 1263, 1159, 1144, 1100, 1077, 1061, 1027, 938, 782, 721, 700, 596, 533 |

Tablica 20. ^{1}H NMR podaci za 1-acilsemikarbazide NSAID **13a**-**y**

Spoj	R^1	R^2	^{1}H NMR (DMSO-d_6, δ ppm)
13a			9,63, 7,59, (2s, 2H, 1, 2), 7,15 (dd, 4H, arom, J = 7,55 Hz, 87,09 Hz), 6,50 (bs, 1H, 2'), 3,84–3,80 (m, 1H, 3'), 3,59 (q, 1H, 4, J = 7,02 Hz), 2,40 (d, 2H, 12, J = 7,17 Hz), 1,84–1,20 (m, 9H, 13, 4'–7'), 1,32 (d, 3H, 5, J = 7,02 Hz), 0,85 (d, 6H, 14,15, J = 6,58 Hz)
13b			9,67, 7,64, (2d, 2H, 1, 2, J = 1,77 Hz), 7,15 (dd, 4H, arom., J = 7,76 Hz, 39,23 Hz), 5,71 (d, 1H, 2', J = 6,43 Hz), 3,59 (q, 1H, 4, J = 6,87 Hz), 3,39–3,28 (m, 2H, 3'), 2,40 (d, 2H, 12, J = 7,10 Hz), 1,84–1,75 (m, 1H, 13), 1,69–0,95 (m, 10H, 4'–8'), 1,32 (d, 3H, 5, J = 6,87 Hz), 0,85 (d, 6H, 14, 15, J = 6,65 Hz)
13c			9,65 7,66 (2s, 2H, 1, 2), 7,15 (dd, 4H, arom., J = 7,74 Hz, 40,61 Hz), 5,99 (t, 1H, 2', J = 4,78 Hz), 3,59 (q, 1H, 4, J = 6,86 Hz), 2,82 (t, 2H, 3', J = 6,22 Hz), 2,40 (d, 2H, 12, J = 7,02 Hz), 1,84–1,75 (m, 1H, 13), 1,66–0,78 (m, 11H, 4'–9'), 1,33 (d, 3H, 5, J = 6,53 Hz), 0,85 (d, 6H, 14, 15, J = 5,87 Hz)
13d			9,70, 7,85 (2s, 2H, 1, 2), 7,32–7,05 (m, 9H, arom.), 6,70 (t, 1H, 2', J = 6,01 Hz), 4,22 (d, 2H, 3', J = 6,01 Hz), 3,59 (q, 1H, 4, J = 6,94 Hz), 2,39 (d, 2H, 12, J = 6,94 Hz), 1,83–1,74 (m, 1H, 13), 1,34 (d, 3H, 5, J = 6,94 Hz), 0,84 (d, 6H, 14, 15, J = 6,48 Hz)
13e			9,66, 7,79 (2s, 2H, 1, 2), 7,38–7,00 (m, 9H, arom.), 6,15 (t, 1H, 2', J = 5,52 Hz), 3,59 (q, 1H, 4, J = 6,81 Hz), 3,22 (q, 2H, 3', J = 6,49 Hz), 2,67 (t, 2H, 4', J = 7,14 Hz), 2,40 (d, 2H, 12, J = 6,81 Hz), 1,85–1,76 (m, 1H, 13), 1,34 (d, 3H, 5, J = 7,14 Hz), 0,86 (d, 6H, 14, 15, J = 6,49 Hz)
13f			9,76, 7,84 (2s, 2H, 1, 2), 7,34–7,05 (m, 14H, arom.), 6,95 (bs, 1H, 2'), 5,91 (d, 1H, 3', J = 8,38 Hz), 3,58 (q, 1H, 4, J = 6,85 Hz), 2,39 (d, 2H, 12, J = 7,11 Hz), 1,83–1,74 (m, 1H, 13), 1,33 (d, 3H, 5, J = 6,85 Hz), 0,84 (d, 6H, 14, 15, J = 6,60 Hz)

|			
13g			9,69, 7,63 (2s, 2H, 1, 2), 7,42–6,82 (m, 9H, arom.), 5,94 (d, 1H, 2', *J* = 6,73 Hz), 3,89–3,78 (m, 2H, 3'), 3,63 (q, 1H, 4, *J* = 6,73 Hz), 1,79–1,22 (m, 8H, 4'–7'), 1,32 (d, 3H, 5, *J* = 6,73 Hz)
13h			9,70, 7,66 (2s, 2H, 1, 2), 7,42–6,83 (m, 9H, arom.), 5,84 (d, 1H, 2', *J* = 7,00 Hz), 3,63 (q, 1H, 4, *J* = 6,73 Hz), 3,39–3,33 (m, 2H, 3'), 1,71–1,00 (m, 10H, 4'–8'), 1,33 (d, 3H, 5, *J* = 7,00 Hz)
13i			9,70, 7,70 (2s, 2H, 1, 2), 7,43–6,84 (m, 9H, arom.), 6,09 (t, 1H, 2', *J* = 5,20 Hz), 3,63 (q, 1H, 4, *J* = 6,82 Hz), 2,84 (t, 2H, 3', *J* = 6,17 Hz), 1,62–0,79 (m, 11H, 4'–9'), 1,34 (d, 3H, 5, *J* = 6,82 Hz)
13j			9,74, 7,89 (2s, 2H, 1, 2), 7,41–6,82 (m, 14H, arom.), 6,76 (t, 1H, 2', *J* = 5,58 Hz), 4,22 (d, 2H, 3', *J* = 5,58 Hz), 3,63 (q, 1H, 4, *J* = 6,50 Hz), 1,34 (d, 3H, 5, *J* = 6,81 Hz)
13k			9,70, 7,82 (2s, 2H, 1, 2), 7,42–6,84 (m, 14H, arom.), 6,21 (t, 1H, 2', *J* = 5,36 Hz), 3,63 (q, 1H, 4, *J* = 6,80 Hz), 3,23 (q, 2H, 3', *J* = 6,59 Hz), 2,68 (t, 2H, 4', *J* = 7,21 Hz), 1,34 (d, 3H, 5, *J* = 7,00 Hz)
13l			9,78, 7,85 (2s, 2H, 1, 2), 7,38–6,98 (m, 19H, arom.), 6,83 (d, 1H, 2', *J* = 7,36 Hz), 5,91 (d, 1H, 3', *J* = 8,83 Hz), 3,64 (q, 1H, 4, *J* = 6,31 Hz), 1,33 (d, 3H, 5, *J* = 6,75 Hz)
13m			9,67, 7,60 (2s, 2H, 1, 2), 7,31–7,05 (m, 9H, arom.), 5,90 (d, 1H, 2', *J* = 6,27 Hz), 3,91 (s, 2H, 12), 3,82 (m, 1H, 3'), 3,59 (q, 1H, 4, *J* = 6,86 Hz), 1,76–1,22 (m, 8H, 4'–7'), 1,32 (d, 3H, 5, *J* = 7,05 Hz)
13n			9,68, 7,64 (2s, 2H, 1, 2), 7,30–7,05 (m, 9H, arom.), 5,80 (d, 1H, 2', *J* = 7,29 Hz), 3,91 (s, 2H, 12), 3,59 (q, 1H, 4, *J* = 6,97 Hz), 3,38–3,29 (m, 1H, 3'), 1,70–0,97 (m, 10H, 4'–8'), 1,32 (d, 3H, 5, *J* = 6,97 Hz)
3o			9,67, 7,66 (2s, 2H, 1, 2), 7,31–7,05 (m, 9H, arom.), 6,04 (t, 1H, 2', *J* = 5,23 Hz), 3,91 (s, 2H, 12), 3,59 (q, 1H, 4, *J* = 6,82 Hz), 2,82 (t, 2H, 3', *J* = 6,14 Hz), 1,66–0,78 (m, 11H, 4'–9'), 1,32 (d, 3H, 5, *J* = 6,82 Hz)
13p			9,72, 7,86 (2s, 2H, 1, 2), 7,32–7,04 (m, 14H, arom.), 6,73 (t, 1H, 2', *J* = 6,19 Hz), 4,22 (d, 2H, 3', *J* = 5,77 Hz), 3,89 (s, 2H, 12), 3,60 (q, 1H, 4, *J* = 7,01 Hz), 1,34 (d, 3H, 5, *J* = 7,01 Hz)
13r			9,66, 7,78 (2s, 2H, 1, 2), 7,29–7,04 (m, 14H, arom.), 6,17 (t, 1H, 2', *J* = 5,61 Hz), 3,90 (s, 2H, 12), 3,58 (q, 1H, 4, *J* = 6,83 Hz), 3,21 (q, 2H, 3', *J* = 6,58 Hz), 2,65 (t, 2H, 4', *J* = 7,31 Hz), 1,32 (d, 3H, 5, *J* = 7,07 Hz)
13s			9,78, 7,84 (2s, 2H, 1, 2), 7,33–7,00 (m, 19H, arom.), 6,99 (d, 1H, 2', *J* = 8,85 Hz), 5,91 (d, 1H, 3', *J* =8,38 Hz), 3,89 (s, 2H, 12), 3,60 (q, 1H, 4, *J* = 6,99 Hz), 1,33 (d, 3H, 5, *J* = 6,99 Hz)

13t			9,73, 9,47, 8,71 (3s, 3H, 1, 2, 2'), 7,43–7,32 (m, 5H, arom.), 7,17 (dd, 4H, arom., *J* = 8,03 Hz, 45,43 Hz), 4,74 (s, 2H, 3'), 3,62 (q, 1H, 4, *J* = 6,81 Hz), 2,40 (d, 2H, 12, *J* = 6,99 Hz), 1,87–1,76 (m, 1H, 13), 1,34 (d, 3H, 5, *J* = 7,16 Hz), 0,85 (d, 6H, 14, 15, *J* = 6,46 Hz)
13u			9,74, 9,47, 8,70 (3s, 3H, 1, 2, 2'), 7,41–6,83 (m, arom., 14H), 4,75 (s, 2H, 3'), 3,66 (q, 1H, 4, *J* = 6,94 Hz), 1,35 (d, 3H, 5, *J* = 6,94 Hz)
13v			9,72, 9,46, 8,69 (3s, 3H, 1, 2, 2'), 7,37–7,02 (m, arom., 14H), 4,72 (s, 2H, 3'), 3,88 (s, 2H, 12), 3,59 (q, 1H, 4, *J* = 6,46 Hz), 1,31 (d, 3H, 5, *J* = 6,85 Hz)
13w			9,65, 8,70, 8,64, 8,41 (4s, 4H, 1, 2, 2', 3'), 7,15 (dd, 4H, arom, *J* = 7,92 Hz, 46,47 Hz), 3,61 (q, 1H, 4, *J* = 6,89 Hz), 2,40 (d, 2H, 12, *J* = 7,11 Hz), 1,85–1,76 (m, 1H, 13), 1,33 (d, 3H, 5, *J* = 6,89 Hz), 0,85 (d, 6H, 14, 15, *J* = 6,45 Hz)
13x		-OH[3']	9,68, 8,72, 8,65, 8,45 (4s, 4H, 1, 2, 2', 3'), 7,42–6,82 (m, arom., 9H), 3,65 (q, 1H, 4, *J* = 6,95 Hz), 1,33 (d, 3H, 5, *J* = 6,95 Hz)
13y			9,66, 8,73, 8,66, 8,43 (4s, 4H, 1, 2, 2', 3'), 7,32–7,05 (m, arom., 9H), 3,92 (s, 2H, 12), 3,62 (q, 1H, 4, *J* = 6,81 Hz), 1,34 (d, 3H, 5, *J* = 7,01 Hz)

Tablica 21. ^{13}C NMR podaci za 1-acilsemikarbazide NSAID **13a-y**

| Spoj	R[1]	R[2]	^{13}C NMR (DMSO-*d*₆, *δ* ppm)
13a			175,27 (3), 159,64 (1'), 141,54, 141,08 (6, 9), 130,96, 129,18 (7, 8, 10, 11), 53,09 (3'), 46,42 (12), 44,76 (4), 34,86, 25,33 (4'–7'), 31,76 (13), 24,34 (14, 15), 20,37 (5)
13b			173,56 (3), 157,60 (1'), 139,84, 139,36 (6, 9), 129,27, 127,47 (7, 8, 10, 11), 48,28 (3'), 44,70 (12), 43,03 (4), 33,42, 33,38, 24,90 (4', 5', 7', 8'), 30,09 (13), 25,65 (6'), 22,64 (14, 15), 18,64 (5)
13c			173,66 (3), 158,47 (1'), 139,79, 139,35 (6, 9), 129,22, 127,50 (7, 8, 10, 11), 45,80 (3'), 44,71 (12), 43,06 (4), 38,37 (4'), 30,67, 30,65, 25,88 (5', 6', 8', 9'), 30,09 (13), 26,56 (7'), 22,64 (14, 15), 18,69 (5)

13d	5', 6', 7', 3', 4', 9', 8'	173,83 (3), 158,59 (1'), 140,90 (4'), 139,78, 139,34 (6, 9), 129,21, 128,58, 127,55, 127,35, (7, 8, 10, 11, 5', 6', 8', 9'), 127,00 (7'), 44,70 (12), 43,11 (4), 43,07 (3'), 30,08 (13), 22,64 (14, 15), 18,81 (5)
13e	3', 4', 5', 6', 7', 10', 9', 8'	173,72 (3), 158,36 (1'), 139,99, 139,79, 139,33 (6, 9, 5'), 129,21, 129,10, 128,78, 127,54 (7, 8, 10, 11, 6', 7', 9', 10'), 126,48 (8'), 44,70 (12), 43,06 (4), 41,32 (3'), 36,38 (4'), 30,08 (13), 22,64 (14, 15), 18,78 (5)
13f	14', 15', 10', 3', 4', 5', 6', 13', 11', 12', 9', 7', 8'	173,70 (3), 157,58 (1'), 143,51, 143,46 (4', 10'), 139,83, 139,26 (6, 9), 129,25, 128,81, 128,79, 127,49, 127,47, 127,44 (7, 8, 10, 11, 5', 6', 8', 9', 11', 12', 14', 15'), 127,35, 127,31 (7', 13'), 57,14 (3'), 44,71 (12), 43,05 (4), 30,06 (13), 22,65 (14, 15), 18,78 (5)
13g	3', 4', 5', 7', 6'	173,08 (3), 157,89 (1'), 156,99, 156,94, 144,29 (6, 10, 12), 130,49, 119,01 (13, 14, 16, 17), 130,23, 123,87 , 122,93, 118,17, 117,12 (7–9, 11, 15), 51,40 (3'), 43,25 (4), 33,13, 24,91 (4'–7'), 18,66 (5)
13h	3', 4', 5', 8', 6', 7'	173,08 (3), 157,55 (1'), 156,99, 156,94, 144,29 (6, 10, 12), 130,49, 119,01 (13, 14, 15, 16), 130,24, 123,87 , 122,95, 118,16, 117,12 (7–9, 11, 15), 48,33 (3'), 43,24 (4), 33,41, 24,91 (4', 5', 7', 8'), 25,65 (6'), 18,66 (5)
13i	3', 4', 5', 6', 9', 8', 7'	173,18 (3), 158,43 (1'), 157,03, 156,91, 144,29 (6, 10, 12), 130,19, 118,98 (13, 14, 16, 17), 130,21, 123,85 , 122,98, 118,23, 117,14 (7–9, 11, 15), 45,82 (3'), 43,29 (4), 38,38 (4'), 30,68, 25,88 (5', 6', 8', 9'), 26,56 (7'), 18,70 (5)
13j	5', 6', 3', 4', 7', 9', 8'	173,35 (3), 158,54 (1'), 157,03, 156,90, 144,28 (6, 10, 12), 140,91 (4'), 130,49, 128,59, 127,34, 119,00 (13, 14, 16, 17, 5', 6', 8', 9'), 130,20, 127,00, 123,84, 123,02, 118,29, 117,14 (7–9, 11, 15, 7'), 43,36 (4), 43,08 (3'), 18,77 (5)
13k	3', 5', 6', 4', 7', 10', 9', 8'	173,23 (3), 158,31 (1'), 157,03, 156,90, 144,29 (6, 10, 12), 139,99 (5'), 130,49, 129,11, 128,79, 119,00, (13, 14, 16, 17, 6', 7', 9', 10'), 130,21, 126,48, 123,85, 123,02, 118,26, 117,14 (7–9, 11, 15, 8'), 43,29 (4), 41,32 (3'), 36,38 (4'), 18,78 (5)
13l	15', 10', 3', 4', 5', 6', 14', 13', 11', 12', 9', 7', 8'	172,70 (3), 157,02 (1'), 156,50 156,47, 143,70 (6, 10, 12), 142,96, 143,03 (4', 10'), 129,97, 118,53 (13, 14, 16, 17), 129,73, 123,35, 122,43, 117,71, 116,65 (7–9, 11, 15), 128,37, 128,33, 126,97, 126,93 (5', 6', 8', 9', 11', 12', 14', 15'), 126,85, 126,81 (7',13'), 56,71 (3'), 42,80 (4), 18,24 (5)
13m	3', 4', 5', 7', 6'	173,40 (3), 157,93 (1'), 142,22, 141,61, 141,55 (6, 10, 13), 129,14, 128,86 (14, 15, 17, 18), 128,76, 128,25, 127,48, 126,42, 125,45 (7–9, 11, 16), 51,38 (3'), 43,36 (4), 41,65 (12), 33,13, 23,62 (4'–7'), 18,73 (5)
13n	3', 4', 5', 8', 6', 7'	173,40 (3), 157,60 (1'), 142,22, 141,61, 141,55 (6, 10, 13), 129,14, 128,86 (14, 15, 17, 18), 128,77, 128,24, 127,48, 126,42, 125,45 (7–9, 11, 16), 48,31 (3'), 43,36 (4), 41,65 (12), 33,38, 24,89 (4', 5', 7', 8'), 25,66 (6'), 18,73 (5)

13o		3' 5' 4' 6' 9' 8' 7'	173,48 (3), 158,47 (1'), 142,21, 141,62, 141,52 (6, 10, 13), 129,13, 128,86 (14, 15, 17, 18), 128,74, 128,24, 127,46, 126,41, 125,47 (7–9, 11, 16), 45,81 (3'), 43,38 (4), 41,65 (12), 38,36 (4'), 30,66, 25,88 (5', 6', 8', 9'), 26,55 (7'), 18,76 (5)
13p	5 18 13 11 6 4 17 12 10 16 14 9 7 15 8	5' 6' 7' 4' 8' 3' 9'	173,67 (3), 158,59 (1'), 142,23, 141,63, 141,52 (6, 10, 13), 140,92 (4'), 129,15, 128,87, 128,59, 127,35 (14, 15, 17, 18, 5', 6', 8', 9'), 128,74, 128,28, 127,46, 127,01, 126,41, 125,55 (7–9, 11, 16, 7'), 43,46 (4), 43,08 (3'), 41,64 (12), 18,88 (5)
13r		6' 3' 4' 5' 7' 10' 8' 9'	173,55 (3), 158,37 (1'), 142,23, 141,63, 141,52 (6, 10, 13), 140,00 (5'), 129,15, 129,11, 128,87, 128,79 (14, 15, 17, 18, 6', 7', 9', 10'), 128,75, 128,28, 127,46, 126,48, 126,41, 125,54 (7–9, 11, 16, 8'), 43,41 (4), 41,65 (12), 41,33 (3'), 36,39 (4'), 18,87 (5)
13s		15' 10' 5' 14' 3' 4' 6' 13' 11' 9' 7' 12' 8'	173,67 (3), 157,56 (1'), 143,52, 143,47 (4', 10'), 142,13, 141,59, 141,56, (6, 10, 13), 129,14, 128,86, 128,82, 128,80, 127,45 (14, 15, 17, 18, 5', 6', 8', '9', 11', 12', 14', 15'), 128,22, 127,34, 127,32, 126,40, 125,47 (7–9, 11, 16, 7', 13'), 57,16 (3'), 43,48 (4), 41,63 (12), 18,84 (5)
13t	5 15 10 11 6 4 14 13 12 9 7 8		173,55 (3), 159,52 (1'), 139,77, 139,25 (6, 9), 136,90 (4'), 129,17, 129,12, 128,61, 127,62 (7, 8, 10, 11, 5', 6', 8', 9'), 128,42 (7'), 77,90 (3'), 44,71 (12), 43,05 (4), 30,10 (13), 22,65 (14,15), 18,93 (5)
13u	5 17 12 O 11 6 4 16 10 15 13 9 7 14 8	O 4' 2' 3' 5' 8' 6' 7'	172,59 (3), 158,95 (1'), 156,57, 156,38, 143,70 (6, 10, 12), 136,37 (4'), 129,98, 128,62, 128,11, 118,48 (13, 14, 16, 17, 5', 6', 8', 9'), 129,65, 127,93, 123,32, 122,59, 117,87, 116,65 (7–9, 11, 15, 7'), 77,42 (3'), 42,80 (4), 18,37 (5)
13v	5 18 13 11 6 4 17 12 10 16 14 9 7 15 8		173,40 (3), 159,52 (1'), 142,13, 141,65, 141,47 (6, 10, 13), 136,90 (4'), 129,16, 129,13, 128,87, 128,61 (14, 15, 17, 18, 5', 6', 8', 9'), 128,70, 128,43, 128,34, 127,44, 126,41, 125,61 (7–9, 11, 16, 7'), 77,90 (3'), 43,39 (4), 41,65 (12), 19,00 (5)
13w	5 15 10 11 6 4 14 13 12 9 7 8		173,45 (3), 160,82 (1'), 139,71, 139,33 (6, 9), 129,14, 127,62 (7, 8, 10,11), 44,71 (12), 43,00 (4), 30,09 (13), 22,65 (14,15), 19,01 (5)
13x	5 17 12 O 11 6 4 16 10 15 13 9 7 14 8	-OH³'	172,98 (3), 160,78 (1'), 157,06, 156,84, 144,29 (6, 10, 12), 130,49, 118,98 (13, 14,16, 17), 130,13, 123,81, 123,10, 118,36, 117,11 (7–9, 11, 15), 43,24 (4), 18,95 (5)
13y	5 18 13 11 6 4 17 12 10 16 14 9 7 15 8		173,29 (3), 160,82 (1'), 142,22, 141,66, 141,45 (6, 10, 13), 129,16, 128,87 (14, 15, 17, 18), 128,68, 128,34, 127,38, 126,40, 125,60 (7–9, 11, 16), 43,34 (4), 41,65 (12), 19,08 (5)

3.1.4.5. *Sinteza 1-acil-5-benziloksi i 1-acil-5-hidroksihidroksikarbamoilkarbazida NSAID*
14a-f

Serija derivata NSAID bogata dušikom i kisikom pripravljena je aminolizom 1-(1-benzotriazolkarbonil)-4-benziloksisemikarbazida **9** s NSAID hidrazidima **11a**-**c**. Time su dobiveni benziloksi derivati **14a**-**c** koji su hidrogenolizom dali hidroksi derivate **14d**-**f** (Shema 30). Za razliku od reakcija **13a**-**s** u kojima je korišten TEA kao katalizator, u sintezi derivata **14a**-**c** TEA je izostavljen zbog moguće ciklizacije spoja **9**. Reakcije su također provođene u talini na minimalnoj temperaturi taljenja smjese reaktanata (90 °C) i bez otapala. U reakcijama nije uočena ciklizacija niti raspad bilo reaktanata bilo produkata.

	14a,d	**14b,e**	**14c,f**
R			

Shema 30. Sinteza 1-acil-5-benziloksi i 1-acil-5-hidroksikarbamoilkarbazida NSAID **14a**-**f**

Pripravljeni su sljedeći 1-acilkarbamoilkarbazidi:

5-benziloksikarbamoil-1-[2-(4-izobutilfenil)propanoil]karbazid (**14a**),

5-benziloksikarbamoil-1-[2-(3-fenoksifenil)propanoil]karbazid (**14b**),

5-benziloksikarbamoil-1-[2-(3-benzilfenil)propanoil]karbazid (**14c**),

5-hidroksikarbamoil-1-[2-(4-izobutilfenil)propanoil]karbazid (**14d**),

5-hidroksikarbamoil-1-[2-(3-fenoksifenil)propanoil]karbazid (**14e**),

5-hidroksikarbamoil-1-[2-(3-benzilfenil)propanoil]karbazid (**14f**).

Tijek sinteze i čistoća spojeva praćeni su tankoslojnom kromatografijom, a njihove strukture potvrđene su IR, ^{1}H i ^{13}C NMR spektroskopijom i elementarnom analizom.

IR spektri derivata **14a-f** pokazuju karakteristične vrpce kod 3032–3266 (NH i OH), 1602–1677 (C=O, amid I) i 1513–1583 (C=O, amid II) cm^{-1}. U ^{1}H NMR spektrima NH i OH javljaju se u području 7,92–9,80 ppm. Karbonilna skupina na položaju 3 u ^{13}C NMR spektrima nalazi se u području 172,90–173,52 ppm, a na položaju 1' i 4' u području 158,30–161,24 ppm.

Svi spojevi serije **14** su novi. Njihovi analitički i spektroskopski podaci dani su u Tablicama 22–24.

Tablica 22. Analitički i IR podaci za 1-acilkarbamoilkarbazide NSAID **14a-f**

Spoj	R^1	R^2	t_t (°C)	Mol. formula (M_r)	IR (KBr) ν_{max} (cm^{-1})
14a			85–90	C$_{22}$H$_{29}$N$_5$O$_4$ (427,50)	3266, 3032, 2955, 2930, 2869, 1677, 1513, 1466, 1455, 1366, 1309, 1271, 1212, 1188, 1075, 1030, 1002, 934, 909, 849, 751, 699, 620, 547
14b			72–76	C$_{24}$H$_{25}$N$_5$O$_5$ (463,49)	3251, 3062, 3034, 2971, 2933, 2873, 1677, 1583, 1523, 1488, 1455, 1369, 1312, 1243, 1211, 1163, 1073, 1023, 1002, 942, 914, 816, 752, 694, 614
14c			73–77	C$_{25}$H$_{27}$N$_5$O$_4$ (461,51)	3248, 3060, 3028, 2880, 2836, 1675, 1602, 1519, 1494, 1453, 1369, 1310, 1270, 1210, 1075, 1030, 974, 941, 908, 751, 699, 620, 556
14d			145–148 (raspad)	C$_{15}$H$_{23}$N$_5$O$_4$ (337,37)	3261, 2955, 2928, 2870, 1670, 1514, 1466, 1383, 1367, 1281, 1206, 1077, 1002, 934, 850, 783
14e		H	100–103 (raspad)	C$_{17}$H$_{19}$N$_5$O$_5$ (373,36)	3263, 2978, 2925, 2855, 1670, 1583, 1540, 1488, 1456, 1445, 1376, 1313, 1244, 1210, 1163, 1074, 943, 917, 755, 692
14f			101–105 (raspad)	C$_{18}$H$_{21}$N$_5$O$_4$ (371,39)	3258, 3060, 3027, 2981, 2934, 1670, 1601, 1538, 1494, 1453, 1375, 1321, 1195, 1075, 1030, 943, 784, 728, 699, 622, 557

**Tablica 23**. ^{1}H NMR podaci za 1-acilkarbamoilkarbazide NSAID **14a-f**

Spoj	R^1	R^2	^{1}H NMR (DMSO-d_6, δ ppm)
14a			9,75, 9,43, 8,54, 8,15, 8,03 (5s, 5H, 1, 2, 2', 3', 5'), 7,44–7,30 (m, 5H, arom., 8'–12'), 7,16 (dd, 4H, arom., J = 7,99 Hz, 46,08 Hz), 4,77 (s, 2H, 6'), 3,62 (q, 1H, 4, J = 6,94 Hz), 2,41 (d, 2H, 12, J = 7,15 Hz), 1,85–1,76 (m, 1H, 13), 1,35 (d, 3H, 5, J = 6,94 Hz), 0,86 (d, 6H, 14, 15, J = 6,52 Hz)
14b			9,78, 9,43, 8,55, 8,18, 8,05 (5s, 5H, 1, 2, 2', 3', 5'), 7,44–6,82 (m, 14H, arom.), 4,77 (s, 2H, 6'), 3,65 (q, 1H, 4, J = 6,97 Hz), 1,34 (d, 3H, 5, J = 7,12 Hz)
14c			9,76, 9,43, 8,55, 8,16, 8,03 (5s, 5H, 1, 2, 2', 3', 5'), 7,44–7,05 (m, 14H, arom.), 4,78 (s, 2H, 6'), 3,92 (s, 2H, 12), 3,62 (q, 1H, 4, J = 6,77 Hz), 1,34 (d, 3H, 5, J = 7,02 Hz)
14d		H$^{6'}$	9,73, 8,66, 8,57, 8,23, 8,08, 7,92 (5s, bs, 6H, 1, 2, 2', 3', 5', 6'), 7,15 (dd, 4H, arom., J = 7,93 Hz, 95,99 Hz), 3,61 (q, 1H, 4, J = 7,01 Hz), 2,40 (d, 2H, 12, J = 7,28 Hz), 1,82–1,78 (m, 1H, 13), 1,33 (d, 3H, 5, J = 7,01 Hz), 0,85 (d, 6H, 14, 15, J = 6,47 Hz)
14e			9,80, 8,67, 8,29, 8,14, 7,96 (5s, bs, 6H, 1, 2, 2', 3', 5', 6'), 7,42–6,81 (m, 9H, arom.), 3,64 (q, 1H, 4, J = 7,03 Hz), 1,34 (d, 3H, 5, J = 6,95 Hz)
14f			9,78, 8,67, 8,28, 8,11, 7,95 (5s, bs, 6H, 1, 2, 2', 3', 5', 6'), 7,31–7,04 (m, 9H, arom.), 3,91 (s, 2H, 12), 3,61 (q, 1H, 4, J = 6,88 Hz), 1,33 (d, 3H, 5, J = 7,14 Hz)

Tablica 24. ^{13}C NMR podaci za 1-acilkarbamoilkarbazide NSAID **14a-f**

Spoj	R^1	R^2	^{13}C NMR (DMSO-d_6, δ ppm)
14a			173,52 (3), 160,03, 158,37 (1', 4'), 139,75, 139,34, (6, 9), 136,97 (7'), 129,17, 129,14, 128,61, 127,59 (7, 8, 10, 11, 8', 9', 11', 12'), 128,41 (10'), 77,87 (6'), 44,71 (12), 43,00 (4), 30,09 (13), 22,65 (14, 15), 18,85 (5)

14b			173,03 (3), 160,03, 158,32 (1', 4'), 157,05, 156,87, 144,28 (6, 10, 12), 136,97 (7'), 130,50, 129,14, 128,61, 118,99 (13, 14, 16, 17, 8', 9', 11', 12'), 130,16, 128,41, 123,83, 123,06, 118,33,117,13 (7–9, 11, 15, 10'), 77,88 (6'), 43,25 (4), 18,79 (5)
14c			173,35 (3), 160,02, 158,36 (1', 4'), 142,21, 141,64, 141,48 (6, 10, 13), 136,96 (7'), 129,15, 128,87, 128,61 (14, 15, 17, 18, 8', 9', 11', 12'), 128,70, 128,41, 128,31, 127,42, 126,40, 125,58 (7–9, 11, 16, 10'), 77,88 (6'), 43,34 (4), 41,65 (12), 18,91 (5)
14d			172,90 (3), 160,70, 157,83 (1', 4'), 139,24, 138,85 (6, 9), 128,6, 127,07 (7, 8, 10, 11), 44,22 (12), 42,49 (4), , 29,55 (13), 22,14 (14, 15), 18,35 (5)
14e		H[6']	172,92 (3), 161,24, 158,30 (1', 4'), 157,03, 156,88, 144,28, (6, 10, 12), 130,50, 119,01 (13, 14, 16, 17), 130,16, 123,84, 123,03, 118,30, 117,11 (7–9, 11, 15), 43,22 (4), 18,78 (5)
14f			173,23 (3), 161,24, 158,34 (1', 4'), 142,22, 141,64, 141,48 (6, 10, 13), 129,16, 128,88 (14, 15, 17, 18), 128,71, 128,29, 127,42, 126,41, 125,56 (7–9, 11, 16), 43,32 (4), 41,65 (12), 18,90 (5)

3.2. BIOLOŠKA ISPITIVANJA

3.2.1. Antitumorska ispitivanja

Antitumorska ispitivanja provedena su na Institutu Rudjer Bošković i na Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgija prema ranije opisanoj metodi (Perković *et al*, 2010; Perković *et al*, 2008).

3.2.1.1. *Ureidoamidi 4a-o*

Citostatsko djelovanje ureidoamida **4a**-**o** ispitano je *in vitro* na sljedeće maligne stanične linije: karcinom dojke (MCF-7), kolorektalni adenokarcinom (SW620), karcinom debelog crijeva (HCT 116), akutna limfoblastna leukemija (MOLT-4) i karcinom pluća (H460) (Perković *et al*, 2010).

Antitumorska ispitivanja su pokazala da ureidoamidi nisu značajno inhibirali rast ispitanih stanica u najvećoj ispitanoj koncentraciji ($IC_{50} \geq 100$ µmol L^{-1}).

3.2.1.2. *N- i O-Supstituirane hidroksiuree* **6a-l**

Citostatsko djelovanje hidroksiurea **6a-l** ispitano je *in vitro* na sljedeće maligne stanične linije: karcinom grlića maternice (HeLa), MCF-7, karcinom gušterače (MiaPaCa-2), karcinom prostate (PC-3), SW620, karcinom stanica jetre (Hep G2), leukemija (L1210), zloćudno preobraženi T-limfociti (Molt4/C8 i CEM) i na staničnu liniju normalnih fibroblasta porijeklom iz čovjeka (WI 38) (Tablica 25) (Perković *et al*, 2008). Iz rezultata je vidljivo da su općenito bolje djelovanje na sve stanične linije pokazali *O*-benzilni derivati (**6a**,**c**,**e**,**g**,**i**,**k**) u usporedbi s derivatima sa slobodnom hidroksilnom skupinom (*N*-metil derivati **6b**,**d**,**f**,**h**,**j**,**l** i nesupstituirane hidroksiuree sintetizirane u prijašnjim istraživanjima).

Usporedbom hidroksiurea **6** i nesupstituiranih ranije sintetiziranih i ispitanih hidroksiurea (Opačić *et al*, 2005) koje su sve derivati istih aminokiselina (L-leucina, D-fenilglicina i L-fenilalanina) može se zaključiti da derivati D-fenilglicina i L-fenilalanina imaju snažnije citostatsko djelovanje od derivata L-leucina i da njihovi *N*-metilni derivati imaju najslabije djelovanje uz nekoliko iznimaka koje će biti spomenute kasnije (Slika 12).

**Slika 12.** Biološko djelovanje hidroksiurea s obzirom na supstituent na terminalnom dušiku.

Ako se promatraju *O*-benzilni derivati **6** s benzhidrilnim amidnim supstituentom može se uočiti da aktivnost raste s obzirom na aminokiselinu prisutnu u molekuli na sljedeći način: L-leucin < D-fenilglicin < L-fenilalanin za sve stanične linije. To pravilo vrijedi i ako se promatraju *N*-metilni derivati s benzhidrilnim amidnim supstituentom, uz nekoliko već spomenutih iznimaka.

Najjače citostatsko djelovanje ($IC_{50} \leq 1$ μmol L^{-1}) na dvije stanične linije, SW620 i/ili Hep G2, pokazala su tri *N*-metilna derivata, **6d,f,l** od kojih je najbolje selektivno djelovanje pokazao derivat **6l** i to na staničnu liniju SW 620 ($IC_{50} = 0{,}1$ μmol L^{-1}). Od *O*-benzilnih derivata, najjače citostatsko djelovanje ($IC_{50} \leq 1$ μmol L^{-1}), također na stanične linije SW620 i/ili Hep G2, pokazali su spojevi **6e** i **6k**. Od navedenih spojeva derivat **6l** osim najjačeg djelovanja na staničnu liniju SW620 ima i najslabije djelovanje na staničnu liniju normalnih fibroblasta WI 38 ($IC_{50} = 44$ μmol L^{-1}) što ukazuje na njegovu manju toksičnost na zdrave stanice.

Tri *N*-metilna derivata (**6b,h,j**) bila su gotovo potpuno inaktivna u najvećoj ispitanoj koncentraciji ($IC_{50} > 100$ μmol L^{-1}) na sve testirane stanične linije. Većina *O*-benzilnih derivata (**6a,c,e,k**) pokazali su izraženo citostatsko djelovanje na najveći broj testiranih staničnih linija ($IC_{50} = 0{,}8$ do $48{,}1$ μmol L^{-1}); najjače na HeLa stanice ($IC_{50} = 14{,}4$ do $28{,}6$ μmol L^{-1}), na MCF-7 stanice (**6c,e,k**, $IC_{50} = 4{,}9$ do $9{,}6$ μmol L^{-1}), na MIA PaCa-2 stanice (**6c,k**, $IC_{50} = 11{,}8$ i $22{,}1$ μmol L^{-1}), na PC-3 stanice (**6c,e,k,l**, $IC_{50} = 7{,}4$ do $19{,}5$ μmol L^{-1}) i na limfocitne i stanične linije leukemije (**6a,e,k**, $IC_{50} = 11$ do 28 μmol L^{-1}). Većina istaknutih derivata sadrži benzhidrilni (**6a,e,k**) osim derivata **6c** koji sadrži cikloheksanmetilni amidni supstituent.

Rezultati inhibitornog djelovanja *N*- i *O*- supstituiranih hidroksiurea dani su u Tablici 25.

Tablica 25. Inhibitorno djelovanje *N*- i *O*- supstituiranih hidroksiurea **6a-l** na rast malignih staničnih linija i normalnih fibroblasta (WI 38)

Spoj	Struktura	Stanične linije ($IC_{50}{}^{a}$ /μmol L^{-1})									
		HeLa	MCF-7	MIAPaCa-2	PC-3	SW620	Hep G2	L1210	Molt4/C8	CEM	WI 38
6a		28,6	29,9	48,1	42,9	31,2	33,8	23	28	28	27,9
6b		96,7	>100	>100	>100	>100	>100	>100	>100	>100	>100
6c		24,5	9,6	11,8	19,5	6,9	8,4	39	32	42	9,2
6d		>100	>100	43,8	44,6	0,7	1	>100	>100	>100	9,3
6e		25,7	5,9	38,4	15,2	0,8	4,6	12	14	28	20,1
6f		>100	63,4	>100	45,7	0,7	65,9	77	66	92	31,5
6g		49,6	40,9	78,1	52,2	53	27,1	44	45	51	47,1

6h		>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
6i		54,1	77,4	59,9	>100	92,2	>100	73	98	135	68,4
6j		>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
6k		14,4	4,9	22,1	7,8	1	0,9	11	12	12	8,1
6l		39,8	>100	50,9	7,4	0,1	24,8	61	57	89	44

[a] IC_{50} – koncentracija spoja kod koje je rast stanica inhibiran za 50 %.

3.2.1.3. *4-Benziloksisemikarbazid (8) i 1-(1-benzotriazolkarbonil)-4-benziloksisemikarbazid (9)*

Citostatsko djelovanje spojeva **8** i **9** ispitano je *in vitro* na sljedeće maligne stanične linije: L1210, CEM, HeLa, HCT 116, MCF-7 i H460. Navedeni spojevi predstavljaju prekursore u sintezi semikarbazidnih derivata NSAID te prema očekivanjima nisu značajno inhibirali rast ispitanih stanica u najvećoj ispitanoj koncentraciji ($IC_{50} > 250$ µmol L^{-1} za stanične linije L1210, CEM i HeLa; $IC_{50} > 100$ µmol L^{-1} za stanične linije HCT 116, MCF-7 i H460).

3.2.1.4. *Hidrazidi NSAID 11a-c*

Citostatsko djelovanje spojeva **11a**-**c** ispitano je *in vitro* na sljedeće maligne stanične linije: L1210, CEM, HeLa, HCT 116, MCF-7 i H460. Navedeni spojevi predstavljaju prekursore u sintezi semikarbazidnih derivata NSAID te su pokazali vrlo slabo antitumorsko djelovanje. Rezultati inhibitornog djelovanja hidrazida dani su u Tablici 26.

Tablica 26. Inhibitorno djelovanje hidrazida **11a**-**c** na rast malignih staničnih linija.

Spoj	Struktura	Stanične linije (IC_{50}[a] /µmol L^{-1})					
		L1210	CEM	HeLa	HCT 116	MCF-7	H460
11a		170±26	147±22	129±24	>100	>100	>100
11b		212±9	154±6	120±4	>100	>100	>100
11c		212±26	150±23	142±17	>100	>100	>100

[a] IC_{50} – koncentracija spoja kod koje je rast stanica inhibiran za 50 %.

3.2.1.5. *1-Acil-4-cikloalkil, 1-acil-4-aril i 1-acil-4-hidroksi semikarbazidi NSAID 13a-y*

Citostatsko djelovanje spojeva **13a**-**y** ispitano je *in vitro* na sljedeće maligne stanične linije: L1210, CEM, HeLa, HCT 116, MCF-7 i H460. Većina ispitanih derivata pokazala je najjače djelovanje na MCF-7 stanice što se može pripisati i njihovoj jačoj osjetljivosti u odnosu na druge stanične linije.

Najjače djelovanje pokazali su derivati **13f** (derivat ibuprofena), **13l** (derivat fenoprofena) i **13s** (derivat reduciranog ketoprofena) koji svi imaju benzhidrilni supstituent ($IC_{50} = 3$ do 23

μmol L^{-1}). Ako promatramo derivate s istim bočnim lancem (cikloalkilni ili arilni supstituent) aktivnost raste na sljedeći način: ibuprofen < reducirani ketoprofen < fenoprofen. Općenito alifatski derivati su pokazali nešto slabije djelovanje u odnosu na aromatske. Najslabije djelovanje u seriji **13** pokazali su *O*-benzilni i derivati sa slobodnom hidroksilnom skupinom (**13t**-**y**) te su bili ili slabo aktivni ili inaktivni u najvećoj ispitanoj koncentraciji. Upravo za te derivate se očekivalo najbolje rezultate s obzirom da sadrže hidroksamsku kiselinu u strukturi. Međutim, spojevi s lipofilnim benzidrilnim supstituentom dali su najbolje rezultate.

Rezultati inhibitornog djelovanja semikarbazida dani su u Tablici 27.

Tablica 27. Inhibitorno djelovanje semikarbazida **13a**-**y** na rast malignih staničnih linija

Spoj	Struktura	Stanične linije (IC_{50}[a] /μmol L^{-1})					
		L1210	CEM	HeLa	HCT 116	MCF-7	H460
13a		103±62	74±22	80±44	32±4	18±1	32±8
13b		30±7	53±6	69±45	28±0.2	19±3	35±0.01
13c		44±29	26±6	142±109	21±7	13±0.7	29±2
13d		110±10	74±18	173±8	34±1	29±12	59±11
13e		180±12	148±45	≥250	26±2	23±5	51±14
13f		20±0	23±4	22±12	13±0.06	6±1	16±1
13g		55±16	73±27	39±20	36±20	20±5	33±17
13h		35±7	53±8	48±5	22±7	17±2	24±2
13i		22±1	24±1	24±0	15±0.1	13±0.5	19±1

Spoj	Struktura						
13j		63±1	72±14	70±14	27±0.2	17±1	19±13
13k		53±1	71±9	64±8	18±1	19±4	22±1
13l		15±1	11±7	5.7±0.2	5±0.7	7±3	3±0.4
13m		69±12	66±4	43±12	33±8	19±2	38±2
13n		25±1	25±5	45±12	22±1	16±3	23±0.4
13o		22±1	20±1	20±0	16±3	18±10	18±0.5
13p		31±3	49±6	94±42	24±0.4	12±8	28±2
13r		31±3	29±3	58±7	20±5	15±0.8	22±2
13s		19±0	15±0	5.0±0.5	8±2	5±1	4±0.6
13t		192±81	≥250	178±3	76±10	50±11	>100
13u		84±10	91±9	76±4	76±21	81±7	>100
13v		79±4	101±11	78±2	56±10	41±18	82±19
13w		108±11	205±63	160±13	>100	>100	>100
13x		125±11	183±95	≥250	>100	>100	>100
13y		113±11	155±71	176±26	>100	>100	>100

[a] IC_{50} – koncentracija spoja kod koje je rast stanica inhibiran za 50 %.

3.2.1.6. *1-Acil-5-benziloksi i 1-acil-5-hidroksikarbamoil karbazidi NSAID **14a-f***

Citostatsko djelovanje spojeva **14a-f** ispitano je *in vitro* na sljedeće maligne stanične linije: L1210, CEM, HeLa, HCT 116, MCF-7 i H460.

Derivati **14** nisu pokazali značajnu aktivnost na ispitane stanične linije osim *O*-benzilnih (**14a-c**) na staničnu liniju MCF-7 (IC_{50} = 19 do 26 µmol L^{-1}). Derivati sa slobodnom hidroksilnom skupinom (**14d-f**) bili su inaktivni u najvećoj ispitanoj koncentraciji (IC_{50} > 250 µmol L^{-1} za stanične linije L1210, CEM i HeLa; IC_{50} > 100 µmol L^{-1} za stanične linije HCT 116, MCF-7 i H460).

Rezultati inhibitornog djelovanja derivata **14a-f** dani su u Tablici 28.

Tablica 28. Inhibitorno djelovanje 1-acil karbazida **14a-f** na rast malignih staničnih linija

Spoj	Struktura	Stanične linije (IC_{50}^{a} /µmol L^{-1})					
		L1210	CEM	HeLa	HCT 116	MCF-7	H460
14a		105±10	106±34	98±55	56±31	19±8	71±30
14b		103±5	90±10	88±4	84±16	26±10	>100
14c		102±1	96±3	76±20	64±21	19±10	>100
14d		>250	>250	>250	>100	>100	>100
14e		>250	>250	≥250	>100	>100	>100
14f		>250	>250	≥250	>100	>100	>100

[a] IC_{50} – koncentracija spoja kod koje je rast stanica inhibiran za 50 %.

3.2.2. ANTIVIRUSNA ISPITIVANJA

Antivirusna ispitivanja provedena su na Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgija, prema ranije opisanoj metodi (Perković *et al*, 2008).

3.2.2.1. *N- i O-Supstituirane hidroksiuree* **6a-l**

Antivirusno djelovanje *N-* i *O-* supstituiranih hidroksiurea ispitano je na sljedeće viruse: virus humane imunodeficijencije tip 1 i 2 (HIV-1 i 2) u kulturi CEM stanica, herpes simpleks virus tip 1 (KOS) i tip 2 (G), vaccinia virus i vesicular stomatitis virus u kulturi HEL stanica, Coxsackie virus B4 i respiracijski sincicijski virus (RSV) u kulturi HeLa stanica, parainfluenza-3 virus, reovirus-1, Sindbis virus i Punta Toro virus u kulturi Vero stanica, Feline corona virus u kulturi CRFK stanica i virus influence tip A (H1N1 i H3N2 subtipovi) i tip B u kulturi MDCK stanica.

Hidroksiuree **6** nisu pokazale specifično antivirusno djelovanje, tj. minimalna efektivna koncentracija (EC_{50}, efektivna koncentracija kod koje je stvaranje plakova virusa smanjeno za 50 %) bila je veća od 1/5 minimalne citotoksične koncentracije (*MCC*, minimalna citotoksična koncentracija kod koje je mikroskopski vidljiva promjena morfologije normalne stanice, subtoksična koncentracija) (rezultati nisu pokazani).

3.2.2.2. *Derivati* **8**, **9**, **11**, **13**, **14**

Antivirusno djelovanje derivata **8**, **9**, **11**, **13** i **14** ispitano je na sljedeće viruse: HIV-1 i 2, KOS i G, vaccinia virus i vesicular stomatitis, parainfluenza-3, reovirus-1, Sindbis, Coxsackie B4, Punta Toro virus, RSV, Feline herpes i corona virus, virus influence tip A (H1N1 i H3N2 subtipovi) i tip B, varicella zoster i citomegalovirus u HEL stanicama.

Ispitani derivati nisu pokazali specifično antivirusno djelovanje tj. inhibiciju u subtoksičnim koncentracijama na sve ispitane viruse u kulturama stanica osim derivata **13a**, **g** i **m** na citomegalovirus u HEL stanicama (sojevi AD-169 i Davis). Spoj **13a** (derivat ibuprofena) imao je EC_{50} (efektivna koncentracija kod koje je stvaranje plakova virusa smanjeno za 50 %) 11,19 (AD-169) i 7,16 µmol L^{-1} (Davis); **13g** (derivat fenoprofena) 14,47 (AD-169) i 7,49 µmol L^{-1} (Davis); **13m** (derivat ketoprofena) 14,89 (AD-169) i 11,24 µmol L^{-1} (Davis). Minimalna citotoksična koncentracija (*MCC*) je za navedene derivate bila 100 µmol L^{-1} (indeks selektivnosti MCC/EC_{50} = 7–14) (rezultati nisu pokazani). Sva tri navedena derivata imaju ciklopentilni supstituent pa se može zaključit da je on bitan za antivirusno djelovanje.

3.2.3. Antimikrobna ispitivanja derivata aminokiselina 4 i 6

Antimikrobno ispitivanje provedeno je na Zavodu za mikrobiologiju Farmaceutsko-biokemijskog fakulteta u Zagrebu.

Antimikrobno i antifungalno djelovanje spojeva **4** i **6** ispitano je korištenjem difuzijske metode (bušenjem cilindrima: visine 10, vanjskog promjera 8, a unutrašnjeg 6 mm) (European Pharmacopoeia, 2006). Korištene su sljedeće vrste: *B. subtilis* (ATCC 6633), *S. aureus* (ATCC 25923), *E. faecalis* (ATCC 29212), *K. rhizophila* (ATCC 9341), *E. coli* (ATCC 10536), *S. enterica* subsp. *enterica* (ATCC 13076), *P. aeruginosa* (ATCC 27853), *C. albicans* (ATCC 10231). Niti jedan od ispitanih spojeva nije pokazao zone inhibicije rasta te su smatrani antimikrobno inaktivnima pri ispitivanoj koncentraciji (serija **4**: 20 mg mL^{-1}, serija **6**: 31,75 mg mL^{-1}) i provedenoj metodi, djelomično i zbog njihove slabe topljivosti (serija **6**) u Müller-Hinton agaru (prilikom izvođenja pokusa supstancije su se taložile, rezultati nisu prikazani). Niti jedan od ispitanih spojeva nije pokazao antifungalno djelovanje.

Minimalna inhibitorna (*MIC*) i minimalna mikrobicidna koncentracija (*MMcC*) određene su metodom serijalnog mikrorazrijeđenja (CLSI) (NCCLS, 1997).

Oksitetraciklin, norfloksacin i nistatin su korišteni kao kontrola osjetljivosti mikrobnih kultura u metodi difuzije.

3.2.4. Antioksidativno djelovanje, inhibicija lipidne peroksidacije linolne kiseline i inhibicija lipooksigenaze

Ispitivanje antioksidativnog djelovanja, inhibicije lipidne peroksidacije linolne kiseline i inhibicija lipooksigenaze provedena su na Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotles University of Thessaloniki, Solun, Grčka prema ranije opisanoj metodi (Pontiki *et al*, 2007; Re *et al*, 1999; Taraborewala *et al*, 1990).

3.2.4.1. *Ureidoamidi 4a-o*

Ispitivanje antioksidativnog djelovanja temelji se na mjerenju stupnja interakcije supstancija sa stabilnim slobodnim radikalom 1,1-difenil-2-pikrilhidrazil radikalom (DPPH) i

opisuje njihovu sposobnost hvatanja slobodnih radikala u sustavu bez željeza što pokazuje kolika je njihova reducirajuća aktivnost.

Na temelju te činjenice ispitana je interakcija ureidoamida **4** s DPPH, prema ranije opisanoj metodi (Pontiki *et al*, 2007) mjerenjem apsorbancije ispitivanih otopina nakon 20 i 60 min kod dvije koncentracije ispitivanih spojeva (0,05 i 0,1 mmol L^{-1}), a rezultati su prikazani u Tablici 29. Rezultati pokazuju da je interakcija s DPPH bila vrlo slaba (ispod 10 % za sve ispitane spojeve) te da nije došlo do promjene u jačini interakcije ovisno o koncentraciji ispitivanih derivata i vremenu.

Princip ispitivanja stupnja inhibicije lipidne peroksidacije linolne kiseline koristi sposobnost azo spojeva da generiraju slobodne radikale spontanom termičkom razgradnjom (koriste se za *in vitro* studije nastajanja slobodnih radikala). U ovim pokusima korišten je vodotopljivi 2,2'-azobis(2-amidinopropan) dihidroklorid (AAPH) kao inicijator slobodnih radikala, koji oksidiraju linolnu kiselinu do konjugiranog peroksidnog diena (Re *et al*, 1999).

Rezultati ispitivanja sposobnosti inhibicije lipidne peroksidacije linolne kiseline pokazuju slabu do umjerenu inhibiciju lipidne peroksidacije linolne kiseline za većinu ispitanih derivata. Iznimka su derivati **4c,m,g,j** (vrijednosti od 59,6–94,6 %, Tablica 29).

Lipooksigenaze (LO) oksidiraju masne kiseline koje u svojoj strukturi sadrže konjugiranu triensku strukturu na specifičnim položajima, do hidroperoksida, prekursora leukotriena (medijatori upale). Većina inhibitora lipooksigenaze su antioksidansi ili hvatači slobodnih radikala, zbog toga što se lipooksigenacija događa preko ugljikovih radikala.

Sposobnost inhibicije LO ispitana je enzimskim testom temeljenim na mjerenju UV apsorpcije (Tablica 29) (Pontiki *et al*, 2007; Taraborewala *et al*, 1990). Ureidoamidi su umjereno inhibirali LO što pokazuju vrijednosti IC_{50} izmjerene za derivate **4b**, **4d**, **4g**, **4j**, **4k**, **4m** (88–100 µmol L^{-1}).

Kao poredbene tvari korišteni su antioksidansi kavena kiselina, nordihidrogvajaretična kiselina (NDGA) i troloks.

Tablica 29. Interakcija s DPPH, inhibicija lipidne peroksidacije linolne kiseline i *in vitro* inhibicija LO ureidoamida **4**

Spoj	Struktura	DPPH 20 min[a] (%)	DPPH 60 min[a] (%)	DPPH 20 min[b] (%)	DPPH 60 min[b] (%)	Inhibicija LP[b] (%)	Inhibicija LO[b]
4a		1,7	0,5	n.a.[c]	n.a.	n.a.	28,1
4b		n.a.	0,9	0,3	1	32,9	49,5[d]
4c		3,2	3,9	1,4	4,8	94,6	22,6
4d		3,4	6,3	2,1	3,5	24,2	55,7[d]
4e		2,7	6,3	5,0	4,7	15,0	37,8
4f		n.a.	1,2	2,3	5,2	43,7	36,1
4g		1,2	0,9	n.a.	1,5	59,6	52,8[d]
4h		n.a.	3,2	0,9	3,6	16,1	42,6
4i		1,2	1,1	2,7	2,8	11,1	42,5
4j		2,3	3,8	5,7	7,5	63,1	50,1[d]
4k		n.a.	2,2	4,9	1,3	47,9	55,6[d]
4l		1,6	2,4	0,9	3,7	3,9	36,9
4m		0,5	3,0	n.a.	1,1	87,4	49,2[d]

Spoj	Struktura						
4n		0,9	1,8	n.a.	0,9	19,9	39,7
4o		1,8	3,3	2,5	3,7	16,6	27,6
Kavena kiselina		n.o.[e]	n.o.	n.o.	n.o.	n.o.	600
NDGA		81	83	93	97	n.o.	n.o.
Troloks		n.o.	n.o.	n.o.	n.o.	63	n.o.

Koncentracije: [a] 5×10^{-5} mol L^{-1}; [b] 1×10^{-4} mol L^{-1}; [c] n.a. – nema aktivnosti; [d] IC_{50} (µmol L^{-1}) su određene: 100 (**4b**), 92,5 (**4d**), 98 (**4g**), 100 (**4j**), 88 (**4k**), 100 (**4m**); [e] n.o. – nije određeno.

3.2.4.2. *Derivati 8 i 9*

Interakcija derivata **8** i **9** s DPPH promatrana je kod jedne koncentracije spojeva (0,1 mmol L^{-1}) u ovisnosti o vremenu (nakon 20 i 60 min). Rezultati su pokazali da spoj **9** stupa u snažnu interakciju s DPPH (85 %) za razliku od spoja **8** (14 %). Nije bilo značajnih promjena u interakciji spojeva s DPPH u ovisnosti o vremenu.

Rezultati ispitivanja inhibicije lipidne peroksidacije linolne kiseline pokazali su slabu aktivnost za oba derivata (36 i 31 %) (Tablica 30).

Sposobnost inhibicije LO derivatima **8** i **9** ispitana enzimskim testom temeljenim na mjerenju UV apsorpcije polazala je inaktivnost oba derivata za danu koncentraciju.

Tablica 30. Teorijski izračunate clog *P* vrijednosti, interakcija s DPPH, inhibicija lipidne peroksidacije linolne kiseline i *in vitro* inhibicija lipooksigenaze derivata **8** i **9**

Spoj	Struktura	clog *P*[a]	DPPH 20 min[b] (%)	DPPH 60 min[b] (%)	Inhibicija LP (%)	Inhibicija LO[c]
8		0,27	6	14	36	n.a.[d]
9		0,27	6	14	36	n.a.
NDGA		n.o.[e]	80	91	n.o.	84[f]
Troloks		n.o.	n.o.	n.o.	63	n.o.

115

ª Lipofilnost molekule teorijski je izračunata kao clog P u smjesi n-oktanola i pufera CLOGP programom (Biobyte Corp). Koncentracije: ^b 5×10^{-5} mol L^{-1}; ^cIC_{50} (µmol L^{-1}); ^dn.a. – nema aktivnosti; ^e n.o. – nije određeno; ^f IC_{50} = 28 µM

3.2.4.3. *NSAID derivati* **11***,* **13** *i* **14**

Interakcija NSAID derivata **11**, **13** i **14** s DPPH promatrana je kod koncentracije spojeva 0,1 mmol L^{-1} u ovisnosti o vremenu (nakon 20 i 60 min). Rezultati su pokazali da hidrazidi NSAID **11** ne stupaju u interakciju s DPPH, semkarbazidi **13a**-**s** stupaju u vrlo slabu interakciju s DPPH (najbolja interakcija uočena je za fenoprofenski derivat **5j**, 24 %) i aktivnost pada s obzirom na NSAID u molekuli (fenoprofen > reducirani ketoprofen > ibuprofen). *O*-Benzilni derivati **13t**-**v** također ne stupaju u interakciju s DPPH za razliku od derivata sa slobodnom hidroksilnom skupinom **13w**-**y** koji su pokazali nabolju interakciju koja je rasla u ovisnosti o vremenu (54–66 %). Lipofilnost spojeva ne utječe na njihovu interakciju s DPPH. Interakcija svih ispitanih spojeva s DPPH slabija je od interakcije NDGA s DPPH.

Nekoliko derivata pokazalo je vrlo snažnu inhibiciju lipidne peroksidacije linolne kiseline (99–100 %) i to fenoprofenski derivat **13l**, ibuprofenski derivat **13t** i ketoprofenski derivat **14c**. Osim njih još su neki derivati pokazali jaku inhibiciju, **13f**, **13r** i **13s** (71–88 %). Općenito, bolje djelovanje su pokazali derivati s aromatskim supstituentom od onih s cikloalkilnim. Derivati s benzhidrilnim supstituentom pokazali su jako dobro djelovanje koje se može korelirati s njihovim citostatskim djelovanjem. Za razliku od toga, derivati koji su najbolje inhibirali lipidnu peroksidaciju linolne kiseline vrlo su slabo stupali u interakciju s DPPH.

Sposobnost inhibicije LO derivatima **11**, **13** i **14** ispitana je enzimskim testom temeljenim na mjerenju UV apsorpcije (Tablica 31) (Pontiki *et al*, 2007; Taraborewala *et al*, 1990). Najsnažniji inhibitori bili su **13s**, **13l** i **13j**, (68–96 %), ponovo spojevi s benzhidrilnim supstituentom (**13s,l**) te s benzilnim supstituentom (**13j**). Za njih su izmjerene i pripadajuće inhibitorne koncentracije (*IC*$_{50}$).

Tablica 31. Teorijski izračunate clog P vrijednosti, interakcija s DPPH, inhibicija lipidne peroksidacije linolne kiseline i *in vitro* inhibicija lipooksigenaze derivata **11**, **13** i **14**

Spoj	Struktura	clog P[a]	DPPH 20 min[b] (%)	DPPH 60 min[b] (%)	Inhibicija LP[c] (%)	Inhibicija LO[b]
11a		2,41	n.a.[g]	1	6	8
11b		2,55	n.a.	1	10	3
11c		2,52	n.a.	n.a.	6	10
13a		4,04	4	7	26	n.a.
13b		4,60	n.a.	n.a.	33	n.a.
13c		5.22	3	6	16	25
13d		4.34	n.a.	n.a.	12	n.a.
13e		4,67	n.a.	n.a.	33	n.a.
13f		6,11	n.a.	n.a.	74	46
13g		4,19	16	19	21	n.a.
13h		4,74	19	22	63	13
13i		5,36	18	21	64	12
13j		4,48	22	24	11	68[c]
13k		4,81	4	7	51	20

Compound	Structure					
13l	(chemical structure)	5,83	2	4	99	81[d]
13m	(chemical structure)	4,15	4	12	n.a.	n.a.
13n	(chemical structure)	4,71	3	10	31	10
13o	(chemical structure)	5,33	5	12	61	9
13p	(chemical structure)	4,45	3	9	48	n.a.
13r	(chemical structure)	4,78	8	15	71	17
13s	(chemical structure)	5,80	4	9	88	96[e]
13t	(chemical structure)	4,09	n.a.	n.a.	100	n.a.
13u	(chemical structure)	4,24	n.a.	n.a.	8	6
13v	(chemical structure)	4,20	3	6	n.a.	n.a.
13w	(chemical structure)	1,57	29	54	20	7
13x	(chemical structure)	1.71	39	66	22	3
13y	(chemical structure)	1,68	36	59	8	8
14a	(chemical structure)	2,93	11	18	13	n.a.
14b	(chemical structure)	3,07	8	15	26	n.a.
14c	(chemical structure)	3,04	10	19	100	n.a.

14d		0,41	24	46	15	n.a.
14e		0,55	23	48	13	n.a.
14f		0,52	28	53	28	1
NDGA		n.o.[h]	80	91	n.o.	84[e]
Troloks		n.o.	n.o.	n.o.	63	n.o.

[a] Lipofilnost molekule teorijski je izračunata kao clog P u smjesi n-oktanola i pufera CLOGP programom (Biobyte Corp). Koncentracije: [b] 1×10^{-4} mol L^{-1}; [c] $IC_{50} = 75$ μmol L^{-1}; [d] $IC_{50} = 60$ μmol L^{-1}; [e] $IC_{50} = 51,5$ μmol L^{-1}; [f] $IC_{50} = 28$ μmol L^{-1}; [g] n.a. – nema aktivnosti; [h] n.o. – nije određeno.

4. ZAKLJUČCI

1. U ovom doktorskom radu ukupno je sintetizirano 94 spoja, od čega je 68 novih, do sada nepoznatih spojeva. Strukture novih spojeva karakterizirane su uobičajenim analitičkim i spektroskopskim metodama (talište, elementarna analiza, IR, ^{1}H i ^{13}C NMR).

2. Sintetizirani su derivati aminokiselina: *N*-Btc-aminokiseline **2**, njihovi kloridi **3**, ureidoamidi **4**, amidi **5** i *N*- i *O*- supstituirane hidroksiuree **6**. Novi spojevi su svi ureidoamidi **4** koji su pripravljeni aminolizom iz odgovarajućih klorida **3** i aminoalkohola i sve *N*- i *O*- supstituirane hidroksiuree **6** koje su pripravljene aminolizom iz odgovarajućih amida **5** i hidroksilamina.

3. Sintetizirani su prekursori u sintezi semikarbazidnih derivata NSAID:
   - 1-Karbamoilbenzotriazoli (amidi 1-benzotriazolkarboksilne kiseline, aktivne uree) **7** sintetizirani su u reakcijama BtcCl-a (**1**) i amina. Korišteni su u sintezi semikarbazidnih derivata NSAID **13**. Novi spojevi su **7a**,**c**,**d** i **f**.
   - Iz 4-benziloksisemikarbazida (**8**) dobiven je 1-(1-benzotriazolkarbonil)-4-benzil-oksisemikarbazid (**9**), prekursor za sintezu 1-acil-5-benziloksi/hidroksikarbamoil-karbazida NSAID **14**. Spoj **9** se pokazao kao pogodan reagens za uvođenje acil semikarbazidne skupine u molekulu. U reakcijama sa slobodnom amino skupinom NSAID hidrazida reagirao je u dobrim iskorištenjima.

4. Sintetizirani su derivati NSAID:
   - NSAID benzotriazolidi **10** bili su prekursori u sintezi hidrazida **11** i estera **12**. Hidrazidi **11** korišteni su u sintezi semikarbazidnih derivata NSAID **13** i **14**. Dobiveni su reakcijom nukleofilne supstitucije u kojoj je benzotriazol u NSAID benzotriazolidima **10a**-**c** zamijenjen hidrazinom. Novi spojevi su **11b** i **c**.
   - Sintetizirani su novi esterski derivati ketoprofena **12**, koji su ujedno i aminokiselinski derivati (u reakciji nukleofilne supstitucije benzotriazol u benzotriazolidu ketoprofena **10d** zamijenjen je alkoholnom skupinom iz ureidoamida **4b**,**i**,**j**,**m**). Dobiveni spojevi su dvojni lijekovi jer sadrže dvije molekule lijeka (ketoprofena).
   - 1-Acilsemikarbazidi NSAID **13a**-**v** sintetizirani su iz 1-karbamoilbenzotriazola **7** i hidrazida NSAID **11** reakcijom u talini. Spojevi **13w**-**y** sintetizirani su katalitičkim hidrogeniranjem *O*-benzilnih derivata **13t**-**v**, uz katalizator Pd/C. Svi spojevi su novi.

- 1-Acil-5-benziloksikarbamoilkarbazidi NSAID **14a-c** sintetizirani su iz 1-(1-benzotriazolkarbonil)-4-benziloksisemikarbazida (**9**) i hidrazida NSAID **11** reakcijama u talini. Spojevi **14d-f** pripravljeni su katalitičkim hidrogeniranjem *O*-benzilnih derivata **14a-c** uz katalizator Pd/C. Svi spojevi su novi.

5. Provedena su sljedeća biološka ispitivanja: antitumorsko, antimikrobno, antivirusno i antioksidativno djelovanje, inhibicija lipooksigenaze i lipidne peroksidacije.

   - Antitumorsko djelovanje ispitano je za derivate **4**, **6**, **8**, **9**, **11**, **13** i **14**. Hidroksiuree **6** su pokazale značajno bolje djelovanje od ureidoamida **4** i derivata **8** i **9** koji su bili inaktivni u ispitanim koncentracijama i derivata NSAID **11**, **13** i 1**4** koji su bili slabo aktivni (najbolje djelovanje imali su benzhidrilni derivati **13f,l,s** za staničnu liniju MCF-7 (IC_{50} < 10 μmol L^{-1}). Za staničnu liniju SW620 sljedeći derivati imali su najsnažnije djelovanje: IC_{50} (**6l**) = 0,1 μmol L^{-1}; IC_{50} (**6f** i **d**) = 0,7 μmol L^{-1}; IC_{50} (**6e**) = 0,8 μmol L^{-1}. Spoj **6k** pokazao je najjači učinak na rast stanične linije Hep G2 (IC_{50} = 0,9 μmol L^{-1}).

   - Antimikrobno djelovanje ispitano je za derivate **4** i **6**. Svi ispitani spojevi bili su ili inaktivni ili vrlo slabog djelovanja.

   - Antivirusno djelovanje ispitano je za derivate **6**, **8**, **9**, **11**, **13** i **14**. Djelovanje svih ispitanih spojeva bilo je slabo. Iznimka su ciklopentilni derivati NSAID **13a,g**,**m** koji su imali relativno dobar indeks selektivnosti (MCC/EC_{50} = 7-14) za citomegalovirus u kulturi HEL stanica.

   - Antioksidativno djelovanje ispitano je za derivate **4**, **8**, **9**, **11**, **13** i **14**. Najbolje antioksidativno djelovanje pokazao je benzotriazolid **9** (interakcija s DPPH 85 %). Svi ostali derivati bili su slabo aktivni ili inaktivni.

   - Inhibicija lipooksigenaze i lipidne peroksidacije linolne kiseline ispitana je za derivate **4**, **8**, **9**, **11**, **13** i **14**, koji su pokazali umjerenu inhibiciju LO i LP. Najsnažniji inhibitor LO bio je benzhidrilni derivat reduciranog ketoprofena **13s** (IC_{50} = 51,5 μmol L^{-1}). Najsnažniji inhibitor lipidne peroksidacije bili su ibuprofenski derivati **13t** (*O*-benzilhidroksisemikarbazid) i **14c** (1-acil-5-hidroksikarba-moilkarbazid) (100 % inhibicije) i fenoprofenski derivat **13l** (benzhidrilni supstituent) (99 % inhibicije).

5. LITERATURA

Adams JL, Garigipati RS, Sorenson M, Schmidt SJ, Brian WR, Newton JF, Tyrrell KA, Garver E, Yodis LA, Chabot-Fletcher M, Tzimas M, Webb EF, Breton JJ, Griswold DE. Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and *in vitro* metabolic studies characterizing *N*-hydroxy-*N*-(2,3-dihydro-6-(phenylmetoxy)-3--benzofuranyl)urea. *J Med Chem* **39** (1996) 5053–5046.

Amir M, Kumar S. Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of some new 2-[(2,6-dichloroanilino)phenyl]acetic acid derivatives. *Eur J Med Chem* **39** (2004) 535–545.

Amir M, Kumar S. Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of 3,5-dimethyl pyrazoles, 3-methyl pyrazol-5-ones and 3,5-disubstituted pyrazolines. *Indian J Chem* **44B** (2005) 2532–2537.

Amir M, Kumar S Synthesis and evaluation of anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation properties of ibuprofen derivatives. *Acta Pharm* **57** (2007) 31–45.

Amtul Z, Atta-ur-Rahman, Siddiqui RA, Choudhary MI. Chemistry and mechanism of urease inhibition. *Curr Med Chem* **9** (2002) 1323–1348.

Andrews P, Zhao X, Allen J, Li F, Chang M. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. *Cancer Chemother Pharmacol* **61** (2008) 203–214.

Aries R (1970) FR 1,579,495; ref. *Chem Abstr* **73**: 3797.

Asghar SF, Yasin KA, ur-Rehman H, Aziz S. Synthesis and cyclisation of 1,4-disubstituted semicarbazides. *Nat Prod Res* **24** (2010) 315–325.

Baker JW, Stenseth RE (1966) US Patent 3,285,957.

Beraldo H, Gambino D. Wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. *Mini-Rev Med Chem* **4** (2004) 159–165.

Bhatia PA, Brooks CDW, Basha A, Ratajczyk JD, Gunn BP, Bouska JB, Lanni C, Young PR, Bell RL, Carter GW. 5-Lipoxygenase inhibitors: synthesis and structure-activity relationships of a series of 1-aryl-2*H*,4*H*-tetrahydro-1,2,4-triazin-3-ones. *J Med Chem* **39** (1996) 3938–3950.

Biobyte Corp., C-QSAR Database 201 West 4th Str., Suite 204, Claremont CA, California 91711, USA

Božnar B, Žmitek J, Kocjan D (1987) EP 203,379; ref. *Chem Abstr* **106**: 84185.

Brantley RK (1970) US Patent 3,511,875.

Butula I, Proštenik MV, Vela V. Reactions with 1-benzotriazolecarboxylic acid chloride. I. Synthesis of the 2,6-bis(hydroxymethyl)pyridinedicarbamates. *Croat Chem Acta* **49** (1977) 837–842.

Butula I, Vela V, Ivezić B. Reaktionen mit 1-Benzotriazolcarbonsäurechlorid. IV. Synthese von substituierten Harnstoffen, Semicarbaziden und Carbaziden. *Croat Chem Acta* **51** (1978) 339–346.

Butula I, Zorc B, Vela V. Reaktionen mit 1-Benzotriazol Carbonsaurechlorid.VII. Die Umsetzung mit Aminosäuren. *Croat Chem Acta* **54** (1981a) 435–440.

Butula I, Jadrijević Mladar-Takač M. Reactions with 1-benzotriazolecarboxylic acid chloride. VIII. Synthesis of *N*-hydroxyisocyanate derivatives. *Croat. Chem. Acta* **73** (2000) 569–574.

Butula I, Zorc B. Čudesna molekula benzotriazol. *Kem Ind* **56** (2007)123–134

Cetenko WA, Connor DT, Flynn DL, Sircar JC (1990) EP 342,682; ref. *Chem Abstr* **112**: 216688j.

Charlier C, Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. *Eur J Med Chem* **38** (2003) 645–659.

Chung SJ, Kim DH. *N*-(Hydroxyaminocarbonyl)phenylalanine: a novel class of inhibitor for carboxypeptidase A. *Bioorg Med Chem* **9** (2001) 185–189.

Connolly PJ, Wetter SK, Beers KN, Hamel SC, Chen RHK, Wachter MP, Ansell J, Singer MM, Steber M, Ritchie DM, Argentieri DC. N-Hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase. *Bioorg Med Chem Lett* **9** (1999) 979–984.

Degenghi R. Hydroxyurea. *Org Synth* **40** (1960) 60.

Dresler WFC, Stein R. Ueber den Hydroxylharnstoff. *Justus Liebigs. Ann Chem Pharmacol* **150** (1869) 242–252.

Edwards LH (1985) U.S. Patent 4,500,539.

El-Sabbagh OI, Rady HM. Synthesis of new acridines and hydrazones derived from cyclic β--diketone for cytotoxic and antiviral evaluation. *Eur J Med Chem* **44** (2009) 3680–3686.

European Pharmacopoeia, 5th Edition (2006): Strasbourg: Council of Europe

Fadl TA, Omar FA. Paracetamol (acetaminophen) esters of some non-steroidal anti-inflammatory carboxylic acids as mutual prodrugs with improved therapeutic index. *Inflammopharmacol* **6** (1998) 143–157.

Farshori NN, Banday MR, Ahmad A, Khan AU, Rauf A. Synthesis, characterisation, and in vitro antimicrobial activities of 5-alkenyl/hydroalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles. *Bioorg Med Chem Lett* **20** (2010) 1933–1938.

Finch, RA, Liu MC, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng YC, Sartorelli AC. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. *Biochem Pharmacol* **59** (2000) 983–991.

Fishbein WN, Winter TS, Davidson JD. Urease catalysis: I. Stoichiometry, specificity, and kinetics of a second substrate: hydroxyurea. *J Biol Chem* **240** (1965) 2402–2406.

Flynn DL, Capiris T, Cetenko WJ, Connor DT, Dyer RD, Kostlan CR, Nies DE, Schrier DJ, Sircar JC. Nonsteroidal anti-inflamatory drug hydroxamic acids. Dual inhibitors of both cyclooxygenase and 5-lipoxygenase. *J Med Chem* **33** (1990) 2070–2072.

Fogli S, Banti I, Stefanelli F, Picchianti L, Digiacomo M, Macchia M, Breschi MC, Lapucci A. Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells. *Eur J Med Chem* **45** (2010) 5100–5107.

Fun HK, Kia R, Jebas SR, Sujith KV, Kalluraya B. 1-[2-(4-Isobutylphenyl)propanoyl] thiosemicarbazide. *Acta Cryst* E**65** (2009) o621.

Ghosh AK, Doung TT, McKee SP, Thompson WJ. *N,N′*-dissuccinimidyl carbonate: a useful reagent for alkoxycarbonylation of amines. *Tetrahedron Lett* **33** (1992) 2781–2784.

Gobec S, Brožič P, Lanišnik Rižner T. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: New lead compounds for the development of anticancer agents. *Bioorg Med Chem Lett* **15** (2005) 5170–5175.

Goldstein SW, McDermott RE, Gibbs EM, Stevenson RW. Hydroxyurea derivatives as hypoglycemic agents. *J Med Chem* **36** (1993) 2238–2240.

Grobner P, Muller E. 4-Hydroxysemicarazide und derivat. *Eur J Med Chem* **9** (1974) 341–343.

Hacking MAPJ, van Rantwijk F, Sheldon RA. Lipase catalysed synthesis of diacyl hydrazines: an indirect method for kinetic resolution of chiral acids. *J Mol Catal B-Enzim* **9** (2000) 183–191.

Harmon RE, Dabrowiak, Brown DJ, Gupta SK, Herbert M, Chitharanjan D. Metal complexes of 1-substituted 3-hydroxyureas. *J Med Chem* **13** (1970) 577–579.

Hellberg MR, Namil A, Delgado P, David KC, Kessler TL, Graff G, Haggard KS, Nixon JC. Novel esters and amides of nonsteroidal antiinflammatory carboxylic acids as antioxidants and antiproliferative agents. *J Med Chem* **42** (1999) 267–276.

Higgin JJ, Yakovlev GI, Mitkevich VA, Makarov AA, Raines RT. Zinc(II)-mediated inhibition of a ribonuclease by an *N*-hydroxyurea nucleotide. *Bioorg Med Chem Lett* **13** (2003) 409–412.

Hirai K, Uchida A, Watanabe A, Abe T, Ueda T, Sakurai H (2010) US Patent 2010/0152443.

Huguenin S, Vacherot F, Fleury-Feith J, Riffaud JP, Chopin DK, Bolla M, Jaurand MC. Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti--inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines. *Cancer Lett* **218** (2005) 163–170.

Huzjak M, Rajić Z, Zorc B. Dvojni lijekovi s identičnim i neidentičnim podjedinicama. *Kem Ind* **57** (2008) 511–519.

Inayat MS, Chendil D, Mohiuddin M, Elford HL, Gallicchio VS, Ahmed MM. Didox (a novel ribonucleotide reductase inhibitor) overcomes bcl-2 mediated radiation resistance in prostate cancer cell line PC-3. *Cancer Biol Ther* **1** (2002) 539–545.

Inayat MS, El-Amouri IS, Bani-Ahmad M, Elford HL, Gallicchio VS. Inhibition of allogenic inflammatory responses by the ribonucleotide reductase inhibitors, Didox and Trimidox. *J Inflamm* **7** (2010) 43.

Kalčić I, Zovko M, Jadrijević-Mladar Takač, Zorc B, Butula I. Synthesis and reactions of some azolecarboxylic acid derivatives. *Croat Chem Acta* **76** (2003) 217–228.

Katritzky AR, Lan X, Yang JZ, Denisko OV. Properties and synthetic utility of *N*-substituted benzotriazoles. *Chem Rev* **98** (1998) 409–548.

Katritzky AR, Rachwal S. Synthesis of heterocycles mediated by benzotriazole. 1. Monocyclic systems. *Chem Rev* **110** (2010) 1564–1610.

Khan MSY, Akhter M. Synthesis, pharmacological activity and hydrolytic behavior of glyceride prodrugs of ibuprofen. *Eur J Med Chem* **40** (2005) 371–376.

Kleeman A, Engel J, Kutscher B, Reichert D. Pharmaceutical substances, synthesis, patents, applications. 4th Edition, Stuttgart (2001) Thieme.

Kolasa T, Brooks CDW, Rodriques KE, Summers JB, Dellaria JF, Hulkower KI, Bouska J, Bell RL, Carter GW. Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors. *J Med Chem* **40** (1997) 819–824.

Kolasa T, Stewart AO, Brooks CDW. Asymmetric synthesis of (R)-*N*-3-butyn-2-yl-*N*-hydroxyurea, a key intermediate for 5-lipoxygenase inhibitors. *Tetrahedron-Asymmetr* **7** (1996) 729–736.

Kolesar JM, Brundage RC, Pomplun M, Alberti D, Holen K, Traynor A, Ivy P, Wilding G. Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine) in cancer patients. *Cancer Cehemother Pharmacol* **67** (2011a) 393–400.

Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Cytotoxic evaluation of 3--aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP, in peripheral blood lymphocytes of patients with refractory solid tumors using electron paramagnetic resonance. *Exp Ther Med* **2** (2011b) 119–123.

Kraljević Pavelić S, Sedić M, Poznić M, Rajić Z, Zorc B, Pavelić K, Balzarini J, Mintas M. Evaluation of *in vitro* biological activity of *O*-alkylated hydroxamic derivatives of some nonsteroidal anti-inflammatory drugs. *Anticancer Res* **30** (2010) 3987–3994.

Kürti L, Czakó B. Strategic applications of named reactions in organic synthesis. London (2005) Elsevier Academic Press.

Leavel UW, Yarbro JW. Hydroxyurea. A new treatment of psoriasis. *Arch Dermatol* **102** (1970) 144–150.

Lemke TL, Williams DA, Roche VF, Zito SW. Foye's principles of medicinal chemistry. 6th Edition, Philadelphia (2008) Lippincott Williams & Wilkins.

Li B, Bemish RJ, Bill DR, Brenek S, Buzon RA, Chiu CKF, Newel L. Preparation of pivaloyl hydrazide in water. *Org Synth* **81** (2005) 254–261.

Liu W, Zhou J, Bensdorf K, Zhang H, Liu H, Wang Y, Qian H, Zhang Y, Wellner A, Rubner G, Huang W, Guo C, Gust R. Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives. *Eur J Med Chem* **46** (2011) 907–913.

Mai X, Lu X, Xia H, Cao Y, Liao Y, Lv X. Synthesis, antitumor evaluation and crystal structure of hydroxyurea derivatives. *Chem Pharm Bull* **58** (2010) 94–97.

Marjanović M, Zorc B, Pejnović L, Zovko M, Kralj M. Fenoprofen and ketoprofen amides as potential antitumor agents. *Chem Biol Drug Des* **69** (2007) 222–226.

Marshall WS (1971) FR 2,015,728; ref. *Chem Abstr* **75**: 48707.

Metwally KA, Yaseen SH, Lashine ESM, El-Fayomi HM, El-Sadek ME. Non-carboxylic analogues of arylpropionic acids: Synthesis, anti-inflammatory activity and ulcerogenic potential. *Eur J Med Chem* **42** (2007) 152–160.

Mitsunobu O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. *Synthesis* (1981) 1–28.

Muri EMF, Nieto MJ, Sindelar RD, Williamson JS. Hydroxamic acids as pharmacological agents. *Curr Med Chem* **9** (2002) 1631–1653.

Muri EMF, Mishra H, Stein SM, Williamson JS. Molecular modeling, synthesis and biological evaluation of heterocyclic hydroxamic acids designed as *Helicobacter pylori* urease inhibitors. *Lett Drug Des Discov* **1** (2004) 30–34.

Müller KH, König K, Santel HJ, Dollinger M, Stenzel K (1996) WO 9611188.

Nakaguchi O, Shimazaki N, Kawai Y, Hashimoto M, Nakatuka M (1988) US Patent 4,725,608.

Navarra P, Grohmann U, Nocentini G, Tringali G, Puccetti P, Riccardi C, Preziosi P. Hydroxyurea induces the gene expression and synthesis of proinflammatory cytokines in vivo. *J Pharmacol Exp Ther* **280** (1997) 477–482.

Navarra P, Preziosi P. Hydroxyurea: new insights on an old drug. *Crit Rev Oncol Hemat* **29** (1999) 249–255.

NCCLS, National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial tests for bacteria that grow aerobically, 4th Edition, Approved standard. NCCLS document M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa, USA, 1997.

Nocentini G. Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. *Crit Rev Oncol Hemat* **22** (1996) 89–126.

Odake S, Morikawa T, Tsuchia M, Imamura L, Kobashi K. Inhibition of *Helicobacter pylori* urease activity by hydroxamic acid derivatives. *Biol Pharm Bull* **17** (1994) 1329–1332.

Ohme R, Preuschhof H. Bildung und Zersetzung von 4-Methoxy-semicarbaziden. *J Prakt Chem* **313** (1971) 636–641.

Omar FA, Mahfouz NM, Rahman MA. Design, synthesis and antiinflammatory activity of some 1,3,4-oxadiazole derivatives. *Eur J Med Chem* **31** (1996) 819–825.

Onuchina OA, Zaitsev SA, Arzamastsev AP, Kalinkina MA, Granik VG. Synthesis and pharmacological activity of benzofurylhydroxyureas and benzofurylhydroxamic acids. *Pharm Chem J* **40** (2006) 530–536.

Opačić N, Barbarić M, Zorc B, Cetina M, Nagl A, Frković D, Kralj M, Pavelić K, Balzarini J, Andrei G, Snoeck R, De Clercq E, Raić-Malić S, Mintas M. The novel L-and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. *J Med Chem* **48** (2005) 475–482.

Orzalesi G, Selleri R (1974) DE 2,400,531; ref. *Chem Abstr* **81**: 120272j.

Parrish DA, Zou Z, Allen CL, Day CS, King SB. A convenient method for the synthesis of *N*-hydroxyureas. *Tetrahedron Lett* **46** (2005) 8841–8843.

Perioli L, Ambrogi V, Bernardini C, Grandolini G, Ricci M, Giovagnoli S, Rossi C. Potential prodrugs of non-steroidal anti-inflammatory agents for targeted drug delivery to the CNS. *Eur J Med Chem* **39** (2004) 715–727.

Perković I, Butula I, Rajić Z, Hadjipavlou-Litina D, Pontiki E, Zorc B. Novel ureidoamides derived from amino acids: synthesis and preliminary biological screening. *Croat Chem Acta* **83** (2010) 151–161.

Perković I, Butula I, Zorc B, Hock K, Kraljević Pavelić S, Pavelić K, De Clercq E, Balzarini J, Mintas M. Novel lipophilic hydroxyurea derivatives: synthesis, cytostatic and antiviral activity evaluations. *Chem Biol Drug Des* **71** (2008) 546–553.

Perković I, Butula I, Kralj M, Mikecin AM, Balzarini J, Hadjipavlou-Litina D, Katsori AM, Zorc B. Novel NSAID 1-acyl-4-cycloalkyl(or 4-aryl)semicarbazides and 1-acyl-5-benzyloxy(or 5-hydroxy)carbamoylcarbazides as potential anticancer agents and antioxidants. *Eur J Med Chem* (u tisku)

Petersen U, Petersen S, Stoepel K (1972) DE 2,044,834.

Pomarnacka E, Kozlarska-Kedra I. Synthesis of 1-(6-chloro-1,1-dioxo-1,4,2-benzodithiazin-3-yl)semicarbazides and their transformation into 4-chloro-2-mercapto-*N*-(4,5-dihydro-5-oxo-4-phenyl-1*H*-1,2,4-triazol-3-yl)benzenesulfonamides as potential anticancer and anti-HIV agents. *Farmaco* **58** (2003) 423–429.

Pontiki E, Hadjipavlou-Litina D. Synthesis and pharmacochemical evaluation of novel aryl.acetic acid inhibitors of lipoxygenase, antioxidants, and antiinflammatory agents. *Bioorg Med Chem* **15** (2007) 5819–5827.

Raichurkar AV, Kulkarni VM. Understanding the antitumor activity of novel hydroxysemicarbazide derivatives as ribonucleotide reductase inhibitors using CoMFA and CoMSIA. *J Med Chem* **46** (2003) 4419–4427.

Rajić Z, Butula I, Zorc B, Kraljević Pavelić S, Hock K, Pavelić K, Naesens L, De Clercq E, Balzarini J, Przyborowska M, Ossowski T, Mintas M. Cytostatic and antiviral activity evaluations of hydroxamic derivatives of some non-steroidal anti-inflammatory drugs. *Chem Biol Drug Des* **73** (2009a) 328–338.

Rajić Z, Perković I, Butula I, Zorc B, Hadjipavlou-Litina D, Pontiki E, Pepeljnjak S, Kosalec I. Synthesis and biological evaluation of *O*-methyl and *O*-ethyl NSAID hydroxamic acids. *J Enzym Inhib Med Ch* **24** (2009b) 1179–1187.

Rajić Z, Hadjipavlou-Litina D, Pontiki E, Kralj M, Šuman L, Zorc B. The novel ketoprofen amides-synthesis and biological evaluation as antioxidants, lipoxygenase inhibitors and cytostatic agents. *Chem Biol Drug Des* **75** (2010) 641–652.

Rajić Z, Hadjipavlou-Litina D, Pontiki E, Balzarini J, Zorc B. The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity. *Med Chem Res* **20** (2011) 210–219.

Rayburn ER, Ezell SJ, Zhang R. Anti-inflammatory agents for cancer therapy. *Mol Cell Pharmacol* **1** (2009) 29–43.

Re R, Pellegrini N, Proteggente A, Pannala A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorisation assay. *Free Rad Biol Med* **26** (1999) 1231–1237.

Ren S, Wang R, Komatsu K, Bonaz-Krause P, Zyrianov Y, McKenna CE, Csipke C, Tokes ZA, Lien EJ. Synthesis, biological evaluation and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents. *J Med Chem* **45** (2002) 410–419.

Sallmann A, Pfister R (1972) DE 2,144,641; ref. *Chem Abstr* **77**: 19403v.

Sallmann A (1991) EP 377,896; ref. *Chem Abstr* **114**: 61703.

Sayin U, Türkkan E, Dereli Ö, Yüksel H, Birey M. EPR study of gamma-irradiated single crystal 4-phenylsemicarbazide. *Radiat Phys Chem* **79** (2010) 863–869.

Schnatbaum K, Schaudt M, Stragies R, Pfeifer JR, Gibson C, Locardi E, Scharn D, Richter U, Kalkhof H, Dinkel K, Zischinsky G. Novel small molecule bradykinin B_1 receptor antagonists. Part 3: Hydroxyurea derivatives. *Bioorg Med Chem Lett* **20** (2010) 1233–1236.

Shanbhag VR, Crider AM, Gokhale R, Harpalani A, Dick RM. Ester and amide prodrugs of ibuprofen and naproxen: synthesis, anti-inflammatory activity, and gastrointestinal toxicity. *J Pharm Sci* **81** (1992) 149–154.

Sharma V, Khan MSY. Prodrugs and mutual prodrugs: synthesis of some new pyrazolone and oxadiazole analogues of a few non-steroidal anti-inflammatory drugs. *Pharmazie* **58** (2003) 99–103.

Sivak-Sears NR, Schwartzbaum JA, Miike R, Moghadassi M, Wrensch M. Case-control study of use of nonsteroidal antiinflammatory drugs and glioblastoma multiforme. *Am J Epidemiol* **159** (2004) 1131–1139.

Staab HA, Bauer H, Schneider KM. Azolides in organic synthesis and biochemistry. Weinheim (1998) Wiley VCH.

Steinberg GM, Bolger J. *N*-Hydroxyaryl Carbamates. A class of hydroxamic acids which form stable phosphorilated and sulfated derivatives. *J Org Chem* **21** (1956) 660–662.

Stewart AO, Bhatia PA, Martin JG, Summers JB, Rodriques KE, Martin MB, Holms JH, Moore JL, Craig RA, Kolasa T, Ratajczyk JD, Mazdiyasni H, Kerdesky FAJ, DeNinno SL, Maki RG, Bouska JB, Young PR, Lanni C, Bell RL, Carter GW, Brooks CDW. Structure-activity relationship of *N*-hydroxyurea 5-lipoxygenase inhibitors. *J Med Chem* **40** (1997) 1955–1968.

Summers JB, Gunn BP, Mazdiyasni H, Goetze AM, Young PR, Bouska JB, Dyer RD, Brooks DW, Carter GW. In vivo caracterization of hydroxamic acid inhibitors of 5-lipoxygenase. *J Med Chem* **30** (1987) 2121–2126.

Szekeres T, Fritzer-Szekeres M, Elford HL. The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. *Crit Rev Cl Lab Sci* **34** (1997) 503–528.

Šaban N, Bujak M. Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. *Cancer Chemother Pharmacol* **64** (2009) 213-221.

Taraborewala RB, Kauffman JM. Synthesis and structure-activity relationships of anti-inflammatory 9,10-dihydro-9-oxo-2-acridine-alcanoic acids and 4-(2-carboxyphenyl)-aminobenzenealkanoic acids. *J Pharm Sci* **79** (1990) 173–178.

Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. *J Natl Cancer Inst* **94** (2002) 252–266.

Tomita K, Plager JE. *In vivo* cell cycle synchronization of the murine sarcoma 180 tumor following alternating periods of hydroxyurea blockade and release. *Cancer Res* **39** (1979) 4407–4411.

Udupi RH, Suresh GV, Ramachandra Setty S, Bhat AR. Synthesis and biological evaluation of 3-substituted-4-[2'-(4''-isobutylphenyl)propionamido]-5-mercapto-1,2,4-triazoles and their derivatives. *J Indian Chem Soc* **77** (2000) 302–304.

Uesato S, Hashimoto Y, Nishino M, Nagaoka Y, Kuwajima H. *N*-Substituted hydroxyureas as urease inhibitors. *Chem Pharm Bull* **50** (2002) 1280–1282.

Wang D, DuBois RN. Prostaglandins and cancer. *Gut* **55** (2006) 115–122.

Wang D, DuBois RN. Eicosanoids and cancer. *Nat Rev Cancer* **10** (2010) 181–193.

Zaitsev SA, Onuchina OA, Alekseeva LM, Arzamastsev AP, Kalinkina MA, Granik VG. Synthesis and antiinflammatory activity of N-[1-(5-R-oxy-2-methylbenzofuran-3-yl)ethyl]-N-hydroxyureas. *Pharm Chem J* **39** (2005) 636–640.

Zhao X, Tao X, Wei D, Song Q. Pharmacological activity and hydrolysis behavior of novel ibuprofen glucopyranoside conjugates. *Eur J Med Chem* **41** (2006) 1352–1358.

Zinner G. Darstellung des 4-Hydroxysemicarbazids und Cyclisierung zu Derivaten des 1,2,4--Triazolon-(5). *Arch Pharmaz* **11** (1968) 827–829.

Zilz S. Heterocyclische Bindungssysteme aus 4-Hydroxysemicarbaziden und 4-Hydroxythio-semicarbaziden. Disertacija, Hamburg, 2000.

Zorc B, Butula I. Reaktionen mit *N*-(1-Benzotriazolylcarbonyl)-aminosäuren.I. Synthese von Hydantoinen und Hydantoinsäure-amiden. *Croat Chem Acta* **54** (1981b) 441–449.

Zorc B, Antolić S, Butula I. Macromolecular prodrugs. I. Synthesis of nonsteroidal anti--inflammatory drug esters. *Acta Pharm* **43** (1993) 127–133.

Zorc B, Butula I. Macromolecular prodrugs. III. Esters of fenoprofen and probenecid. *Acta Pharm* **44** (1994) 103–108.

Zovko M, Zorc B, Jadrijević-Mladar Takač M, Zorc D. The novel fenoprofenamides – synthesis and spectroscopic characterisation. *Acta Pharm* **51** (2001) 107–115.

Zovko M, Zorc B, Jadrijević-Mladar Takač M, Metelko B, Novak P. The novel ketoprofenamides: synthesis and spectroscopic characterisation. *Croat Chem Acta* **76** (2003) 335–341.

Zovko Končić M, Rajić Z, Petrić N, Zorc B. Antioxidant activity of NSAID hydroxamic acids. *Acta Pharm* **59** (2009) 235–242.

6. ŽIVOTOPIS

Ivana Perković rođena je u Zagrebu, 03. kolovoza 1982. godine. U Zagrebu je završila osnovnu školu i V. gimnaziju. Od 2000. do 2005. godine. studirala je na Farmaceutsko-biokemijskom fakultetu u Zagrebu, studij Farmacije. Tijekom studija primala je stipendiju Ministarstva znanosti i tehnologije RH dodjeljenu za prvo mjesto na klasifikacijskom ispitu. Diplomski rad pod nazivom *Priprava polimer-lijek konjugata diklofenaka i fenoprofena* izradila je na Zavodu za farmaceutsku kemiju Farmaceutsko-biokemijskog fakulteta pod vodstvom prof. dr. sc. Branke Zorc te je diplomirala 8. rujna 2005.

Od 1.12.2005. zaposlena je na Farmaceutsko-biokemijskom fakultetu prvo kao asistent na zamjeni, a od 1.6.2009. kao asistent-znanstveni novak. Uz znanstveni rad sudjeluje u izvođenju nastave na kolegijima Zavoda za farmaceutsku kemiju. Godine 2007. upisala je poslijediplomski doktorski studij Farmaceutsko-biokemijske znanosti na Farmaceutsko-biokemijskom fakultetu. Stručni ispit propisan za magistre farmacije-pripravnike pred komisijom Ministarstva zdravstva i socijalne skrbi Republike Hrvatske položila je u listopadu 2008. nakon odrađenog propisanog pripravničkog staža i dobila licencu za samostalan rad. Član je Hrvatske ljekarničke komore.

Do sada je objavila sedam znanstvenih i sedam stručnih radova, sudjelovala s priopćenjima na više domaćih i inozemnih kongresa te održala jedno predavanje.
Udana je i majka jedne djevojčice.

Znanstveni radovi (CC):

Barbarić M, Kralj M, Marjanović M, **Husnjak (Perković) I**, Pavelić K, Filipović-Grčić J, Zorc D, Zorc B. Synthesis and in vitro antitumor effect of diclofenac and fenoprofen thiolated and nonthiolated polyaspartamide-drug conjugates. *Eur J Med Chem* **42** (2007) 20–29.

Perković I, Butula I, Zorc B, Hock K, Kraljević Pavelić S, Pavelić K, De Clercq E, Balzarini J, Mintas M. Novel Lipophilic Hydroxyurea Derivatives: Synthesis, Cytostatic and Antiviral Activity Evaluations. *Chem Biol Drug Des* **71** (2008) 546–553.

Rajić Z, **Perković I**, Butula I, Zorc B, Hadjipavlou-Litina D, Pontiki E, Pepeljnjak S, Kosalec I. Synthesis and biological evaluation of *O*-methyl and *O*-ethyl NSAID hydroxamic acids. *J Enz Inhib Med Chem* **24** (2009) 1179–1187.

Šimunović M, **Perković I**, Zorc B, Ester K, Kralj M, Hadjipavlou-Litina D, Pontiki E. Urea and carbamate derivatives of primaquine: Synthesis, cytostatic and antioxidant activities. *Bioorg Med Chem* **17** (2009) 5605−5613.

Perković I, Butula I, Rajić Z, Hadjipavlou-Litina D, Pontiki E, Zorc B. Novel Ureidoamides Derived from Amino Acids: Synthesis and Preliminary Biological Screening *Croat Chem Acta* **83** (2010) 151−161.

Zovko Končić M, Barbarić M, **Perković I**, Zorc B. Antiradical, chelating and antioxidant activities of hydroxamic acids and hydroxyureas. *Molecules* **16** (2011) 6232−6242.

Znanstveni radovi (drugi časopisi):

Rajić Z, Zovko Končić M, Miloloža K, **Perković I**, Butula I, Bucar F, Zorc B. Primaquine-NSAID twin drugs: Synthesis, radical scavenging, antioxidant and Fe^{2+} chelating activity. *Acta Pharm* **60** (2010) 325−337.

7. PRILOG A

Prilog sadrži IR i NMR spektre odabranih spojeva opisanih u ovom doktorskom radu.

4l

6а

6h

7f

100.00
%T

0.00

4000 3500 3000 2500 2000 1500 1000 cm⁻¹ 500

PPM 10.4 10.0 9.6 9.2 8.8 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4

PPM 150 140 130 120 110 100 90 80 70 60 50 40

9

144

11c

12a

13a

13v

13y

14a

14e

8. PRILOG B

Prilog sadrži tri znanstvena rada objavljena u časopisima zastupljenim u bazi Current Contents koji obrađuju problematiku iznesenu u ovom doktorskom radu:

Perković I, Butula I, Zorc B, Hock K, Kraljević Pavelić S, Pavelić K, De Clercq E, Balzarini J, Mintas M. Novel Lipophilic Hydroxyurea Derivatives: Synthesis, Cytostatic and Antiviral Activity Evaluations. *Chem Biol Drug Des* **71** (2008) 546–553.

Perković I, Butula I, Rajić Z, Hadjipavlou-Litina D, Pontiki E, Zorc B. Novel Ureidoamides Derived from Amino Acids: Synthesis and Preliminary Biological Screening. *Croat Chem Acta* **83** (2010) 151−161.

Zovko Končić M, Barbarić M, **Perković I**, Zorc B. Antiradical, chelating and antioxidant activities of hydroxamic acids and hydroxyureas. *Molecules* **16** (2011) 6232−6242.

TEMELJNA DOKUMENTACIJSKA KARTICA

SINTEZA, KARAKTERIZACIJA I BIOLOŠKO DJELOVANJE KARBAMIDNIH, SEMIKARBAZIDNIH, KARBAZIDNIH I ESTERSKIH DERIVATA AMINOKISELINA I NESTEROIDNIH PROTUUPALNIH LIJEKOVA

Ivana Perković

SAŽETAK

U okviru ovog doktorskog rada, koji je nastavak istraživanja o mogućnostima korištenja benzotriazola u sintetskoj kemiji na Zavodu za Farmaceutsku kemiju Farmaceutsko-biokemijskog fakulteta u Zagrebu, sintetizirano je nekoliko serija spojeva. Polazni spoj u sintezi svih prekursora bio je klorid 1-benzotriazolkarboksilne kiseline (BtcCl) koji daje vrlo reaktivne derivate. BtcCl vrlo lako reagira s nukleofilima dajući cijeli niz reaktivnih spojeva iz kojih je do sada pripravljen velik broj organskih spojeva. Derivati aminokiselina ureidoamidi **4a-o** pripravljeni su reakcijom klorida *N*-(1-benzotriazolkarbonil)aminokiselina **3** i odgovarajućih aminoalkohola, a *N*- i *O*- supstituirane hidroksiuree **6a-l** iz amida *N*-(1-benzotriazolkarbonil)aminokiselina i odgovarajućih hidroksilamina. Derivati nesteroidnih protuupalnih lijekova (NSAID, ibuprofena, fenoprofena i ketoprofena) sintetizirani su iz NSAID hidrazida **11** koji su dobiveni aminolizom NSAID benzotriazolida **10** i hidrazina. Hidrazidi **11** su u reakciji s 1-karbamoilbenzotriazolima (aktivne uree, **7**) dali 1-acilsemikarbazidne derivate NSAID **13a-v**, a u reakciji s 1-(1-benzotriazolkarbonil)-4-benziloksisemikarbazidom (**9**) 1-acil-5-benziloksikarbamoilkarbazide **14a-c**. Reakcije u talini uz TEA bitno su skratile vrijeme reakcije. 4-Hidroksisemikarbazidni derivati NSAID **13w-y** i **14d-f** pripravljeni su katalitičkim hidrogeniranjem *O*-benzilnih derivata **13t-v** i **14a-c** uz Pd/C. Iz benzotriazolida ketoprofena (**10d**) i odgovarajućih ureidoamida (**4b,i,j,m**) pripravljeni su esteri s dvije molekule ketoprofena kovalentno povezane ureidoamidima u jednu molekulu („dvojni lijekovi").

Svi sintetizirani spojevi karakterizirani su uobičajenim analitičkim postupcima i spektroskopskim metodama te biološki ispitani *in vitro* na citostatsko, antivirusno, antimikrobno i antioksidativno djelovanje. Nadalje, ispitana je inhibicija lipooksigenaze i lipidne perkosidacije. Najbolje antitumorsko djelovanje pokazao je spoj **6l**, antivirusno **13a,g,m**, a antiooksidativno spoj **9**. Najjači inhibitor lipooksigenaze bio je spoj **13s**, a lipidne peroksidacije **13c,l,t**. Uočeno je ponavljanje benzhidrilnog supstituenta u spojevima s istaknutom aktivnosti, što je dobar pokazatelj za daljnje usmjeravanje istraživanja.

BASIC DOCUMENTATION CARD

SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL ACTIVITY OF CARBAMIDE, SEMICARBAZIDE, CARBAZIDE AND ESTER DERIVATIVES OF AMINO ACIDS AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS

Ivana Perković

SUMMARY

The research described in the thesis is a continuation of the previous work on the use of benzotriazole in the synthetic chemistry which has been carring out at Department of Medicinal Chemistry, Faculty of Pharmacy and Biochemistry in Zagreb for many years. The thesis includes synthesis of several types of compounds. The initial compound for the synthesis of all the intermediates was benzotriazole carboxylic acid chloride (BtcCl), which upon the reaction with nucleophiles gives reactive products, useful in the preparation of various organic compounds. Amino acid derivatives ureidoamides **4a-o** were syntehsized by aminolysis of *N*-(1-benzotriazolecarbonyl)amino acid chlorides **3** with corresponding aminoalcohols and *N*- i *O*- substituted hydroxyureas **6a-l** were synthesizes from *N*-(1-benzotriazolecarbonyl)amino acid amides **5** and hydroxylamines. Nonsteroidal antiinflammatory drugs (NSAID, ibuprofen, fenoprofen and ketoprofen) derivatives were prepared from NSAID hydrazides **11** which were obtained by aminolysis of NSAID benzotriazolides **10** and hydrazine hydrate. The reaction of hydrazides **11** and 1-benzotriazole carboxylic acid amides **7** gave 1-acylsemicarbazides **13a-v**, while with 1-(1-benzotriazolecarbonyl)-4-benzyloxysemicarbazide (**9**) gave 1-acyl-5-benzyloxycarbamoyl-carbazides **14a-c**. Reactions in melted state in the presence of TEA significantly reduced the reaction time. 4-Hydroxysemicarbazide compounds **13w-y** and **14d-f** were prepared by catalytic hydrogenation of *O*-benzylated compounds **13t-v** i **14a-c** with Pd/C. Ketoprofen benzotriazolide (**10d**) reacted with several ureidoamides (**4b,i,j,m**) and gave esters with two molecules of ketoprofen combined covalently in one („twin drugs").

The compounds were evaluated for their biological activity *in vitro*: antitumor, antimicrobial, antiviral and antioxidant activity, inhibition of lipoxygenase and linoleic acid lipid peroxidation. The best antitumor activity was exerted by **6l**, antiviral by **13a,g,m**, antioxidant by compound **9**. The strongest inhibitor of lipoxygenase was **13s**. Compounds **13c,l,t** showed the highest inhibition of linoleic acid lipid peroxidation. It is worth to note that compounds with the highest biological activity contained benzhydryl substituent.

Novel Lipophilic Hydroxyurea Derivatives: Synthesis, Cytostatic and Antiviral Activity Evaluations

Ivana Perković[1], Ivan Butula[1], Branka Zorc[1,]*, Karlo Hock[2], Sandra Kraljević Pavelić[2], Krešimir Pavelić[2], Erik De Clercq[3], Jan Balzarini[3] and Mladen Mintas[4,]*

[1]*Department of Medicinal Chemistry, Faculty of Pharmacy and Biochemistry, A. Kovačića 1, HR-10 000 Zagreb, Croatia*
[2]*Division of Molecular Medicine, Rudjer Bošković Institute, Bijenička cesta 54, HR-10 000 Zagreb, Croatia*
[3]*Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium*
[4]*Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, Marulićev trg 20, HR-10000 Zagreb, Croatia*
Corresponding authors: Branka Zorc, bzbz@pharma.hr, Mladen Mintas, mmintas@fkit.hr

The novel hydroxyurea derivatives of L- and D-amino acid amides 5a–l were prepared by aminolysis of *N*-(1-benzotriazolecarbonyl)-amino acid amides 4a–f with *O*-benzylhydroxylamine and *N*-methylhydroxylamine and evaluated for their antiviral and cytostatic activity against malignant tumor cell lines and normal human fibroblasts. Compounds 5a, 5c, 5e and 5k showed the highest antiproliferative effects against all tumor cell lines tested. The strongest non-specific cytostatic activities against HeLa cells were affected by compounds 5a, 5c, 5e and 5k on MCF-7 cells by 5c, 5e and 5k and MIA PACa-2 cells by 5c and 5k. Differential effects at micromolar concentrations were observed for compounds 5a, 5c, 5e, 5k and 5l in Hep G2 cells, for compounds 5c, 5e, 5k and 5l in PC-3 cells and for compounds 5e, 5k and 5l in SW 620 cells.

Key words: antiviral activity, cytostatic activity, human tumor cell lines, hydroxyureas

N-hydroxyureas are inhibitors of various metal-containing enzymes including carboxypeptidase A, urease, ribonuclease, carbonic anhydrase and redox enzymes such as lipo-oxygenase and ribonucleotide reductase (1,2). The simplest member of this class, *N*-hydroxyurea, is a well-known antineoplastic agent used to treat leukemia and other malignant tumor diseases (3). Hydroxyurea is also an effective drug for both adult and pediatric sickle cell anemia (4). In addition, it has been used in anti-HIV therapy in combination with a reverse transcriptase inhibitors and it is surprisingly well tolerated by HIV-infected patients (5). A series of *N*-hydroxycarbamoyl amino acid amides was previously prepared by us and evaluated for their cytostatic and antiviral effects (6). D-Phenylglycine derivatives with lipophilic substituents in the amide region inhibited the growth of all tumor cell lines tested but not the growth of normal fibroblasts WI 38. Cyclohexyl amide and cyclohexanemethyl amide of another aromatic amino acid, L-phenylalanine, inhibited specifically murine leukemia cells and human T lymphocytes with some selectivity with respect to normal human fibroblasts (6). These encouraging results prompted us to prepare more lipophilic *N*-hydroxyurea derivatives, bearing either an *O*-benzylated hydroxy group or a *N*-methylated terminal urea nitrogen atom (**5a–l**). In this study, we report the synthesis and evaluation of the inhibitory effect of modified *N*-hydroxyureas on the proliferation of human tumor cell lines as well as their potential as antiviral agents.

Results and Discussion

Chemistry

New hydroxyureas **5a–l**, derivatives of aminoacid amides, were prepared by aminolysis of *N*-[1-benzotriazolecarbonyl (Btc)]-amino acid amides (**4a–f**) with *O*-benzylhydroxylamine and *N*-methyl-hydroxylamine, following previously described procedures (6). To obtain compounds with different physico-chemical properties, two lipophylic aliphatic amines (cyclohexylamine and cyclohexanemethyl-amine) and bulky aromatic amine (benzhydrylamine) were used for the preparation of the amides **4** and hydroxyureas **5**. Aminoacid residues were both aliphatic (isobutyl in leucine) or aromatic (in phenylalanine and phenylglycine), while stereochemistry of chiral carbon atom was either L (L-leucine and L-phenylalanine) or D (D-phenylglycine). Scheme 1 depicts the general method for the conversion of aminoacids to *N*-hydroxyurea derivatives.

Structures of compounds **5a–l** were deduced from analysis of their ^{1}H and ^{13}C NMR spectra and confirmed by elemental analysis. The chemical shifts were consistent with the proposed structures of the novel compounds (Supplementary Material). IR spectra of hydroxyureas **5a–l** showed characteristic bands at 3439–3371 (OH), 3347–3288 (NH), 1668–1627 (amide and urea carbonyls) and 1580–1520 (amide II) cm^{-1}.

Scheme 1 Synthesis of hydroxy- and *O*-benzylhydroxyurea derivatives **5a–l**.

Cytostatic activity

Hydroxyurea derivatives **5a–l** were evaluated *in vitro* for their cyto-static effects against malignant tumor cell lines: cervical carcinoma (HeLa), breast epithelial adenocarcinoma (MCF-7), pancreatic carcinoma (MIA PaCa-2), prostate adenocarcinoma (PC-3), colorectal adenocarcinoma (SW620), hepatocellular carcinoma (Hep G2), leukemia (L1210) and lymphocytic Molt4/C8 and CEM cells and compared with their effects on the growth of human normal fibroblasts (WI 38) (Tables 1 and 2, Figure 1).

The results of the *in vitro* cytostatic activity evaluations of the amino acid hydroxyurea derivatives **5a–l** showed that compounds **5b**, **5h** and **5j** lacked antiproliferative activity even at the highest concentration tested. The most pronounced antiproliferative activity was observed for compounds **5a**, **5c**, **5e** and **5k** on all the tested cell lines (Tables 1 and 2). The strongest non-specific antiproliferative effect on HeLa cells was afforded by compounds **5a**, **5c**, **5e** and **5k**, on MCF-7 cells by compounds **5c**, **5e** and **5k**, on MIA PaCa-2 cells by compounds **5c** and **5k** (Figure 1) and on L1210, Molt4/C8 and CEM cells by compounds **5a**, **5e** and **5k** (Table 2).

Interestingly, it was possible to monitor two distinct patterns of action among the tested compounds on the growth of cell lines Hep G2, PC-3 and SW 620 (Figure 1). Compounds **5c**, **5d**, **5e, 5f**, **5k** and **5l** exerted a trend towards a differential effect on hepatocarcinoma cell lines (Hep G2) at micromolar concentrations

(1×10^{-6} M and 1×10^{-5} M) but the compounds **5d**, **5f** and **5l** were less effective at the highest concentration tested. Further, compounds **5c**, **5e**, **5f, 5k** and **5l** exerted a similar antiprolifera-tive effect at micromolar concentrations on the growth of prostate adenocarcinoma (PC-3) although compounds **5f** and **5l** were not as much effective at the highest concentration tested. In the same way, compounds **5a**, **5d**, **5e**, **5f**, **5k** and **5l** exerted a comparable antiproliferative effect on the growth of colorectal adenocarcinoma (SW 620) including a strong inhibition of the cell growth at micromolar concentrations by compounds **5d**, **5f** and **5l**.

Antiviral activity

Compounds **5a–l** were also evaluated for their activity against human immunodeficiency virus type 1 and 2 (HIV-1 and 2) in CEM cell cultures, herpes simplex virus type 1 (KOS) and type 2 (G), vaccinia virus and vesicular stomatitis virus in human embryonic lung (HEL) cell cultures, Coxsackie virus B4 and respiratory syncy-tial virus (RSV) in HeLa cell cultures, parainfluenza-3 virus, reovi-rus-1, Sindbis virus and Punta Toro virus in Vero cell cultures, Feline corona virus in Crandel feline kidney (CRFK) cell cultures, as well as influenza viruses types A (H1N1 and H3N2 subtypes) and B in MDCK cell cultures. No specific antiviral effects (i.e. minimal antivirally effective concentration >fivefold lower than the minimal cytotoxic concentration) were noted for any of the compounds against any of the viruses evaluated (data not shown).

Table 1: Inhibitory effects of hydroxyurea derivatives **5a–l** on the growth of malignant tumor cell lines in comparison with their effects on the growth of normal human diploid fibroblasts (WI 38)

Compound **5a–l**	Tumor cell growth [IC_{50}[a] (μM)]						
	HeLa	MCF-7	MIAPaCa-2	PC-3	SW620	Hep G2	WI 38
a	28.6	29.9	48.1	42.9	31.2	33.8	27.9
b	96.7	>100	>100	>100	>100	>100	>100
c	24.7	9.6	11.8	19.5	6.9	8.4	9.2
d	>100	>100	43.8	44.6	0.7	1	9.3
e	25.7	5.9	38.4	15.2	0.8	4.6	20.1
f	>100	63.4	>100	45.7	0.7	65.9	31.5
g	49.6	40.9	78.1	52.2	53	27.1	47.1
h	>100	>100	>100	>100	>100	>100	>100
i	54.1	77.4	59.9	>100	92.2	>100	68.4
j	>100	>100	>100	>100	>100	>100	>100

Table 1: Continued

Compound **5a–l**	Tumor cell growth [IC$_{50}$^{a} (μM)]						
	HeLa	MCF-7	MIAPaCa-2	PC-3	SW620	Hep G2	WI 38
k	14.4	4.9	22.1	7.8	1	0.9	8.1
l	39.8	>100	50.9	7.4	0.1	24.8	44

^{a}50% inhibitory concentration or compound concentration required to inhibit tumor cell proliferation by 50%.

Table 2: Cytostatic activity of hydroxyurea derivatives against leukemia and lymphocytic cancer cells

Compound	IC$_{50}$^{a} (μM)		
	L1210	Molt4/C8	CEM
5a	23	28	28
5b	>100	>100	>100
5c	39	32	42
5d	>100	>100	>100
5e	12	14	28
5f	77	66	92
5g	44	45	51
5h	>100	>100	>100
5i	73	98	135
5j	>100	>100	>100
5k	11	12	12
5l	61	57	89

^{a}50% inhibitory concentration.

Conclusions

Compounds **5b**, **5h** and **5j** were almost completely inactive against the tumor cell lines even at the highest tested concentration (100 μM). The most pronounced antiproliferative activity was observed for the compounds **5a**, **5c**, **5e** and **5k** in all the tumor cell lines tested. Compounds **5c** and **5k** exhibited the strongest non-specific antiproliferative effect on HeLa cells, MCF-7 cells and MIA PaCa-2 cells. Compounds **5c**, **5e** and **5k** that showed a differential antiproliferative effect on Hep G2, PC-3 and SW 620 at micromolar concentrations were not cytotoxic for the control fibroblasts, thus making them suitable candidates for further biological studies and lead drug candidate optimization.

The results of antiproliferative activity of the tested compounds were compared with analogous hydroxyurea derivatives previously published by us (6). All *O*-benzyl derivatives (**5a**, **5c**, **5e**, **5g**, **5i** and **5k**) showed significantly higher antiproliferative effect against all tumor cell lines than derivatives with free hydroxy group. The highest activity was observed for compounds **5e** and **5k** bearing four benzene rings in amino acid, amide and urea moieties. These compounds are certainly the most lipophilic in the series investigated. On the other hand, *N*-methyl derivatives and non-substituted urea derivatives have comparable antiproliferative effects, e.g. methylation of terminal nitrogen atom in urea has no significant impact on activity. The most active *N*-methyl derivative were **5l** and **5f** with both benzhydryl and phenyl/benzyl substituents. Quantitative structure–activity relationship study is in progress and will be published elsewhere.

Experimental Section

Chemistry

General methods

Melting points were determined on a Stuart SMP 3 melting apparatus (Barloworld Scientific, Staffordshire, England, UK) and were uncorrected. IR spectra were recorded on a FTIR Perkin Elmer Paragon 500 spectrometer (Perkin Elmer, Waltham, Massachusetts, USA). ^{1}H and ^{13}C NMR spectra were recorded on a Varian Gemini 300 spectrometer (Paolo-Alto, California, USA), operating at 300 and 75.5 MHz for the ^{1}H and ^{13}C nuclei, respectively. Samples were measured in DMSO-d_6 solutions at 20 °C in 5 mm NMR tubes. Chemical shifts (δ) in ppm were referred to tetramethylsilane (TMS). Precoated Merck silica gel 60 F$_{254}$ plates were used for thin-layer chromatography. Solvent systems were cyclohexane/ethyl acetate (1:1), dichloromethane/methanol (9.5:0.5) and cyclohexane/ethyl acetate/ methanol (3:1:0.6). Spots were visualized by short-wave UV light and iodine vapour. Column chromatography was performed on silica gel (0.063–0.200 mm), with cyclohexane/ethyl acetate (1:1), cyclohexane/ethyl acetate/methanol (3:1:0.6) or dichloromethane/methanol (94:6) as eluents.

1-Benzotriazole carboxylic acid chloride (**1**), *N*-(1-benzotriazolecarbonyl)-amino acids (**2a–c**), chlorides **3a–c** and amides **4a–f** were prepared according to the procedures previously published (7–9).

Figure 1: Differential dose response curves at micromolar concentrations (1×10^{-5} M and 1×10^{-4} M) for compounds **5c**, **5d**, **5e**, **5k** and **5l** in Hep G2 cells (A), for compounds **5c**, **5e**, **5k** and **5l** in PC-3 cells (B) and for compounds **5e, 5k** and **5l** in SW 620 cells (C). Dose response curves for compounds **5a–l** in normal fibroblasts WI 38 are shown (D). All compounds tested, with the exception of compounds **5b**, **5h** and **5j**, strongly inhibited the growth of **WI 38** at the highest tested concentrations (1×10^{-4} M and 1×10^{-5} M) in a non-specific manner.

Aminoacids were purchased from Kemika (Zagreb, Croatia), and amines (cyclohexylamine, cyclohexanemethylamine, benzhydrylamine, triethylamine, O-benzylhydroxylamine hydrochloride and N-methylhydroxylamine hydrochloride) from Aldrich (Seelze, Germany).

Hydroxyurea derivatives (5a–l). General procedure

To a suspension of N-(1-benzotriazolecarbonyl)-amino acid amide (**4**) (1 mmol) and 0.191 g (1.2 mmol) O-benzylhydroxylamine hydrochloride or 0.100 g (1.2 mmol) N-methylhydroxylamine hydrochloride in toluene (8 mL), a solution of triethylamine 0.121 g (1.2 mmol) in toluene (8 mL) was added. The reaction mixture was stirred at room temperature from 10 min to 3 days and evaporated in vacuum. The obtained residue was dissolved in acetone/water mixture and made acidic (pH 1) with 10% HCl. Acetone was evaporated under reduced pressure and precipitated product **5** was filtered off.

N-Benzhydryl-2-(*N'*-benzyloxyureido)-L-4-methylpentanamide (*N'*-Benzyloxycarbamoyl-L-leucine benzhydrylamide) (5a)

From the reaction of 0.442 g (1 mmol) N-(1-benzotriazolecarbonyl)-L-leucine benzhydrylamide (**4a**) and 0.191 g (1.2 mmol) O-benzylhydroxylamine hydrochloride at 70 °C for 15.5 h and at 114 °C for 4.5 h and purification of the product by column chromatography (eluent dichloromethane/methanol 94:6) was obtained 0.122 g (27%) of **5a**; mp 100–103 °C; IR (KBr, v/cm^{-1}) 3308, 3062, 3031, 2934, 1668, 1642, 1534, 1496. Anal. ($C_{27}H_{31}N_3O_3$) C, H, N.

N-Benzhydryl-2-(*N'*-methyl-*N'*-hydroxyureido)-L-4-methylpentanamide (*N'*-Methyl-*N'*-hydroxycarbamoyl-L-leucine benzhydrylamide) (5b)

From the reaction of 0.442 g (1 mmol) N-(1-benzotriazolecarbonyl)-L-leucine benzhydrylamide (**4a**) and 0.100 g (1.2 mmol) N-meth-

ylhydroxylamine hydrochloride, without solvent, at 125 °C for 10 min and purification of product by triturating with ether was obtained 0.283 g (77%) of **5b**; mp 219–222 °C (decomposition); IR (KBr, ν/cm^{-1}) 3407, 3309, 3162, 2963, 2930, 2400, 2872, 1648, 1548, 1515. Anal. (C$_{21}$H$_{27}$N$_3$O$_3$) C, H, N.

N-Cyclohexanemethyl-2-(*N'*-benzyloxyureido)-D-2-phenylethamide (*N'*-Benzyloxycarbamoyl-D-phenylglycine cyclohexanemethylamide) (5c)

From the reaction of 0.391 g (1 mmol) *N*-(1-benzotriazolecarbonyl)-D-phenylglycine cyclohexanemethylamide (**4b**) and 0.191 g (1.2 mmol) *O*-benzylhydroxylamine hydrochloride at 114 °C for 5 h and purification of the product by column chromatography (eluent cyclohexane/ethyl acetate/methanol 3:1:0.6) was obtained 0.117 g (30%) of **5c**; mp 148–150 °C; IR (KBr, ν/cm^{-1}) 3310, 3091, 3063, 3032, 2926, 2854, 1639, 1533. Anal. (C$_{23}$H$_{29}$N$_3$O$_3$) C, H, N.

N-Cyclohexanemethyl-2-(*N'*-methyl-*N'*-hydroxyureido)-D-2-phenylethamide (*N'*-Methyl-*N'*-hydroxycarbamoyl-D-phenylglycine cyclohexanemethylamide) (5d)

From the reaction of 0.391 g (1 mmol) *N*-(1-benzotriazolecarbonyl)-D-phenylglycine cyclohexanemethylamide (**4b**) and 0.100 g (1.2 mmol) *N*-methylhydroxylamine hydrochloride at 20 °C for 24 h and purification of the product by column chromatography (eluent cyclohexane/ethyl acetate 1:1) was obtained 0.127 g (40%) of **5d**; mp 123–126 °C; IR (KBr, ν/cm^{-1}) 3425, 3310, 2925, 2853, 1650, 1532. Anal. (C$_{17}$H$_{25}$N$_3$O$_3$) C, H, N.

N-Benzhydryl-2-(*N'*-benzyloxyureido)-D-2-phenylethamide (*N'*-Benzyloxycarbamoyl-D-phenylglycine benzhydrylamide) (5e)

From the reaction of 0.462 g (1 mmol) *N*-(1-benzotriazolecarbonyl)-D-phenylglycine benzhydrylamide (**4c**) and 0.191 g (1.2 mmol) *O*-benzylhydroxylamine hydrochloride at 114 °C for 4.5 h and purification of the product by recrystallization from acetone and water was obtained 0.093 g (20%) of **5e**; mp 161–165 °C; IR (KBr, ν/cm^{-1}) 3307, 3062, 3031, 2924, 2854, 1668, 1642, 1532, 1496. Anal. (C$_{29}$H$_{27}$N$_3$O$_3$) C, H, N.

N-Benzhydryl-2-(*N'*-methyl-*N'*-hydroxyureido)-D-2-phenylethamide (*N'*-Methyl-*N'*-hydroxycarbamoyl-D-phenylglycine benzhydrylamide) (5f)

From the reaction of 0.462 g (1 mmol) *N*-(1-benzotriazolecarbonyl)-D-phenylglycine benzhydrylamide (**4c**) and 0.100 g (1.2 mmol) *N*-methylhydroxylamine hydrochloride at 70 °C for 2 h and purification of the product by triturating with ether was obtained 0.331 g (85%) of **5f**; mp 165–168 °C (decomposition); IR (KBr, ν/cm^{-1}) 3439, 3376, 3210, 3064, 3031, 2924, 1637, 1520, 1496. Anal. (C$_{23}$H$_{23}$N$_3$O$_3$) C, H, N.

N-Cyclohexyl-2-(*N'*-benzyloxyureido)-L-3-phenylpropanamide (*N'*-Benzyloxycarbamoyl-L-phenylalanine cyclohexylamide) (5g)

From the reaction of 0.391 g (1 mmol) of *N*-(1-benzotriazolecarbonyl)-L-phenylalanine cyclohexylamide (**4d**) and 0.191 g (1.2 mmol) *O*-benzylhydroxylamine hydrochloride at 114 °C for 1 h and purification of the product by triturating with ether was obtained 0.267 g (65%) of **5g**; mp 129–131 °C; IR (KBr, ν/cm^{-1}) 3296, 3203, 3063, 3032, 2934, 2854, 1639, 1533, 1498. Anal. (C$_{23}$H$_{29}$N$_3$O$_3$) C, H, N.

N-Cyclohexyl-2-(*N'*-methyl-*N'*-hydroxyureido)-L-3-phenylpropanamide (*N'*-Methyl-*N'*-hydroxycarbamoyl-L-phenylalanine cyclohexylamide) (5h)

From the reaction of 0.391 g (1 mmol) *N*-(1-benzotriazolecarbonyl)-L-phenylalanine cyclohexylamide (**4d**) and 0.100 g (1.2 mmol) *N*-methylhydroxylamine hydrochloride at 20 °C for 48 h and purification of the product by triturating with ether was obtained 0.183 g (58%) of **5h**; mp 153–155 °C; IR (KBr, ν/cm^{-1}) 3390, 3289, 1648, 1627, 1550. Anal. (C$_{17}$H$_{25}$N$_3$O$_3$) C, H, N.

N-Cyclohexanemethyl-2-(*N'*-benzyloxyureido)-L-3-phenylpropanamide (*N'*-Benzyloxycarbamoyl-L-phenylalanine cyclohexanemethylamide) (5i)

From the reaction of 0.405 g (1 mmol) *N*-(1-benzotriazolecarbonyl)-L-phenylalanine cyclohexanemethylamide (**4e**) and 0.191 g (1.2 mmol) *O*-benzylhydroxylamine hydrochloride at 70 °C for 4.5 h and purification of the product by triturating with ether was obtained 0.243 g (60%) of **5i**; mp 130–131 °C; IR (KBr, ν/cm^{-1}) 3313, 3214, 3064, 3031, 2921, 2852, 1661, 1640, 1542, 1496. Anal. (C$_{24}$H$_{31}$N$_3$O$_3$) C, H, N.

N-Cyclohexanemethyl-2-(*N'*-methyl-*N'*-hydroxyureido)-L-3-phenylpropanamide (*N'*-Methyl-*N'*-hydroxycarbamoyl-L-phenylalanine cyclohexanemethylamide) (5j)

From the reaction of 0.405 g (1 mmol) *N*-(1-benzotriazolecarbonyl)-L-phenylalanine cyclohexanemethylamide (**4e**) and 0.100 g (1.2 mmol) *N*-methylhydroxylamine hydrochloride at 40 °C for 2 h and purification of the product by triturating with ether was obtained 0.268 g (81%) of **5j**; mp 157–159 °C; IR (KBr, ν/cm^{-1}) 3371, 3329, 3194, 2924, 2853, 1658, 1642, 1580, 1528. Anal. (C$_{18}$H$_{27}$N$_3$O$_3$) C, H, N.

N-Benzhydryl-2-(*N'*-benzyloxyureido)-L-3-phenylpropanamide (*N'*-Benzyloxycarbamoyl-L-phenylalanine benzhydrylamide) (5k)

From the reaction of 0.476 g (1 mmol) *N*-(1-benzotriazolecarbonyl)-L-phenylalanine benzhydrylamide (**4f**) and 0.191 g (1.2 mmol) *O*-benzylhydroxylamine hydrochloride at 70 °C for 53 h and purification of the product by triturating with ether was obtained 0.185 g (39%) of **5k**; mp 161–164 °C; IR (KBr, ν/cm^{-1}) 3288, 3062, 3030, 1649, 1535, 1495. Anal. (C$_{30}$H$_{29}$N$_3$O$_3$) C, H, N.

N-Benzhydryl-2-(N′-methyl-N′-hydroxyureido)-ʟ-3-phenylpropanamide (N′-Methyl-N′-hydroxycarbamoyl-ʟ-phenylalanine benzhydrylamide) (5l)

From the reaction of 0.476 g (1 mmol) N-(1-benzotriazolecarbonyl)-ʟ-phenylalanine benzhydrylamide (4f) and 0.100 g (1.2 mmol) N-methylhydroxylamine hydrochloride at 20 °C for 72 h and purification of the product by triturating with ether was obtained 0.179 g (45%) of 5l; mp 152–154 °C (with decomposition); IR (KBr, v/cm^{-1}) 3432, 3347, 3062, 3030, 2867, 1664, 1629, 1536, 1496. Anal. ($C_{24}H_{25}N_3O_3$) C, H, N.

Biological studies

Cell culturing

The cell lines HeLa (cervical carcinoma), MIAPaCa-2 (pancreatic carcinoma), MCF-7 (breast epithelial adenocarcinoma, metastatic), Hep G2 (hepatocellular carcinoma), SW 620 (colorectal adenocarcinoma, metastatic) and WI 38 (normal diploid human fibroblasts) were cultured as monolayers and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM ʟ-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin in a humidified atmosphere with 5% CO_2 at 37 °C. The cell line PC-3 (prostate adenocarcinoma), murine leukemia L1210 and human lymphocytic Molt4/C8 and CEM cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 2 mM ʟ-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin also in a humidified atmosphere with 5% CO_2 at 37 °C.

Proliferation assays

The panel cell lines depicted in Table 1 were inoculated into a series of standard 96-well microtiter plates on day 0, at 3000 cells to 6000 cells per well according to the doubling times of the specific cell line. Test agents were then added in five, 10-fold dilutions (10^{-8} to 10^{-4} M) and incubated for another 72 h. Working dilutions were freshly prepared on the day of testing in the growth medium. After 72 h of incubation, the cell growth rate was evaluated by performing the MTT assay, which detects mitochondrial dehydrogenase activity in viable cells. The MTT Cell Proliferation Assay is a colorimetric assay system, which measures the reduction of a tetrazolium dye (MTT) into an insoluble formazan product by the mitochondria of viable cells (10). The absorbance (OD, optical density) was measured at 570 nm using a microplate reader. The absorbance is directly proportional to the cell viability. The percentage of growth (PG) of the cell lines was calculated according to one or the other of the following two expressions:

If (mean OD_{test} − mean OD_{tzero}) ≥ 0, then:

$$PG = 100 \times (\text{mean}\, OD_{test} - \text{mean}\, OD_{tzero})/(\text{mean}\, OD_{ctrl} - \text{mean}\, OD_{tzero})$$

If (mean OD_{test} − mean OD_{tzero}) < 0, then:

$$PG = 100 \times (\text{mean}\, OD_{test} - \text{mean}\, OD_{tzero})/OD_{tzero}$$

where mean OD_{tzero}, the average of optical density measurements before exposure of cells to the test compound; mean OD_{test}, the average of optical density measurements after the desired period of time; mean OD_{ctrl}, the average of optical density measurements after the desired period of time with no exposure of the cells to the test compound.

The IC_{50} and LC_{50} values for each compound were calculated from dose–response curves using linear regression analysis by fitting the test concentrations that give PG values above and below the reference value. If, however, for a given cell line all of the tested concentrations produce PGs exceeding the respective reference level of effect (e.g. PG value of 50), then the highest tested concentration is assigned as the default value (in the screening data report that default value is preceded by a '>' sign).

Each test-point was performed in quadruplicate in three individual experiments. The results were statistically analyzed (ANOVA, Tukey *post hoc* test at p < 0.05) and showed graphically as dose response curves of the mean values.

The cytostatic activity of the suspension cell lines L1210, CEM and Molt4/C8 were determined by seeding ∼5–7.5 × 10^4 cells/200 μL-well of a 96-well microtiter plate after which different dilutions of the test compounds were added. At 2 (L1210) and 3 (CEM, Molt4/C8) days of cultivation at 37 °C, cells were counted in a Coulter counter. The IC_{50} was defined as the compound concentration at which the cell proliferation was inhibited by 50%.

Acknowledgments

References

1. Parrish D.A., Zou Z., Allen C.L., Day C.S., King S.B. (2005) A convenient method for the synthesis of N-hydroxyureas. Tetrahedron Lett;46:8841–8843.
2. Scozzafava A., Supuran C.T. (2003) Hydroxyurea is a carbonic anhydrase inhibitor. Bioorg Med Chem;11:2241–2246.
3. Mutschler E., Derendorf H. (1995) Drug Actions, Basic Principles and Therapeutic Aspects. Stuttgart, Germany: Medpharm Scientific Publishers.
4. Hankins J.S., Ware R.E., Rogers Z.R., Wynn L.W., Lane P.A., Scott J.P., Wang W.C. (2005) Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood;106:2269–2275.
5. Navarra P., Preziosi P. (1999) Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol;29:249–255.

6. Opačić N., Barbarić M., Zorc B., Cetina M., Nagl A., Frković D., Kralj M., Pavelić K., Balzarini J., Andrei G., Snoeck R., De Clercq E., Raić-Malić S., Mintas M. (2005) The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. J Med Chem;48:475–482.

7. Butula I., Zorc B., Vela V. (1981) Reaktionen mit 1-Benzotriazol carbonsäurechlorid.VII. Die Umsetzung mit Aminosäuren. Croat Chem Acta;54:435–440.

8. Zorc B., Butula I. (1981) Reaktionen mit N-(1-Benzotriazolylcarbonyl)-aminosäuren.I. Synthese von Hydantoinen und Hydantoinssäuren-amiden. Croat Chem Acta;54:441–449.

9. Butula I., Jadrijević-Mladar Takač M. (2000) Reaction with 1-benzotriazolecarboxylic acid chloride. VIII. Synthesis of N-hydroxy-isocyanate derivatives. Croat Chem Acta;73:569–574.

10. Mossman T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods;65:55–63.

Supplementary Material

The following supplementary material is available for this article:

^{13}C NMR and ^{1}H data for hydroxyurea derivatives **5a–l**

This material is available as part of the online article from: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1747-0285.2007.00660.x

(This link will take you to the article abstract).

Please note: Blackwell Publishing are not responsible for the content or functionality of any supplementary materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

Novel Ureidoamides Derived from Amino Acids: Synthesis and Preliminary Biological Screening

Ivana Perković,[a] Ivan Butula,[a] Zrinka Rajić,[a] Dimitra Hadjipavlou-Litina,[b] Eleni Pontiki,[b] and Branka Zorc[a,*]

[a]*Faculty of Pharmacy and Biochemistry, University of Zagreb, HR-10000 Zagreb, Croatia*
[b]*Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece*

Abstract. A series of novel amino acid ureidoamides **4a-o** were prepared from *N*-(1-benzotriazole-carbonyl)-amino acid chloride **3**, derived from L-alanine, L-valine, L-leucine, D-phenylglycine and L-phenylalanine, and the corresponding aminoalcohols (2-amino-1-ethanol, 3-amino-1-propanol and 5-amino-1-pentanol). The compounds were fully characterized by standard spectroscopic methods (IR, ^{1}H and ^{13}C NMR) and their structure was confirmed by elemental analysis. Antioxidant screenings (interaction with 1,1-diphenyl-2-picrylhydrazyl, soybean lipoxygenase inhibition activity, inhibition of linoleic acid lipid peroxidation) revealed that the prepared compounds possessed only modest activity. On the other hand, no significant antiproliferative activity against five human cell lines and very weak antimicrobial activity against several bacteria and fungi were detected.

Keywords: urea, amide, amino acid, benzotriazole, hydantoin, hydroxylamine, antioxidant activity

INTRODUCTION

Benzotriazole is a very useful synthetic auxiliary with versatile applications in organic chemistry. Since 1985, Katritzky and collaborators have published more than 300 papers and several reviews dealing with benzotriazole.[1–7] Our group started benzotriazole chemistry research in 1977 and the results have been published in approximately 30 papers.[8–11] We have used benzotriazole in the synthesis of various heterocyclic compounds (benzoxazine, quinazoline, triazinetrione, hydantoin and oxadiazine derivatives), amino acid derivatives, polymer-drug and thiomer-drug conjugates, carbamates, ureas, semicarbazides, carbazides, sulfonylureas, sulfonylcarbazides, nitroalkanic acid esters, hydantoic acids, *etc*. This paper is a continuation of two previous papers dealing with hydroxyurea derived from amino acid amides bearing benzotriazole moiety.[12,13] Some of the synthesized hydroxyureas showed significant cytostatic activity and we found it worth preparing a series of analogue compounds with hydroxyl group detached from urea nitrogen with two or more methylene spacers. Their synthesis and preliminary biological screening are reported herein.

EXPERIMENTAL

Materials and Methods

Melting points were determined on a Stuart SMP 3 melting apparatus and were uncorrected. IR spectra (v_{max}/cm^{-1}) were recorded on a FTIR Perkin Elmer Paragon 500 spectrometer and UV/VIS spectra on a Varian Cary 100Bio UV-visible spectrometer. ^{1}H and ^{13}C NMR spectra were taken on a Varian Gemini 300 spectrometer, operating at 300 and 75.5 MHz for the ^{1}H and ^{13}C nuclei, respectively. Samples were measured in DMSO-d_6 solutions at 20 ºC in 5 mm NMR tubes. Chemical shifts (δ/ppm) were referred to TMS. Precoated silica gel 60 F_{254} plates were used for thin-layer chromatography. Solvent systems were CH_2Cl_2/MeOH (9:1 and 4:1). Spots were visualized by phosphomolybdic acid. Column chromatography was performed on silica gel (0.063–0.200 mm) with CH_2Cl_2/MeOH (9:1, 8.5:1.5 and 4:1) and $CHCl_3$/MeOH = 9.5:0.5 as eluents.

Amino acids (L-alanine, L-valine, L-leucine, D-phenylglycine and L-phenylalanine) were purchased from Kemika (Croatia), and amines (2-amino-1-ethanol, 3-amino-1-propanol, 5-amino-1-pentanol, hydroxylamine, *O*-benzylhydroxylamine and triethylamine

---

* Author to whom correspondence should be addressed. (E-mail: bzbz@pharma.hr)

(TEA)) from Sigma-Aldrich (USA). 1-Benzotriazole carboxylic acid chloride (**1**), *N*-(1-benzotriazolecarbonyl)-amino acids **2** and chlorides **3** were prepared according to previously published procedures.[8,14–16]

Ureido Derivatives 4a-o. General Procedure

A mixture of *N*-(1-benzotriazolecarbonyl)-amino acid chloride (**3a-e**) (1 mmol) and an appropriate amine (3 mmol) in 10 mL of dry dioxane was stirred at room temperature for 24 h and evaporated. Crude product **4a-o** was purified by column chromatography and then triturated or recrystallized using the solvents given below.

1-(1-(2-Hydroxyethylcarbamoyl)ethyl)-3-(2-hydroxyethyl)urea **4a**
Crude product **4a** was purified by column chromatography (eluent $CH_2Cl_2/MeOH = 8.5:1.5 \rightarrow 4:1$) and triturated with Et_2O. Yield: 0.132 g (61 %); m.p. 150–154 ºC; IR (KBr) ν_{max}/cm^{-1}: 3422, 3274, 2969, 2937, 2879, 1644, 1570, 1056.
Anal. Calcd. mass fractions of elements, $w/\%$, for $C_8H_{17}N_3O_4$ ($M_r = 219.24$) are: C 43.83, H 7.82, N 19.17; found: C 43.93, H 7.73, N 19.05.

1-(1-(3-Hydroxypropylcarbamoyl)ethyl)-3-(3-hydroxypropyl)urea **4b**
Crude product **4b** was purified by column chromatography (eluent $CH_2Cl_2/MeOH = 4:1$) and triturated with Et_2O. Yield: 0.139 g (56 %); m.p. 152–156 ºC; IR (KBr) ν_{max}/cm^{-1}: 3345, 3275, 2941, 2875, 1638, 1560, 1060.
Anal. Calcd. mass fractions of elements, $w/\%$, for $C_{10}H_{21}N_3O_4$ ($M_r = 247.29$) are: C 48.57, H 8.56, N 16.99; found: C 48.35, H 8.77, N 16.84.

1-(1-(5-Hydroxypentylcarbamoyl)ethyl)-3-(5-hydroxypentyl)urea **4c**
Crude product **4c** was purified by column chromatography (eluent $CH_2Cl_2/MeOH = 4:1$) and triturated with Et_2O. Yield: 0.180 g (59 %); m.p. 142–146 ºC; IR (KBr) ν_{max}/cm^{-1}: 3360, 3282, 3111, 2936, 2862, 1627, 1561, 1056.
Anal. Calcd. mass fractions of elements, $w/\%$, for $C_{14}H_{29}N_3O_4$ ($M_r = 303.40$) are: C 55.42, H 9.63, N 13.8; found: C 55.62, H 9.47, N 14.02.

1-(1-(2-Hydroxyethylcarbamoyl)-2-methylpropyl)-3-(2-hydroxyethyl)urea **4d**
Crude product **4d** was purified by column chromatography (eluent $CH_2Cl_2/MeOH = 8.5:1.5 \rightarrow 4:1$) and recrystallized from MeOH/Et_2O. Yield: 0.140 g (57 %); m.p. 194–198 ºC; IR (KBr) ν_{max}/cm^{-1}: 3351, 3280, 3102, 2969, 2874, 1626, 1571, 1063.
Anal. Calcd. mass fractions of elements, $w/\%$, for $C_{10}H_{21}N_3O_4$ ($M_r = 247.29$) are: C 48.57, H 8.56, N 16.99; found: C 48.88, H 8.53, N 16.61.

1-(1-(3-Hydroxypropylcarbamoyl)-2-methylpropyl)-3-(3-hydroxypropyl)urea **4e**
Crude product **4e** was purified by column chromatography (eluent $CH_2Cl_2/MeOH = 9:1 \rightarrow 4:1$) and recrystallized from MeOH/Et_2O. Yield: 0.154 g (56 %); m.p. 178–181 ºC; IR (KBr) ν_{max}/cm^{-1}: 3350, 3279, 3102, 2963, 2874, 1630, 1566, 1234, 1078, 1044.
Anal. Calcd. mass fractions of elements, $w/\%$, for $C_{12}H_{25}N_3O_4$ ($M_r = 275.34$) are: C 52.34, H 79.15, N 15.26; found: C 52.53, H 9.01, N 15.44.

1-(1-(5-Hydroxypentylcarbamoyl)-2-methylpropyl)-3-(5-hydroxypentyl)urea **4f**
Crude product **4f** was purified by column chromatography (eluent $CH_2Cl_2/MeOH = 9:1 \rightarrow 4:1$) and triturated with Et_2O. Yield: 0.171 g (52 %); m.p. 159–162 ºC; IR (KBr) ν_{max}/cm^{-1}: 3349, 3278, 3107, 2935, 2861, 1628, 1572, 1236, 1059.
Anal. Calcd. mass fractions of elements, $w/\%$, for $C_{16}H_{33}N_3O$ ($M_r = 331.45$) are: C 57.98, H 10.04, N 12.68; found: C 57.75, H 10.17, N 12.93.

1-(1-(2-Hydroxyethylcarbamoyl)-3-methylbutyl)-3-(2-hydroxyethyl)urea **4g**
Crude product **4g** was purified by column chromatography (eluent $CH_2Cl_2/MeOH = 8.5:1.5$). Yield: 0.138 g (53 %); m.p. 157–161 ºC; IR (KBr) ν_{max}/cm^{-1}: 3354, 3290, 3098, 2954, 2928, 2872, 1625, 1569, 1059.
Anal. Calcd. mass fractions of elements, $w/\%$, for $C_{11}H_{23}N_3O_4$ ($M_r = 261.32$) are: C 50.56, H 8.87, N 16.08; found: C 50.56, H 8.87, N 16.08.

1-(1-(3-Hydroxypropylcarbamoyl)-3-methylbutyl)-3-(3-hydroxypropyl)urea **4h**
Crude product **4h** was purified by column chromatography (eluent $CH_2Cl_2/MeOH = 8.5:1.5$) and triturated with Et_2O. Yield: 0.150 g (52 %); m.p. 109–111 ºC; IR (KBr) ν_{max}/cm^{-1}: 3351, 3308, 3098, 2957, 2872, 1630, 1572, 1252, 1073.
Anal. Calcd. mass fractions of elements, $w/\%$, for $C_{13}H_{27}N_3O_4$ ($M_r = 289.37$) are: C 53.96, H 9.40, N 14.52; found: C 53.69, H 9.23, N 14.79.

1-(1-(5-Hydroxypentylcarbamoyl)-3-methylbutyl)-3-(5-hydroxypentyl)urea **4i**
Crude product **4i** was purified by column chromatography (eluent $CH_2Cl_2/MeOH = 9:1 \rightarrow 8.5:1.5$) and triturated with Et_2O. Yield: 0.270 g (78 %); m.p. 83–86 ºC; IR (KBr) ν_{max}/cm^{-1}: 3349, 3280, 3100, 2937, 2862, 1626, 1562, 1262, 1059.
Anal. Calcd. mass fractions of elements, $w/\%$, for $C_{17}H_{35}N_3O_4$ ($M_r = 345.48$) are: C 59.10, H 10.21, N 12.16; found: C 59.30, H 10.11, N 12.19.

1-((2-Hydroxyethylcarbamoyl)(phenyl)methyl)-3-(2-hydroxyethyl)urea **4j**
Crude product **4j** was purified by column chromatography (eluent $CH_2Cl_2/MeOH = 8.5:1.5 \rightarrow 4:1$) and tritu-

rated with Et$_2$O. Yield: 0.171 g (61 %); m.p. 206–208 ºC; IR (KBr) v_{max}/cm^{-1}: 3422, 3274, 2969, 2937, 2879, 1644, 1570, 1056.
Anal. Calcd. mass fractions of elements, w/%, for C$_{13}$H$_{19}$N$_3$O$_4$ (M_r = 281.31) are: C 55.50, H 6.81, N 14.94; found: C 55.78, H 6.57, N 14.77.

1-((3-Hydroxypropylcarbamoyl)(phenyl)methyl)-3-(3-hydroxypropyl)urea **4k**

Crude product **4k** was purified by column chromatography (eluent CH$_2$Cl$_2$/MeOH = 8.5:1.5) and recrystallized from MeOH/Et$_2$O. Yield: 0.170 g (55 %); m.p. 182–185 ºC; IR (KBr) v_{max}/cm^{-1}: 3354, 3289, 3092, 2942, 2883, 1626, 1561, 1059.
Anal. Calcd. mass fractions of elements, w/%, for C$_{15}$H$_{23}$N$_3$O$_4$ (M_r = 309.36) are: C 58.24, H 7.49, N 13.58; found: C 58.37, H 7.26, N 13.73.

1-((5-Hydroxypentylcarbamoyl)(phenyl)methyl)-3-(5-hydroxypentyl)urea **4l**

Crude product **4l** was purified by column chromatography (eluent CH$_2$Cl$_2$/MeOH = 8.5:1.5) and recrystallized from MeOH/Et$_2$O. Yield: 0.222 g (61 %); m.p. 178–180 ºC; IR (KBr) v_{max}/cm^{-1}: 3362, 3286, 3093, 2937, 2861, 1628, 1564, 1352, 1061.
Anal. Calcd. mass fractions of elements, w/%, for C$_{19}$H$_{31}$N$_3$O$_4$ (M_r = 365.47) are: C 62.44, H 8.55, N 11.50; found: C 62.65, H 8.71, N 11.69.

1-(1-(2-Hydroxyethylcarbamoyl)-2-phenylethyl)-3-(2-hydroxyethyl)urea **4m**

Crude product **4m** was purified by column chromatography (eluent CH$_2$Cl$_2$/MeOH = 8.5:1.5). Yield: 0.230 g (78 %); m.p. 140–143 ºC; IR (KBr) v_{max}/cm^{-1}: 3377, 3310, 3105, 2937, 2876, 1626, 1569, 1496, 1231, 1056.
Anal. Calcd. mass fractions of elements, w/%, for C$_{14}$H$_{21}$N$_3$O$_4$ (M_r = 295.33) are: C 56.94, H 7.17, N 14.23; found: C 56.69, H 7.32, N 14.44.

1-(1-(3-Hydroxypropylcarbamoyl)-2-phenylethyl)-3-(3-hydroxypropyl)urea **4n**

Crude product **4n** was purified by column chromatography (eluent CH$_2$Cl$_2$/MeOH = 8.5:1.5). Yield: 0.243 g (75 %); m.p. 110–113 ºC; IR (KBr) v_{max}/cm^{-1}: 3358, 3280, 3106, 2942, 2878, 1628, 1564, 1235, 1050.
Anal. Calcd. mass fractions of elements, w/%, for C$_{16}$H$_{25}$N$_3$O$_4$ (M_r = 323.39) are: C 59.42, H 7.79, N 12.99; found: C 59.38, H 7.88, N 12.75.

1-(1-(5-Hydroxypentylcarbamoyl)-2-phenylethyl)-3-(5-hydroxypentyl)urea **4o**

Crude product **4o** was purified by column chromatography (eluent CH$_2$Cl$_2$/MeOH = 9:1) and trituration with Et$_2$O. Yield: 0.197 g (52 %); m.p. 89–93 ºC; IR (KBr) v_{max}/cm^{-1}: 3362, 3282, 3106, 2931, 2859, 1626, 1559, 1236, 1060.

Anal. Calcd. mass fractions of elements, w/%, for C$_{20}$H$_{33}$N$_3$O$_4$ (M_r = 379.49) are: C 63.30, H 8.76, N 11.07; found: C 63.45, H 8.92, N 11.31.

N-*(1-benzotriazolecarbonyl)-L-alanine* N-*hydroxyamide* **5a**

A solution of 0.339 g (1 mmol) N-(1-benzotriazolecarbonyl)-L-alanine O-benzyloxyamide (**8a**) in 20 mL MeOH was hydrogenolyzed using 50 mg Pd/C as a catalyst. After 2.5 h the reaction mixture was filtered, evaporated and the thus obtained crude product was triturated with Et$_2$O and filtered off. Yield: 0.231 g (93 %). IR (KBr) v_{max}/cm^{-1}: 3613, 3225, 3079, 1714, 1694, 1657, 1523, 1068, 843, 772.
Anal. Calcd. mass fractions of elements, w/%, for C$_{10}$H$_{11}$N$_5$O$_3$ (M_r = 249.23) are: C 48.19, H 4.45, N 28.10; found: C 48.45, H 4.72, N 28.46; ^{1}H NMR (DMSO-d$_6$) δ 10.81 (s, 1H, OH), 9.09–9.06 (d, 1H, NCONH), 8.94 (s, 1H, NHO), 8.23–7.53 (m, 4H, arom.), 4.46–4.37 (q, 1H, CH), 1.48–1.45 (d, 3H, CH$_3$); ^{13}C NMR (DMSO-d$_6$) δ 168.58 (CO amide), 149.04 (CO urea), 145.90–113.99 (arom.), 48.56 (CH), 18.39 (CH$_3$).

3-Hydroxyhydantoins 6

3-Hydroxy-5-methylhydantoin **6a**

To a solution of 0.249 g (1 mmol) N-(1-benzotriazole-carbonyl)-L-alanine N-hydroxyamide (**5a**) in acetone (40 mL), 5 % Na$_2$CO$_3$ solution (4 mL) was added.[17] The reaction mixture was stirred at r.t. for 2 h. Acetone was evaporated *in vacuo* and the precipitated product **6a** was filtered off, washed with water and recrystallized from acetone and water. Analytical data of compound **6a** are consistent with the literature data.[18]

3-Hydroxy-5-benzylhydantoin **6b**

A solution of 0.207 g (0.7 mmol) of 3-benzyloxy-5-benzylhydantoin (**9b**) in 30 mL MeOH was hydrogenolyzed using 50 mg Pd/C as a catalyst. After 2.5 h the reaction mixture was filtered, methanol was evaporated and the thus obtained crude product was triturated with Et$_2$O. Yield: 0.086 g (60 %). Analytical data of compound **6b** are consistent with the literature data.[18]

N-*(1-benzotriazolecarbonyl)-L-amino acid* *O*-*benzyloxyamides 8. General Procedure*

A solution of 2.5 mmol N-(1-benzotriazolecarbonyl)-L-amino acid **2** in 10 mL SOCl$_2$ was stirred at room temperature and evaporated after 24 h. Crude chloride **3** was dissolved in 20 mL toluene and cooled to 0 °C. A mixture of 0.308 g (2.5 mmol) O-benzylhydroxylamine and 0.253 g (2.5 mmol) TEA in 25 mL toluene was added dropwise. The reaction mixture was stirred on an ice bath for 1 h, extracted several times with water, dried over sodium sulphate and evaporated.

N-*(1-benzotriazolecarbonyl)-L-alanine* O-*benzyloxyamide* **8a**

Crude product **8a** was triturated with Et$_2$O and filtered off. Yield: 0.474 g (56 %). The sample for analysis was recrystallized from toluene. IR (KBr) v_{max}/cm^{-1}: 3414, 3357, 3224, 1719, 1671, 1530, 1449, 1231, 1058, 756, 696.

Anal. Calcd. mass fractions of elements, w/%, for C$_{17}$H$_{17}$N$_5$O$_3$ (M_r = 339.13) are: C 60.17, H 5.05, N 20.64; found: C 60.38, H 5.32, N 20.31; ^{13}C NMR (DMSO-d$_6$) δ 169.73 (CONH), 153.06 (NCONH), 134.06−125.66 (arom.), 78.81 (OCH$_2$), 50.39 (CH), 17.38 (CH$_3$).

N-*(1-benzotriazolecarbonyl)-L-phenylalanine* O-*benzyloxyamide* **8b**

Crude product **8b** was purified by column chromatography (eluent CHCl$_3$/MeOH = 9.5:0.5) and recrystallized from Et$_2$O/petrolether. Yield: 0.353 g (34 %); IR (KBr) v_{max}/cm^{-1}: 3370, 3173, 2971, 1743, 1697, 1674, 1508, 1448, 1048, 756, 701.

Anal. Calcd. mass fractions of elements, w/%, for C$_{23}$H$_{21}$N$_5$O$_3$ (M_r = 415.44) are: C 66.49, H 5.09, N 16.86; found: C 66.45, H 4.92, N 16.51; ^{13}C NMR (DMSO-d$_6$) δ 168.44 (CONH), 153.28 (NCONH), 135.64−127.65 (arom.), 79.17 (OCH$_2$), 55.71 (CH), 37.10 (CH$_2$).

3-Benzyloxyhydantoins 9. General Procedure

A solution of 2 mmol *N*-(1-benzotriazolecarbonyl)-L-amino acid **2** in 10 mL SOCl$_2$ was stirred at room temperature and evaporated after 24 h. Crude chloride **3** was dissolved in 20 mL toluene. A mixture of 0.246 g (2 mmol) *O*-benzylhydroxylamine and 0.202 g (2 mmol) TEA in 20 mL toluene was added. The reaction mixture was stirred at r.t. for 5 h, extracted several times with 5 % NaOH solution, then with water, dried over sodium sulphate and evaporated.

3-Benzyloxy-5-i-*butylhydantoin* **9a**

Crude product **9a** was triturated with Et$_2$O and filtered off. Yield: 0.428 g (82 %). The sample for analysis was recrystallized from toluene. Analytical data of compound **9a** are consistent with the literature data.[19]

3-Benzyloxy-5-benzylhydantoin **9b**

Crude product **9b** was triturated with Et$_2$O, filtered off and recrystallized from toluene. Yield: 0.255 g (43 %). IR (KBr) v_{max}/cm^{-1}: 3244, 1783, 1728, 1425, 1214, 748, 724, 696.

Anal. Calcd. mass fractions of elements, w/%, for C$_{17}$H$_{16}$N$_2$O$_3$ (M_r = 296.32) are: C 68.91, H 5.44, N 9.45; found: C 68.55 H 5.62, N 9.31. ^{1}H NMR (DMSO-d$_6$) δ 8.44 (s, 1H, NH), 7.40−7.19 (m, 10H, arom.), 4.73−4.64 (dd, 2H, OCH$_2$), 4.42 (t, 1H, CH), 2.99−2.97 (d, 2H, CH$_2$); ^{13}C NMR (DMSO-d$_6$) δ 168.13 (CO), 152.96 (CO), 135.27−127.37 (arom.), 78.85 (OCH$_2$), 55.38 (CH), 36.73 (CH$_2$).

Biological Evaluation

General Experimental Details

Each experiment *in vitro* was performed at least in triplicate and the standard deviation of absorbance was less than 10 % of the mean. 1,1-Diphenyl-picrylhydrazyl (DPPH), 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH), nordihydroguaiaretic acid (NDGA), sodium linoleate, soybean lipoxygenase (LO), caffeic acid and Trolox were purchased from Aldrich-Sigma (USA). All the tested compounds were dissolved in DMSO.

Interaction with DPPH Activity[20]

To a solution of DPPH (c = 0.05 mmol dm^{-3}) in absolute ethanol, an equal volume of ethanolic solution of the tested compound (c = 0.1 or 0.05 mmol dm^{-3}) was added. After 20 and 60 min, the absorbance was recorded at 517 nm and compared with the appropriate standard NDGA. Ethanol was used as a control.

Soybean Lipoxygenase Inhibition Activity

DMSO solution of the tested compound was incubated with sodium linoleate (c = 0.1 mmol dm^{-3}) and 0.2 mL of soybean lipoxygenase solution ($1/9 \times 10^{-4}$ w/v in saline) at room temperature. Conversion of sodium linoleate to 13-hydroperoxylinoleic acid was recorded at 234 nm and compared with the standard inhibitor caffeic acid, according to the procedure previously reported.[20]

Inhibition of Linoleic Acid Lipid Peroxidation[21]

Peroxidation of linoleic acid to conjugated diene hydroperoxide in an aqueous dispersion was monitored at 234 nm. AAPH was used as a free radical initiator. Ten microliters of linoleic acid dispersion (c = 16 mmol dm^{-3}) was added to the UV cuvette containing 0.93 mL phosphate buffer (c = 0.05 mmol dm^{-3}), pH = 7.4, prethermostated at 37 °C. The oxidation reaction was initiated at 37 °C under air by adding 50 μL of AAPH solution (c = 40 mmol dm^{-3}). Oxidation was carried out in the presence of the tested compounds (10 μL, final concentration 0.1 mmol dm^{-3}). In the assay with no antioxidant, lipid peroxidation was measured in the presence of the same level of DMSO. The rate of oxidation was monitored at 37 °C by recording the increase of absorption at 234 nm caused by conjugated diene hydroperoxides. The results were compared to the standard inhibitor Trolox.

Cytostatic Activity Assays

Cytostatic activity against five human cell lines, derived from 4 cancer types, was measured as described previously.[17] The following cell lines were used: MCF-7 (breast carcinoma), SW 620 (colon carcinoma), HCT 116 (colon carcinoma), MOLT-4 (acute lymphoblastic leukaemia) and H 460 (lung carcinoma).

	4a	**4b**	**4c**	**4d**	**4e**	**4f**	**4g**	**4h**
R^1	CH_3	CH_3	CH_3	$CH(CH_3)_2$	$CH(CH_3)_2$	$CH(CH_3)_2$	$CH_2CH(CH_3)_2$	$CH_2CH(CH_3)_2$
R^2	$(CH_2)_2OH$	$(CH_2)_3OH$	$(CH_2)_5OH$	$(CH_2)_2OH$	$(CH_2)_3OH$	$(CH_2)_5OH$	$(CH_2)_2OH$	$(CH_2)_3OH$

	4i	**4j**	**4k**	**4l**	**4m**	**4n**	**4o**
R^1	$CH_2CH(CH_3)_2$	Ph	Ph	Ph	Bn	Bn	Bn
R^2	$(CH_2)_5OH$	$(CH_2)_2OH$	$(CH_2)_3OH$	$(CH_2)_5OH$	$(CH_2)_2OH$	$(CH_2)_3OH$	$(CH_2)_5OH$

Scheme 1. Synthesis of ureidoamides **4a-o**.

Antimicrobial Activity

Microbial species (*Bacillus subtilis* ATCC 6633, *Staphylococcus aureus* ATCC 25923, *Escherichia coli* ATCC 10536, *Pseudomonas aeruginosa* ATCC 27853, *Candida albicans* ATCC 10231 and *Aspergilus niger* ATCC 16404) used in the study were obtained from the American Type Culture Collection, LGC Promochem, UK. Trypticasa soy agar and Müller-Hinton agar were purchased from Merck (Germany), Sabouraud 2 % (*m/V*)-glucose agar from BBL (Germany), amphotericin B from Sigma and norfloxacin from Krka (Slovenia).

RESULTS AND DISCUSSION

Chemistry

New ureidoamides **4a-o**, derivatives of amino acids, were prepared from *N*-(1-benzotriazolecarbonyl)-amino acid chlorides **3a-e** and the corresponding aminoalcohols. Synthesis of analogous ureidoamides with various monofunctional amines or *N*-hydroxyurea amides was previously described by us,[12,13,16] as well as the synthesis of the starting compounds 1-benzotriazolecarboxylic acid chloride (**1**)[8,14] and *N*-(1-benzotriazolecarbonyl)-

Scheme 2. Reactions with hydroxylamines.

Table 1. Spectroscopic data and atom enumeration for ureidoamides **4a–o**

Compound	Structure	^{1}H and ^{13}C NMR (DMSO-d_6, δ/ppm)
4a	*(structure)*	7.87 (t, 1H, 1' (amide), J = 5.4 Hz), 6.21 (d, 1H, 3, J = 7.9 Hz), 6.14 (t, 1H, 1' (ureido), J = 5.5 Hz) 4.69, 4.67 (2t, 2H, 4', J = 5.6 Hz, J = 5.2 Hz), 4.16–4.06 (m, 1H, 2), 3.38–3.32 (m, 4H, 3'), 3.13–3.00 (m, 4H, 2'), 1.12 (d, 3H, 5, J = 7.4 Hz) 173.78 (1), 157.98 (4), 61.19, 60.21 (3'), 49.07 (2), 42.46, 41.86 (2'), 20.11 (5)
4b	*(structure)*	7.85 (t, 1H, 1' (amide), J = 5.5 Hz), 6.05–6.02 (d, t, 2H, 3, 1' (ureido)), 4.43, 4.42 (2t, 2H, 5', J = 4.8 Hz, J = 5.1 Hz), 4.14–4.05 (m, 1H, 2), 3.39 (q, 4H, 4', J = 6.1 Hz), 3.12–3.00 (m, 4H, 2'), 1.58–1.44 (m, 4H, 3'), 1.12 (d, 3H, 5, J = 6.8 Hz) 173.63 (1), 157.97 (4), 58.83, 58.82 (4'), 49.02 (2), 36.70, 36.12 (2'), 33.66, 32.79 (3'), 20.23 (5)
4c	*(structure)*	7.84 (t, 1H, 1' (amide), J = 5.3 Hz), 6.03 (t, 1H, 1' (ureido), J = 5.5 Hz), 5.96 (d, 1H, 3, J = 7.8 Hz), 4.34 (t, 2H, 7', J = 5.1 Hz), 4.15–4.05 (m, 1H, 2), 3.37 (q, 4H, 6', J = 5.8 Hz), 3.05–2.92 (m, 4H, 2'), 1.45–1.29 (m, 12H, 3'–5'), 1.12 (d, 3H, 5) 173.44 (1), 157.77 (4), 61.13, 61.08 (6'), 48.95 (2), 39.63, 38.89 (2'), 32.72, 32.63 (5'), 30.35, 29.39 (3'), 23.39, 23.30 (4'), 20.36 (5)
4d	*(structure)*	7.87 (t, 1H, 1' (amide), J = 5.4 Hz), 6.16 (t, 1H, 1' (ureido), J = 5.5 Hz), 6.11 (d, 1H, 3, J = 9.1 Hz), 4.65, 4.64 (2t, 2H, 4', J = 4.8 Hz, J = 5.1 Hz), 3.97 (dd, 1H, 2, J = 6.0 Hz, J = 2.9 Hz), 3.45–3.33 (m, 4H, 3'), 3.18–3.03 (m, 4H, 2'), 1.91–1.80 (m, 1H, 5), 0.82 (d, 3H, 6, J = 6.8 Hz), 0.78 (d, 3H, 7, J = 6.8 Hz), 172.60 (1), 158.44 (4), 61.25, 60.28 (3'), 58.34 (2), 42.49, 41.76 (2'), 31.59 (5), 19.73, 18.25 (6, 7)
4e	*(structure)*	7.90 (t, 1H, 1' (amide), J = 5.6 Hz), 6.06 (t, 1H, 1' (ureido), J = 5.7 Hz), 5.96 (d, 1H, 3, J = 9.1 Hz), 4.42, 4.41 (2t, 2H, 5', J = 5.4 Hz), 3.95 (dd, 1H, 2, J = 6.1 Hz, J = 3.0 Hz), 3.39 (q, 4H, 4', J = 6.0 Hz), 3.19–3.00 (m, 4H, 2'), 1.89–1.78 (m, 1H, 5), 1.58–1.45 (m, 4H, 3'), 0.82 (d, 3H, 6, J = 6.8 Hz), 0.79 (d, 3H, 7, J = 7.0 Hz) 172.40 (1), 158.45 (4), 58.89, 58.79 (4'), 58.28 (2), 36.68, 36.07 (2'), 33.71, 32.86 (3'), 31.72 (5), 19.71, 18.35 (6, 7)
4f	*(structure)*	7.89 (t, 1H, 1' (amide), J = 5.5 Hz), 6.05 (t, 1H, 1' (ureido), J = 5.4 Hz), 5.90 (d, 1H, 3, J = 9.0 Hz), 4.35–4.32 (m, 2H, 7'), 3.95 (dd, 1H, 2, J = 6.2 Hz, J = 2.7 Hz), 3.38–3.35 (m, 4H, 6'), 3.12–2.93 (m, 4H, 2'), 1.88–1.77 (m, 1H, 5), 1.44–1.25 (m, 12H, 3'–5'), 0.81 (d, 3H, 6, J = 6.8 Hz), 0.78 (d, 3H, 7, J = 6.9) 172.23 (1), 158.25 (4), 61.13, 61.08 (6'), 58.21 (2), 39.67, 38.83 (2'), 32.72, 32.62 (5'), 31.78 (5), 30.35, 29.41 (3'), 23.39, 23.35 (4'), 19.70, 18.33 (6,7)

4g

7.87 (t, 1H, 1' (amide), J = 5.3 Hz), 6.11 (d, 1H, 3, J = 8.9 Hz), 6.04 (t, 1H, 1' (ureido), J = 5.4 Hz), 4.65–4.64 (m, 2H, 4'), 4.15–4.07 (m, 1H, 2), 3.40–3.34 (m, 4H, 3'), 3.13–3.01 (m, 4H, 2'), 1.60–1.52 (m, 1H, 6), 1.42–1.27 (m, 2H, 5), 0.88–0.84 (m, 6H, 7, 8) 173.69 (1), 158.18 (4), 61.21, 60.24 (3'), 51.95 (2), 42.84, 42.49 (2'), 41.83 (5), 24.69 (6), 23.51, 22.39 (7, 8)

4h

7.89 (t, 1H, 1' (amide), J = 5.5 Hz), 5.97–5.94 (m, 2H, 3, 1' (ureido)), 4.42, 4.40 (2t, 2H, 5', J = 5.3 Hz), 4.13–4.05 (m, 1H, 2), 3.42–3.35 (m, 4H, 4'), 3.15–2.99 (m, 4H, 2'), 1.59–1.44 (m, 5H, 6, 3'), 1.39–1.30 (m, 2H, 5), 0.87 (d, 3H, 7, J = 6.2 Hz), 0.85 (d, 3H, 8, J = 6.2 Hz) 173.50 (1), 158.19 (4), 58.90, 58.85 (4'), 51.95 (2), 42.92 (5), 36.73, 36.11 (2'), 33.68, 32.81 (3'), 24.74 (6), 23.43, 22.49 (7, 8)

4i

7.88 (t, 1H, 1' (amide), J = 5.4 Hz), 5.94 (t, 1H, 1' (ureido), J = 5.7 Hz), 5.88 (d, 1H, 3, J = 9.0 Hz), 4.33 (t, 2H, 7', J = 5.1 Hz), 4.13–4.06 (m, 1H, 2), 3.39–3.33 (m, 4H, 6'), 3.08–2.92 (m, 4H, 2'), 1.58–1.22 (m, 15H, 6, 5, 3'–5'), 1.39–1.30 (m, 2H, 5), 0.87 (d, 3H, 7, J = 6.1 Hz) 0.85 (m, 3H, 8, J = 6.1 Hz) 173.29 (1), 157.98 (4), 61.13, 61.09 (6'), 51.90 (2), 43.03 (5), 39.70, 38.87 (2'), 32.73, 32.64 (5'), 30.35, 29.37 (3'), 24.74 (6), 23.41, 22.57 (7, 8), 23.38, 23.31 (4')

4j

8.31 (t, 1H, 1' (amide), J = 5.5 Hz), 7.37–7.21 (m, 5H, 6–10), 6.78 (d, 1H, 3, J = 8.4 Hz), 6.29 (t, 1H, 1' (ureido), J = 5.5 Hz), 5.31 (d, 1H, 2, J = 8.4 Hz), 4.66, 4.64 (2t, 2H, 4', J = 5.3 Hz, J = 5.1 Hz), 3.40–3.34 (m, 4H, 3'), 3.23–2.97 (m, 4H, 2') 171.25 (1), 157.63 (4), 141.05 (5), 128.61 (6, 10), 127.57 (8), 127.10 (7, 9), 61.18, 60.11 (3'), 56.93 (2), 42.46, 42.01 (2')

4k

8.27 (t, 1H, 1' (amide), J = 5.5 Hz), 7.36–7.22 (m, 5H, 6–10), 6.65 (d, 1H, 3, J = 8.3 Hz), 6.21 (t, 1H, 1' (ureido), J = 5.5 Hz), 5.26 (d, 1H, 2, J = 8.5 Hz), 4.41, 4.39 (2t, 2H, 5', J = 5.2 Hz), 3.42–3.32 (m, 4H, 4'), 3.12–2.99 (m, 4H, 2'), 1.56–1.44 (m, 4H, 3') 171.06 (1), 157.67 (4), 141.10 (5), 128.63 (6, 10), 127.59 (8), 126.96 (7, 9), 58.79, 58.72 (4'), 56.98 (2), 39.15, 36.69 (2'), 36.33, 36.28 (3')

4l

8.26 (t, 1H, 1' (amide), $J = 5.5$ Hz), 7.36–7.21 (m, 5H, 6–10), 6.60 (d, 1H, 3, $J = 8.4$ Hz), 6.21 (t, 1H, 1' (ureido), $J = 5.5$ Hz), 5.26 (d, 1H, 2, $J = 8.4$ Hz), 4.35, 4.31 (2t, 2H, 7', $J = 5.3$ Hz), 3.40–3.30 (m, 4H, 6'), 3.05–2.92 (m, 4H, 2'), 1.44–1.16 (m, 12H, 3'–5') 170.90 (1), 157.49 (4), 141.21 (5), 128.59 (6, 10), 127.54 (8), 126.93 (7, 9), 61.13, 61.06 (6'), 56.94 (2), 39.63, 39.04 (2'), 32.71, 32.58 (5'), 30.31, 29.24 (3'), 23.38, 23.25 (4')

4m

7.90 (t, 1H, 1' (amide), $J = 5.1$ Hz), 7.28–7.17 (m, 5H, 6–10), 6.16 (d, 1H, 3, $J = 8.6$ Hz), 6.10 (t, 1H, 1' (ureido), $J = 5.1$ Hz), 4.64–4.59 (m, 2H, 4'), 4.37–4.30 (m, 1H, 2), 3.33–3.29 (m, 4H, 3'), 3.12–2.67 (m, 6H, 2', 5) 172.51 (1), 158.00 (4), 138.41 (6), 129.71 (6, 10), 128.43 (7, 9), 126.58 (8), 61.16, 60.18 (3'), 54.80 (2), 42.42, 41.81 (2'), 39.42 (5)

4n

7.88 (t, 1H, 1' (amide), $J = 4.6$ Hz), 7.27–7.14 (m, 5H, 6–10), 6.04–6.02 (d, t, 2H, 3, 1' (ureido)), 4.42–4.28 (m, 3H, 2, 5'), 3.39–3.34 (m, 4H, 4'), 3.12–2.69 (m, 6H, 2', 5), 1.50–1.43 (m, 4H, 3') 172.28 (1), 158.00 (4), 138.35 (5), 129.68 (8, 10), 128.43 (7, 11), 126.58 (9), 58.93 (4'), 54.79 (2), 39.46 (5), 36.68, 36.14 (2'), 33.61, 32.72 (3')

4o

7.86 (t, 1H, 1' (amide), $J = 5.5$ Hz), 7.27–7.14 (m, 5H, 6–10), 6.01 (t, 1H, 1' (ureido), $J = 5.5$ Hz), 5.96 (d, 1H, 3, $J = 8.7$ Hz), 4.35–4.28 (m, 3H, 2, 7'), 3.37–3.33 (m, 4H, 6'), 3.07–2.69 (m, 6H, 2', 5), 1.43–1.16 (m, 12H, 3'–5') 172.06 (1), 157.79 (4), 138.34 (5), 129.70 (8, 10), 128.40 (7, 11), 126.55 (9), 61.13, 61.07 (6'), 54.72 (2), 39.62, 39.55 (2'), 38.91 (5), 32.72, 32.67 (5'), 30.30, 29.33 (3'), 23.36, 23.29 (4')

Table 2. Interaction with DPPH, *in vitro* inhibition of soybean lipoxygenase (LO) and lipid peroxidation (LP). All values are expressed in percents

Compound	DPPH 20 min[a]	DPPH 60 min[a]	DPPH 20 min[b]	DPPH 60 min[b]	LO inhibition[b]	LP inhibition[b]
4a	1.7	0.5	n.a.[c]	n.a.	28.1	n.a.
4b	n.a.	0.9	0.3	1	49.5[d]	32.9
4c	3.2	3.9	1.4	4.8	22.6	94.6
4d	3.4	6.3	2.1	3.5	55.7[d]	24.2
4e	2.7	6.3	5.0	4.7	37.8	15.0
4f	n.a.	1.2	2.3	5.2	36.1	43.7
4g	1.2	0.9	n.a.	1.5	52.8[d]	59.6
4h	n.a.	3.2	0.9	3.6	42.6	16.1
4i	1.2	1.1	2.7	2.8	42.5	11.1
4j	2.3	3.8	5.7	7.5	50.1[d]	63.1
4k	n.a.	2.2	4.9	1.3	55.6[d]	47.9
4l	1.6	2.4	0.9	3.7	36.9	3.9
4m	0.5	3.0	n.a.	1.1	49.2[d]	87.4
4n	0.9	1.8	n.a.	0.9	39.7	19.9
4o	1.8	3.3	2.5	3.7	27.6	16.6
Caffeic acid	n.d.[e]	n.d.	n.d.	n.d.	600	n.d.
NDGA	81	83	93	97	n.d.	n.d.
Trolox	n.d.	n.d.	n.d.	n.d.	n.d.	63

Concentrations of the tested compounds:
[a] 5×10^{-5} mol dm^{-3}.
[b] 1×10^{-4} mol dm^{-3}.
[c] n.a. – no activity under the reported experimental conditions.
[d] IC$_{50}$ value was also determined: 100 (**4b**), 92.5 (**4d**), 98 (**4g**), 100 (**4j**), 88 (**4k**), 100 (**4m**) μmol dm^{-3}.
[e] n.d. – not determined.

amino acids (**2**).[15] The optimal molar ratio of aminoalcohol to chloride **3** was 3:1. Amino groups selectively reacted with 2-amino-1-ethanol, 3-amino-1-propanol and 5-amino-1-pentanol and the reaction products were ureidoamides **4** (Scheme 1).

However, when hydroxylamine was used as aminoalcohol, a mixture of products was obtained. *N*-hydroxyureido hydroxamic acids of the general formula **7** were obtained only in traces, while the main products were 3-hydroxyhydantoins **6**, obtained by cyclization of *N*-(1-benzotriazolecarbonyl)-L-amino acid *N*-hydroxyamides **5**. Compounds **5** could be obtained in quantitative yield by catalytic hydrogenation of *N*-(1-benzotriazolecarbonyl)-L-amino acid *O*-benzyloxyamides **8**. L-alanine and L-phenylalanine derivatives **8a** and **8b** were isolated in the reaction of the corresponding chlorides **3** with *O*-benzylhydroxylamine, while L-leucine derivative **8c** spontaneously cyclized to 3-benzyloxyhydantoin **9a**. Phenylalanine hydantoin **9b** was also prepared directly from chloride **3**, without isolation of amide **8b**, when the reaction time was prolonged. Hydantoins **9** were readily hydrogenated to 3-hydroxyhydantoins **6**. Compounds **6** could be obtained by cyclization of amide **5** in alkaline medium as well.[17]

In our previous research, reactions of chlorides **3** with *N*-phenylhydroxylamine afforded hydroxamic acids **10**, which readily cyclized to 1,2,5-oxadiazine derivatives **11** under basic conditions.[22] In that case, hydroxamic acids **10** could be successfully isolated. Scheme II depicts the reactions of amino acid derivatives with hydroxylamines.

To obtain compounds with different physicochemical properties, amino acids with both aliphatic (L-alanine, L-valine and L-leucine) and aromatic (D-phenylglycine and L-phenylalanine) residues were used. Structures of compounds **4a-o** were deduced from analyses of their IR, ^{1}H and ^{13}C NMR spectra and were confirmed by elemental analysis. The chemical shifts were consistent with the proposed structures of the novel compounds (Table 1). IR spectra of ureidoamides **4a-o** showed characteristic bands at 3422−3345 (OH), 3310−3100 (NH), 1644−1625 (amide and urea carbonyls) and 1572−1559 (amide II) cm^{-1}. In ^{1}H NMR spectra, amide NH (1') in all aliphatic amino acid and phenylalanine derivatives showed as triplets between 7.90 and 7.84 ppm, while in phenylglycine derivatives **4j-l** it was slightly shifted downfield (8.31−8.26 ppm). Ureido NH (3) showed as doublets between 6.21

and 5.88 ppm, except in phenylglycine derivatives (6.78−6.60 ppm). Ureido NH (1') appeared as triplets between 6.14 and 6.01 ppm. Signals from phenylglycine derivatives were again slightly shifted to 6.29−6.21. Hydroxyl groups appeared as one or two superimposed triplets between 4.68 and 4.32 (ppm values decreased with the length of the chain). All three NH groups and OH were exchangeable with D_2O. Amide carbonyl group (1) in ^{13}C NMR spectra appeared between 173.78 and 172.06, except in phenylglycine derivatives (171.25−170.96), while ureido carbonyl was uniformly located between 158.45 and 157.49 ppm.

Biological Activity

Newly synthesized ureidoamides **4a-o** were screened for antioxidative, antimicrobial and cytostatic activities. The results have shown that biological activity of the tested compounds was rather modest.

Interaction of the tested compounds with the free radical DPPH was very weak (Table 2). The results were below 10 % and no increase was observed with the increase of ureidoamide concentration (0.05 mmol dm^{-3} and 0.1 mmol dm^{-3}) and the time of interaction (20 min and 60 min). Soybean lipoxygenase inhibition activity assay showed that the tested ureidoamides were modest LO inhibitors (Table 2). IC_{50} values for compounds **4b**, **4d**, **4g**, **4j**, **4k**, **4m** were between 92.5 and 100 μmol dm^{-3}, while the percent of inhibition for the other compounds ranged from 22.6 to 42.6 % at the concentration $c = 1 \times 10^{-4}$ mol dm^{-3}. Most of the tested compounds exerted no significant inhibition of lipid peroxidation, with the exception of compounds **4c** and **4m**, followed by **4g** and **4j** (Table 2). From the results it was not possible to delineate the influence of certain structural characteristics and physicochemical properties in terms of (Q)SAR.

Evaluation of cytostatic activities against malignant tumor cell lines has shown that ureidoamides **4a-o** possess very weak antiproliferative activity (data not shown), significantly lower than the urea amides with hydroxyl group directly attached to urea nitrogen.[12,13]

Results of microbiological screening using the hole-plate diffusion method[23] revealed that ureidoamides **4a-o** showed no growth inhibition zones, and were considered inactive at the concentration used (data not shown). The minimum inhibitory (MIC) and minimum microbicidal concentrations (MMcC) were determined by the microdilution broth method.[24] MIC/MMcC values were high (data not shown). The strongest activity was exerted towards *Pseudomonas aeruginosa* (1.25/2.5 mg dm^{-3}).

Abbreviations. AAPH, 2,2'-azobis(2-amidinopropane) dihydrochloride; BtcCl, 1-benzotriazole carboxylic acid chloride; BtH, benzotriazole, DPPH, 1,1-diphenyl-2-picrylhydrazyl radical; LO, soybean lipoxygenase; LP, lipid peroxidation; MIC, minimal inhibitory concentration; MMcC, minimal microbicidal concentration; NDGA, nordihydroguaiaretic acid; TEA, triethylamine.

REFERENCES

1. A. R. Katritzky, S. Rachwal, and G. J. Hitchings, *Tetrahedron* **47** (1991) 2683–2732.
2. A. R. Katritzky, X. Lan, and W. Q. Fan, *Synthesis* **1994** 445–446.
3. A. R. Katritzky and B. Yang, *J. Heterocyclic Chem.* **33** (1996) 607–610.
4. A. R. Katritzky, X. Lan, J. Z. Yang, and O. V. Denisko, *Chem. Rev.* **98** (1998) 409–548.
5. A. R. Katritzky, H. Y. He, and K. Suzuki, *J. Org. Chem.* **65** (2000) 8210–8213.
6. A. R. Katritzky, N. Kirichenko, and B. V. Rogovoy, *Arkivoc.* **8** (2003) 8–14.
7. A. R. Katritzky, M. Yoshioka, T. Narindoshvili, A. Chung, and N. M. Khashab, *Chem. Biol. Drug Des.* **72** (2008) 182–188.
8. I. Butula, M. V. Proštenik, and V. Vela, *Croat. Chem. Acta* **49** (1977) 837–842.
9. I. Butula and B. Zorc, *Kem. Ind.* **56** (2007) 123–134.
10. G. Džimbeg, B. Zorc, M. Kralj, K. Ester, K. Pavelić, J. Balzarini, E. De Clercq, and M. Mintas, *Eur. J. Med. Chem.* **43** (2008) 1180–1187.
11. Z. Rajić, I. Butula, B. Zorc, S. Kraljević Pavelić, K. Hock, K. Pavelić, L. Naesens, E. De Clercq, J. Balzarini, M. Przyborowska, T. Ossowski, and M. Mintas, *Chem. Biol. Drug Des.* **73** (2009) 328–338.
12. N. Opačić, M. Barbarić, B. Zorc, M. Cetina, A. Nagl, D. Frković, M. Kralj, K. Pavelić, J. Balzarini, G. Andrei, E. De Clerq, S. Raić-Malić, and M. Mintas, *J. Med. Chem.* **48** (2005) 475–482.
13. I. Perković, I. Butula, B. Zorc, K. Hock, S. Kraljević Pavelić, K. Pavelić, E. De Clercq, J. Balzarini, and M. Mintas, *Chem. Biol. Drug Des.* **71** (2008) 546–553.
14. I. Butula and M. Jadrijević-Mladar Takač, *Croat. Chem. Acta* **73** (2000) 569–574.
15. I. Butula, B. Zorc, and V. Vela, *Croat. Chem. Acta* **54** (1981) 435–440.
16. B. Zorc and I. Butula, *Croat. Chem. Acta* **54** (1981) 441–449.
17. Z. Rajić, B. Zorc, S. Raić-Malić, K. Ester, M. Kralj, K. Pavelić, J. Balzarini, E. De Clercq, and M. Mintas, *Molecules* **11** (2006) 837–848.
18. P. Fankhauser and M. Brenner, *Helv. Chim. Acta* **53** (1970) 2298–2313.
19. T. Teramoto, T. Kurosaki, and M. Okawara, *Tetrahedron Lett.* **18** (1977) 1523–1526.
20. E. Pontiki and D. Hadjipavlou-Litina, *Bioorg. Med. Chem.* **15** (2007) 5819–5827.
21. E. R. Re, N. Pellegrini, A. Proteggente, A. Pannala, M. Yang, and C. Rice-Evans, *Free Rad. Biol. Med.* **26** (1999) 1231–1237.
22. M. Barbarić, S. Kraljević, M. Grce, and B. Zorc, *Acta Pharm.* **53** (2003) 175–186.

23. *European Pharmacopoeia*, 5th Ed., Council of Europe, Strasbourg, 2006.

24. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th Ed. Approved Standard, NCCLS document M7-A4, National Committee for Clinical Laboratory Standards, Wayne, Pa, USA, **1997**.

SAŽETAK

Novi ureidoamidi iz aminokiselina: Sinteza i biološko djelovanje

Ivana Perković,[a] Ivan Butula,[a] Zrinka Rajić,[a] Dimitra Hadjipavlou-Litina,[b] Eleni Pontiki[b] i Branka Zorc[a]

[a]*Faculty of Pharmacy and Biochemistry, University of Zagreb, HR-10000 Zagreb, Croatia*
[b]*Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki 54 124, Greece*

U radu je opisana sinteza novih aminokiselinskih ureidoamida **4a-o** polazeći iz klorida *N*-(1-benzotriazolkarbonil)-aminokiselina **3**, derivata L-alanina, L-valina, L-leucina, D-fenilglicina i L-fenilalanina, i odgovarajućih aminoalkohola (2-amino-etan-1-ol, 3-amino-propan-1-ol i 5-amino-pentan-1-ol). Struktura spojeva potvrđena je uobičajenim spektroskopskim metodama (IR, ^{1}H i ^{13}C NMR) i elementarnom analizom. Antioksidativna ispitivanja pokazuju da sintetizirani spojevi posjeduju blago djelovanje (interakcija s 1,1-difenil-pikrilhidrazil radikalom, inhibicija lipoksigenaze iz soje, inhibicija peroksidacije linolne kiseline). Preliminarna citostatska ispitivanja na pet humanih staničnih linija i antimikrobna ispitivanja na nekoliko mikroorganizama pokazuju da sintetizirani ureidoamidi imaju slabo antiproliferativno, odnosno antimikrobno djelovanje.

Communication

Antiradical, Chelating and Antioxidant Activities of Hydroxamic Acids and Hydroxyureas

Marijana Zovko Končić *, Monika Barbarić, Ivana Perković and Branka Zorc

Faculty of Pharmacy and Biochemistry, University of Zagreb, A. Kovačića 1, Zagreb HR-10000, Croatia; E-Mails: mbarbaric@pharma.hr (M.B.); iperkovic@pharma.hr (I.P.); bzbz@pharma.hr (B.Z.)

* Author to whom correspondence should be addressed; E-Mail: mzovko@pharma.hr; Tel.: +385-1-6394-792; Fax: +385-1-6394-400.

Abstract: Reactive oxygen species, along with reactive nitrogen species, may play an important role in the pathogenesis and progress of many diseases, including cancer, diabetes and sickle cell disease. It has been postulated that hydroxyurea, one of the main treatments in sickle cell disease, achieves its activity partly also through its antioxidant properties. A series of hydroxyurea derivatives of L- and D-amino acid amides and cycloalkyl-*N*-aryl-hydroxamic acids was synthesized and investigated for their radical scavenging activity, chelating properties and antioxidant activity. All the compounds showed exceptional antiradical activities. For example, free radical scavenging activities of investigated hydroxyureas were higher than the activity of standard antioxidant, butylated hydroxyanisole (BHA). Moreover, most of the investigated hydroxamic acids were stronger Fe^{2+} ion chelators than quercetin. In addition, the investigated compounds, especially hydroxamic acids, were proven to be excellent antioxidants. They were as effective as BHA in inhibiting β-carotene-linoleic acid coupled oxidation. It is reasonable to assume that the antioxidant activity of the investigated compounds could contribute to their previously proven biological properties as cytostatic and antiviral agents.

Keywords: hydroxamic acids; hydroxyureas; free radical; oxidative stress; reactive oxygen species

1. Introduction

A growing body of evidence suggests that endo- and exogenous reactive oxygen species (ROS) may have an important role in the expansion and progression of tumors. In addition, the research has shown that the various types of cancer examined to date exhibit an imbalance in their antioxidant mechanisms. In the near future new insights in cancer therapies, based on modulation of cellular redox status, may lead the way to additional tools against carcinogenesis induced by ROS [1]. Oxidative stress is an imbalanced state of oxidants and antioxidants in organism, initiated by endogenous ROS, such as superoxide anion and hydrogen peroxide. These moderately strong oxidants can, in reaction with substances such as nitric oxide (NO) or transition metals, be converted into species with pronounced reactivity such as peroxynitrite and hydroxyl radicals. Those are molecules capable of attacking sensitive cellular targets like lipids, proteins and nucleic acids causing their inhibition and accelerated degradation. Thus, oxidative stress inflicts multiple levels of cellular damage, which propagates a vicious cycle. These consequences of oxidative stress construct the molecular basis in the development of many diseases. One of the ROS-mediated causes of cancer is gene mutations (modification of pyridine and purine bases) and post-translational modifications leading to disruption of cellular processes [2]. Therefore, in the last decade antioxidant compounds have received increased attention from medical researchers for their potential activities in preventing cancer, cardiovascular disorders, as well as aging. Analysis of activities of new antioxidant compounds of synthetic and natural origin have been subject of several publications [3-5].

One of the diseases where oxidative stress is especially pronounced is sickle cell disease (SCD). Today, hydroxyurea is considered by most physicians in the developing world as the treatment of choice for severe SCD. It seems that hydroxyurea exerts its activity through several mechanisms such as promotion of increase of fetal hemoglobin level, erythrocyte alterations, myelosuppression, and others [6]. In addition, it seems that some of its biological activity is achieved by ameliorating the damage caused by oxidative stress. Overproduction of ROS by enzymatic and non-enzymatic pathways promotes intravascular oxidative stress that can disrupt NO homeostasis [7]. However, hydroxyurea can be oxidized by heme groups to produce NO *in vitro*. Thus, the NO-donor properties of hydroxyurea may contribute to its beneficial effects in SCD [6].

In our previous papers, synthesis of hydroxyureas and hydroxamic acids with cytostatic and antiviral activities was described [8,9]. Thus, in an attempt to further study potential beneficial effects of those substances, their antioxidant activity was thoroughly investigated and compared.

2. Results and Discussion

Hydroxyurea derivatives of L- and D-amino acid amides **1**–**5** and cycloalkyl-*N*-arylhydroxamic acids **6**–**11** were synthesized and their structures were confirmed as described in literature. All analytical and spectral data were in agreement with the previously published data [8-10]. The structures of the synthesized compounds are presented in Figure 1.

Figure 1. Hydroxyureas **1**–**5** and hydroxamic acids **6**–**11** investigated in this study.

2.1. DPPH Radical Scavenging Activity

At high concentrations, free radicals are mediators of damage to cell structures, nucleic acids, lipids and proteins. Examples of ROS-induced DNA damage products involve single- or double-stranded DNA breaks, purine, pyrimidine, or deoxyribose modifications, and DNA cross-links. Such modification of genetic material may represent the first step in mutagenesis, carcinogenesis and ageing. Free radical-mediated DNA damage has been found in various cancer tissues. Thus, it has been hypothesized that the free radical scavengers are molecules that could prevent or limit the damage provoked by free radicals [11,12]. Capability of hydroxamic acids and hydroxyureas to scavenge free radicals has been assessed in reaction with DPPH, a relatively stable free radical.

DPPH, in its radical form, has strong visible absorption and high molar extinction coefficient at 517 nm. Upon reaction with an antioxidant the absorbance diminishes [13]. Investigated hydroxyureas **1**–**5** demonstrated remarkable radical scavenging activity (Figure 2) with EC_{50} values lower than 0.06 mM. Moreover, with the exception of **2**, all the hydroxyureas showed activity statistically higher than the activity of synthetic antioxidant BHA. Such exceptional activity was not surprising because a previous investigation of primaquine derivatives indicated that introduction of hydroxyureas in the molecule had high positive impact on the reactivity towards DPPH free radical [14]. Hydroxamic acids in this study were less reactive towards DPPH free radical than hydroxyureas (Figure 2). Compounds **6**–**10** displayed relatively weak free radical scavenging activity in comparison to BHA. Despite the fact that halogenation increases free radical scavenging activity of some compounds [15] the most potent hydroxamic acid in this study was the only non-halogenated derivative **11** with activity statistically equal to the activity of BHA. This might be explained by the proximity of aromatic furane ring to the

hydroxamic moiety and possibility of dislocation of unpaired electron formed in reaction with DPPH radical. Activity of the substances was not in correlation with their log *P* values (Table 1).

Figure 2. Radical scavenging activities of hydroxyureas **1**–**5** and hydroxamic acids **6**–**11** expressed as EC_{50} (means ± SD, *n* = 3). Statistically significant differences: * less active than BHA; † more active than BHA (*P* < 0.05).

Table 1. Log *P* and reactivity in β-carotene-linoleate assay.

Compound	Log *P*	*ANT* (%) [a,b]	*AA-60* (%) [a,c]
1	3.12	62.45 ± 5.55 *	63.46 ± 3.01 *
2	2.30	64.47 ± 5.55 *	65.72 ± 3.06 *
3	3.23	60.67 ± 5.43 *	63.15 ± 3.37 *
4	2.46	60.66 ± 1.38 *	62.80 ± 0.89 *
5	3.41	67.33 ± 4.71 *	69.93 ± 2.84 *
6	2.02	72.73 ± 2.45 *	73.76 ± 1.14
7	3.79	89.13 ± 1.89 †	88.55 ± 0.92
8	3.34	88.61 ± 1.74 †	88.03 ± 1.15
9	3.82	94.39 ± 1.03 †	94.22 ± 1.19
10	4.25	89.86 ± 0.97 †	89.54 ± 1.80 †
11	1.53	54.96 ± 4.67 *	57.43 ± 2.53 *
BHA	*n.c.*	79.59 ± 2.06	80.55 ± 1.43

[a] means ± SD (*n* = 3); [b] antioxidant activity; [c] normalized antioxidant activity at 60-min of incubation; *n.c.*: not calculated; Statistically significant differences within columns: * less active than BHA; † more active than BHA (*P* < 0.05).

2.2. Chelating Activity

Direct reaction of a substance is not the only mechanism by which the antioxidants may display their activity. Secondary, preventive, or type 2, antioxidants act through numerous possible mechanisms. These antioxidants do not convert free radicals to more stable products but slow the rate of oxidation by several different mechanisms. One of the most important mechanisms of action of secondary antioxidants is chelation of prooxidant metals. Iron and other transition metals (copper, chromium, cobalt, vanadium, cadmium, arsenic, nickel) promote oxidation by acting as catalysts of free radical reactions. These redox-active transition metals transfer single electrons during changes in oxidation states. Chelation of metals by certain compounds decreases their prooxidant effect by reducing their redox potentials and stabilizing the oxidized form of the metal. Chelating compounds may also sterically hinder formation of the metal hydroperoxide complex [16]. Chelating activity of hydroxamic acids and hydroxyureas was compared to two chelating standards, EDTA and quercetin (Figure 3).

Figure 3. Fe^{2+} chelating activities of hydroxyureas **1–5** and hydroxamic acids **6–11** expressed as EC_{50} (means ± SD, $n = 3$). Statistically significant differences: * less active than EDTA; † less active than quercetin; ‡ more active than quercetin ($P < 0.05$).


All the investigated substances were capable of chelating Fe^{2+} ions. The metal chelating effects of the samples were dependent on concentration and linearly increased with the sample concentration increase. The affinity of hydroxyureas **1–4** for ferrous ions was relatively low in comparison to quercetin and EDTA. However the activity of hydroxyurea **5** was the same as the activity of quercetin. On the other hand, hydroxamic acids **6–11** investigated in this assay were stronger chelating agents than hydroxyureas. Although somewhat weaker chelators than EDTA, they demonstrated relatively high activity in comparison to quercetin. The chelating activity of substance **11** was lower than

quercetin, while the other hydroxamic acids were either equally active (**6**,**10**) or even even stronger (**7**–**9**) ferrous ion chelators. Therapeutically, the ion chelating activity of drugs may be especially important in diseases that include extensive hemolysis or frequent blood transfusions, such as SCD. For example, deferoxamine, deferasirox and other iron chelators have been shown efficient in treatment of iron overload caused by blood transfusions in SCD [17]. Thus, excellent activity of the investigated hydroxamic acids may also implicate the use of the investigated compounds as iron chelators, similarly to some other compounds of that class [17,18].

2.3. β-Carotene Linoleic Acid Assay

Oxidation of an aqueous emulsion of β-carotene and linoleic acid was employed as a test for measuring total antioxidant activity of the hydroxamic acids and hydroxyureas. In this particular model, heat induces formation of linoleic acid free radical. The radical then reacts with conjugated double bonds of β-carotene, causing a rapid degradation and discoloration [19]. Thus, by simulation of the oxidation of the membrane lipid components in the presence of antioxidants, this test gives an insight of the inhibitory effect of substances on the lipid peroxidation. It also measures the capacity to inhibit the formation of conjugated diene hydroperoxide arising from linoleic acid oxidation [20]. The presence of an antioxidant can reduce the extent of β-carotene destruction by reacting with the linoleate free radical or any other free radical formed within the system. The substances investigated in this study were able to reduce the rate of degradation of β-carotene significantly in comparison with the control (Figure 4). Antioxidant activity was measured as a percentage of inhibition of lipid peroxidation (*ANT*) (Table 1). Hydroxyureas **1**–**5** demonstrated relatively low antioxidant activity in comparison with BHA. Hydroxamic acids **6**–**11**, on the other hand, displayed outstanding antioxidant properties in this assay. Not only was their *ANT* value statistically higher than the activity of investigated hydroxyureas, but most of them (**7**–**10**) were also more potent antioxidants than BHA. According to Amarowicz *et al.* [19], the antioxidant activity expressed as the percent of inhibition of coupled oxidation of β-carotene and linoleic acid against the water and BHA control samples, based on absolute changes of absorbance at distinct points in time during the assay (*AA-60*), rather than as an average rate, provides another way of evaluating antioxidant activity in β-carotene-linoleic acid assay. In present study, if antioxidant activity was evaluated as *AA-60* (Table 1), the activities of compounds **6**–**9** were statistically equal to that of BHA while **10** was more potent antioxidant. Hydroxamic acids have been previously shown as potent lipid peroxidation inhibitors [21]. Moreover, it has been proven that the introduction of hydroxamic moiety into some organic acids creates potent antioxidants, capable of hindering linoleic acid degradation in a similar manner as butylated hydroxytoluene, one of the antioxidant used by food industry [22]. Outstanding protective effect of hydroxamic acids towards heat-induced linoleic acid oxidation found in this study confirms those findings. Both, *ANT* and *AA-60* values of hydroxamic acids and log *P* correlated linearly with r^2 values of 0.87. This high correlation coefficient could be explained by better diffusion of lipophilic compounds into micelles with linoleic acid and β-carotene where they can exhibit their antioxidant activity.

Figure 4. Bleaching of emulsion with β-carotene in presence of hydroxyureas **1–5** and hydroxamic acids **6–11** (means ± SD, $n = 3$). Absorbance was measured at $\lambda = 470$ nm.

3. Experimental

3.1. General

Melting points were determined on a Stuart Melting Point Apparatus SMP3 (Stuart Barworld Scientific, UK) and are uncorrected. IR spectra were recorded on a FTIR Perkin Elmer Paragon 500 spectrometer (Perkin Elmer, UK). ^{1}H- and ^{13}C-NMR spectra were recorded on a Varian Gemini 300 spectrometer (Varian, USA), operating at 300 and 75.5 MHz for the ^{1}H and ^{13}C nuclei, respectively. For absorbance measurements, a Stat Fax 3200 (Awareness Technologies, USA) microplate reader was used.

3.2. Chemicals

Hydroxyureas, namely *N*-benzhydryl-2-(*N'*-methyl-*N'*-hydroxyureido)-L-4-methylpentanamide (*N'*-methyl-*N'*-hydroxycarbamoyl-L-leucine benzhydrylamide) (**1**), *N*-cyclohexanemethyl-2-(*N'*-methyl-*N'*-hydroxyureido)-D-2-phenylethamide (*N'*-methyl-*N'*-hydroxycarbamoyl-D-phenylglycine cyclohexane methylamide) (**2**), *N*-benzhydryl-2-(*N'*-methyl-*N'*-hydroxyureido)-D-2-phenylethamide (*N'*-methyl-*N'*-hydroxycarbamoyl-D-phenylglycine benzhydrylamide) (**3**), *N*-cyclohexanemethyl-2-(*N'*-methyl-*N'*-

hydroxyureido)-L-3-phenylpropanamide (*N'*-methyl-*N'*-hydroxycarbamoyl-L-phenylalanine cyclohexane methylamide) (**4**), *N*-benzhydryl-2-(*N'*-methyl-*N'*-hydroxyureido)-L-3-phenylpropanamide (*N'*-methyl-*N'*-hydroxycarbamoyl-L-phenylalanine benzhydrylamide) (**5**) and the following hydroxamic acids: *N*-(4-chlorophenyl)-*N*-hydroxycyclopropanecarboxamide (**6**), *N*-(4-chlorophenyl)-3-cyclo-pentyl-*N*-hydroxypropanamide (**7**), *N*-(4-chlorophenyl)-*N*-hydroxycyclohexanecarboxamide (**8**), *N*-(4-chlorophenyl)-2-cyclohexyl-*N*-hydroxyacetamide (**9**) and *N*-(4-chlorophenyl)-3-cyclohexyl-*N*-hydroxypropanamide (**10**) were synthesized according to our published procedures [8,9]. *N*-phenyl-2-furohydroxamic (**11**) was prepared following reference [5]. All analytical and spectral data were in agreement with the previously published data [8-10]. Butylated hydroxyanisole (BHA), 2,2-diphenyl-1-picrylhydrazyl (DPPH), β-carotene, linoleic acid and ferrozine were purchased from Sigma-Aldrich (USA). Other chemicals and solvents used were of analytical grade.

3.3. Antiradical Activity

Free radical scavenging activity (*RSA*) was evaluated by the scavenging of DPPH radicals as described by Yen and Chen [23] with some modifications. Methanolic solution of DPPH (20 μL, 0.735 mg/mL) was added to 200 μL of either ethanolic solution of the test sample or methanol (negative control). The mixture was vortexed for 1 min and then left to stand at room temperature in the dark. After 30 min absorbance was read at 545 nm. BHA was used as a positive control. *RSA* for DPPH free radical was calculated using A_{cont} (absorbance of the negative control, e.g., blank solution without test compound) and A_{sample} (absorbance of the substance solution). *RSA* was expressed as the concentration that scavenges 50% of DPPH free radicals (EC_{50}).

3.4. Fe^{2+} Chelating Activity

The chelating activity (*ChA*) of the investigated substances toward ferrous ions was studied as described in reference [24]. To an aliquot of the methanolic solution of the test substance (150 μL), 0.25 mM $FeCl_2$ solution (50 μL) was added. After 5 min, the reaction was initiated by adding 1.0 mM ferrozine solution (100 μL). Absorbance at 545 nm was recorded after 10 min of incubation at room temperature. A reaction mixture containing methanol (150 μL) instead of substance solution served as a control. Quercetin and EDTA were used as the chelating standards. *ChA* was calculated using A_{cont} (absorbance of the negative control, e.g., blank solution without test compound) and A_{sample} (absorbance of the substance solution). Chelating activity was expressed as EC_{50}, the concentration that chelates 50% of Fe^{2+} ions.

3.5. β-Carotene-linoleic Acid Assay

The antioxidant activity of the substances was evaluated using the β-carotene-linoleic acid system according to modified literature procedures [19,24]. Tween 40 (200 mg) and β-carotene solution in chloroform (1.0 mL, $\gamma = 0.2$ g/L) were mixed. After removing chloroform in a rotary evaporator, linoleic acid (20 mg) and aerated distilled water (30 mL) were added to the oily residue with vigorous stirring. Aliquots (200 μL) of thus obtained emulsion were added to sample solution in methanol (50 μL, 0.02 mM). A reaction mixture containing methanol (50 μL) instead of sample solution served as a

control. BHA was used as an antioxidant standard. After adding the emulsion to the sample solution, the reaction mixture was incubated at 50 °C for 1 h. During that period, the absorbance was measured at 450 nm at 15-minute intervals, starting immediately after sample preparation ($t = 0$ min) until the end of the experiment ($t = 60$ min). The percent of antioxidant activity (*ANT*) was calculated using R_{cont} and R_{sample}, average bleaching rates of the water control and antioxidant (test compound or BHA), respectively. In addition, antioxidant activity was calculated from the absolute changes in absorbance at $t = 60$ min and was expressed as *AA-60* value as described by Amarowicz *et al.* [19].

3.6. Statistical and Log P Analysis

All assays were performed in triplicate. The results were expressed as mean ± SD. Statistical comparisons were made using one-way ANOVA, followed by Dunnett's post-hoc test for multiple comparisons with the control and Student's *t*-test with Welch correction for comparison of two groups of compounds. *P* values <0.05 were considered statistically significant. Statistical analyses were performed using the JMP V6 from SAS software (SAS Institute, Cary, NC, USA). Log *P* values were calculated at Virtual Computational Chemistry Laboratory (VCCLAB, http://www.vcclab.org, 2005) [25].

4. Conclusions

In the present study, radical scavenging, metal chelating and antioxidant activities of several hydroxyureas and hydroxamic acids were investigated by scavenging effect on the DPPH free radical, metal chelation effect in the Fe^{2+}-ferrozin test system, as well as by β-carotene-linoleic acid assay. Hydroxyureas investigated in this study were excellent radical scavengers, with activity similar to that of BHA. On the other hand, hydroxamic acids were more successful in chelation of ferrous ions. They also demonstrated pronounced antioxidant activities in the prevention of heat-induced oxidation of linoleic acid. The results of this study imply that antioxidant activity of investigated compounds may significantly contribute to their cytostatic activity. In addition, similarly to some other compounds of the two classes, investigated hydroxyureas and hydroxamic acids may also have potential in treatment of SCD due to their antioxidant, antiradical and chelating properties.

Conflict of Interest

The authors declare no conflict of interest.

References and Notes

1. Trueba, G.P.; Sánchez, G.M.; Giuliani, A. Oxygen free radical and antioxidant defense mechanism in cancer. *Front. Biosci.* **2004**, *9*, 2029–2044.

2. Venkat Ratnam, D.; Ankola, D.D.; Bhardwaj, V.; Sahana, D.K.; Ravi Kumar, M.N.V. Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. *J. Control. Release* **2006**, *113*, 189–207.

3. Autore, G.; Caruso, A.; Marzocco, S.; Nicolaus, B.; Palladino, C.; Pinto, A.; Popolo, A.; Sinicropi, M.S.; Tommonaro, G.; Saturnino, C. Acetamide derivatives with antioxidant activity and potential anti-inflammatory activity. *Molecules* **2010**, *15*, 2028–2038.

4. Shirinzadeh, H.; Eren, B.; Gurer-Orhan, H.; Suzen, S.; Özden, S. Novel indole-based analogs of melatonin: Synthesis and *in vitro* antioxidant activity studies. *Molecules* **2010**, *15*, 2187–2202.

5. Čačić, M.; Molnar, M.; Šarkanj, B.; Has-Schön, E.; Rajković, V. Synthesis and antioxidant activity of some new coumarinyl-1,3-thiazolidine-4-ones. *Molecules* **2010**, *15*, 6795–6809.

6. Davies, S.C.; Gilmore, A. The role of hydroxyurea in the management of sickle cell disease. *Blood Rev.* **2003**, *17*, 99–109.

7. Wood, K.C.; Hsu, L.L.; Gladwin, M.T. Sickle cell disease vasculopathy: A state of nitric oxide resistance. *Free Radic. Biol. Med.* **2008**, *44*, 1506–1528.

8. Perković, I.; Butula, I.; Zorc, B.; Hock, K.; Kraljević Pavelić, S.; Pavelić, K.; De Clercq, E.; Balzarini, J.; Mintas, M. Novel lipophilic hydroxyurea derivatives: Synthesis, cytostatic and antiviral activity evaluations. *Chem. Biol. Drug Des.* **2008**, *71*, 546–553.

9. Barbarić, M.; Uršić, S.; Pilepić, V.; Zorc, B.; Hergold-Brundić, A.; Nagl, A.; Grdiša, M.; Pavelić, K.; Snoeck, R.; Andrei, G.; *et al.* Synthesis, X-ray crystal structure study, and cytostatic and antiviral evaluation of the novel cycloalkyl-*N*-aryl-hydroxamic acids. *J. Med. Chem.* **2005**, *48*, 884–887.

10. Tandon, S.G.; Bhattacharyya, S.C. Preparation and properties of some *N*-aryl hydroxamic acids. *J. Chem. Engineer. Data* **1962**, *7*, 553–555.

23. Yen, G.C.; Chen, H.Y. Antioxidant activity of various tea extracts in relation to their antimutagenicity. *J. Agric. Food Chem.* **1995**, *43*, 27–37.

24. Rajić, Z.; Zovko Končić, M.; Miloloža, K.; Perković, I.; Butula, I.; Bucar, F.; Zorc, B. Primaquine-NSAID twin drugs: Synthesis, radical scavenging, antioxidant and Fe^{2+} chelating activity. *Acta Pharmaceut.* **2010**, *60*, 325–337.

19. Amarowicz, R.; Pegg, R.B.; Rahimi-Moghaddam, P.; Barl, B.; Weil, J.A. Free-radical scavenging capacity and antioxidant activity of selected plant species from the Canadian prairies. *Food Chem.* **2004**, *84*, 551–562.

25. Tetko, I.V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V.A.; Radchenko, E.V.; Zefirov, N.S.; Makarenko, A.S.; *et al.* Virtual computational chemistry laboratory—Design and description. *J. Comput. Aid. Mol. Des.* **2005**, *19*, 453–463.

11. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.D.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. *Int. J. Biochem. Cell Biol.* **2007**, *39*, 44–84.

12. Valko, M.; Rhodes, C.J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. *Chem.-Biol. Inter.* **2006**, *160*, 1–40.

13. Alkan, M.; Yüksek, H.; Gürsoy-Kol, Ö.; Calapoğlu, M. Synthesis, acidity and antioxidant properties of some novel 3,4-disubstituted-4,5-dihydro-1*H*-1,2,4-triazol-5-one derivatives. *Molecules* **2008**, *13*, 107–121.

14. Šimunović, M.; Perković, I.; Zorc, B.; Ester, K.; Kralj, M.; Hadjipavlou-Litina, D.; Pontiki, E. Urea and carbamate derivatives of primaquine: Synthesis, cytostatic and antioxidant activities. *Bioorg. Med. Chem.* **2009**, 17, 5605–5613.

15. Bozkaya, P.; Olgen, S.; Coban, T.; Nebioglu, D. Synthesis of *N*-substituted indole-2-carboxamides and investigation of their biochemical responses against free radicals. *J. Enzym. Inhibit. Med. Ch.* **2007**, *22*, 319–325.

16. Reische, D.W.; Lillard, D.A.; Eitenmiller, R.R. Antioxidants. In *Food Lipids Chemistry Nutrition, and Biotechnology*, 3rd ed; Akoh, C.C., Min, D.B., Eds.; CRC Press: New York, NY, USA, 2008; pp. 409–433.

17. Inati, A. Recent advances in improving the management of sickle cell disease. *Blood Rev.* **2009**, *23*, S9–S13.

18. Kontoghiorghes, G.J. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. *Toxicol. Lett.* **1995**, *80*, 1–18.

20. Sarikurkcu, C.; Arisoy, K.; Tepe, B.; Cakir, A.; Abali, G.; Mete, E. Studies on the antioxidant activity of essential oil and different solvent extracts of *Vitex agnus castus* L. fruits from Turkey. *Food Chem. Toxicol.* **2009**, *47*, 2479–1483.

21. Rajić, Z.; Perković, I.; Butula, I.; Zorc, B.; Hadjipavlou-Litina, D.; Pontiki, E.; Pepeljnjak, S.; Kosalec, I. Synthesis and biological evaluation of *O*-methyl and *O*-ethyl NSAID hydroxamic acids. *J. Enzym. Inhibit. Med. Chem.* **2009**, *24*, 1179–1187.

22. Liu, Y.H.; Lin, S.Y.; Lee, C.C.; Hou, W.C. Antioxidant and nitric oxide production inhibitory activities of galacturonyl hydroxamic acid. *Food Chem.* **2008**, *109*, 159–166.

Sample Availability: Samples of the compounds **1**–**11** are available from the authors.